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Abstract 
 
Microglia,  the  immune  cells  of  the  central  nervous  system  (CNS),  are  important  in  the 
protection of the CNS, but may be implicated in the pathogenesis of neuroinflammatory 
disease.  Upon  activation,  microglia  produce  reactive  oxygen  and  nitrogen  species; 
intracellular antioxidants are therefore likely to be important in their self-defence. Here, it 
was confirmed that cultured microglia contain high levels of glutathione, the predominant 
intracellular  antioxidant  in  mammalian  cells.  The  activation  of  microglia  with 
lipopolysaccharide (LPS) or LPS + interferon- was shown to affect their glutathione levels. 
GSH levels in primary microglia and those of the BV-2 cell line increased upon activation, 
whilst levels in N9 microglial cells decreased.  
 
Microglial glutathione synthesis is dependent upon cystine uptake via the xc
- transporter, 
which exchanges cystine and glutamate. Glutamate is an excitatory neurotransmitter whose 
extracellular concentration is tightly regulated by excitatory amino acid transporters, as high 
levels  cause  toxicity  to  neurones  and  other  CNS  cell  types  through  overstimulation  of 
glutamate receptors or by causing reversal of xc
- transporters. Following exposure to LPS, 
increased  extracellular  glutamate  and  increased  levels  of  messenger  ribonucleic  acid 
(mRNA) for xCT, the specific subunit of xc
-, were observed in BV-2 and primary microglial 
cells, suggesting upregulated GSH synthesis. An activation-induced decrease in N9 GSH 
levels suggests that this cell line is more susceptible to oxidative damage, and may be less 
able to upregulate GSH synthesis. Albumin, to which microglia may be exposed following 
blood-brain  barrier  damage,  increased  iNOS  expression,  glutamate  release,  xCT  mRNA 
levels and intracellular levels of GSH and ATP in BV-2 and primary microglia. Primary and 
BV-2  microglial  conditioned  medium  contained  low  levels  of  GSH,  suggesting  that 
microglia may release GSH.  
 
Modulation of microglial metabotropic glutamate receptors (mGluRs) may alter microglial 
activation and neurotoxicity. Here, stimulation of the neuroprotective mGluR5 and group III 
mGluRs caused a decline in GSH levels in BV-2 and N9 microglia, respectively. In contrast 
mGluR1  stimulation  may  increase  BV-2  GSH  levels.  The  work  presented  in  this  thesis 
therefore  extends  current  knowledge  regarding  microglial  GSH  and  its  regulation,  and 
contributes to the understanding of microglial neurotoxicity and neuroprotection. 
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AIDA    (RS)-1-aminoindan-1,5-dicarboxylic acid 
AIDS  acquired immune deficiency syndrome 
ALS  amyotrophic lateral sclerosis 
AMPA    α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA    analysis of variance 
APA    aminopimelic acid 
APICA    (RS)-1-amino-5-phosphonoindan-1-carboxylic acid 
ApN    aminopeptidase N 
ApoE  apolipoprotein E 
APP    β amyloid precursor protein 
ATP  adenosine triphosphate 
Aβ    β amyloid 
Aβx-y  residues x-y of β amyloid peptide (e.g. 1-42, 25-35) 
BBB  blood-brain barrier 
BDNF  brain-derived neurotrophic factor 
BM    basic medium 
BSO  L-buthionine sulfoximine 
cAMP    cyclic adenosine monophosphate 
CaR  Ca
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CD  cluster of differentiation 
CDPPB    3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide 
CGA    chromogranin A 
CGC  cerebellar granule cell (neurone) 
CHO    Chinese hamster ovary (cell line) 
CHPG    (RS)-2-chloro-5-hydroxyphenylglycine 
CM    conditioned medium 
CNQX    6-cyano-7-nitroquinoxaline-2,3-dione 
CNS  central nervous system 
COX  cyclooxygenase 
CPG    (S)-4-carboxyphenylglycine 
CSF    cerebrospinal fluid 
DAPI  4',6-diamidino-2-phenylindole 
dbcAMP    dibutyryl-cyclic adenosine monophosphate 
DCG IV    (2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine 
DHK    dihydrokainate 
DHPG    (RS)-3,5-dihydroxyphenylglycine 
DIV  days in vitro 
D-MEM    Dulbecco‟s modified Eagle medium 
DMSO  dimethyl sulfoxide 
EA    ethacrynic acid 
EAAC1    excitatory amino acid carrier 1 
EAAT    excitatory amino acid transporter 
EAE  experimental autoimmune encephalomyelitis 
EBV  Epstein-Barr virus 
ERK    extracellular signal-regulated kinase 
FasL  Fas ligand 
FBS    foetal bovine serum 
fig.  figure 
GABA    -aminobutyric acid 
Gβ  G protein β subunit 
GCL    glutamate-cysteine ligase 
GCP II  glutamate carboxypeptidase II 21 
 
GDH    glutamic dehydrogenase 
GDP  guanine diphosphate 
GFAP  glial fibrillary acidic protein 
GLAST    L-glutamate/L-aspartate transporter 
GLT-1    L-glutamate transporter 1 
GPCR  G protein-coupled receptor 
GPx  glutathione peroxidase 
GR  glutathione reductase 
GSH    reduced glutathione; also used as a general term for 
glutathione 
GSSG    oxidised glutathione 
GST  glutathione S-transferase 
GTP  guanine triphosphate 
h    hour(s) 
HEK    human embryonic kidney (cell) 
HIV    human immunodeficiency virus 
HLA  human leukocyte antigen 
HNE  4-hydroxy-2-nonenal 
HPLC    high-performance liquid chromatography 
IFN    interferon- 
iGluR    ionotropic glutamate receptor 
IL  interleukin 
iNOS    inducible nitric oxide synthase 
IP3  inositol triphosphate 
IP-10  IFN-inducible protein-10 
KA    kainic acid 
L-AP4    L-(+)-2-amino-4-phosphonobutyric acid 
LBP  LPS-binding protein 
L-CCG-I  (2S,1'S,2'S)-2-(carboxycyclopropyl)glycine 
LDH    lactate dehydrogenase 
LPS    lipopolysaccharide 
L-SOP  L-serine-O-phosphate 
LTD  long-term depression 22 
 
LTD4    leukotriene D4; cysteinylglycine leukotriene 
LTP    long-term potentiation 
LY 367385    (+)-2-methyl-4-carboxyphenylglycine 
MAP4    (S)-2-amino-2-methyl-4-phosphonobutanoic acid 
MBP  myelin basic protein 
MCB    monochlorobimane 
MCCG    2S,3S,4S-2-methyl-2-(carboxycyclopropyl)glycine 
MCP-1  monocyte chemoattractant protein 1 
M-CSF  macrophage colony-stimulating factor 
MEM    minimum essential medium 
MG    microglia(l) 
mGluR    metabotropic glutamate receptor 
MHC  major histocompatibility complex 
min    minute(s) 
MIP  macrophage inflammatory protein 
MK-801    (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-
5,10-imine 
MMP  matrix metalloproteinase 
MPP
+    1-methyl-4-phenylpyridinium 
MRI  magnetic resonance imaging 
mRNA    messenger ribonucleic acid 
Mrp    multidrug resistance-associated protein 
MS    multiple sclerosis 
MTEP    3-((2-methyl-1,3-thiazol-4-yl)ethynyl)-pyridine 
n.s.    not significant 
NAAG    N-acetyl-L-aspartyl-L-glutamic acid 
NAC  N-acetyl-cysteine 
NAD
+    nicotinamide adenine dinucleotide 
NADH  reduced nicotinamide adenine dinucleotide 
NADP
+  nicotinamide adenine dinucleotide phosphate 
NADPH  reduced nicotinamide adenine dinucleotide phosphate 
NCS    newborn calf serum 
NFT  neurofibrillary tangle 23 
 
NGF  nerve growth factor 
NMDA    N-methyl-D-aspartate 
NO    nitric oxide 
NSAID  non-steroidal anti-inflammatory drug 
O2
-  superoxide 
ONOO
-  peroxynitrite 
OPA  orthophosphoric acid 
PAMP  pathogen-associated molecular pattern 
PCR    polymerase chain reaction 
PDGF  platelet-derived growth factor 
PDL  poly-D-lysine 
PG  prostaglandin 
PI    propidium iodide 
PKA    protein kinase A 
PKC    protein kinase C 
PLC    phospholipase C 
PNS  peripheral nervous system 
PRR  pattern recognition receptor 
PSD  post-synaptic density 
RANTES  regulated upon activation, normal T cell expressed and 
secreted 
RNS  reactive nitrogen species 
ROS    reactive oxygen species 
RR(MS)  relapsing-remitting (multiple sclerosis) 
(RS)-PPG    (RS)-4-phosphonophenylglycine 
SCM    serum-containing medium 
s.e.m.  standard error of the mean 
SFM    serum-free medium 
SIB-1757    6-methyl-2-(phenylazo)-3-pyridinol 
tADA    trans-azetidine-2,4-dicarboxylic acid 
TES    N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic 
acid 
TLR  Toll-like receptor 24 
 
TNFα    tumour necrosis factor α 
VIP    vasoactive intestinal peptide 
VPAC2    VIP receptor 2 
xc
-    xc
- glutamate/cystine antiporter system 
xCT    system xc
- transporter related protein; the specific subunit 
of xc
-  
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1.1. The Central Nervous System  
 
The mammalian brain and spinal cord constitute the central nervous system (CNS), 
which contains four main groups of resident cells; neurones, astrocytes, microglia 
and oligodendrocytes. Non-neuronal cells are collectively known as glia, which, in 
the  human  CNS,  far  outnumber  the  neurones  (Hawkins  and  Olszewski  1957; 
Pfrieger  and  Barres  1995).  The  CNS  circulation  is  separated  from  the  main 
circulation by the blood-brain barrier (BBB), which acts as a filter, preventing large 
or potentially hazardous molecules from entering the CNS.  
 
 1.1.1. Neurones 
 
Neurones  transmit  impulses  within  the  CNS  and  the  peripheral  nervous  system 
(PNS). Afferent or sensory neurones detect information throughout the body and 
transmit this information, in the form of a wave of depolarisation called an action 
potential, to the CNS. Efferent or motor neurones transmit responses from the CNS 
to effector tissues in the periphery. Interneurones are those which are fully contained 
within the CNS, often transmitting impulses between neurones in different regions. 
 
Neurones consist of a cell body of between 4 and 100 µm in diameter, containing the 
nucleus and the majority of the organelles, which has branched extensions called 
dendrites; these receive the majority of the inputs to the cell. Most neurones also 
have one or more axons which are long, thin structures usually surrounded by myelin 
sheaths, allowing fast transmission of an action potential. The axon terminal is also 
branched,  allowing  each  neurone  to  synapse  with  a  number  of  different  effector 
neurones. At the synapse, the arrival of an action potential causes influx of calcium 
ions (Ca
2+) and fusion of neurotransmitter vesicles with the plasma membrane. The 
neurotransmitter  released  diffuses  across  the  synapse,  to  be  detected  by  specific 
receptors in the dendrites of the effector cell, thus eliciting an action potential in the 
postsynaptic  neurone.  Neurotransmitters  are  diverse  compounds,  and  certain 
monoamines, amino acids,  purines  and peptides have all been shown to mediate 
neurotransmission at synapses. A second compound may be co-released with the 
primary  neurotransmitter and act  upon its  own  specific  receptor population, thus 27 
 
further diversifying neurotransmission at the synapse and potential effects upon the 
postsynaptic neurone. In addition the receptors at the postsynaptic membrane may be 
modified  by  other  compounds  and  transition  metal  ions  present  extracellularly, 
which  may  enhance  or  reduce  their  activity.  The  expression  of  neurotransmitter 
receptors may also be modified in response to the environment, as detected by the 
postsynaptic neurone.  
 
Neurones  are  also  functionally  coupled  through  gap  junctions,  rendering  the 
cytoplasm of the two cells continuous through nanometre-sized channels, and thus 
allowing  bidirectional  transmission  of  ions  and  other  small  molecules.  Electrical 
impulses can therefore be transmitted at these electrical synapses without the need 
for a neurotransmitter (Connors and Long 2004; Hormuzdi et al. 2004).  
 
1.1.2. Astrocytes 
 
Astrocytes are the largest of the glial cells, and support neurones structurally and 
metabolically. Astrocytes associate closely with axon terminals (Spacek 1985), with 
one astrocyte in direct contact with up to 140 000 synapses (Bushong et al. 2002). 
Independent  control  of  individual  synapses  is  permitted  by  the  existence  of 
functionally distinct microdomains within each astrocyte (Grosche et al. 1999). The 
importance of bidirectional signalling between neurones and astrocytes in normal 
synaptic function has become apparent within the last decade, and synapses are now 
often considered as tripartite in recognition of this (Araque et al. 1999). Astrocytes 
respond to the presence of neurotransmitters and intercellular signalling molecules, 
and can release neuromodulatory compounds.  
 
Other functions of astrocytes include supplying energy to neurones under conditions 
of hypoglycaemia or intense neural activity (Brown and Ransom 2007), buffering of 
CNS  K
+  (Kofuji  and  Newman  2004),  promotion  of  myelination  in  response  to 
neuronal  activity  (Ishibashi  et  al.  2006),  and  activity-dependent  control  of  brain 
microcirculation  (Zonta  et  al.  2003).  Astrocytes  are  also  crucial  for  functional 
synapse development (Ullian et al. 2001). 
 
Axon 
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Astrocytes  communicate  with  one  another  through  propagation  of  waves  of 
intracellular Ca
2+ ([Ca
2+]i) (Cornell-Bell et al. 1990; Schipke et al. 2002), transmitted 
extracellularly by adenosine triphosphate (ATP) release and detection (Guthrie et al. 
1999; Arcuino et al. 2002; Schipke et al. 2002). Such astrocyte ATP release also 
appears to affect microglia, acting upon their purinergic receptors (Schipke et al. 
2002). 
 
1.1.3. Oligodendrocytes 
 
The main function of oligodendrocytes is the insulation of axonal conductance by the 
formation  of  the  myelin  sheath.  The  myelin  sheath  comprises  layers  of  plasma 
membrane extensions, from which the cytoplasm has largely been extruded, which 
wrap around the axon. The membranes which constitute myelin are lipid-rich, with 
high  levels  of  glycosphingolipids  and  cholesterol,  and  contain  myelin-specific 
proteins. Myelin sheaths in the CNS each insulate about 1 mm of axon. A fully-
myelinated axon therefore has many myelin sheaths, with small gaps, or nodes of 
Ranvier, between successive sheaths. The myelination of axons in this way allows 
saltatory  conduction,  first  demonstrated  by  Lillie  (1925),  in  which  the  wave  of 
depolarisation “jumps” from one node to the next.  
 
Oligodendrocytes  are  highly  vulnerable  to  glutamate  excitotoxicity  and  oxidative 
damage (McTigue and Tripathi 2008). The functional unit formed by the axon and 
the myelinating oligodendrocyte is such that oligodendrocyte death and subsequent 
demyelination may lead to axonal damage and loss of function and even neuronal 
death. 
 
1.1.4. Microglia 
 
Like  many  mammalian  organ  systems,  the  CNS  contains  resident  macrophages 
which protect the largely immune-privileged CNS. These are known as microglia, 
and as the focus of this thesis, are described in detail in section 1.2 below. 
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1.1.5. The Blood-Brain Barrier  
 
The blood-brain barrier (BBB) separates the circulation of the brain from the rest of 
the circulatory system, protecting the CNS against pathogens and foreign molecules, 
and helping to regulate the environment for the vulnerable cells of the CNS. The 
BBB is important in the context of microglial function as endogenous components of 
whole  blood, as  well as foreign particles  carried in  the circulation, may  activate 
microglia. 
 
The physical  barrier function is  mediated by the tight junctions present  between 
adjacent endothelial cells. These junctions consist of transmembrane proteins such as 
claudins (Furuse et al. 1998), occludin (Furuse et al. 1993) and junctional adhesion 
molecule (Martin-Padura et al. 1998), which are anchored to the cytoskeleton and 
prevent the paracellular passage of solutes. Transcellular transport is therefore the 
only  method  by  which  substances  can  enter  the  brain.  Only  small,  lipophilic 
molecules are able to diffuse through the nonfenestrated endothelial cells (Ballabh et 
al. 2004). Specific transporters exist for other molecules essential for brain function, 
such as amino acids and glucose, and larger molecules are transported by means of 
receptor-mediated endocytosis (Ballabh et al. 2004). Conversely, transporters such 
as  P  glycoprotein  and  multidrug  resistance-associated  protein  remove  certain 
substances from the brain by actively pumping them through the luminal plasma 
membrane into the circulation (Cordon-Cardo et al. 1989; Huai-Yun et al. 1998). 
The endothelial cells also provide a metabolic barrier, biochemically altering certain 
molecules entering the cell from the blood to control their entry into the brain (Minn 
et al. 1991). 
 
Leukocyte  entry  into  the  brain  is  mediated  by  cytokines  and  complementary 
adhesion molecules (Pryce et al. 1997; Imhof and Aurrand-Lions 2004). The process 
of BBB penetration begins with chemoattraction and rolling of the cells, followed by 
firm adhesion on the luminal surface of the endothelium. Leukocyte transmigration 
was initially thought to occur at the tight junction, through specific protein-protein 
interactions (Bianchi et al. 1997), but more recent evidence suggests that under some 
circumstances at least, leukocytes may migrate through endothelial cells, without 
disrupting tight junctions (Wolburg et al. 2005; Carman and Springer 2008). Finally, 30 
 
proteases secreted by the infiltrating leukocyte degrade the basal lamina surrounding 
the endothelial cells of the BBB and gain access to the brain (Yadav et al. 2003).  
 
The endothelial cells of the BBB are closely associated with pericytes and astrocyte 
end-feet.  Such  accessory  cells  provide  biochemical  and  trophic  support  to  the 
endothelial cells of the BBB, thus ensuring that the barrier is maintained (Ballabh et 
al. 2004). Conversely, activated microglia may enhance the permeability of the BBB 
and upregulate the expression of cytokines, chemokines and adhesion molecules by 
the endothelial cells, through the secretion of proinflammatory cytokines such as 
tumour necrosis factor-α (TNFα) (Prat et al. 2001). 
 
The BBB presents a problem for the pharmacological treatment of CNS disorders. 
Compounds must not  only be  able to  transverse the barrier, but  also  avoid  both 
enzymatic degradation and removal from the CNS by the multidrug transporters. 
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1.2. Microglia 
 
Microglia, the resident immune cell of the CNS, were first described in 1919 by del 
Rio-Hortega (del Rio-Hortega 1919; see Kreutzberg 1996). During the development 
of the CNS, microglia are important in axonal pruning, as well as for the clearance of 
debris and apoptotic cells (Ashwell 1990; Brockhaus et al. 1996; Mallat et al. 2005). 
Microglia have a role throughout life in the protection of the immune-privileged 
CNS  against  foreign  entities,  and  represent  the  link  between  the  CNS  and  the 
immune system. Like other elements of the CNS, such as neuronal dendrites and 
astrocyte processes, microglial processes are constantly motile, allowing microglia to 
monitor the environment and respond accordingly with changes in their morphology 
and  gene  expression  profile  (Davalos  et  al.  2005;  Nimmerjahn  et  al.  2005). 
Microglia may also be mobile within the CNS and able to migrate as a response to 
tissue damage, or to specific chemoattractants released by CNS or immune cells 
(Carbonell et al. 2005). 
 
1.2.1. Origin 
 
Microglia  bear  a  certain  resemblance  to  the  resident  cells  of  the  mononuclear 
phagocyte lineage which exist in other tissues. Indeed, after decades of debate, it is 
now widely accepted that microglia too are of haematopoietic origin and derive from 
infiltrating monocytes during early development (Ling and Wong 1993; Kreutzberg 
1996). However, unlike other resident monocyte populations, microglia appear to 
constitute a self-renewing population throughout adulthood, separated from the bone 
marrow-derived  monocyte  lineage.  The  large  increase  in  the  local  microglial 
population (microgliosis) following CNS insult was until fairly recently believed to 
originate at least partly from bone marrow-derived progenitors (Hickey and Kimura 
1988;  Flugel  et  al.  2001;  Djukic  et  al.  2006).  However,  the  latest  studies  have 
utilised novel methodology to generate data suggesting that in mouse models of CNS 
disease  and  injury,  microgliosis  is  due  entirely  to  proliferation  of  resident  cells 
(Ajami et al. 2007; Mildner et al. 2007).  
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1.2.2. Morphology of microglia 
 
During early postnatal development, monocytes infiltrate the brain and  transform 
into amoeboid microglia, characterised morphologically by their large cell body and 
short processes (Ling and Wong 1993). This allows them to move within the brain, 
pruning axons where appropriate and phagocytosing apoptotic cells and other debris 
associated with CNS development (Ashwell 1990; Brockhaus et al. 1996; Mallat et 
al. 2005). Within weeks of their appearance in the CNS, microglia adopt a more 
ramified, downregulated phenotype (Ling and Wong 1993). 
 
Under normal circumstances, microglia in the adult CNS exist in this branched state. 
Such ramified microglia were until recently often referred to as “resting” microglia. 
The recent discovery that microglia are in fact constantly active, monitoring the CNS 
environment,  has  prompted  a  re-evaluation  of  the  role  of  ramified  microglia 
(Davalos  et  al.  2005;  Nimmerjahn  et  al.  2005).  At  a  given  moment,  individual 
microglia appear to be responsible for specific portions of brain volume; adjacent 
microglia are closely opposed, and the boundaries between them may move over 
time, but their processes mutually repel one another (Nimmerjahn et al. 2005). Little 
is  known regarding the true characteristics of  ramified microglia  in  vivo, as  any 
manipulation or investigation is likely to activate microglia to some extent (Streit et 
al. 1999). 
 
Microglia  adopt  an  activated  phenotype  when  exposed  to  substances  not  usually 
present  in  the  CNS  environment  (Kreutzberg  1996).  Activated  microglia  are 
morphologically  similar  to  the  amoeboid  microglia  present  during  development 
(Dheen et al. 2007). Microglial activation is also associated with  changes in the 
release  profile  of  microglia  and  altered  receptor  expression.  Under  conditions  of 
neuronal degeneration, microglia may transform into ovoid phagocytic cells, also 
known as foamy macrophages (Kreutzberg 1996), distinguished by the presence of 
phagosomes (Streit and Kreutzberg 1988; Rieske et al. 1989). 
 
The  different  morphologies  adopted  by  microglia,  and  the  relationships  between 
them, are illustrated in figure 1.1. It is important to note that this is a simplified view,33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Diagrammatic representation of microglial morphology. During CNS development, monocytes infiltrate the brain and transform into amoeboid 
microglia, and later ramified microglia. In the adult CNS, microglia exist in a ramified state and assume a rounded phenotype only when activated. Microglia 
may become phagocytic under conditions of neuronal death and degeneration. Microglial activation is associated with increased release of cytokines and 
expression of cytokine receptors and MHC antigens. Adapted from Kreutzberg (1996). 
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and  that  there  is  more  likely  a  morphological  continuum,  with  different  triggers 
having subtly different effects upon microglia.  
 
1.2.3. Microglial activation 
 
Microglia  may  be  activated  by  a  whole  host  of  apparently  structurally  unrelated 
compounds. Microglia are activated in infectious diseases of the CNS, and pathogens 
and pathogen components activate microglia in vitro (Aloisi 2001). Microglia detect 
pathogens by means  of pattern recognition  receptors  (PRRs) on the cell surface, 
which  recognise  so-called  pathogen-associated  molecular  patterns  (PAMPs), 
molecular structures associated with pathogens but not with host cells (Medzhitov 
and Janeway, Jr. 2000). Most PRRs are expressed only at low levels on ramified 
microglia, if at all, and are upregulated upon microglial activation (Aloisi 2001). 
 
The  most  commonly  used  compound  to  stimulate  microglial  activation 
experimentally  in  vitro  and  in  vivo  is  the  bacterial  endotoxin  lipopolysaccharide 
(LPS), the major mediator of shock induced by gram-negative bacteria (Rietschel et 
al.  1994).  This  therefore  mimics  gram-negative  bacterial  infection  of  the  brain, 
which is prevented under normal circumstances by the BBB. The PRRs Toll-like 
receptor  4  (TLR4)  (Poltorak  et  al.  1998;  Qureshi  et  al.  1999)  and  cluster  of 
differentiation  (CD)  14  (Wright  et  al.  1990;  Haziot  et  al.  1996)  expressed  by 
microglia and other cells of the monocyte/macrophage lineage are involved in the 
detection of LPS, along with the accessory proteins MD2 (Shimazu et al. 1999) and 
LPS-binding protein (LBP) (Tobias et al. 1989; Schumann et al. 1990).  
 
Other PRRs expressed by microglia include TLR2, TLR9 and the mannose receptor. 
In addition, microglial receptors exist allowing detection and phagocytosis of other 
pathogens  which  have  been  opsonised  (coated)  by  soluble  components  of  the 
immune system (Aloisi 2001). The receptors expressed by microglia which allow 
detection of pathogens are summarised in table 1.1. 
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Receptor 
 
 
Pathogen-associated molecular 
pattern recognised 
References 
TLR2  gram-positive bacterial 
peptidoglycans and lipoteichoic 
acids 
Schwandner et al.( 1999); 
Yoshimura et al. (1999) 
TLR4  gram-negative bacterial endotoxin, 
LPS 
Poltorak et al.( 1998); 
Qureshi et al. (1999) 
TLR9  bacterial DNA  Hemmi et al. (2000) 
CD14  LPS  Wright et al. (1990);  
Haziot et al. (1996) 
Mannose 
receptor 
pathogen-specific oligosaccharides  Linehan et al. (2000) 
Fc receptors  pathogens opsonised by 
immunoglobulins 
Aloisi (2001) 
Complement 
receptors 
pathogens opsonised by 
complement 
Aloisi (2001) 
Complement 
receptor 3 
- pathogens opsonised by 
complement component C3b 
- diverse protein and non-protein 
pathogen components 
Ehlers (2000) 
 
 
Table  1.1.  Receptors  expressed  by  microglia  allowing  the  detection  of  pathogens.  CD, 
cluster of differentiation; DNA, deoxyribonucleic acid; LPS, lipopolysaccharide; TLR, Toll-
like receptor. 36 
 
Microglia  react  rapidly  to  local  tissue  damage,  suggesting  that  a  signal  from 
damaged  cells  may  be  sufficient  to  activate  microglia  (Gehrmann  et  al.  1991; 
Morioka et al. 1992). Accordingly, ATP, large amounts of which are released mainly 
by astrocytes under pathological conditions (Ciccarelli et al. 2001), has been shown 
in vitro to affect microglial morphology (Honda et al. 2001), to cause elevation of 
intracellular Ca
2+ (McLarnon et al. 1999), and release of cytokines (Inoue 2002), and 
to have a chemotactic effect (Honda et al. 2001; Davalos et al. 2005). These effects, 
characteristic  of  microglial  activation,  may  be  mediated  via  the  P2Y  purinergic 
receptor  (Honda  et  al.  2001;  Davalos  et  al.  2005),  or  the  P2X7  ATP-gated  ion 
channel  (Monif  et  al.  2009).  Elevated  extracellular  K
+,  also  indicative  of  tissue 
damage, depolarises the membrane potential of microglia and may enhance aspects 
of microglial  activation  (Colton et al. 1994a; Abraham et al. 2001). In addition, 
inwardly-rectifying K
+ channels expressed by microglia (Kettenmann et al. 1990; 
Norenberg  et  al.  1994),  current  through  which  is  enhanced  under  conditions  of 
elevated K
+, may be involved in cytokine-dependent proliferation and differentiation 
(Schlichter et al. 1996; Shirihai et al. 1996).  
 
The antibody ED1 may be used experimentally to detect activated microglia. ED1 
recognises  the  rat  homologue  of  the  lysosomal  glycoprotein  CD68  (Holness  and 
Simmons 1993; Damoiseaux et al. 1994), the expression of which is upregulated 
following microglial activation (Tran et al. 1998). 
 
1.2.4. Microglia and the immune system 
 
Like other cells of the mononuclear phagocyte lineage, microglia are equipped to 
phagocytose pathogens, dead cells and other debris (Giulian and Baker 1986; Streit 
and Kreutzberg 1988; Rieske et al. 1989), and to communicate with other cells of the 
immune system. The most evident microglial phagocytosis is undertaken by ovoid 
foamy macrophages (Streit and Kreutzberg 1988; Rieske et al. 1989). Phagocytosis 
of  pathogen  components  and  subsequent  processing  leads  to  the  presentation  of 
antigens  by  the  major  histocompatibility  complex  (MHC)  molecules  for  T  cell 
activation  (Cash  et  al.  1993).  This  is  accompanied  by  an  upregulation  of  other 
molecules associated with activation, including a number of cell adhesion molecules, 
which allow microglia to further detect and internalise diverse debris (Raivich et al. 37 
 
1999). The removal of apoptotic cells and debris is important in the homeostasis of 
the CNS environment. The process of phagocytosis leads to antigen presentation and 
may induce a general pro-inflammatory phenotype in the microglia. 
 
The main mode of communication between microglia and other cells of the immune 
system is through the secretion of cytokines and the expression of cytokine receptors 
(see  fig.  1.2).  This  may  mediate  recruitment  of  further  microglia  and  peripheral 
immune cells, and affect the activation state of such cells. Cytokines are broadly 
grouped  into  pro-inflammatory  and  anti-inflammatory  mediators.  Microglial 
activation may induce the release of cytokines of both groups, and alter cytokine 
receptor expression, depending on the type and intensity of the stimulus. 
 
Microglia express receptors for the lymphocyte-derived cytokine interferon  (IFN) 
and  respond  to  it  both  in  vitro  and  in  vivo  with  an  upregulation  in  microglial 
expression of MHC molecules, suggesting enhanced antigen presenting ability (Vass 
and Lassmann 1990; Loughlin et al. 1992; Panek and Benveniste 1995; Deckert-
Schluter  et  al.  1999).  IFN  appears  to  amplify  the  pro-inflammatory  effects  of 
microglial activators (Colton et al. 1994b; Hausler et al. 2002) and is often used in 
vitro as a co-stimulator for LPS-mediated activation. 
 
The  effects  of  anti-inflammatory  cytokines  may  be  largely  attributed  to  the 
downregulation  of  pro-inflammatory  cytokines  or  functional  antagonism  of  their 
effects (Hanisch 2002). For example, LPS has been shown to induce transforming 
growth factor β (TGFβ) production by microglia, through a tumour necrosis factor α- 
(TNFα-) dependent pathway. TGFβ was then shown to inhibit LPS-stimulated TNFα 
production  (Chao  et  al. 1995). A self-regulating mechanism  may  therefore exist, 
with the potential to control inflammation.  
 
1.2.5. Expression and release profiles of activated microglia 
 
Different microglial receptors and signalling pathways are involved in the detection 
of and response to different molecules which activate microglia (Pocock and Liddle 
2001). It is therefore likely that different microglial activators cause the upregulation 
of specific genes and therefore lead to slightly different activated phenotypes. The38 
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Figure 1.2. (previous page) Microglial expression and release profiles. Microglia express 
receptors  allowing  the  detection  of  cytokines,  chemokines,  neurotransmitters  and  other 
signalling  molecules,  and  may  release  cytokines,  chemokines,  other  pro-  and  anti-
inflammatory  molecules  and  cytotoxic  compounds.  ATP,  adenosine  triphosphate;  EP 
receptor, E-prostaglandin receptor; FasL, Fas ligand; GABA, -aminobutyric acid; IFN, 
interferon-; iGluR, ionotropic glutamate receptor; IL, interleukin; IP-10, IFN-inducible 
protein-10;  MCP,  monocyte  chemoattractant  protein;  mGluR,  metabotropic  glutamate 
receptor; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; P2X 
receptor,  metabotropic  purinergic  receptor;  P2Y  receptor,  purinergic  ligand-gated  ion 
channel; PGE2, prostaglandin E2; R, receptor; RANTES, regulated upon activation, normal 
T  cell  expressed  and  secreted;  RNS,  reactive  nitrogen  species;  ROS,  reactive  oxygen 
species; TGFβ, transforming growth factor β; TNFα, tumour necrosis factor α.
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receptors  which  may  be  expressed,  and  compounds  which  may  be  released  by 
microglia  are  summarised  in  figure  1.2.  Microglial  activation  may  lead  to  the 
expression of the so-called death receptor, Fas, and its ligand FasL, and the release 
of  reactive  oxygen  and  nitrogen  species  (ROS  and  RNS),  proteolytic  enzymes, 
prostanoids  and  glutamate.  Microglia  may  release  glutamate  through  increased 
expression  or  activity  of  the  cystine/glutamate  antiporter  xc
-  or  the  reversal  of 
excitatory  amino  acid  transporters.  The  regulation  of  these  transporters  and 
implications for CNS disease are discussed in detail in section 1.4.2 below. 
 
The release of ROS and RNS by activated microglia represents a cytotoxic attack 
mechanism against invading pathogens. Activated microglia may express inducible 
nitric oxide synthase (iNOS), allowing the production of the vasodilator and non-
specific inflammatory mediator nitric oxide (NO) from L-arginine (Chao et al. 1992; 
Ding et al. 1997; Possel et al. 2000). Microglial activation may also induce the rapid 
generation of superoxide by reduced nicotinamide adenine dinucleotide phosphate 
(NADPH)  oxidase,  known  as  the  respiratory  burst  (Colton  and  Gilbert  1987; 
Klegeris and McGeer 1994; Sankarapandi et al. 1998). Either NO or superoxide may 
be  cytotoxic  alone;  alternatively  they  may  combine  to  form  the  highly  reactive 
species  peroxynitrite  (Ischiropoulos  et  al.  1992;  Szabo  et  al.  1997;  Noack  et  al. 
1999). ROS and RNS have the potential to cause bystander damage and death, by 
reacting with proteins, nucleic acids and lipids of neighbouring cells (Valko et al. 
2007).  Peroxynitrite  has  dual  effects  upon  mitochondrial  energy  metabolism;  its 
actions  causing  the  collapse  of  the  mitochondrial  membrane  potential  and 
dysregulation of mitochondrial respiration, leading to energy crisis and cell death, 
are  well-characterised  (Bolaños  et  al.  1995).  However,  in  some  cell  types 
peroxynitrite may be protective through the upregulation of the pentose phosphate 
pathway, leading to enhanced NADPH levels to regenerate the reduced form of the 
antioxidant  glutathione  (Almeida  et  al.  2005).  Alternatively,  NO  may  cause  an 
upregulation  of  glycolysis,  leading  to  compensatory  ATP  production  and 
maintenance of the mitochondrial membrane potential (Almeida et al. 2001). This 
suggests that under some conditions ROS and RNS may have a role in the control of 
energy metabolism (Bolaños et al. 2008). 
 
Pro-inflammatory cytokines  
TNFα
16, IL-1β
17,18, IL-12
7,19, IL-18
3,20 
Anti-inflammatory cytokines 
TGFβ
21, IL-10
6, IL-15
22 
Degradation and 
remodelling of 
extracellular matrix 
Excitotoxicity 
Oxidative 
glutamate toxicity 
Vasodilation and 
vasoconstriction 
Development and 
resolution of 
inflammation 41 
 
1.2.6. Neurone-microglia interactions: neuroprotection and neurotoxicity 
 
The different resident cell types of the CNS are all closely associated in vivo, and 
intercellular communication mechanisms between cells are likely to be complex. As 
the  only  resident  immune  cell  in  the  otherwise  largely  immune-privileged  CNS 
(Aloisi  et  al.  2001),  microglia  are  crucial  in  the  protection  of  neurones  from 
potentially  damaging  insults  (Streit  2002).  As  described  previously,  damaged 
neurones are able to elicit a microglial response by the release of ATP and K
+, as 
well as chemokines such as fractalkine (CX3CL1) (Chapman et al. 2000). Excessive 
inflammation may however be harmful, and the CNS may provide a general anti-
inflammatory environment through the production of anti-inflammatory cytokines 
and neuropeptides, and the expression of FasL to induce apoptosis of Fas-expressing 
immune cells crossing the BBB (Bechmann et al. 1999; Aloisi et al. 2001). Evidence 
also  exists  that  neurones  may  directly  downregulate  the  level  of  microglial 
activation.  This  may  occur  by  direct  contact  between  neuronal  CD200  and  the 
inhibitory CD200 receptor expressed by microglia (Hoek et al. 2000), or by release 
of soluble mediators by neurones. Soluble neurone-derived CD22 has been shown to 
bind  to  microglial  CD45  and  inhibit  LPS-induced  TNFα  production  (Mott  et  al. 
2004),  and  the  neurotrophins  nerve  growth  factor  (NGF)  and  neurotrophin-3  act 
upon  microglial  neurotrophin  receptors  to  decrease  expression  of  MHC  class  II 
molecules  (Neumann  et  al.  1998).  The  lack  of  such  neurone-derived  inhibitory 
stimuli may indicate neuronal damage and may be an important step in the initiation 
of microglial activation. 
 
The  phagocytic  capability  of  microglia  makes  them  important  in  the  everyday 
maintenance of homeostasis in the CNS environment, clearing apoptotic cells and 
other debris, without necessarily transforming to a rounded phenotype (Streit et al. 
1999).  During  the  resolution  of  inflammation,  microglia  are  important  in  the 
promotion  of  repair.  Microglia  make  direct  contact  with  stressed  neurones  and 
perform synaptic stripping (Neumann et al. 2006; Trapp et al. 2007), phagocytose 
damaged or dead cells, and release anti-inflammatory cytokines such as TGFβ (Chao 
et al. 1995; Kreutzberg 1996). In addition, microglia may enhance neuronal survival; 
unstimulated  microglia  have  been  shown  to  release  neurotrophic  factors  such  as 
PDGF, epidermal growth factor, basic fibroblast growth factor, hepatocyte growth 42 
 
factor and brain-derived neurotrophic factor (BDNF) in vitro (Araujo and Cotman 
1992; Presta et al. 1995; Hamanoue et al. 1996; Nakajima et al. 2001a; Morgan et al. 
2004). 
 
However, it is clear from the previous discussions that by eliciting and amplifying an 
immune  response,  microglia  may  directly  or  indirectly  cause  neuronal  damage. 
Indeed a number of microglial release products are directly neurotoxic. Activated 
microglia  produce  NO  and  superoxide  as  an  anti-microbial  defence  (Colton  and 
Gilbert 1987; Chao et al. 1992), but neurones are susceptible to oxidative damage, 
particularly the inhibition of mitochondrial energy metabolism (Bolaños et al. 1995). 
The  neuronal  antioxidant  capacity  is  relatively  low  (Wang  et  al.  2003a),  and 
neurones  lack  the  ability  to  upregulate  glycolysis  to  maintain  the  mitochondrial 
membrane  potential  (Almeida  et  al.  2001).  Enhanced  release  of  glutamate  by 
activated microglia may be toxic to neurones through overactivation of glutamate-
gated ion  channels and the subsequent intracellular pathways (Piani  and Fontana 
1994; Barger and Basile 2001). FasL and TNFα released by activated microglia have 
the ability to activate apoptotic cascades in cells expressing the appropriate receptors 
(Tartaglia et al. 1993; Kischkel et al. 1995). In vitro studies consistently demonstrate 
that the neurotoxicity of LPS is entirely microglia-dependent (Boje and Arora 1992; 
Kim et al. 2000; Taylor et al. 2003; Zujovic and Taupin 2003), and mice lacking 
TLR4, the LPS recognition receptor, which is only expressed by microglia in the 
CNS did not suffer LPS-induced neuronal injury (Lehnardt et al. 2003). 
 
1.2.7. Microglia in ageing, neuroinflammatory and neurodegenerative disease 
 
Proteins  which  are  upregulated  in  neurological  diseases  characterised  by  an 
inflammatory component have also been found to activate microglia in vitro. These 
include  components  of  the  blood  which  may  be  encountered  at  elevated 
concentrations by microglia following BBB damage, such as albumin (Si et al. 1997; 
Hooper  et  al.  2005,  2009)  and  thrombin  (Choi  et  al.  2003),  as  well  as  proteins 
present in the lesions characteristic of particular neurodegenerative diseases, such as 
β amyloid (Aβ) and chromogranin A (CGA) in Alzheimer‟s disease (Taupenot et al. 
1996; McDonald et al. 1997; Kingham et al. 1999; Combs et al. 2001; Le et al. 
2001),  and  Prion  proteins  in  spongiform  encephalopathies  (Brown  et  al.  1996; 43 
 
Combs et al. 1999; Fabrizi et al. 2001). Indeed, in vitro evidence suggests that the 
neurotoxicity  of  albumin  (Hooper  et  al.  2009)  and  CGA  (Kingham  et  al.  1999; 
Taylor et al. 2002) is dependent upon the presence of microglia. Such observations 
clearly  implicate  microglia  and  the  downstream  consequences  of  microglial 
activation in disease pathogenesis. 
 
In chronic neuroinflammatory diseases, microglia are continually exposed to such 
disease-related  activators.  This  leads  to  chronic  activation  of  microglia  as  they 
persistently attempt to clear these entities through the release of toxic compounds, 
the  initiation  and  maintenance  of  an  inflammatory  response  and  an  upregulated 
phagocytic activity (Eikelenboom et al. 2002). The release of chemokines and pro-
inflammatory  cytokines  recruits  and  activates  further  microglia  by  a  positive 
feedback  mechanism  (Aloisi  2001;  Hanisch  2002)  and  stimulates  microglial 
proliferation  (Graeber  et  al.  1988;  Ajami  et  al.  2007),  thus  causing  microglial 
expansion at the site of the original lesion.  
 
Such an enlarged population of chronically activated microglia may cause bystander 
damage to neurones and other cells and structures within the CNS, thus contributing 
to pathology (Lehnardt et al. 2003; Heneka and O'Banion 2007). Microglial release 
products such as TNFα, glutamate, proteases and ROS and RNS derived from NO 
and superoxide have all been implicated in such bystander damage.  Interestingly 
however,  a  recent  paper  has  demonstrated  a  neuroprotective  effect  of  microglia-
derived TNFα following ischaemia (Lambertsen et al. 2009), challenging the widely-
accepted  view  that  TNFα  has  neurotoxic  actions  in  the  pathogenesis  of 
neuroinflammatory  diseases.  This  also  highlights  the  complexity  of  microglial 
involvement in neurological disease. 
 
In ageing mouse brain, an upregulation of genes associated with inflammation was 
observed  (Lee  et  al.  2000),  including  some  factors  associated  with  microglial 
activation. Microglia in vivo tend to become progressively more activated with age 
(Streit et al. 1999), indeed, an age-related microglial dystrophy has been reported in 
human brain (Streit et al. 2004). These observations may have implications for age-
related neuroinflammatory and neurodegenerative diseases. 
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The main neuroinflammatory conditions relevant to this thesis are multiple sclerosis 
(MS) and Alzheimer‟s  disease (AD). These diseases, and specifically the role of 
microglia in disease, are discussed in more detail in the next section. 
 
1.3. Neuroinflammatory disease 
 
Although  microglia  are  implicated  to  some  extent  in  the  vast  majority  of  CNS 
diseases, particularly those involving inflammation, this thesis focuses largely upon 
their role in multiple sclerosis and Alzheimer‟s disease. Detailed descriptions will 
therefore be limited to these conditions. 
 
1.3.1. Multiple sclerosis 
 
Multiple  sclerosis  (MS)  is  thought  to  be  an  autoimmune  disorder  of  the  CNS 
(Steinman  1996;  Zamvil  and  Steinman  2003).  It  consists  of  inflammation  and 
neurodegeneration and is characterised by areas of focal demyelination and axonal 
damage within the white matter (Conlon et al. 1999; Compston and Coles 2002). 
Most cases of MS begin with a relapsing-remitting (RR) disease. RRMS consists of 
acute  inflammatory  attacks,  with  some  axonal  loss  but  little  obvious  functional 
deterioration between relapses. RRMS usually develops into a chronic secondary 
progressive  disease  with  time,  characterised  by  a  loss  of  the  relapsing-remitting 
pattern,  less  inflammation  and  more  axonal  degeneration,  along  with  clear 
accumulating disability (Bjartmar and Trapp 2001). In approximately 10% of cases 
MS  takes  a  primary  progressive  course,  a  chronic  disease  characterised  by  less 
inflammation, more neurodegeneration, clear functional deterioration and a lack of 
acute attacks (Zamvil and Steinman 2003). 
 
There is approximately a 25% concordance rate of MS among monozygotic twins 
(Ebers  et  al.  1986;  Mumford  et  al.  1994),  suggesting  that  both  genetic  and 
environmental factors influence disease development. The major histocompatibility 
complex (MHC) has consistently been shown to be associated with MS (Haines et 
al. 1996; Sawcer et al. 1996, 2005; Hafler et al. 2007). This genetic locus contains 
the  genes  for  the  human  leukocyte  antigen  (HLA),  responsible  for  antigen 45 
 
presentation  to  CD4
+  T  cells,  as  well  as  those  for  TNFα,  components  of  the 
complement  cascade  and  myelin  oligodendrocyte  glycoprotein,  all  of  which  are 
involved in MS pathogenesis (Zamvil and Steinman 2003). Environmental factors 
hypothesised to have a role in the development of MS include infectious agents, 
particularly Epstein-Barr virus (EBV), sunlight exposure and vitamin D levels, and 
increased sanitation levels, which, by limiting exposure of the immune system to 
pathogenic antigens, may lead to compromised development of the immune system 
and predispose to autoimmunity (Fleming and Cook 2006; Giovannoni and Ebers 
2007). 
 
Current MS treatments are mainly immunomodulatory and immunosuppressive, and 
act on the inflammatory stage, decreasing the duration and frequency of relapses. 
Immunosuppression  may  however  have  serious  side  effects.  Some  patients, 
particularly  those  with  progressive  MS,  do  not  respond  to  these  treatments,  and 
although  they  reduce  inflammation,  they  do  not  appear  to  prevent  subsequent 
neurodegeneration associated with the later progressive stages of disease. 
 
1.3.1.1. MS pathology and pathogenesis 
 
The  white  matter  lesions  characteristic  of  MS  correspond  to  areas  of  focal 
demyelination, a consequence of immune attack against myelin antigens (Conlon et 
al.  1999).  Such  lesions  are  characterised  by  the  presence  of  inflammatory 
lymphocytes, as well as macrophages and activated microglia containing phagocytic 
vesicles of myelin debris (Adams et al. 1989). During the inflammatory phase of 
MS, a limited amount of remyelination by oligodendrocytes may occur, giving rise 
to shadow plaques (Prineas et al. 1993), so-called because of their reduced myelin 
density, and therefore less prominent myelin-specific staining compared with normal 
white matter. Axonal damage only occurs in the presence of demyelination, and may 
be due to the lack of protection and trophic support by the myelin sheath (Kornek et 
al. 2000; Wilkins et  al. 2001;  Compston  and Coles 2002), or to  an  independent 
process initiated by inflammatory mediators (Coleman and Perry 2002; Centonze et 
al. 2009). Following damage to axons, the distal portion of the neurone is subject to 
Wallerian degeneration, and the cell body may also die due to lack of connections 
with other neurones (Coleman and Perry 2002). Some lesions have been observed 46 
 
which  lack  significant  inflammatory  pathology  but  are  instead  characterised  by 
oligodendrocyte  apoptosis,  perhaps  representing  a  different  disease  stage  or 
heterogeneity in the mechanisms of demyelination (Lucchinetti et al. 2000; Barnett 
and Prineas 2004). 
 
In the initial stages of MS and the animal model of MS, experimental autoimmune 
encephalomyelitis  (EAE),  T  cells  specific  for  myelin  proteins  encounter  their 
antigens  in  the  CNS,  undergo  clonal  expansion  and  recruit  other  immune  cells, 
initiating  an  inflammatory  cascade.  The  epitope  spread  theory  suggests  that  as 
inflammation and demyelination progress, new, previously cryptic, myelin epitopes 
appear,  which  recruit  their  own  specific  T  cells  and  exacerbate  inflammation 
(Lehmann et al. 1992). 
 
There are two theories relating to the apparent link between MS development and 
viral  or bacterial infection.  The most long-standing of these is  that of molecular 
mimicry.  Peptides  derived  from  EBV  can  activate  human  myelin  basic  protein- 
(MBP-)  specific  T  cells  (Wucherpfennig  and  Strominger  1995)  and  bind  MBP-
specific autoantibodies (Wucherpfennig et al. 1997), indicating portions of structural 
homology and suggesting that following EBV infection, presentation of particular 
EBV  antigens  could  induce  an  autoimmune  response.  Superantigens,  viral  and 
bacterial exotoxins which bind to the T cell receptor and non-specifically activate T 
cells (Marrack and Kappler 1990), have also been implicated in MS development 
and relapse rate. Bacterial superantigens have the ability to activate T cells specific 
for myelin proteins, and may modulate the induction, symptoms and relapse rate of 
EAE (Brocke et al. 1993; Matsumoto and Fujiwara 1993; Schiffenbauer et al. 1993; 
Soos et al. 1995; Zhang et al. 1995). 
 
1.3.1.2. Microglia in MS 
 
As  the  resident  immune  cell  of  the  brain,  it  is  not  surprising  that  microglia  are 
implicated in the pathogenesis of a disease with such a clear immune involvement as 
MS. Indeed, MS lesions are characterised by infiltration of activated microglia and 
macrophages, which phagocytose myelin breakdown products and are consequently 
filled with lipid-containing vesicles (Adams et al. 1989). Microglia express MHC 47 
 
class II molecules and are thought to participate in the initiation of inflammation and 
demyelination in MS by presenting the autoantigen to CD4
+ T cells (Matsumoto et 
al. 1992; Bo et al. 1994). The identification of MHC class II molecules as a genetic 
risk  factor  for  MS  (Sawcer  et  al.  2005;  Hafler  et  al.  2007)  may  indicate  the 
importance of this interaction in MS pathogenesis.  
 
Soluble factors released by microglia may also be important in the pathogenesis of 
MS. The cytokine TNFα is expressed at high levels by activated microglia in EAE 
and MS lesions (Selmaj et al. 1991; Baker et al. 1994; Renno et al. 1995), and is 
implicated in oligodendrocyte death and myelin damage (Selmaj and Raine 1988; 
D'Souza et al. 1995; Akassoglou et al. 1998). Microglial TNFα has been shown to 
induce oligodendrocyte death through direct contact between cell surface TNFα and 
oligodendrocyte TNF receptor 1 (Zajicek et al. 1992; Merrill et al. 1993), which 
couples to a signal transduction pathway culminating in apoptosis (Tartaglia et al. 
1991,  1993;  Chinnaiyan  et  al.  1996).  Oligodendrocyte  TNF  receptor  1  may  be 
upregulated in response to stress (Tchelingerian et al. 1995) and in the presence of 
TNFα  (Dopp  et  al.  1997).  TNFα  is  also  implicated  in  leukocyte  chemotaxis  via 
upregulation  of  chemokine  expression  (Sedgwick  et  al.  2000).  TNFα  induces 
microglial proliferation in vitro in the presence of astrocytes, suggesting a role in 
amplification  of  the  immune  response  (Dopp  et  al.  1997).  Mice  overexpressing 
TNFα suffered a chronic inflammatory demyelinating disease (Probert et al. 1995), 
and injection of TNFα worsens the clinical course of EAE (Kuroda and Shimamoto 
1991; Crisi et al. 1995). Administration of antibodies against TNFα or soluble TNF 
receptors significantly inhibits the development of EAE (Ruddle et al. 1990; Baker 
et  al. 1994; Martin  et  al.  1995; Selmaj  et  al. 1995; Klinkert et  al. 1997). More 
recently, studies with mice lacking TNF receptor 1 have suggested that this receptor 
is essential for the development of clinical signs of EAE (Gimenez et al. 2006). 
Some studies have however reported protective effects of TNFα in EAE (Willenborg 
et al. 1995; Frei et al. 1997; Liu et al. 1998a). This protective role may be due to a 
proliferative effect of oligodendrocyte precursor cell TNF receptor 2 stimulation, 
leading to remyelination (Arnett et al. 2001).  
 
Microglia are both a source and a target of chemokines (Hanisch 2002; Sanders and 
De Keyser 2007), which mediate the recruitment of cells to the lesion site (Sellebjerg 48 
 
and  Sorensen  2003).  Microglia  also  secrete  anti-inflammatory  cytokines  such  as 
TGFβ and IL-10, which play a regulatory role in EAE and MS, downregulating the 
immune  response  (Imitola  et  al.  2005).  Accordingly,  the  presence  of  activated 
microglia appears to be important for remyelination (Diemel et al. 1998; Kotter et al. 
2001; Li et al. 2005). 
 
Activated  microglia  associated  with  lesions  in  MS  and  EAE  express  iNOS  and 
release NO (Okuda et al. 1995; Hill et al. 2004), which has been implicated in a 
number of elements of disease pathogenesis. Indeed, inhibition of iNOS has been 
shown to reduce inflammation, demyelination and axonal necrosis in a mouse model 
of MS (Rose et al. 1998). By dilating cerebral vessels and reducing the velocity of 
blood  flow,  NO  may  facilitate  leukocyte  binding  and  migration  across  the  BBB 
(Smith  and  Lassmann  2002).  Oligodendrocytes  are  highly  susceptible  to  NO-
mediated  damage  in  vitro  (Merrill  et  al.  1993;  Mitrovic  et  al.  1994).  The  NO 
derivative peroxynitrite may cause neuronal death by inhibiting the mitochondrial 
respiratory chain, leading to ATP depletion (Bolaños et al. 1995). Like neurones, 
oligodendrocytes have high rates of oxidative metabolism (Juurlink 1997) and may 
have  low  levels  of  the  antioxidant  glutathione  (Thorburne  and  Juurlink  1996; 
Juurlink et al. 1998; Almazan et al. 2000; Fragoso et al. 2004); evidence suggests 
that  oligodendrocytes  may  also  be  susceptible  to  peroxynitrite-mediated 
mitochondrial  dysfunction  (Scott  et  al.  2003).  NO  exposure  during  periods  of 
electrical  activity  has  been  demonstrated  to  cause  a  block  of  axonal  conduction 
(Smith et al. 2001), with demyelinated and recently remyelinated axons particularly 
susceptible (Redford et al. 1997). The mechanism involved in this conduction block 
is  currently  unclear.  NO  may  however  also  have  immunomodulatory  effects, 
beneficial in the context of MS, such as the inhibition of antigen presentation and T 
cell  proliferation,  and  the  promotion  of  T  cell  apoptosis  in  the  clearance  of 
inflammation (Smith and Lassmann 2002). 
 
Glutamate levels have been found to be elevated in the CSF of MS patients (Stover 
et al. 1997) and in active MS lesions (Srinivasan et al. 2005). Elevated extracellular 
glutamate may cause ionotropic glutamate receptor-mediated excitotoxicity towards 
oligodendrocytes  and neurones;  indeed,  oligodendrocytes  have been shown to  be 
vulnerable  to  kainate-mediated  toxicity  in  vitro  and  in  vivo  (Matute  et  al.  1997; 49 
 
McDonald  et  al.  1998).  In  addition,  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) / kainate receptor antagonists prevented neurone 
and  oligodendrocyte  death,  reduced  disease  pathology  and  ameliorated  clinical 
symptoms  in  EAE  (Pitt  et  al.  2000;  Smith  et  al.  2000).  Receptor-independent 
oxidative glutamate toxicity may also be involved, in which elevated extracellular 
glutamate  competitively  inhibits  oligodendrocyte  cystine  uptake  via  the  xc
- 
glutamate/cystine antiporter, limiting cystine supply for synthesis of the antioxidant 
glutathione, and increasing the susceptibility of the cell to oxidative stress (Rosin et 
al. 2004). As explained previously, a high metabolic rate and low glutathione content 
renders oligodendrocytes highly vulnerable to oxidative stress.  
 
Oligodendrocytes  contribute  to  the  maintenance  of  glutamate  homeostasis  in  the 
white matter, and evidence suggests that oligodendrocyte glutamate transporters may 
be downregulated in MS (Werner et al. 2001; Pitt et al. 2003; Domercq et al. 2005). 
In  addition,  mitochondrial  dysfunction  and  energy  failure,  such  as  may  occur 
following oxidative glutamate toxicity or peroxynitrite exposure in MS, may lead to 
a reversal of glutamate transporters due to a loss of the Na
+ and K
+ gradients across 
the plasma membrane (Nicholls and Attwell 1990), further elevating extracellular 
glutamate  levels.  Interestingly,  TNFα  has  been  shown  to  downregulate 
oligodendrocyte  glutamate  transporters  and  inhibit  glutamate  uptake  (Pitt  et  al. 
2003), and the toxicity of TNFα towards oligodendrocytes was prevented by AMPA 
receptor  antagonists  (Takahashi  et  al.  2003).  These  findings  seem  to  suggest  a 
pathway,  in  which  TNFα-mediated  downregulation  of  oligodendrocyte  glutamate 
transporters  elevates  extracellular  glutamate  and  causes  excitotoxic  cell  death  of 
oligodendrocytes through AMPA receptor stimulation, and which may be involved 
in the pathogenesis of MS.  However, since other cytokines and chemokines and NO 
have  also  been  implicated  in  MS  pathogenesis,  alongside  a  clear  immune 
involvement, the pathway leading to the pathology associated with MS is likely to be 
much  more  complicated,  involving  oligodendrocytes,  neurones,  microglia  and 
infiltrating immune cells. 
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1.3.1.3. Albumin as an in vitro model of BBB damage in MS 
 
By  its  nature,  the  BBB  excludes  large  molecules  including  blood-borne  proteins 
from  the  brain.  Albumin,  the  most  abundant  plasma  protein,  is  present  at  a 
concentration  of  35  –  50  mg.ml
-1  in  the  plasma,  but  at  an  approximately 
thousandfold lower concentration in the CNS under normal circumstances (Hooper 
et  al.  2005).  Thus,  a  damaged  or  dysfunctional  BBB  may  expose  the  brain  to 
abnormally high levels of proteins such as albumin. MS lesions usually occur in 
close proximity to blood vessels (Adams et al. 1989), and have been found to be 
associated with BBB dysfunction (Gay and Esiri 1991; Vos et al. 2005), suggesting 
an  influential  role  for  a  blood-derived  factor  in  MS  pathogenesis.  Indeed, 
extravasation of albumin into the CNS in chronic relapsing EAE, a model of MS, 
was shown to correlate with inflammation and clinical signs of disease (Butter et al. 
1991). Albumin has been shown to cause microglial activation and proliferation in 
vitro (Si et al. 1997; Hooper et al. 2005, 2009), suggesting a role of albumin in the 
initiation of an inflammatory response at the site of the plaque. 
 
Compromised BBB integrity and elevated CSF albumin levels are also associated 
with other acute and chronic neurodegenerative conditions including Alzheimer‟s 
disease and vascular dementia (Alafuzoff et al. 1983; Skoog et al. 1998; Fiala et al. 
2002), ischaemic stroke (Hornig et al. 1983) and human immunodeficiency virus 
(HIV) infection of the CNS (Kim et al. 2003b; Kanmogne et al. 2007). 
 
Partially purified, “fraction V” albumin (Cohn et al. 1944) contains bound fatty acids 
and  coagulation  factors,  but  has  been  shown  to  have  very  similar  effects  upon 
microglia  as  pure  albumin  (Hooper  et  al.  2005).  Fraction  V  albumin  is  used  to 
activate microglia in vitro in this thesis, to further investigate the effects of albumin 
upon microglia in the context of disease pathogenesis. 
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1.3.2. Alzheimer’s disease 
 
Alzheimer‟s disease (AD) is a neurodegenerative disorder associated with advanced 
age and characterised by memory loss and cognitive impairment. The characteristic 
histopathological features of AD are extracellular plaques of insoluble β amyloid 
(Aβ) (Masters et al. 1985) and intracellular accumulations of hyperphosphorylated 
tau, known as neurofibrillary tangles (NFTs) (Goedert et al. 1988), both of which are 
predominantly  found  in  the  hippocampus  and  cortex.  These  aggregates  are 
accompanied by activated microglia and reactive astrocytes, neuronal cell death and 
vascular  damage.  Definite  diagnosis  of  AD  is  only  possible  post-mortem,  with 
confirmation of the presence of the plaques and tangles characteristic of the disease. 
 
1.3.2.1. Aβ and the amyloid cascade hypothesis 
 
The main constituent of extracellular plaques in AD, Aβ, is produced by proteolytic 
cleavage of β amyloid precursor protein (APP) (see fig. 1.3). APP may be cleaved by 
three protease complexes, termed α, β and  secretase (Checler 1995). Cleavage of 
the extracellular domain of APP by α secretase occurs within the Aβ peptide region, 
releasing an apparently harmless fragment which cannot yield Aβ. An alternative 
cleavage of APP by the sequential actions of β and  secretase produces the Aβ 
peptide (Checler 1995). Whilst α and β secretases usually cleave APP at a specific 
dipeptide  bond,    secretase  cleavage  does  not  appear  to  be  as  precise,  and  the 
resulting Aβ peptide may be 39 to 42 amino acids in length (Checler 1995). The 
presenilins, mutations of which have been linked with AD susceptibility (Rogaev et 
al. 1995; Sherrington et al. 1995; Wisniewski et al. 1995), have been shown to form 
part of the  secretase complex, directly implicating these proteins in Aβ production 
(Wolfe et al. 1999; Kimberly et al. 2000). Aβ may exist as soluble monomers or 
aggregate into insoluble oligomers, as found in Aβ plaques (Soto 1999). It has been 
demonstrated  in  vitro  that  the  peptide  of  42  amino  acids  (Aβ1-42)  has  a  higher 
propensity to aggregate and is the predominant species found in Aβ plaques (Burdick 
et al. 1992; Jarrett et al. 1993). 
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Figure 1.3. Diagrammatic representation of the cleavage of amyloid precursor protein by 
secretases. Amyloid precursor protein (APP) is a transmembrane protein, which may be 
cleaved by α secretase or by β and  secretase. Only β and  secretase cleavage leads to the 
production of β amyloid peptide. The approximate cleavage sites of α, β and  secretase are 
indicated by α, β and , respectively. 
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The amyloid cascade hypothesis is probably the most well-known and influential 
theory  regarding  AD  pathogenesis.  This  hypothesis  states  that  Aβ  produced  by 
abnormal APP processing is the causative agent in AD (Hardy and Higgins 1992; 
Hardy  and  Selkoe  2002).  The  formation  of  Aβ  plaques  is  said  to  precede  the 
appearance  of  NFTs,  neuronal  death,  vascular  damage  and  cognitive  impairment 
(Hardy  and  Higgins  1992).  Indeed,  familial  AD  is  associated  with  mutations 
affecting the processing of APP and favouring the production of Aβ1-42 (Chartier-
Harlin et al. 1991; Goate et al. 1991; Murrell et al. 1991; Hendriks et al. 1992; 
Mullan et al. 1992; Scheuner et al. 1996).  
 
The neurotoxicity of aggregated Aβ has been demonstrated in vitro (Yankner et al. 
1990;  Rapoport  et  al.  2002),  and  may  be  due  to  the  loss  of  antioxidant  and 
neuroprotective properties of monomeric Aβ (Zou et al. 2002), or the binding of 
transition metal ions and catalysis of oxygen radical generation (Huang et al. 1999; 
Zou et al. 2002). The amyloid cascade hypothesis of AD pathogenesis is however 
not  universally  accepted;  it  has  been  hypothesised  that  Aβ  plaques  may  be  a 
consequence of the disease process rather than the primary aetiological factor (Smith 
et  al.  2002;  Lee  et  al.  2004a).  This  is  supported  by  reports  of  Aβ  plaques  in 
apparently  cognitively  normal  individuals  (Vehmas  et  al.  2003).  Thus,  the 
sequestering  of  redox-active  metal  ions  by  Aβ  has  been  suggested  to  be  a 
neuroprotective  measure  (Lovell  et  al.  1998a;  Dong  et  al.  2003).  In  addition, 
observations  suggest  that  neurones  containing  NFTs  may  be  protected  from 
immediate cell death (Morsch et al. 1999). 
 
1.3.2.2. Oxidative stress in AD 
 
Whether or not plaques and tangles cause the cognitive decline associated with AD, 
oxidative stress undoubtedly plays an important role in its pathogenesis. Oxidative 
stress increases with advancing age, and all known risk factors for AD enhance the 
production  of  ROS  and/or  compromise  the  antioxidant  capacity  of  the  CNS 
(Nunomura et al. 2006). The inhibition of ROS production and the promotion of 
antioxidant capabilities have been found to decrease the incidence of AD (Nunomura 
et al. 2006).  
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The protein apolipoprotein E (ApoE) constitutes a genetic polymorphism which has 
been identified as a risk factor for late-onset AD (Saunders et al. 1993). ApoE is 
important in lipoprotein transport and metabolism (Mahley 1988), and of the cells of 
the CNS, ApoE is released at appreciable levels by astrocytes and microglia (Pitas et 
al. 1987; Saura et al. 2003; Mori et al. 2004; Qin et al. 2006). There are three ApoE 
alleles, ApoE2, ApoE3 and ApoE4 (Mahley 1988), and the expression of one or two 
ApoE4  alleles  is  associated  with  increased  risk  of  late-onset  AD  (Alzheimer's 
Disease Collaborative Group 1993; Noguchi et al. 1993; Payami et al. 1993; in 't 
Veld et al. 2001). The difference between the three alleles relates to the presence of 
cysteine or arginine at two positions in the primary structure of the protein. ApoE 
has been shown to possess allele-specific antioxidant activity, the level of which is 
inversely correlated with AD risk (Miyata and Smith 1996). Thus, ApoE2 has the 
highest level of antioxidant activity and ApoE4, the AD-risk allele, the lowest. The 
differing  antioxidant  protection  offered  by  the  ApoE  alleles  may  be  due  to  the 
reducing power of the sulfhydryl group of the cysteine residues, as ApoE2 contains 
two cysteines  and ApoE4 two arginines  (Ramassamy  et  al. 1999). Alternatively, 
different metal ion-binding abilities may be implicated (Ramassamy et al. 1999).  
 
1.3.2.3. Microglia in AD 
 
Microglia and reactive astrocytes are found in the vicinity of Aβ plaques in AD; 
moreover, microglial migration and activation occurs early in the disease process 
(Cagnin et al. 2001; Vehmas et al. 2003). Inflammation has therefore been proposed 
to play a part in the pathogenesis of AD (Blasko et al. 2004; Griffin 2006). Indeed, 
the process of ageing is itself associated with a shift in innate immunity towards a 
more pro-inflammatory state (Blasko et al. 2004). Genetic polymorphisms of the 
inflammatory  cytokines  TNFα  and  IL-1,  both  of  which  may  be  produced  by 
microglia, have been shown to be risk factors for the development of AD (Grimaldi 
et al. 2000; Nicoll et al. 2000; Perry et al. 2001). However, immunoglobulins and T 
cells are not detectable in AD brain, and adhesion molecules on the endothelial cells 
of the BBB which allow leukocyte migration are not upregulated in AD, suggesting 
a lack of involvement of the peripheral immune system (Eikelenboom et al. 2002). 
The extent of the inflammatory response in AD therefore appears to be much more 
localised compared with that in MS, for example.  55 
 
 
Aβ has been shown to be chemotactic for microglia in vitro (Davis et al. 1992; Yan 
et  al.  1996;  Nakai  et  al.  1998;  Le  et  al.  2001),  and  may  stimulate  microglial 
proliferation (Goodwin et al. 1995). Microglia may be activated by Aβ (McDonald 
et  al.  1997;  Combs  et  al.  2001;  Le  et  al.  2001)  and  by  the  secretory  protein 
chromogranin A (CGA), which is upregulated in Aβ plaques (Taupenot et al. 1996; 
Kingham et al. 1999). Activated microglia localised to plaques in AD brain may 
have both beneficial and deleterious effects. 
 
Some studies have implicated microglia in the production of Aβ at the site of senile 
plaques. Aβ has been shown to be present in endoplasmic reticulum in microglia 
associated with plaques, a location associated with protein synthesis and secretion 
rather than phagocytosis (Frackowiak et al. 1992). In addition, exposure to Aβ25-35 or 
proinflammatory stimuli enhanced Aβ release by microglia of the BV-2 cell line 
(Bitting et al. 1996). Activated microglia in rat brain following nerve injury showed 
enhanced  APP  synthesis  (Banati  et  al.  1993),  which  the  authors  interpreted  as 
providing increased substrate for Aβ production and thereby contributing to plaque 
formation. However the function of uncleaved APP is unknown, although recent 
proposals include a role in the regulation of synaptic function (Hoe et al., 2009), or 
activity as a damage-response protein (Hardy 2009). This latter hypothesis suggests 
that  upregulated  APP  synthesis  may  be  a  protective  measure  rather  than  an 
amyloidogenic process.  
 
Microglia may also have detrimental effects through their inflammatory function. 
Indeed, in vitro studies have demonstrated that microglia exposed to Aβ peptides are 
neurotoxic (Meda et al. 1995; Combs et al. 1999, 2001; Qin et al. 2006). Microglia 
stimulated with Aβ25-35 or Aβ1-40 upregulate TNFα (Meda et al. 1995; Yan et al. 
1996;  Yates  et  al.  2000;  Combs  et  al.  2001;  Lue  et  al.  2001).  TNFα  induces 
microglial glutamate release (Piani and Fontana 1994; Takeuchi et al. 2006) and 
subsequent  neurotoxicity  (Takeuchi  et  al.  2006).  Exposure  of  microglia  to  Aβ 
peptides  also  causes  NO  release,  which  appears  to  be  downstream  of  TNFα 
upregulation  and  may  be  dependent  upon  the  priming  of  microglia  by  the 
lymphocyte-derived  cytokine  IFN  (Goodwin  et  al.  1995;  Meda  et  al.  1995; 
Hellendall and Ting 1997; Combs et al. 2001). Notably, microglia isolated from AD 56 
 
brain released higher levels of nitrate, a stable metabolite of NO, than did those from 
control aged brain (Lue et al. 2001). 
 
Aβ peptides can also cause the production of superoxide by the respiratory burst in 
microglia (McDonald et al. 1997; Combs et al. 1999) and macrophages (Klegeris 
and McGeer 1997). If simultaneously produced, NO and superoxide can combine to 
form  the  highly  reactive  anion  peroxynitrite  which  causes  oxidative  damage  to 
proteins,  lipids  and  nucleic  acids.  Accordingly,  hippocampal  neurones  from  AD 
brain show enhanced nitration of tyrosine residues within cellular proteins, indicative 
of peroxynitrite-mediated damage (Good et al. 1996; Smith et al. 1997). 
 
Microglia  stimulated  with  Aβ  peptides  may  also  release  increased  levels  of  the 
proinflammatory cytokine IL-1 (Walker et al. 1995; Yates et al. 2000; Lue et al. 
2001). IL-1 has been shown to increase expression of APP (Fogal and Hewett 2008) 
and has been associated with the formation of both Aβ plaques and NFTs in AD 
(Griffin 2006). IL-1 released by microglia also enhances astrocyte activation and 
proliferation  (Giulian  et  al.  1986),  and,  in  combination  with  IFN  may  lead  to 
microglial iNOS expression and NO release (Ding et al. 1997). 
 
Aggregated  Aβ  has  also  been  shown  to  stimulate  microglial  release  of  the 
chemokines  IL-8,  MCP-1  (CCL2)  and  MIP-1α  (CCL3)  and  the 
macrophage/microglial  growth  factor  macrophage  colony-stimulating  factor  (M-
CSF) (Lue et al. 2001). This suggests that microglia at the site of the plaque amplify 
the  inflammatory  response  by  recruiting  further  microglia  and  macrophages  and 
stimulating their proliferation. Microglia isolated from AD brain also release higher 
levels  of  M-CSF  and  the  complement  pathway  component  C1a  than  those  from 
control aged brain (Lue et al. 2001).  
 
Aβ peptides have been shown to induce microglial glutamate release by increased 
activity  of  the  xc
-  cystine/glutamate  antiporter  system  (Qin  et  al.  2006),  and  by 
reversal  of  the  excitatory  amino  acid  transporters  normally  responsible  for  high-
affinity glutamate uptake (Noda et al. 1999). Interestingly, secreted APP, the result 
of APP cleavage by α or β secretase alone, has also been shown to cause microglial 57 
 
neurotoxicity  through  upregulation  of  the  xc
-  transporter  system  and  subsequent 
enhanced glutamate release (Barger and Basile 2001). 
 
Chromogranin A (CGA), which is also upregulated in Aβ plaques, causes microglial 
and neuronal apoptosis in vitro (Kingham et al. 1999; Hooper and Pocock 2007). In 
microglia,  CGA  has  been  shown  to  induce  iNOS  expression  and  NO  release 
(Taupenot et al. 1996; Kingham et al. 1999; Kingham and Pocock 2000), glutamate 
release (Kingham et al. 1999), and cathepsin B release (Kingham and Pocock 2001), 
all of which contributed to neurotoxicity. However, whilst the neurotoxicity of CGA 
appears  to  be  entirely  microglia-dependent  (Kingham  et  al.  1999;  Taylor  et  al. 
2002), Aβ is directly neurotoxic in addition to its effects upon microglia (Taylor et 
al. 2002, 2003). 
 
Further  evidence  for  a  role  of  inflammation  in  AD  pathogenesis  comes  from 
epidemiological studies, which have demonstrated that chronic use of non-steroidal 
anti-inflammatory drugs (NSAIDs) is associated with a decreased risk of developing 
AD (McGeer et al. 1996; Stewart et al. 1997; in 't Veld et al. 2001). Although a 
history  of  chronic  NSAID  use  did  not  appear  to  affect  the  abundance  of  senile 
plaques in non-demented elderly individuals, it was associated with fewer activated 
microglia at the site of plaques, suggesting that NSAIDs may decrease AD risk by 
reducing  microglial  activation  (Mackenzie  and  Munoz  1998).  Accordingly, 
ibuprofen was found to reduce the numbers of activated microglia associated with 
Aβ plaques and the levels of IL-1β in the brain in a transgenic mouse model of AD 
(Lim et al. 2000). A reduction in plaque numbers in ibuprofen-treated animals was 
also observed (Lim et al. 2000). Ibuprofen and certain other NSAIDs have been 
shown to decrease Aβ production by cytokine-stimulated neurones in vitro (Blasko 
et al. 2001; Sastre et al. 2003), and to decrease Aβ1-42 levels in a mouse model of 
AD, perhaps due to effects upon  secretase activity (Weggen et al. 2001; Eriksen et 
al.  2003).  Evidence  exists  to  suggest  that  this  may  be  mediated  both  by  COX 
inhibition (Qin et al. 2003), and independently of it (Weggen et al. 2001; Eriksen et 
al.  2003).  It  therefore  appears  that  NSAIDs  may  decrease  the  production  of  the 
amyloidogenic forms of Aβ as well as reducing microglial activation, to lower the 
risk of developing AD. 
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On the other hand, microglia may protect against disease progression and cognitive 
decline through the phagocytosis of Aβ (Shaffer et al. 1995; Paresce et al. 1996), 
which  has  been  recently  shown  in  vivo  to  be  dependent  upon  microglial  TLR2 
expression (Richard et al. 2008). In AD brain, microglia have been shown to be 
immunoreactive  for  tau  protein,  suggesting  that  they  may  also  phagocytose 
degenerating NFT-containing neurites (Vehmas et al. 2003). In vitro studies have 
suggested that microglia are the predominant producers of ApoE (Saura et al. 2003; 
Mori  et  al.  2004),  which  appears  to  have  antioxidant  properties,  and  is 
neuroprotective (Qin et al. 2006). A recent study demonstrated that the ability of 
macrophages to degrade Aβ in vitro varied according to the ApoE allele expressed. 
Thus, macrophages expressing ApoE4, a known risk factor for AD development, 
were less efficient than those expressing ApoE2 or ApoE3 at clearing Aβ from brain 
slices derived from APP transgenic mice (Zhao et al. 2009). MMP-2 and 9, both of 
which may be released by microglia, have also been shown in vitro to possess Aβ-
degrading properties (Roher et al. 1994; Backstrom et al. 1996). 
 
TGFβ  is  produced  by  microglia  and  upregulated  under  inflammatory  conditions 
(Constam et al. 1992; da Cunha et al. 1993; Peress and Perillo 1995). Elevated TGFβ 
levels have been detected in the serum and CSF of AD patients (Chao et al. 1994), 
and Aβ plaques and NFTs show TGFβ immunoreactivity (van der Wal et al. 1993; 
Peress and Perillo 1995). TGFβ has been identified as a microglial chemoattractant 
(Yao  et  al.  1990),  and  is  generally  recognised  as  having  neuroprotective  and 
neurotrophic properties (Finch et al. 1993; Flanders et al. 1998). TGFβ has been 
demonstrated to be associated with a lower Aβ plaque load, but increased vascular 
amyloid in aged transgenic mice expressing human APP and in AD (Wyss-Coray et 
al. 2001). TGFβ appeared to enhance microglial activation in transgenic mice and to 
enhance Aβ clearance by microglia in vitro (Wyss-Coray  et al. 2001). However, 
TGFβ  has  also  been  demonstrated  to  enhance  Aβ  production  and  deposition  in 
animal models (Frautschy et al. 1996; Wyss-Coray et al. 1997; Lesne et al. 2003), 
suggesting that the actions of this cytokine may be rather more complicated. 
 
Because Aβ peptides and CGA have been shown to cause microglial activation, and 
both are associated with senile plaques in AD, the effects of both these peptides upon 
aspects of microglial function are investigated in this thesis. Aβ25-35 has been shown 59 
 
to replicate the effects of Aβ1-42 in vitro (Yankner et al. 1990), and is used to activate 
microglia here. 
 
1.3.2.4. Treatment of AD 
 
Current  treatment  of  AD  consists  largely  of  acetylcholinesterase  inhibitors,  to 
improve cognitive function, alongside drugs for the management of mood disorders, 
agitation and psychosis associated with the disease (Citron 2002). However such 
drugs purely treat the symptoms of AD rather than modifying the disease course and 
whilst they may slow disease progression, there is currently no known preventative 
or cure for AD. As described above, long-term use of certain NSAIDs may reduce 
the risk of the development of AD, through reduction of microglial activation and 
amyloidogenic  Aβ  production.  Interestingly,  certain  statins,  often  prescribed  to 
reduce blood  cholesterol levels  in  patients  at  risk of cardiovascular disease, also 
appear to reduce AD risk (Wolozin et al. 2007). 
 
AD  treatment  strategies  currently  in  development  include  those  inhibiting  the 
production of Aβ (Petit et al. 2001; Lanz et al. 2003; Silvestri 2009), and preventing 
abnormal protein-protein interactions which may be involved in plaque formation 
(McLaurin  et  al.  2006;  Wright  2006).  In  addition,  either  active  or  passive 
vaccination against Aβ may ameliorate disease, although the mechanism by which 
this occurs is unknown (Schenk et al. 1999; Bard et al. 2000; DeMattos et al. 2001; 
Melnikova 2007). 
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1.4. Glutamate  
 
The amino acid L-glutamate is the most abundant excitatory neurotransmitter in the 
mammalian CNS. Released at synapses to mediate neurotransmission, its effects are 
mediated  through  ionotropic  and  metabotropic  glutamate  receptors.  Glutamate 
transporters expressed by neurones and glia remove glutamate from the extracellular 
environment,  thus  controlling extracellular  glutamate levels  and the  activation of 
glutamate receptors. 
 
 
 
 
 
 
 
 
Figure 1.4. The structure of L-glutamate 
 
 
Extracellular glutamate concentrations have generally been reported to be between 
0.5 and 5 µM in the rat brain (Benveniste et al. 1984; Lerma et al. 1986; Phillis et al. 
1994; Wahl et al. 1994; Miele et al. 1996; Del Arco et al. 1999; Baker et al. 2002; 
Montiel et al. 2005), as measured by microdialysis and analysis of artificial CSF 
superfusate.  However,  more  recent  studies  have  demonstrated  extracellular 
glutamate  concentrations  in  the  range  25  –  90  nM  in  rat  hippocampal  slices  by 
analysis  of  basal  N-methyl-D-aspartate  (NMDA)  currents  (Cavelier  and  Attwell 
2005; Herman and Jahr 2007; Le Meur et al. 2007). This is closer to the theoretical 
minimum glutamate concentration of ~2 nM calculated based upon the analysis of 
K
+, Na
+ and H
+ ion fluxes and their coupling to glutamate transport (Zerangue and 
Kavanaugh 1996).  
 
Since the studies of John Olney in the 1970s (see Olney 1982; Rothman and Olney 
1986), evidence for the involvement of glutamate toxicity in neurological conditions 
has been rapidly  accumulating. Elevated extracellular glutamate levels have been 
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measured directly in animal models following ischaemia (Benveniste et al. 1984; 
Drejer et al. 1985; Hagberg et al. 1985; Lekieffre et al. 1992; O'Regan et al. 1997; 
Ritz et al. 2004; Homola et al. 2006) and traumatic brain injury (Faden et al. 1989; 
Liu et al. 1991). CSF glutamate levels significantly above control have been detected 
in  patients  suffering  from  ALS,  viral  meningitis,  acute  MS  and  myelopathy 
(Rothstein et al. 1990; Stover et al. 1997). Glutamate toxicity is implicated to some 
extent in the vast majority of acute and chronic neurological conditions, including 
stroke,  epilepsy,  AD,  Parkinson‟s  disease,  MS  and  acquired  immune  deficiency 
syndrome (AIDS) dementia (Lipton and Rosenberg 1994; Doble 1999; Pitt et al. 
2000). 
 
1.4.1. Glutamate receptors  
 
Glutamate receptors fall into two classes, the ionotropic glutamate receptors, which 
are  ligand-gated  cation  channels,  and  the  metabotropic  glutamate  receptors,  G 
protein-coupled  receptors  with  heptahelical  transmembrane  domains.  Figure  1.5 
summarises the glutamate receptor subtypes. 
 
1.4.1.1. Ionotropic glutamate receptors 
 
Ionotropic glutamate receptors (iGluRs) are usually found post-synaptically, where 
they mediate fast synaptic transmission by initiating an action potential in the post-
synaptic neurone upon synaptic glutamate release. iGluRs are separated into three 
subtypes according to the selective ligands originally described: NMDA receptors, 
AMPA receptors and kainate receptors. 
 
In the presence of glutamate, iGluRs mediate entry of Na
+, K
+ and/or Ca
2+ into the 
cell. All iGluRs form functional tetramers (Wu et al. 1996; Mano and Teichberg 
1998; Rosenmund et al. 1998), with NMDA receptors consisting of a combination of 
NR1, NR2A, NR2B, NR2C, NR2D, NR3A and NR3B subunits, and AMPA and 
kainate receptors consisting of GluR1-4 subunits and GluR5-7 and KA1 and KA2 
subunits, respectively (see fig. 1.5) (Dingledine et al. 1999; Kew and Kemp 2005). 
The exact combination of subunits confers specific properties upon iGluRs, such as 
the  Ca
2+  permeability  (Burnashev  et  al.  1995;  Matsuda  et  al.  2002),  channel62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.5.  Glutamate  receptor  subtypes.  The  ionotropic  glutamate  receptors,  classified 
according to the selective ligands originally described, are ligand-gated ion channels. The 
metabotropic  glutamate  receptors  are  G  protein-coupled  receptors  and  are  divided into 
three groups according to their specific properties. 
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conductance (Ciabarra et al. 1995; Howe 1996; Swanson et al. 1996) desensitisation 
kinetics (Herb et al. 1992) and pharmacology (Partin et al. 1993; Ishii et al. 1993; 
Alt et al. 2004).  
  
The activation of postsynaptic iGluRs is crucial for long-term potentiation (LTP) and 
long-term depression (LTD), two forms of synaptic plasticity important in learning 
and memory. LTP is defined as an activity-dependent increase in synaptic strength 
(Bliss and Lomo 1973), while LTD is an activity-dependent decrease in synaptic 
strength (Lynch et al. 1977). However, prolonged activation of iGluRs, as may occur 
in pathological situations where extracellular glutamate levels are elevated, causes an 
NMDA receptor-dependent phenomenon known as excitotoxicity (Choi et al. 1988; 
Frandsen et al. 1989). The high levels of Ca
2+ influx caused by continuous NMDA 
receptor  stimulation  lead  to  the  inappropriate  continual  activation  of  cellular 
processes  regulated  by  Ca
2+,  including  the  activity  of  enzymes  such  as 
phospholipases,  endonucleases  and  proteases,  which  can  damage  cell  structures 
(Choi 1988; Tymianski and Tator 1996). Excess intracellular Ca
2+ may also lead to 
the opening of the mitochondrial permeability transition pore (Schinder et al. 1996). 
Effects  of  the  ensuing  loss  of  the  mitochondrial  membrane  potential  include 
mitochondrial swelling (Reed and Savage 1995; Zamzami et al. 1996), release of 
reactive oxygen species (Zamzami et al. 1995; Schinder et al. 1996) and apoptosis-
inducing factor (Susin et al. 1996), and the uncoupling of ATP synthesis (Vayssiere 
et al. 1994; Reed and Savage 1995; Schinder et al. 1996). Excitotoxicity ultimately 
leads to cell death, and is implicated in the pathogenesis of a number of neurological 
conditions. 
 
Primary cultured microglia and microglial cell lines have been shown to express 
AMPA (Noda et al. 2000; Mayer et al. 2001; Hagino et al. 2004; Christensen et al. 
2006; Liu et al. 2006), kainate (Noda et al. 2000; Yamada et al. 2006) and NMDA 
(Liu et al. 2006) receptor subunits. Agonists of iGluRs have been shown to cause 
electrophysiological  responses  (Noda  et  al.  2000;  Hagino  et  al.  2004;  Liu  et  al. 
2006), immediate early gene expression (Eun et al. 2004), TNFα release (Noda et al. 
2000; Mayer et al. 2001; Hagino et al. 2004), ATP release (Liu et al. 2006) and 
cytoskeletal remodelling (Christensen et al. 2006) in microglia in vitro.  
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Microglia have also been shown to express AMPA and NMDA receptor subunits in 
vivo during rat CNS development (Ong et al. 1996; Kaur et al. 2005), in the rat 
following  transient  forebrain  ischaemia  (Gottlieb  and  Matute  1997),  and  within 
active  demyelinating  plaques  in  human  MS  tissue  (Newcombe  et  al.  2008).  Co-
localisation of kainate receptor subunits with the microglial marker OX-42 has been 
demonstrated in the rat hippocampus following ischaemia (Yamada et al. 2006). 
 
1.4.1.2. Metabotropic glutamate receptors 
 
Metabotropic  glutamate  receptors  (mGluRs)  are  G  protein-coupled  glutamate 
receptors (GPCRs) which are found both pre- and post-synaptically, as well as on 
glial cells. G proteins are so-called because of their interaction with the guanine 
nucleotides guanine triphosphate (GTP) and guanine diphosphate (GDP). Ligation of 
a GPCR by an agonist causes displacement of the G protein-associated GDP by 
GTP, thus activating the G protein and allowing it to interact with target effector 
proteins. Intrinsic GTPase activity of the G protein hydrolyses the GTP to GDP to 
terminate  the  signal  transduction  activity.  Because  of  the  slower  kinetics  of 
metabotropic receptors, these are believed to have more of a modulatory role upon 
synaptic transmission. 
 
To data, eight mGluR subtypes have been identified (Houamed et al. 1991; Masu et 
al. 1991; Abe et al. 1992; Tanabe et al. 1992; Nakajima et al. 1993; Okamoto et al. 
1994;  Saugstad  et  al.  1994;  Duvoisin  et  al.  1995).  These  are  divided  into  three 
groups on the basis of their sequence homology, preferred G protein coupling and 
pharmacology. Group I consists of mGluRs 1 and 5; group II, mGluRs 2 and 3; and 
group III, mGluRs 4, 6, 7 and 8 (fig. 1.5).  
 
1.4.1.2.1. Structure 
 
mGluRs are the largest sub-group of the class C GPCR family, which also includes 
the  Ca
2+-sensing  receptor  (CaR)  (Brown  et  al.  1993),  the  GABAB  receptor 
(Kaupmann et al. 1997), pheromone (Herrada and Dulac 1997; Matsunami and Buck 
1997) and taste receptors (Hoon et al. 1999). Family C GPCRs are considerably 
larger than other known GPCRs. 65 
 
The eight known mGluRs all have a similar structure, illustrated in figure 1.6, and 
exist as functional homodimers (Kunishima et al. 2000). Although mGluRs have 
heptahelical transmembrane domains typical of GPCRs (Bhave et al. 2003), there is 
little homology between mGluR heptahelical domains and those of other  GPCRs 
outside of class C. The glutamate binding site of mGluRs is contained within a large 
bi-lobed N-terminal  domain  (O'Hara  et  al. 1993; Okamoto et  al. 1998; Han and 
Hampson 1999; Kunishima et al. 2000; Peltekova et al. 2000; Malherbe et al. 2001; 
Rosemond et al. 2002; Sato et al. 2003), and agonist binding is thought to trigger 
signal  transduction  by  causing  a  conformational  change  and  altering  interactions 
between the receptors forming the dimer (Kunishima et al. 2000; Tsuchiya et al. 
2002; Sato et al. 2003). The C termini of mGluRs vary widely in length and amino 
acid  sequence,  and  are  thought  to  mediate  interactions  with  other  proteins.  The 
second and third intracellular loops and the intracellular C terminus have all been 
implicated in G protein coupling (Pin et al. 1994; Gomeza et al. 1996; Francesconi 
and Duvoisin 1998; Chang et al. 2000). 
 
1.4.1.2.2. Localisation 
 
All mGluRs are found in the CNS. mGluR6 was thought to be exclusively retinal 
(Nakajima et al. 1993), although its expression has since been reported in astrocytes 
and microglia in vitro (Faden et al. 1997; Wroblewska et al. 1998; Taylor et al. 
2003; Yao et al. 2005; Pinteaux-Jones 2007), and in vivo in certain areas of adult rat 
brain (Faden et al. 1997; Hoang and Hay 2001). 
 
Neuronal group I mGluR expression is predominantly postsynaptic (Martin et al. 
1992), generally being localised to the periphery of the post-synaptic density (Baude 
et al. 1993; Nusser et al. 1994; Vidnyanszky et al. 1994, 1996; Lujan et al. 1996, 
1997). Group II mGluRs are implicated in inhibition of neurotransmission (Hayashi 
et al. 1993; Macek et al. 1996; Kew et al. 2002; Mateo and Porter 2007), and tend to 
be located extrasynaptically (Ohishi et al. 1994; Petralia et al. 1996; Yokoi et al. 
1996; Lujan et al. 1997; Shigemoto et al. 1997), suggesting their involvement in 
heterosynaptic  modulation  (Mitchell  and  Silver  2000;  Chen  and  Bonham  2005). 
Group  III  mGluRs  are  predominantly  located  at  the  presynaptic  active  zone 66 
 
 
 
 
 
Figure 1.6. Diagrammatic representation of the structure of mGluRs. The glutamate binding 
site resides within the large bi-lobed N-terminal region, which is linked to the heptahelical 
transmembrane domains typical of G protein-coupled receptors by a cysteine-rich region. 
The intracellular C-terminal domain varies in length and amino acid sequence between 
mGluR subtypes. Adapted from Kew and Kemp (2005). 
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(Shigemoto et al. 1996, 1997), where they act as inhibitory autoreceptors (Trombley 
and Westbrook 1992; Tanabe et al. 1993; Jane et al. 1994; Takahashi et al. 1996). 
  
Glial cells have also been shown to express mGluRs. Astrocytes express mGluR3 
and mGluR5 (Tanabe et al. 1993; Petralia et al. 1996; Biber et al. 1999; Janssens 
and Lesage 2001; Aronica et al. 2003, 2005; Geurts et al. 2003, 2005), and possibly 
other subtypes at lower levels (Biber et al. 1999; Janssens and Lesage 2001; Yao et 
al. 2005). Oligodendrocytes and their precursors may express mGluR1, mGluR3 and 
mGluR5 (Luyt et al. 2003, 2006; Deng et al. 2004). 
 
Microglia in culture have been shown to express mGluRs of all three groups. Of the 
group I mGluRs, the expression of mGluR5 appears to be more prominent (Biber et 
al. 1999; Byrnes et al. 2009), although mGluR1 mRNA and protein expression have 
also been demonstrated (Pinteaux-Jones 2007; Byrnes et al. 2009). Microglia have 
also been shown to express mRNA and protein for all group II and III mGluRs 
except mGluR7 (Taylor et al. 2002, 2003; Pinteaux-Jones 2007). 
 
1.4.1.2.3. Signalling  
 
Group  I  mGluRs  preferentially  couple  to  phosphoinositide  hydrolysis  by 
phospholipase C through the Gq/11 type of G protein (Houamed et al. 1991; Abe et al. 
1992; Daggett et al. 1995; Joly et al. 1995), whilst mGluRs of groups II and III are 
negatively coupled to adenylate cyclase and cAMP via the G proteins Gi/o (Tanabe et 
al. 1992, 1993; Nakajima et al. 1993; Okamoto et al. 1994; Saugstad et al. 1994; 
Duvoisin et al. 1995). These preferred signalling pathways are illustrated in figure 
1.7. 
 
It  has  become  clear  that  in  reality  mGluR  signalling  is  more  complex  and 
heterogeneous. Coupling of mGluRs to individual signalling pathways may depend 
upon  the  expression  and  co-localisation  of  the  relevant  proteins  within  the  cell. 
mGluRs can couple to G proteins other than their “preferred” type (Aramori and 
Nakanishi  1992;  Joly  et  al.  1995;  Sortino  et  al.  1996;  McCool  et  al.  1998; 
Francesconi  and  Duvoisin  2000;  Thandi  et  al.  2002),  and  may  also  mediate 
signalling independent of G proteins (Heuss et al. 1999; Benquet et al. 1999; Gee68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. The preferred signalling pathways of group I (top) and group II and III (bottom) 
mGluRs. Upon binding of glutamate, mGluRs associate with a G protein, and cause binding 
of GTP to the GTP/GDP binding site. This activates the G protein, allowing it to dissociate 
into Gα and Gβ subunits, and interact with target enzymes. Intrinsic GTPase activity of the 
Gα subunit hydrolyses GTP to GDP + Pi, which causes deactivation and reassociation of 
the G protein. Group I mGluRs preferentially signal through Gq/11, activating PLC, which 
causes conversion of PIP2 to the second messengers IP3 and DAG. Group II and III mGluRs 
preferentially signal through Gi/o, which inhibits the activity of AC and therefore decreases 
cAMP production and PKA activation. AC, adenylate cyclase; ATP, adenosine triphosphate; 
cAMP, cyclic adenosine monophosphate; DAG, diacylglycerol; Gα, G protein α subunit; 
Gβ, G protein β subunit; glu, glutamate; GTP, guanosine triphosphate; GDP, guanosine 
diphosphate;  IP3,  inositol  triphosphate;  mGluR,  metabotropic  glutamate  receptor;  PIP2, 
phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A; PLC, phospholipase C. 
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and Lacaille 2004). Certain sequences within the C terminal region of mGluRs have 
been  shown  to  mediate  interactions  with  other  proteins,  such  as  scaffolding  and 
cytoskeletal proteins, signalling proteins, and other cell surface receptors (for review 
see Enz 2007). Such interactions are likely to be important in targeting the receptor 
to  the  correct  region  of  the  plasma  membrane,  anchoring  the  protein  to  the 
cytoskeleton, and determining interactions with other signalling proteins. 
 
Stimulation of microglial mGluR5 has been demonstrated to lead to increases in 
cAMP levels (Byrnes et al. 2009), suggesting positive coupling to adenylate cyclase 
via a Gs G protein, and also to increases in phosphatidylinositol hydrolysis (Byrnes 
et al. 2009) and elevated intracellular Ca
2+ (Biber et al. 1999), suggesting coupling 
via a Gq/11  G protein. The latter pathway  appears to  mediate mGluR5-dependent 
inhibition of LPS-induced microglial activation (Byrnes et al. 2009). Agonists of 
group  II  mGluRs  decreased  forskolin-stimulated  cAMP  production  in  microglia, 
suggesting negative coupling to adenylate cyclase via a Gi/o G protein (Taylor et al. 
2002). Downstream effects include increased staining with ED1 antibody, suggesting 
microglial activation (Taylor et al. 2002), NFκB activation (Kaushal and Schlichter 
2008), release of TNFα (Taylor et al. 2005; Kaushal and Schlichter 2008) and FasL 
(Taylor et al. 2005), and in vivo, increased BDNF mRNA expression (Venero et al. 
2002), suggesting microglial release of this factor. Stimulation of group III mGluRs 
on microglia also decreased forskolin-stimulated cAMP production  (Taylor  et al. 
2003), suggesting that this receptor is also coupled via Gi/o. Increased microglial 
ED1  staining  compared  with  control  was  observed,  demonstrating  a  degree  of 
microglial activation (Taylor et al. 2003). 
 
1.4.1.2.4. Group I mGluRs 
 
mGluR5 is co-localised with the NMDA receptor post-synaptically (Alagarsamy et 
al.  2002),  through  protein-protein  interactions  at  the  post-synaptic  density  (PSD) 
(Naisbitt et al. 1999; Tu et al. 1999). Stimulation of mGluR5 induces excitatory 
currents and potentiates NMDA receptor currents and associated neuronal responses 
in vitro and in vivo (Pisani et al. 1997; Ugolini et al. 1999; Awad et al. 2000; Salt 
and Binns 2000), and evidence suggests an involvement in LTP (Riedel et al. 1995; 
Manahan-Vaughan et al. 1996; Lu et al. 1997; Naie and Manahan-Vaughan 2004; 70 
 
Neyman  and  Manahan-Vaughan  2008).  Group  I  mGluR  and  mGluR5-specific 
antagonists have been shown to be neuroprotective against a range of insults in vitro 
and in vivo (Buisson and Choi 1995; Henrich-Noack et al. 1998; Bruno et al. 1999, 
2000b;  Battaglia  et  al.  2001,  2002),  likely  due  to  a  downregulation  of  NMDA 
receptor activity and therefore a reduced likelihood of excitotoxicity. 
 
Activation of group I mGluRs has been shown to increase APP metabolism to a 
soluble nonamyloidogenic fragment (Lee et al. 1995), and mGluR5 stimulation has 
been demonstrated to be neuroprotective against Aβ toxicity in neuronal cultures and 
a neuronal cell line (Pizzi et al. 2005). Evidence exists for an increase in cortical 
neuronal mGluR5 expression in AD and aged Down‟s syndrome patients (Oka and 
Takashima  1999),  which  could  be  considered  to  be  a  protective  measure  to 
counteract  Aβ  toxicity.  However,  another  group  reported  a  decrease  in  cortical 
mGluR expression in AD, and a decrease in group I mGluR expression in Lewy 
body disease which correlated with AD-like changes (Albasanz et al. 2005), perhaps 
implicating decreased mGluR expression in AD pathogenesis.  
 
Group I mGluR expression is upregulated in astrocytes associated with MS lesions 
(Geurts et al. 2003; Newcombe et al. 2008). Activated microglia have been shown to 
cause  a  downregulation  of  astrocyte  mGluR5,  which  may  be  due  to  microglia-
derived TNFα and/or IL-1β (Kiefer et al. 1994; Lehrmann et al. 1998; Aronica et al. 
2005; Tilleux et al. 2007). Activation of astrocyte group I mGluRs has been shown 
both to upregulate (Vermeiren et al. 2005, 2006) and to downregulate (Gegelashvili 
et al. 2000; Aronica et al. 2003) their glutamate transporter expression and activity. 
 
Microglial mGluR5, found to be upregulated in activated microglia associated with 
MS lesions (Geurts et al. 2003), may be neuroprotective. Stimulation of mGluR5 
inhibited  a  number  of  aspects  of  LPS-induced  microglial  activation  in  vitro, 
including  ROS  and  NO  production,  microglial  proliferation,  TNFα  release, 
expression of the phagocytosis-related protein galectin-3 and neurotoxicity (Byrnes 
et al. 2009). 
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1.4.1.2.5. Group II mGluRs: neurotoxicity of mGluR2 and neuroprotection by 
mGluR3 
 
Group II mGluR agonists are protective against a range of neurotoxic paradigms in 
mixed cultures and in vivo (Bruno et al. 1994, 1995, 1997, 1998b; Buisson and Choi 
1995;  Buisson  et  al.  1996;  Copani  et  al.  1995;  Henrich-Noack  et  al.  1998; 
Matarredona et al. 2001; Battaglia et al. 2003; Yao et al. 2005; Zhou et al. 2006). 
The presence of astrocytes was shown to be necessary for this neuroprotection in 
vitro (Copani et al. 1995; Bruno et al. 1998b; Yao et al. 2005; Zhou et al. 2006), and 
neuroprotection was found to be due to mGluR3 stimulation (Bruno et al. 1998b; 
Thomas et al. 2001, 2003; Berent-Spillson et al. 2004; Corti et al. 2007). Release of 
TGFβ  (Bruno  et  al.  1998a;  Corti et  al. 2007), enhancement of  glutamate uptake 
(Aronica et al. 2003; Yao et al. 2005; Zhou et al. 2006) and inhibition of glutamate 
release  via  xc
-  (Baker  et  al.  2002;  Xi  et  al.  2002)  have  all  been  implicated  in 
astrocyte-dependent mGluR3-mediated neuroprotection. Group II mGluR expression 
by astrocytes has been shown to increase following injection of kainic acid into the 
mouse hippocampus to induce neuronal injury (Ferraguti et al. 2001), as well as in 
active  MS  lesions  (Geurts  et  al.  2003;  Newcombe  et  al.  2008),  suggesting  an 
intrinsic neuroprotective mechanism. 
 
Neuronal group II mGluRs, in this case specifically mGluR2, have been implicated 
in  mechanisms  of  neurotoxicity  (Corti  et  al.  2007).  In  AD,  increased  mGluR2 
expression  has  been  demonstrated  in  neurones  and  dendritic  processes  in 
hippocampal  CA1  and  CA3  regions,  areas  associated  with  pathology.  mGluR2 
staining  co-localised  with  phosphorylated  tau,  suggesting  that  it  is  the  affected 
neurones which have increased mGluR2 expression (Lee et al. 2004b). It is however 
unclear whether the increased mGluR2 expression is involved in the pathogenesis or 
is a consequence of the pathology.  
 
Microglial mGluR2 activation has been found to be neurotoxic and to underlie the 
microglial neurotoxicity of the Alzheimer‟s disease-associated peptide CGA (Taylor 
et al. 2002). Glutamate excitotoxicity was not responsible for neurotoxicity (Taylor 
et  al.  2002),  and  the  mechanism  was  subsequently  shown  to  involve  microglial 
release of TNFα and FasL, which bind to TNFR1 and Fas, respectively, on CGCs 72 
 
(Taylor  et  al.  2005).  In  contrast,  the  mGluR3-specific  agonist  NAAG  was 
completely non-toxic.  
 
Microglia were also neurotoxic when activated with myelin (Pinteaux-Jones et al. 
2008).  Neurotoxicity  was  attenuated  by  the  group  II  mGluR  antagonist  MCCG, 
suggesting involvement of group II mGluRs in this toxicity (Pinteaux-Jones et al. 
2008).  Interestingly,  toxicity  was  also  attenuated  by  NAAG,  suggesting  a 
neuroprotective role of microglial mGluR3 in this case (Pinteaux-Jones et al. 2008). 
Myelin-induced increases in extracellular glutamate levels and TNFα release were 
not  reversed  by  MCCG  or  NAAG,  suggesting  that  the  mechanism  of  myelin 
neurotoxicity  may  be  slightly  different  from  that  of  microglia-dependent  CGA 
neurotoxicity  (Pinteaux-Jones  et  al.  2008).  Increased  microglial  group  II  mGluR 
expression has been shown in activated and amoeboid microglia associated with MS 
lesions (Geurts et al. 2003), but since a non-discriminatory mGluR2/3 antibody was 
used, and neurotoxicity and neuroprotection appear to be receptor subtype-specific, it 
is unclear whether this upregulation would increase microglial neurotoxicity. 
 
DCG IV has also been demonstrated to activate microglia in vivo (Matarredona et al. 
2001), but in this case led to microglial expression of BDNF mRNA (Matarredona et 
al. 2001; Venero et al. 2002), suggesting a neuroprotective microglial phenotype. 
The mGluR subtype responsible was however not determined, so it is possible that 
BDNF  expression  may  be  an  mGluR3-mediated  effect.  DCG  IV  injection  also 
caused  neurotoxicity  (Venero  et  al.  2002),  however  it  was  reversed  by  NMDA 
antagonists and not mGluR antagonists and was therefore probably due to the low-
affinity NMDA agonist property of DCG IV (Hayashi et al. 1993).  
 
Thus,  it  appears  that  the  group  II  mGluRs,  mGluR2  and  mGluR3,  have  distinct 
functions. mGluR3 is responsible for neuroprotection by astrocytes, whilst mGluR2 
expressed by neurones and microglia is involved in mechanisms of neurotoxicity. 
 
1.4.1.2.6. Group III mGluRs: neuroprotective 
 
Group  III  mGluRs  appear  to  be  universally  neuroprotective.  Group  III  mGluR 
agonists protected against a number of neurotoxic paradigms in vitro (Bruno et al. 73 
 
1995, 1996, 2000a; Copani et al. 1995; Faden et al. 1997; Gasparini et al. 1999; Yao 
et al. 2005; Zhou et al. 2006) and against NMDA excitotoxicity in vivo (Gasparini et 
al.  1999;  Bruno  et  al.  2000a).  Whilst  one  group  demonstrated  the  necessity  for 
astrocytes in this group III mGluR-mediated neuroprotection (Yao et al. 2005; Zhou 
et al. 2006), some studies have shown neuroprotection by group III mGluR agonists 
in pure or enriched neuronal cultures (Graham and Burgoyne 1994; Copani et al. 
1995; Maiese et al. 1995). Evidence suggests that the neuroprotective effect of group 
III  mGluR  agonists  is  predominantly  due  to  mGluR4  stimulation  (Bruno  et  al. 
2000a;  Maj  et  al.  2003),  and  may  simply  reflect  the  autoreceptor  function  of 
neuronal group III mGluRs (Bruno et al. 2000a). Alternatively, the neuroprotective 
mechanism may involve a rescue of depleted astrocyte glutamate uptake (Yao et al. 
2005; Zhou et al. 2006). It was suggested that via restoration of the levels of the 
intracellular antioxidant glutathione, group III mGluR stimulation may counteract 
the effects of NO and other ROS and RNS, which may include downregulation of 
glutamate transporter activity (Yao et al. 2005; Zhou et al. 2006). An alternative 
explanation for a group III mGluR-mediated enhancement of glutamate uptake by 
astrocytes involves the classical Gi/o signalling pathway. Protein kinase C (PKC) has 
been  shown  to  decrease  the  cell  surface  expression  of  the  glutamate  transporter 
excitatory  amino  acid  transporter  1  (EAAT1),  and  protein  kinase  A  (PKA),  the 
cAMP-dependent protein kinase, has been found to induce PKC activity. Thus, a 
downregulation of PKA activity may downregulate PKC activity and release a PKC-
mediated inhibition of EAAT1 expression (Zhou et al. 2006). 
 
Microglial group III mGluRs have also been found to be neuroprotective. Despite 
apparently  being  coupled  to  the  same  class  of  G  protein  as  microglial  group  II 
mGluRs,  activation  of  group  III  mGluRs  was  protective  against  microglial 
neurotoxicity due to LPS, CGA, Aβ25-35 or myelin (Taylor et al. 2003; Pinteaux-
Jones et al. 2008). The presence of microglia was necessary for the mGluR-mediated 
protection (Taylor et al. 2003; Pinteaux-Jones et al. 2008), and in the case of myelin 
at least, group III mGluR agonists did not reverse the myelin-induced increases in 
extracellular glutamate levels (Pinteaux-Jones et al. 2008), suggesting that protection 
mediated by microglial group III mGluRs occurs via a distinct mechanism from that 
seen in astrocyte/neurone co-cultures and pure neuronal cultures. 
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Thus,  group  III  mGluRs  appear  to  be  universally  neuroprotective.  In  active  MS 
lesions, the expression of mGluR4 and mGluR8 by astrocytes, and the expression of 
mGluR8 by microglia, have been shown to be upregulated (Geurts et al. 2005). This 
suggests that activated glia in MS lesions may have a neuroprotective function. 
 
 
1.4.1.2.8. Specific mGluR agonists and antagonists used in this thesis 
 
The  mGluR  agonists  and  antagonists  utilised  to  selectively  stimulate  and  block 
specific microglial receptor subtypes in this study are listed in table 1.2. 75 
 
 
Table 1.2. Summary of selective mGluR agonists and antagonists used in this thesis. AIDA, (RS)-1-aminoindan-1,5-dicarboxylic acid; APICA, (RS)-1-amino-
5-phosphonoindan-1-carboxylic  acid;  CDPPB,  3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide;  DCG  IV,  (2S,2'R,3'R)-2-(2',3'-
dicarboxycyclopropyl)glycine; DHPG, (RS)-3,5-dihydroxyphenylglycine; L-AP4, L-(+)-2-amino-4-phosphonobutyric acid; MAP4, (S)-2-amino-2-methyl-4-
phosphonobutanoic  acid;  MCCG,  2S,3S,4S-2-methyl-2-(carboxycyclopropyl)glycine;  MTEP,  3-((2-methyl-1,3-thiazol-4-yl)ethynyl)-pyridine;  NAAG,  N-
acetyl-L-aspartyl-L-glutamic  acid;  (RS)-PPG,  (RS)-4-phosphonophenylglycine;  SIB-1757,  6-methyl-2-(phenylazo)-3-pyridinol;  tADA,  trans-azetidine-2,4-
dicarboxylic acid. 
 
 
Group I-selective compounds 
Compound  Activity  Concentration used  References 
DHPG  Orthosteric agonist or partial agonist  100 μM  Ito et al. (1992); Brabet et al. (1995) 
tADA  Orthosteric agonist  250 μM  Manahan-Vaughan et al. (1996) 
CDPPB  Allosteric mGluR5-specific agonist  500 nM  Lindsley et al. (2004); Kinney et al. (2005) 
AIDA  Competitive antagonist  250 μM  Pellicciari et al. (1995); Moroni et al. (1997) 
MTEP  Non-competitive mGluR5-specific antagonist  100 nM  Cosford et al. (2003b) 
SIB-1757  Non-competitive mGluR5-specific antagonist  50 μM  Varney et al. (1999) 
Group II-selective compounds 
DCG IV  Orthosteric agonist  500 nM  Hayashi et al. (1993); Ishida et al. (1993); Brabet et al. (1998) 
NAAG  Orthosteric mGluR3-specific agonist  50 μM  Wroblewska et al. (1997) 
MCCG  Competitive antagonist  500 μM  Jane et al. (1994); Knopfel et al. (1995); Salt and Eaton (1995) 
APICA  Competitive antagonist or inverse agonist  200 μM  Ma et al. (1997) 
Group III-selective compounds 
L-AP4  Orthosteric agonist  100 μM  Nakanishi (1992); Bushell et al. (1995) 
(RS)-PPG  Orthosteric agonist  100 μM  Gasparini et al. (1999) 
MAP4  Competitive antagonist or partial agonist  500 μM  Jane et al. (1994); Bushell et al. (1995); Knopfel et al. (1995); Salt and 
Eaton (1995) 
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1.4.2. Glutamate transporters  
 
The two main glutamate transporter types are the excitatory amino acid transporter 
(EAAT)  family  and  the  xc
-  glutamate/cystine  antiporter  system,  which  are 
represented in figure 1.8.  
 
1.4.2.1. Excitatory amino acid transporters 
 
The electrogenic Na
+-dependent EAATs mediate high-affinity glutamate uptake. The 
Na
+ gradient, maintained by ATPases in the plasma membrane, allows glutamate 
uptake  to  occur  against  its  concentration  gradient.  One  glutamate  molecule  is 
cotransported with three Na
+ and one proton, whilst one K
+ is transported in the 
opposite direction (see fig. 1.8) (Zerangue and Kavanaugh 1996; Levy et al. 1998; 
Owe et al. 2006). The EAATs prevent inappropriate receptor activation, especially 
important in the case of synaptic iGluRs, of which prolonged stimulation can lead to 
excitotoxicity and neuronal death.  
 
EAAT1 (Storck et al. 1992; Tanaka 1993) and EAAT2 (Pines et al. 1992) (also 
known as L-glutamate/L-aspartate transporter, GLAST and L-glutamate transporter 
1,  GLT-1,  respectively)  are  primarily  astrocytic  transporters  responsible  for  the 
maintenance of extracellular glutamate below neurotoxic levels (Danbolt et al. 1992; 
Rosenberg et al. 1992; Rothstein et al. 1994, 1996; Lehre et al. 1995). EAAT1 is 
expressed at its highest level in the cerebellar cortex, and appears to be expressed at 
a lower level than EAAT2 throughout the rest of the CNS (Rothstein et al. 1994; 
Lehre  et  al.  1995).  EAAT2  is  thought  to  be  responsible  for  more  than  90  % 
glutamate transporter activity under normal circumstances in vivo (Danbolt et al. 
1992; Haugeto et al. 1996; Tanaka et al. 1997).  
 
EAAT3 (Kanai and Hediger 1992) (also known as excitatory amino acid carrier 1, 
EAAC1), is primarily expressed by neurones  (Rothstein et al. 1994; Conti et al. 
1998; Kugler and Schmitt 1999; Plachez et al. 2000), and appears to be responsible 
for the uptake of cysteine for neuronal glutathione synthesis (Chen and Swanson 
2003; Himi et al. 2003; Aoyama et al. 2006). EAAT4 is predominantly expressed in 
the cerebellar Purkinje cells (Fairman et al. 1995; Lin et al. 1998) and EAAT5 is77 
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Figure 1.8. Glutamate transporters: (a) excitatory amino acid transporters (EAATs) and (b) 
the  xc
-  cystine/glutamate  transporter  system.  The  EAATs  cotransport  one  molecule  of 
glutamate and three sodium ions; K
+/H
+ exchange also occurs. The anion channel function 
of EAATs is most pronounced in EAAT4 and EAAT5, which primarily transport chloride 
ions.  The  xc
-  transporter  system  usually imports cystine in  exchange  for  glutamate,  and 
appears to be Cl
--dependent at low cystine concentrations. 
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expressed primarily in the retina (Arriza et al. 1997). Although all the EAATs allow 
a degree of anion transport (Wadiche et al. 1995), this is most pronounced in EAAT4 
and EAAT5, which act as chloride channels. 
 
1.4.2.2. xc
- glutamate/cystine transporter system 
 
The xc
- glutamate/cystine transporter system is an electroneutral antiporter which, 
under normal conditions, imports cystine for glutathione synthesis in exchange for 
glutamate (Bannai 1986) (fig. 1.8). xc
--mediated
 transport appears to be partially Cl
--
dependent at low cystine concentrations  (Murphy et al. 1989). The xc
- system is 
expressed  at  the  plasma  membrane  as  a  heterodimer  consisting  of  the  4F2hc 
glycoprotein,  which  is  associated  with  a  number  of  transport  systems,  and  the 
specific protein xCT (Sato et al. 1999; Bassi et al. 2001). 
 
The xc
- transporter system appears to have a significant impact upon the homeostasis 
of  both  of  its  physiological  substrates,  glutamate  and  cystine.  Pharmacological 
inhibition of xc
- reduced the striatal glutamate concentration in the rat by ~ 60 %, 
suggesting  that  the  majority  of  extracellular  glutamate  in  the  normal  CNS  is  a 
product of xc
- activity (Baker et al. 2002). Mice lacking the xCT gene had increased 
plasma levels of cystine/GSSG and related disulphides, and decreased plasma levels 
of GSH, although the GSH content of all tissues examined, including some CNS 
areas, was not significantly different between wild-type and mutant mice (Sato et al. 
2005). Fibroblasts derived from xCT-deficient animals only survived in culture when 
supplemented with exogenous antioxidants (Sato et al. 2005). 
 
Although under normal circumstances, xc
- mediates cystine uptake and glutamate 
release, high concentrations of glutamate have been shown to inhibit the uptake of 
cystine (Bannai 1986; Watanabe and Bannai 1987; Sato et al. 1999; Tomi et al. 
2002;  Patel  et  al.  2004).  Therefore,  under  conditions  of  elevated  extracellular 
glutamate, it is possible that the xc
- transporter may reverse and therefore function as 
a glutamate uptake transporter.  
 
Of the cells of the CNS, the xc
- system is expressed by microglia (Qin et al. 2006; 
Barger  et  al.  2007;  Domercq  et  al.  2007)  and  astrocytes  (Allen  et  al.  2001; 79 
 
Gochenauer and Robinson 2001; Pow 2001), but not by neurones (Pow 2001; Qin et 
al. 2006).  
 
1.4.2.3. Microglial glutamate transporters  
 
Microglia  express  EAAT2  (Kondo  et  al.  1995;  Lopez-Redondo  et  al.  2000; 
Nakajima et al. 2001b; Jacobsson et al. 2006; O'Shea et al. 2006), and possibly also 
EAAT1  (Kondo  et  al.  1995;  O'Shea  et  al.  2006).  Microglial  EAAT  expression 
appears  to  be  increased  following  infection  or  trauma.  In  vitro,  microglia 
demonstrated increased EAAT2 protein expression and glutamate uptake capacity 
following exposure to LPS (Persson et al. 2005; Jacobsson et al. 2006; O'Shea et al. 
2006), which was found to be TNFα-dependent (Persson et al. 2005). Microglia also 
showed  increased  levels  of  TNFα  production  and  EAAT2  protein  expression 
following  infection  with  Herpes  simplex  virus  (Persson  et  al.  2007).  In  vivo, 
microglial  EAAT2  expression  was  increased  in  the  rat  facial  motor  nucleus 
following  facial  nerve  axotomy  (Lopez-Redondo  et  al.  2000),  in  the  cerebral 
parenchyma  and  in  perivascular  microglia  of  simian  immunodeficiency  virus-
infected macaques (Chretien et al. 2002), and in MS lesions (Werner et al. 2001). 
Following traumatic brain  injury in  the  rat,  an  increase in  EAAT1  and EAAT2-
expressing microglia was detected in all brain areas studied except the trauma zone 
itself (van Landeghem et al. 2001). Marked upregulation of EAAT1 expression has 
been demonstrated in activated microglia in patients suffering with Prion disease 
(Chretien  et  al.  2004)  and  HIV  (Vallat-Decouvelaere  et  al.  2003).  Following 
ischaemia,  microglial  EAAT1  expression  appeared  to  be  restricted  to  early  and 
intermediate  stages  of  activation  and  was  not  present  on  phagocytosing 
microglia/macrophages  or blood-derived infiltrating monocytes (Beschorner et al. 
2007). 
 
Microglia  robustly  express  the  xc
-  transporter,  and  microglial  xc
-  function  is 
considered  to  be  important  in  the  supply  of  cystine  for  microglial  glutathione 
synthesis (McBean 2002; Barger et al. 2007). However the concomitant glutamate 
release has been implicated in excitotoxic damage to neurones (Piani and Fontana 
1994; Barger and Basile 2001; Qin et al. 2006) and oligodendrocytes (Domercq et 
al.  2007).  Microglial  xc
-  expression  and  activity  is  upregulated  following  LPS 80 
 
treatment (Barger et al. 2007; Domercq et al. 2007). Increased microglial glutamate 
release,  attributed  to  xc
-  activity,  has  also  been  shown  following  treatment  with 
soluble  APP  (Barger  and  Basile  2001)  or  Aβ  (Qin  et  al.  2006).  Through  this 
upregulation  of  xc
-,  microglial  activation  may  therefore  enhance  microglial 
antioxidant defence with the consequence of endangering neighbouring cells. 
 
Microglial EAAT activity is much lower compared with that of astrocytes (Leonova 
et al. 2001; Persson et al. 2005). However under conditions of oxidative stress and 
hypoxia, the glutamate uptake capacity of astrocytes may decrease (Volterra et al. 
1994;  Miralles  et  al.  2001;  Dallas  et  al.  2007)  and  microglial  EAAT-mediated 
glutamate uptake may partially replace astrocyte glutamate uptake. Alternatively, the 
concurrent upregulation of microglial EAAT and xc
- following microglial activation 
may indicate complementary functions. Microglial EAAT activity may represent a 
mechanism to take up glutamate released by xc
- and therefore prevent excitotoxicity, 
or a mechanism by which xc
- activity is driven by provision of free intracellular 
glutamate. 
 
Following traumatic brain injury (van Landeghem et al. 2001) or in MS (Newcombe 
et al. 2008), microglia may express EAAT3, the neuronal transporter responsible for 
cysteine uptake for the synthesis of glutathione (Chen and Swanson 2003; Himi et 
al. 2003; Aoyama et al. 2006). Microglia are thought to rely on L-cystine uptake by 
the xc
- transporter system to supply cysteine for glutathione synthesis (Barger et al. 
2007). The function of microglial  EAAT3 expression is therefore unclear, but is 
suggested to be a further mechanism of increasing microglial glutamate uptake under 
conditions of downregulated astrocyte glutamate uptake and elevated extracellular 
glutamate (van Landeghem et al. 2001; Newcombe et al. 2008). 
 
1.4.2.4. Glutamate transporters in AD and MS 
 
Extracellular glutamate levels are elevated in a number of neurological conditions, 
and  may  be  toxic  through  excitotoxicity  or  oxidative  glutamate  toxicity,  a 
phenomenon in which elevated extracellular glutamate inhibits cystine uptake by the 
xc
- system, thus limiting the supply of cystine for glutathione synthesis (Murphy et 
al. 1989). Alterations in the expression or activity of the high affinity EAATs could 81 
 
therefore contribute to the pathogenesis of neurological diseases; these transporters 
may  represent  a  potential  target  for  drugs  to  treat  such  diseases  (Sheldon  and 
Robinson 2007). 
 
Brains  from  patients  suffering  with  Alzheimer‟s  disease  have  a  lower  glutamate 
uptake capacity compared with controls, as assessed by D-aspartate binding (Cross et 
al. 1987; Cowburn et al. 1988; Masliah et al. 1996). Moreover, glutamate uptake in 
the frontal cortex was inversely correlated with cognitive decline  (Masliah et al. 
1996).  Decreased  neuronal  glutamate  transporter  density  was  observed  in  post-
mortem AD brain compared with control (Scott et al. 1995), and EAAT2 protein 
expression in the frontal cortex was found to be lower in AD than in control brains 
(Li et al. 1997). Astrocytes derived from AD cortex were deficient in glutamate 
uptake and had lower EAAT1 and EAAT2 protein expression than controls (Liang et 
al. 2002). However, one study demonstrated de novo neuronal EAAT1 expression 
associated with AD, the expression of EAAT1 being colocalised with tau (Scott et 
al. 2002). Platelets and fibroblasts derived from AD patients have been shown to 
have decreased EAAT1 expression compared with age-matched controls (Zoia et al. 
2004, 2005), as well as decreased glutamate uptake capacity (Ferrarese et al. 2000; 
Begni et al. 2004). Fibroblast EAAT1 protein expression was found to be inversely 
correlated with disease severity (Zoia et al. 2005). In addition, APP transgenic mice, 
a  model  of  AD,  had  decreased  affinity  and  surface  expression  of  glutamate 
transporters,  in  combination  with  decreased  protein  expression  of  EAAT1  and 
EAAT2 in the neocortex (Masliah et al. 2000). There was however no change in the 
mRNA levels of any of the transporters, suggesting a post-transcriptional regulation 
(Masliah et al. 2000).  
 
The  activity  of  EAAT1,  EAAT2  and  EAAT3  may  be  modulated  by  the  cellular 
redox potential. Glutamate uptake activity has been shown to be downregulated by 
oxygen  free  radicals  and  thiol  oxidising  compounds,  and  upregulated  by  thiol 
reducing compounds (Volterra et al. 1994; Trotti et al. 1997a, 1997b). It is suggested 
that disulphide bond formation within or between functional EAATs inhibits their 
activity  (Trotti  et  al.  1998).  Accordingly,  the  lipid  peroxidation  product  HNE 
increased ROS  levels  and decreased the  glutamate uptake capacity of fibroblasts 
derived from AD patients, but not those derived from control subjects (Begni et al. 82 
 
2004). Exogenous antioxidants have been shown to reverse a depleted glutamate 
uptake capacity (Blanc et al. 1998; Begni et al. 2004). 
 
In  multiple  sclerosis,  the  expression  of  the  high-affinity  glutamate  transporters, 
particularly EAAT2, may be downregulated (Werner et al. 2001; Pitt et al. 2003). 
Inhibition  of  oligodendrocyte  glutamate  transporters  led  to  oligodendrocyte 
apoptosis  due  to  AMPA  and  kainate  receptor  activation,  and  consequent  axonal 
damage  (Domercq  et  al.  2005),  implicating  the  downregulation  of  glutamate 
transporters  in  MS  pathogenesis.  However,  increased  glutamate  transporter 
expression  and  glutamate  uptake  in  MS  tissue  has  also  been  reported  (Vallejo-
Illarramendi  et  al. 2006). Following EAE, the  animal  model of MS, spinal cord 
synaptosomes  also  showed  an  increased  glutamate  uptake  capacity;  EAAT1  and 
EAAT2  expression  was  decreased  whilst  EAAT3  expression  was  transiently 
upregulated (Ohgoh et al. 2002). 
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1.5. Glutathione  
 
Glutathione (-L-glutamyl-L-cysteinylglycine; GSH) is a tripeptide thiol, consisting 
of L-glutamate, L-cysteine and L-glycine.  
 
 
 
 
 
 
 
 
Figure 1.9. The structure of glutathione 
 
 
1.5.1. Functions of glutathione 
 
Probably  the  best  known  and  most  extensively  studied  function  of  GSH  is  its 
antioxidant property, which it possesses by virtue of the thiol group of the cysteine 
residue.  GSH  reduces  reactive  oxygen  species  and  free  radicals,  as  well  as 
maintaining  the  thiol  redox  potential  in  cells  by  ensuring  sulfhydryl  groups  of 
cellular  proteins  are  in  the  reduced  state  (Klebanoff  1957).  Upon  oxidation,  the 
disulphide GSSG is produced, and GSH is regenerated in the presence of reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) by the action of glutathione 
reductase  (GR;  EC  1.8.1.7)  (Rall  and  Lehninger  1952).  GSH  has  a  role  in  the 
regeneration of antioxidant vitamins. Redox coupling between GSH and ascorbic 
acid  (vitamin  C)  maintains  the  latter  in  its  active  reduced  state  (Meister  1994; 
Winkler  et  al.  1994),  and  a  second  redox  coupling  between  ascorbic  acid  and 
tocopherol (vitamin E) regenerates the active reduced form of tocopherol (Packer et 
al. 1979; Mukai et al. 1991; Sharma and Buettner 1993). GSH is also a transport and 
storage form of the amino acid cysteine, and acts as a cofactor in some isomerisation 
reactions within the cell (Meister and Anderson 1983).  
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In  the  immune  system,  GSH  appears  to  be  crucial  for  the  proliferation  of 
lymphocytes during activation (Hamilos et al. 1989; Suthanthiran et al. 1990; Smyth 
1991). Evidence suggests that this may be due to thiol-mediated cell cycle control 
(Iwata et al. 1994); a number of transcription factors are redox-sensitive (Powis et al. 
1995;  Arrigo  1999;  Morel  and  Barouki  1999).  Reflecting  its  importance  in  the 
immune  response,  depletion  of  lymphocyte  and  plasma  GSH  is  associated  with 
HIV/AIDS  (Buhl  et  al.  1989;  Roederer  et  al.  1991;  Staal  et  al.  1992a,  1992b); 
indeed, GSH levels appear to be a key determinant of patient survival (Herzenberg et 
al. 1997). 
 
Due to its -glutamyl group as well as its ability to modulate proteins through the 
formation  of  disulphide  bonds,  GSH  may  act  as  a  neuromodulator  at  the  CaR, 
NMDA, AMPA, kainate, µ-opioid and neurokinin-1 receptors (Varga et al. 1989, 
1997; Yoneda et al. 1990; Leslie et al. 1992; Liu and Quirion 1992; Janaky et al. 
1993, 2007, 2008; Ogita et al. 1995; Jenei et al. 1998; Wang et al. 2006). A number 
of studies have identified two GSH binding sites on CNS tissues (Ogita and Yoneda 
1987, 1988; Guo et al. 1992; Janaky et al. 2000), where binding at one site cannot be 
inhibited by glutamate receptor ligands, and is postulated to be a GSH-specific site, 
thus potentially identifying GSH as a novel neurotransmitter (Guo et al. 1992; Guo 
and Shaw 1992; Lanius et al. 1994; Janaky et al. 2000).  
 
1.5.2. Glutathione synthesis and consumption 
 
Glutamate-cysteine  ligase  (GCL,  also  known  as  -glutamylcysteine  synthase;  EC 
6.3.2.2)  catalyses  the  formation  of  -glutamylcysteine  (GC)  from  glutamate  and 
cysteine (Strumeyer and Bloch 1960), the rate limiting step in GSH biosynthesis 
(Meister  and  Anderson  1983).  This  enzymatic  reaction  may  be  limited  by  the 
availability of cysteine, and is regulated by GSH, the end product of the pathway, 
which can competitively inhibit GCL by interacting with the glutamate binding site 
(Richman  and  Meister  1975).  GSH  synthase  (EC  6.3.2.3)  then  catalyses  the 
formation  of  GSH  from  GC  and  glycine  (Snoke  et  al.  1953).  Each  of  the  two 
enzymatic steps are coupled to ATP hydrolysis (Snoke and Bloch 1952; Snoke et al. 
1953). 85 
 
The  simple  reduction  of  free  radicals  and  reactive  oxygen  species  and  oxidised 
sulfhydryl  groups  by  GSH,  producing  GSSG,  occurs  in  the  presence  of  GSH 
peroxidase  (GPx;  EC  1.11.1.9)  (Mills  1957),  although  in  the  case  of  the  highly 
reactive radicals, oxidation may occur spontaneously in the absence of the enzyme 
(Andersson et al. 1982; Moldeus et al. 1982). As described above, GSH is readily 
regenerated in the presence of NADPH by the action of GR (Rall and Lehninger 
1952). Under normal circumstances, the ratio of GSSG to GSH is very low (Hwang 
et al. 1992), due to the reducing environment of the cytosol and the efficiency of 
GSH reductase. GSH may also be irreversibly consumed by conjugation to other 
molecules by  glutathione  S-transferase  (GST;  EC 2.5.1.18)  (Gillham 1971). This 
pathway is involved in the detoxification of xenobiotics (Smith et al. 1977; Younes 
et  al.  1980),  as  well  as  in  normal  metabolic  processes  (Elce  and  Harris  1971; 
Soderstrom et al. 1985). GSH may also be released by the cell, either as the thiol or 
as  a  glutathione-S-conjugate  following  GST  activity.  In  these  situations,  it  is 
important  that  GSH  utilisation  is  balanced  by  de  novo  synthesis,  especially 
considering that cellular depletion of GSH is associated with apoptotic cell death 
(Kane et al. 1993; Merad-Boudia et al. 1998; Anderson et al. 1999; Higuchi and 
Matsukawa 1999; Wullner et al. 1999; Higuchi 2004).  
 
The pathways described here are summarised in figure 1.10. 
 
1.5.3. Glutathione in the CNS 
 
Although GSH is present in almost all cell types, it is especially important in the 
CNS, where metabolic activity and therefore free radical production is high, and 
levels of other antioxidants are relatively low (Dringen 2000). The concentration of 
GSH in the brain is in the range 1 – 3 mM (Dringen 2000); however its distribution 
is  not  homogeneous.  Histochemical  and  immunofluorescent  staining  of  brain 
sections  have  demonstrated  that  neurones  contain  low  levels  of  GSH  whilst  the 
surrounding glial cells have a much higher GSH content (Slivka et al. 1987; Philbert 
et al. 1991; Pearce et al. 1997).  
 
In culture, rather a wide range of values for GSH concentrations of each cell type 
have  been  reported.  Neurones  have  intracellular  GSH  levels  between  10  and  3086 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.10.  Diagrammatic  representation  of  the  cellular  synthesis  and  consumption  of 
glutathione. Glutathione is synthesised from its constituent amino acids by the sequential 
actions of the enzymes GCL and GSH synthase, is reversibly consumed by oxidation and 
irreversibly consumed by conjugation and export. Cys, cysteine; GC, -glutamylcysteine; 
Glu, glutamate; Gly, glycine; GSH, reduced glutathione; GSSG, oxidised glutathione; GS-X, 
glutathione S-conjugate. Enzymes (shown in blue), GCL, glutamate-cysteine ligase; GPx, 
glutathione peroxidase;  GR,  glutathione  reductase; GSH  synthase,  glutathione  synthase; 
GST, glutathione-S-transferase. 
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nmol.mg
-1 protein (Bolaños et al. 1996; Dringen et al. 1999a, 1999b; Wullner et al. 
1999; Hirrlinger et al. 2002c; Sebastia et al. 2003; Gegg et al. 2005), and most 
studies report astrocyte GSH levels in the region 20 – 60 nmol.mg
-1 protein (Raps et 
al. 1989; Yudkoff et al. 1990; Dringen and Hamprecht 1996, 1998; Juurlink et al. 
1996; Sagara et al. 1996; Dringen et al. 1999b; Wang and Cynader 2000; Hirrlinger 
et al. 2002c; Muyderman et al. 2004; Minich et al. 2006; Vargas et al. 2006), with a 
few reports of lower levels around 10 nmol.mg
-1 protein (Chatterjee et al. 1999; 
García-Nogales et al. 1999; Gegg et al. 2005). Where both cell types have been 
studied in parallel, astrocytes were consistently found to contain higher levels than 
neurones (Raps et al. 1989; Dringen et al. 1999a, 1999b; Hirrlinger et al. 2000, 
2002b, 2002c; Wang and Cynader 2000; Keelan et al. 2001).  
 
Microglial cells in culture have a GSH level of 25 – 40 nmol.mg
-1 protein (Hirrlinger 
et al. 2000, 2002c; Persson et al. 2006), although one study reported a much higher 
level  of  110  nmol.mg
-1  protein  (Chatterjee  et  al.  1999).  Evidence  suggests  that 
microglia contain the highest GSH levels amongst the different cell types in the CNS 
(Chatterjee et al. 1999, 2000; Hirrlinger et al. 2000, 2002b; Noack et  al. 2000). 
Oligodendrocytes  are  usually  reported  to  contain  very  low  levels  of  GSH  (≤  10 
nmol.mg
-1 protein) (Thorburne and Juurlink 1996; Juurlink et al. 1998; Almazan et 
al. 2000; Fragoso et al. 2004), although some comparative studies have found levels 
similar to or even higher than those of microglia and astrocytes (Hollensworth et al. 
2000;  Hirrlinger  et  al.  2002b,  2002c).  These  same  studies  reported  that 
oligodendrocyte GPx activity was the highest amongst the different brain cells in 
culture  (Hollensworth  et  al.  2000;  Hirrlinger  et  al.  2002b),  strengthening  their 
conclusion that oligodendrocytes have a high antioxidant capacity. 
 
The variability in reported GSH concentrations of cultured cells is probably due to 
different  methods  used  to  measure  GSH,  or  to  differences  in  culture  conditions; 
indeed GSH levels in neurones were shown to more than double when the culture 
medium  was  supplemented  with  particular  amino  acid/dipeptide  combinations 
(Dringen  et  al.  1999b).  Such  an  effect  of  culture  conditions  upon  GSH  levels 
indicates  that  any  data  relating  to  the  GSH  content  of  cultured  cells  should  be 
interpreted with caution. 
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GSH is present extracellularly in the brain at a concentration of approximately 2 μM 
(Yang et al. 1994; Lada and Kennedy 1997), and in CSF in the range 0.5 – 6 μM 
(Anderson et al. 1989; Do et al. 2000; Wang and Cynader 2000; Calabrese et al. 
2002, 2003; Kawakami et al. 2006). 
 
1.5.4. Glutathione and related enzymes in ageing, AD and MS 
 
Oxidative stress has long been implicated in the ageing process and in a number of 
CNS diseases, especially those associated with ageing (Harman 1956; Ames et al. 
1993;  Halliwell  2006).  The  levels  of  antioxidants  such  as  glutathione  in  these 
situations are therefore of considerable interest.  
 
The gene expression profile of the ageing mouse brain compared with that of the 
young adult mouse is indicative of increased oxidative stress with age (Lee et al. 
2000).  In  accordance with this, there exists  a clear, well-documented age-related 
decrease in GSH, increase in GSSG and consequent decrease in GSH:GSSG ratio in 
a number of brain regions, as demonstrated in aged rodents compared with young 
animals (Ravindranath et al. 1989; Iantomasi et al. 1993; Favilli et al. 1994; Sasaki 
et al. 2001; Liu 2002; Rebrin et al. 2003, 2007; Wang et al. 2003b; Suh et al. 2004; 
Zhu et al. 2006; Parihar et al. 2008). This has been shown to be accompanied by a 
shift in the glutathione redox potential in favour of the pro-oxidising state (Rebrin et 
al. 2003, 2007). 
 
An age-related increase in the activities of the glutathione-consuming enzymes GPx, 
GST and the ectoenzyme  glutamyl transpeptidase (GT) has been demonstrated in 
rat brain (Iantomasi et al. 1993; Favilli et al. 1994; Kim et al. 2003a; Zhu et al. 
2006). Conversely, GCL expression and activity has been widely reported to decline 
with age (Iantomasi et al. 1993; Favilli et al. 1994; Liu and Choi 2000; Liu 2002; 
Wang et al. 2003b; Zhu et al. 2006). This appears to be due to a decline in the 
expression of the regulatory subunit  of the enzyme (Liu 2002; Zhu et al. 2006), 
important  in  lowering  the  affinity  of  GCL  for  GSH  (Huang  et  al.  1993),  which 
inhibits  activity  (Richman  and  Meister  1975).  Accordingly,  an  age-associated 
decrease in the affinity of GCL for the substrate cysteine has been reported (Suh et 
al. 2004).  89 
 
Although AD is also associated with increased oxidative stress, there do not appear 
to be clear, well-documented alterations in the GSH system in AD brain compared 
with controls. This may reflect a disease-associated increase in the generation of 
oxidative  stress  rather  than  a  decrease  in  antioxidant  capacities.  Evidence  does 
however exist for altered peripheral GSH status in AD, suggesting that the oxidative 
stress associated with AD may extend further than the affected areas of the CNS 
(Ceballos-Picot et al. 1996; Liu et al. 2005; Bermejo et al. 2008). 
 
GSH levels have been reported to be higher in the midbrain and hippocampus of AD 
patients than age-matched controls (Adams, Jr. et al. 1991), although other studies 
have failed to show a significant difference in total glutathione and thiol content of a 
number  of  regions  in  control  and  AD  brain  (Perry  et  al.  1987;  Aksenov  and 
Markesbery 2001) or CSF (Konings et al. 1999). Lower protein-bound thiol levels 
were reported in AD hippocampus compared with control (Aksenov and Markesbery 
2001), as were increased levels of GSH conjugates of the lipid peroxidation product 
4-hydroxy-2-nonenal (HNE) in a number of areas of AD brain (Volkel et al. 2006), 
both of which are suggestive of increased oxidative damage. AD patients have also 
been shown to have increased GR and GPx gene expression in the hippocampus, 
parahippocampal gyrus and amygdala, compared with control (Lovell et al. 1995; 
Aksenov and Markesbery 2001), perhaps suggestive of a protective upregulation of 
the GSH/GSSG redox reactions. The activity of GST in a number of brain regions 
and in ventricular CSF were found in one study to be lower in AD patients compared 
with controls (Lovell et al. 1998b). However, in another case there was no difference 
in GST activity in frontal cortex or substantia innominata between control and AD 
brains (Perry et al. 1987). Polymorphisms in certain GST genes have been found to 
affect age at onset and clinical progression of AD (Li et al. 2003, 2006; Kolsch et al. 
2004; Bernardini et al. 2005; Spalletta et al. 2007).  
 
CSF from MS patients has been shown to have decreased GSH and increased GSSG 
levels compared with controls (Calabrese et al. 2002). In addition, increased levels 
of the lipid  peroxidation product  malondialdehyde in  MS CSF suggest  increased 
levels of oxidative stress (Calabrese et al. 1994). CSF from MS patients also had 
increased GR activity and decreased GPx activity (Calabrese et al. 1994). In contrast 
to  the  situation  in  CSF,  in  the  plasma  of  MS  patients,  GSH  levels  and  the 90 
 
GSH:GSSG ratio were found to be increased compared with controls (Calabrese et 
al. 2002).  
 
1.5.5. Astrocytes release GSH 
 
The release of GSH by astrocytes is very well-characterised (Yudkoff et al. 1990; 
Juurlink et al. 1996; Sagara et al. 1996; Dringen et al. 1999b; Stewart et al. 2002). 
GSH is released via the ATP-dependent transporter, multidrug resistance-associated 
protein 1 (Mrp1) (Hirrlinger et al. 2002c; Minich et al. 2006), and subsequently 
cleaved  by  the  astrocyte-associated  ectoenzyme  GT  (EC  2.3.2.2)  to  produce 
cysteinylglycine (Dringen et al. 1997). This provides a supply of GSH precursors for 
neurones. The neurone-associated ectoenzyme aminopeptidase N (ApN) cleaves the 
astrocyte-derived  cysteinylglycine  to  produce  L-cysteine  (Dringen  et  al.  2001), 
which is taken up via EAAT3 (Aoyama et al. 2006), thus providing neurones with 
the limiting substrate for GSH synthesis. Accordingly, the GSH level of neurones 
co-cultured  with  astrocytes  has  been  demonstrated  to  be  much  higher  than  in 
neurones  cultured alone (Bolaños et al. 1996;  Dringen et al. 1999b; Gegg et al. 
2005).  Depletion  of  astrocyte  GSH  leads  to  lower  levels  of  GSH  in  co-cultured 
neurones  and  increased  neuronal  sensitivity  to  nitric  oxide  toxicity  (Gegg  et  al. 
2005), illustrating the importance of this supply for maintenance of neuronal GSH 
levels and neuronal survival. The pathway described here is illustrated in figure 1.11. 
 
1.5.6. Microglial glutathione 
 
As  in  all  cell  types,  the  main,  continuous  source  of  ROS  in  microglia  is  the 
mitochondrial  electron transport chain,  as  a by-product  of cellular respiration.  In 
addition, microglial activation causes expression of iNOS and consequent production 
of  NO  (Chao  et  al.  1992;  Ding  et  al.  1997;  Possel  et  al.  2000),  as  well  as  the 
generation of superoxide by NADPH oxidase (Colton and Gilbert 1987; Klegeris and 
McGeer 1994; Sankarapandi et al. 1998). Either of these species may be damaging 
alone; alternatively they may combine to form peroxynitrite (Ischiropoulos et al. 
1992; Szabo et al. 1997; Noack et al. 1999). The production of ROS and RNS during 
normal microglial function is potentially cytotoxic, and indicates that antioxidants 
such as GSH are likely to be important for microglial protection. 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Astrocytes release GSH to supply neurones with cysteine for GSH synthesis. 
GSH  is  released  by  astrocytes  via  Mrp1,  and  is  cleaved  sequentially  by  the  astrocyte-
associated enzyme GT and the neurone-associated enzyme ApN to yield cysteine, which is 
taken  up  via  neuronal  EAAC1.  ApN,  aminopeptidase  N;  Cys,  cysteine;  CysGly, 
cysteinylglycine; EAAC1, excitatory amino acid carrier 1; GSH, reduced glutathione; GT, 
-glutamyl transpeptidase; Mrp1, multidrug resistance protein 1. 
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Accordingly, microglia have a prominent GSH system, containing the highest levels 
of GSH amongst the cells of the CNS (Chatterjee et al. 1999, 2000; Hirrlinger et al. 
2000, 2002b; Noack et al. 2000), found to be in the region of 25 – 40 nmol.mg
-1 
protein  in  vitro  (Hirrlinger  et  al.  2000,  2002c;  Persson  et  al.  2006).  GPx 
immunoreactivity appeared to be largely confined to microglia in the rat (Lindenau 
et al. 1998) and human CNS (Hirato et al. 2003). In culture, microglial GPx activity 
was significantly higher than that of neurones (Hirrlinger et al. 2000), similar to that 
of astrocytes (Hirrlinger et al. 2000; Hollensworth et al. 2000), but lower than that of 
oligodendrocytes (Hollensworth et al. 2000; Hirrlinger et al. 2002b). 
 
Cultured microglia also demonstrated robust GR immunoreactivity (Gutterer et al. 
1999), and GR activity was significantly higher in microglia than in neurones or 
astrocytes (Hirrlinger et al. 2000), but significantly lower than in oligodendrocytes 
(Hirrlinger  et  al.  2002b).  Inhibition  of  GCL  by  L-buthionine  sulfoximine  (BSO) 
depleted microglial GSH by 70 % in 6 hours in N9 microglial cells (Roychowdhury 
et  al.  2003),  suggesting  a  relatively  high  rate  of  continual  GSH  synthesis  under 
normal circumstances. Microglia are thought to rely on L-cystine uptake by the xc
- 
transporter system to supply cysteine for glutathione synthesis (Barger et al. 2007). 
This cystine is imported in exchange for glutamate, and glutamate is imported by 
EAATs which are expressed at low levels by microglia. 
 
A  number  of  studies  report  alterations  in  microglial  GSH  levels  in  response  to 
microglial  activation;  however,  a  consensus  of  the  effect  of  activation  upon 
intracellular GSH is yet to be reached. In mixed glial cultures containing 10 – 20% 
microglia, fluorescence of monochlorobimane (MCB), a marker of GSH, declined by 
around 40% in microglia following treatment with LPS and IFN (Chatterjee et al. 
2000; Noack et al. 2000), whilst GSH levels in the co-cultured astrocytes remained 
stable. Inhibition of iNOS blocked the GSH decline. GSH levels in the BV-2 and 
N11 microglial cell lines were also shown to decline in the presence of LPS and 
IFN, which was prevented by iNOS inhibition in the case of N11 cells, but not BV-
2 cells (Moss and Bates 2001). Biochemical determination of GSH levels in N9 cells 
also demonstrated a decrease following LPS and IFN treatment (Roychowdhury et 
al. 2003), which was shown to be limited to the cytosolic portion of GSH, while 93 
 
mitochondrial  GSH  levels  remained  stable.  Conversely,  Dopp  et  al.  (2002) 
demonstrated  an  increase  in  microglial  GSH  levels  over  time  in  primary  rat 
microglia in the presence of TNFα. This result was corroborated by Persson et al. 
(2006) in primary rat microglia treated with LPS or TNFα, where GSH levels were 
determined by two independent methods. 
 
Macrophages have been shown to release thiols (Watanabe and Bannai 1987), and 
more  recently,  GSH  specifically  (Sato  et  al.  2001).  Although  one  recent  study 
(Hirrlinger et al. 2002c) failed to detect GSH release by microglia, the conditions 
used were optimised for astrocytes (Dringen et al. 1997, 1999b; Stewart et al. 2002; 
Gegg et al. 2005; Minich et al. 2006; Frade et al. 2008) and may not have favoured 
the  detection  of  microglial  GSH  release.  Microglia  have  been  shown  to  express 
functional Mrps (Ballerini et al. 2002; Dallas et al. 2003); microglial expression of 
Mrp1 is well documented (Ballerini et al. 2002; Hirrlinger et al. 2002a; Dallas et al. 
2003),  and  other  Mrp  subtypes  may  also  be  expressed  (Ballerini  et  al.  2002; 
Hirrlinger et al. 2002a). Mrp1 can transport GSSG (Leier et al. 1996), glutathione 
conjugates (Loe et al. 1996) and drugs in cotransport with GSH (Zaman et al. 1995; 
Loe et al. 1998), as well as some drugs alone or conjugated or cotransported with 
other molecules (Konig et al. 1999; Leslie et al. 2001). Indeed, vincristine export by 
microglia of the MLS-9 cell line has been shown to depend upon intracellular GSH, 
suggesting cotransport via Mrp1 (Dallas et al. 2003). Microglia therefore may have 
the ability to release GSH or glutathione conjugates via Mrp1. Unlike astrocytes, 
microglial GT activity is low or absent (Murata et al. 1997; Ruedig and Dringen 
2004),  suggesting  that  should  microglia  release  GSH,  it  may  have  a  different 
function from astrocyte-derived GSH. 
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1.6. Aims 
 
Microglia are implicated in the pathogenesis of neuroinflammatory conditions such 
as  AD  and  MS.  However,  microglial  activation  may  have  positive  or  negative 
outcomes  in  terms  of the  disease  course  and  neuronal  fate.  The  GSH  system  of 
microglia is  yet to be fully understood. Microglial GSH levels may impact upon 
microglial survival, in that GSH depletion may leave the cell vulnerable to oxidative 
damage and death. This may affect the neuroprotective or neurotoxic properties of 
microglia; for example the death of microglia chronically producing ROS and RNS 
may limit the production of such species and therefore the associated neurotoxicity. 
Alternatively microglial GSH depletion and death may be detrimental to neurones.  
 
Studies  upon  the  effect  of  activation  upon  microglial  glutathione  levels  have 
produced conflicting results; one aim of this thesis is to resolve this and to extend the 
investigation to proteins associated with neuroinflammatory disease, as published 
reports have limited study to the effects of LPS and IFN, and TNFα. Whether or not 
microglia  have  an  ability  to  release  GSH  is  also  disputed,  although  the  likely 
function of such release is unclear as unlike astrocytes, microglia do not possess the 
transferase GT to provide neuronal GSH precursors. A second aim of this thesis is 
to  clarify  whether  or  not  microglial  glutathione  release  occurs  in  vitro  and  to 
investigate the effect of microglial activation upon release. 
 
Changes  in  microglial  GSH  levels  may  relate  to  changes  in  the  expression  of 
glutamate transporters, as these supply glutamate and cystine for microglial GSH 
synthesis. However, alterations in glutamate transporter expression or activity may 
have effects upon the amino acid constitution of the extracellular environment and 
consequences for other cells. Therefore a third aim of this thesis is to investigate the 
expression of glutamate transporters by microglia in vitro in the presence of LPS and 
disease-related microglial activators, and the consequences of such expression upon 
glutamate levels. 
 
Modulation of microglial mGluRs has been shown to affect the neuroprotective or 
neurotoxic nature of microglia in vitro. The final aim of this thesis is to investigate 95 
 
whether  such  mGluR  modulation  also  affects  microglial  GSH  levels,  transporter 
expression  and  glutamate  release,  as  this  may  provide  further  insight  into  the 
mechanisms of neuroprotection and neurotoxicity. 
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Chapter 2 
Materials and Methods 
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2.1 Materials 
 
2.1.1 Animals 
 
Wistar rat pups were obtained from Institute of Neurology in-house colonies and 
Sprague-Dawley rat pups were obtained from University College London in-house 
colonies. 
 
2.1.2 Reagents 
 
Gibco  brand  D-MEM  and  MEM  powder,  phenol  red-free  D-MEM,  FBS,  NCS, 
amphotericin B fungicide and EBSS were obtained from Invitrogen (Paisley, UK). 
DHPG,  tADA,  AIDA,  DCG  IV,  MCCG,  L-AP4,  MAP4,  (RS)-PPG,  SIB-1757, 
APICA, DHK, CNQX, MK-801 and AMT-HCl were obtained from Tocris (Bristol, 
UK). Orthophosphoric acid, concentrated HCl, methanol and Y27632 were obtained 
from VWR International (Leicestershire, UK). Absolute ethanol was obtained from 
the in-house pharmacy or from VWR. CDPPB, MTEP and L-cystine were obtained 
from Calbiochem, Merck Chemicals (Nottingham, UK). IFN was obtained from 
R&D  Systems  (Oxfordshire,  UK).  CGA  was  obtained  from  Scientific  Marketing 
Associates  (Herts,  UK).  Aβ25-35  was  obtained  from  Bachem  (Merseyside,  UK). 
Pierce  BSA  standard  for  the  protein  assay  was  obtained  from  ThermoFisher 
Scientific (Loughborough, UK). The GSH-Glo glutathione assay kit was obtained 
from  Promega  UK  Ltd.  (Southampton,  UK)  and  the  ATP  assay  kit  from  Roche 
Diagnostics  (West  Sussex,  UK).  Rabbit  anti-mouse  iNOS  antibody  was  obtained 
from  BD  Transduction  Laboratories  (Oxford,  UK)  and  goat-anti  rabbit  TRITC-
conjugated antibody was obtained from Sigma-Aldrich (Dorset, UK). Vectashield 
mountant  was  obtained  from  Vector  Laboratories  (Peterborough,  UK).  TRIzol® 
reagent,  Tris/borate/EDTA  buffer,  MMLV  reverse  transcriptase,  oligo(dT)12-18 
primer,  RNase  OUT,  dNTPs  and  Taq  DNA  polymerase  was  obtained  from 
Invitrogen and DNA ladders and gel loading dye from Promega. Oligonucleotide 
primers for β-actin, rat EAAT1, rat EAAT2 and mouse xCT were a kind gift from Dr 
Marcus Rattray, Kings College London. Duplicates of these, and other primers were 
obtained  from  Sigma  Genosys.  Antibiotics  for  tissue  culture,  Percoll®,  poly-D-98 
 
lysine,  accutase®,  LPS,  fraction  V  albumin,  NAAG,  N-acetyl-L-cysteine,  L-
cysteine,  fibrin,  fibrinogen,  aminopimelic  acid,  aminoadipic  acid,  1400W,  GSH, 
GSSG,  glutathione  reductase,  monochlorobimane,  ethacrynic  acid,  L-glutamate 
dehydrogenase, pyruvate kinase, phosphoenol pyruvate, GABA, ATP, ADP, lactate 
dehydrogenase, propidium iodide, agarose, Coomassie reagent for Bradford protein 
assay, and all other chemicals were obtained from Sigma Aldrich.  
 
2.1.3 Consumables 
 
Filtration  units  for  cell  culture,  syringes,  glass  Pasteur  pipettes,  13  mm  glass 
coverslips,  0.5  ml  tubes  and  TriGene  Green  disinfectant  were  obtained  from 
Scientific Laboratory Supplies (SLS; Nottingham, UK). Sterile Petri dishes for cell 
culture were obtained from Marathon Laboratory Supplies (London, UK). Six and 24 
well tissue culture plates and tissue culture flasks were obtained from Triple Red 
(Bucks, UK). Sterile 50 ml centrifuge tubes were obtained from Triple Red and SLS. 
Cell scrapers were obtained from Marathon and Helena Biosciences (Tyne & Wear, 
UK).  Razor  blades  were  obtained  from  Blademail  (Norfolk,  UK).  Glass  slides, 
syringe filters, sterile serological pipettes, sterile 15 ml centrifuge tubes, 96 well 
plates,  1.5  ml  tubes  and  latex  gloves  were  obtained  from  VWR  International 
(Leicestershire, UK). Pipette tips were obtained from VWR International, SLS or 
Anachem (Luton, UK). RNase-free pipette tips were obtained from Starlab (UK) 
Ltd. (Milton Keynes, UK). Eppendorf brand safe-lock 1.5 ml and 2 ml tubes for 
molecular biology were obtained from Helena Biosciences. PCR 0.2 ml tubes and 
caps in strips were obtained from Applied Biosystems (Warrington, UK). Molecular 
BioProducts brand RNase away RNase inhibitor spray for surfaces and gloves was 
obtained from ThermoFisher Scientific (Loughborough, UK). Chromacol brand vials 
and lids for HPLC were obtained from VWR International.  
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2.2 Methods 
 
2.2.1 Cell culture 
 
All cell medium was made up using distilled water (dH2O) which was filtered to 0.2 
m and UV-treated. Once prepared, medium was filtered to 0.2 m again to sterilise. 
A Heraeus HeraSafe class II safety cabinet and Heraeus HeraCell Incubators were 
used for cell culture. Cell culture cabinets and incubators were cleaned regularly 
with TriGene disinfectant and all items placed in hoods and incubators were sprayed 
with 70% ethanol to maintain the sterile environment. 
 
2.2.1.1 Culture of primary rat microglia 
 
All tools used in the dissection of brains during preparation of primary cells were 
autoclaved and then sterilised under UV light before use. Razor blades were flamed 
thoroughly until glowing red-hot and only used once. 
 
2.2.1.1.1 Percoll gradient method 
 
Initially,  primary  rat  microglial  cells  were  obtained  by  a  method  devised  in  this 
laboratory (Kingham et al. 1999). Post-natal day 3-5 Wistar rat pups were killed by 
cervical dislocation and decapitation in accordance with the Scientific Procedures 
Act 1986 (United Kingdom). Brains were removed and all but the cerebellae were 
transferred immediately to ice-cold phosphate-buffered saline (PBS; 137 mM NaCl, 
5.37 mM KCl, 5.65 mM NaH2PO4.H2O, 13.3 mM Na2HPO4.7H2O, 11.1 mM D-
glucose, 0.02% bovine serum albumin (BSA), 100 units.ml
-1 penicillin, 0.1 mg.ml
-1 
streptomycin, 3 g.ml
-1 ampicillin, pH 7.4, made up in filtered, UV-treated dH2O). 
Brains were rinsed and homogenised in PBS and split between 50 ml centrifuge 
tubes such that there were approximately 3 brains per tube. Each tube was topped up 
to 40 ml with PBS and centrifuged in an Eppendorf 5804R benchtop centrifuge at 
4500 rpm (3645 g) for 10 min. Supernatants were removed and discarded and the 
pellets were resuspended in 70% Percoll in PBS. A Percoll gradient was set up with 
15 ml 70% Percoll in PBS, overlaid with 12 ml 30% Percoll in PBS and finally 5 ml 100 
 
PBS, again with the equivalent of approximately 3 brains per tube. The gradients 
were centrifuged at 4000 rpm (2880 g) for 50 min to separate the microglia from the 
rest of the brain matter. Following this centrifugation, microglia were collected from 
the interface between the 70% Percoll and 30% Percoll layers (see fig. 2.1) and 
transferred to fresh PBS.  
 
 
 
Figure  2.1.  Separation of  microglia from  the  rest of  the  brain  matter  using  a  Percoll 
gradient. 
 
 
Microglia were pelleted by centrifuging at 4800 rpm (4147 g) for 10 min and pellets 
were resuspended in microglial medium (glutamine-free minimum essential medium 
(MEM) with Earle‟s salts supplemented with 10% foetal bovine serum (FBS), 21.5 
mM KCl, 33.3 mM D-glucose, 2.05 mM glutamine, 100 units.ml
-1 penicillin, 100 
g.ml
-1 streptomycin, 100 g.ml
-1 kanamycin and 50 g.ml
-1 gentamicin). Cells were 
counted with trypan blue and plated at 1.2 x 10
5 cells on 13 mm glass coverslips or 
4.8 x 10
5 cells per well in 35 mm culture dishes in a small volume (100 l on 13 mm 
coverslips or 400 l in 35 mm dishes). Cells were left to adhere in an incubator at 
37C in a humidified atmosphere of 6% CO2 in air for 45 minutes, then washed 
twice with microglial medium (as above) and replaced in the incubator with a larger 
volume of medium; approximately 500 l MEM per 13 mm coverslip or 2 ml MEM 
per 35 mm dish. Two to 3 hours later microglia were washed again, as before, and 
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left in the incubator overnight. Cells were washed once more the following morning 
and used within 48 hours.  
 
It  has  previously  been  demonstrated  by  immunocytochemistry,  using  antibodies 
directed  against  the  microglial  antigen  OX-42  and  the  astrocyte  antigen  glial 
fibrillary  acidic  protein  (GFAP),  as  well  as  the  microglial  marker  Bandeiraea 
simplicifolia  isolectin  B4,  that  up  to  4  days  in  vitro  (DIV),  primary  microglia 
cultures  prepared  using  the  Percoll  gradient  method  devised  in  this  laboratory 
(Kingham et al. 1999) contain consistently > 90% microglia, with the majority of the 
contaminating cells being astrocytes (Kingham et al. 1999;Morgan et al. 2004). In 
addition it was shown that at 2 DIV < 20% microglia stain positively with the ED1 
antibody, indicating a low level of basal activation (Morgan et al. 2004).  
 
2.2.1.1.2. Mixed glial culture method 
 
The above method, utilising a Percoll gradient to isolate microglia, has been used in 
this laboratory for almost ten years. However, in order to obtain oligodendrocytes 
from the same tissue, we have devised another protocol, following the more widely-
used method involving  establishing  a mixed glial  culture and then removing the 
microglia by shaking. This also has the advantage of a higher microglial yield. The 
method  used  here  is  loosely  based  upon  that  devised  by  (Armstrong  1998). 
Oligodendrocytes  can  be  removed  after  the  microglia  by  further,  more  vigorous 
shaking. 
 
2.2.1.1.2.1 Coating culture flasks with poly-D-lysine 
 
Four millilitres of poly-D-lysine (PDL) at 100 g.ml
-1 in sterile filtered, UV-treated 
dH2O  was  added  to  each  75  cm
2  tissue  culture  flask  and  incubated  at  room 
temperature in a tissue culture hood for 2 hours. The excess liquid was then aspirated 
and the flasks left in the tissue culture hood with their caps off until completely dry. 
PDL-coated  flasks  were  stored  at  -20C  and  placed  in  the  incubator  at  37C 
approximately one hour before use. 
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2.2.1.1.2.2 Preparation of primary mixed glial cultures 
 
Eight post-natal day 2 Sprague-Dawley rat pups were killed by cervical dislocation 
and  decapitation  in  accordance  with  the  Scientific  Procedures  Act  1986  (United 
Kingdom). Brains were removed and immediately transferred to a dish of ice-cold L-
glutamine-free MEM with Earle‟s salts, supplemented with 100 units.ml
-1 penicillin, 
100  g.ml
-1  streptomycin  and  25  mM  4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) (HEPES-MEM). Brains were then dissected one at a 
time in a separate dish. The cerebellum and brainstem were removed and discarded 
and the brain divided into the two hemispheres. The mid-brain was also removed and 
discarded and the two cortical hemispheres placed in a fresh dish of HEPES-MEM. 
The  cortices  were  then  mechanically  dissociated  using  a  syringe  and  needles  of 
progressively smaller gauges (19G, 23G, 25G). Once fully homogenised, the tissue 
was placed in a 50 ml centrifuge tube and made up to 50 ml with HEPES-MEM. 
This was centrifuged in an Eppendorf 5804R benchtop centrifuge for 10 minutes at 
230  g  to  loosely  pellet  the  cells.  The  pellet  was  resuspended  in  pyruvate-free 
Dulbecco‟s  Modified  Eagle  Medium  (D-MEM)  containing  4500  mg/l  D-glucose, 
supplemented with 10% FBS, 1 mM sodium pyruvate and 25 g.ml
-1 gentamicin. 
The cells were divided between three PDL-coated 75 cm
2 tissue culture flasks (see 
2.2.1.1.2.1  above),  each  containing  approximately  15  ml  D-MEM  (as  before). 
Cultures were maintained at 37°C in a humidified atmosphere of 6.0% CO2 in air. 
The medium on the glial cultures was changed on day 3, day 6 and day 10. 
 
2.2.1.1.2.3 Isolation of microglia 
 
By day 13, microglia were clearly visible as the smallest, brightest cells within the 
glial  cultures.  Microglia were  removed by shaking at  125  rpm on a Stuart  Mini 
Orbital  Shaker  model  SSM1  for  4-5  hours  in  a  Hybaid  Midi  Dual  14  oven 
maintained  at  37C  (Sierra  et  al.  2008).  The  medium  was  then  removed  and 
centrifuged at 4500 rpm (3645 g) for 5 min and the pellet resuspended in a small 
volume of D-MEM (as before). Cells were counted using a haemocytometer and 
plated at 1 x 10
5 cells on 13 mm glass coverslips or at 5-6 x 10
5 cells per well in 35 
mm culture dishes or at 1 x 10
6 cells per well in 60 mm culture dishes in a small 103 
 
volume (50 l on 13 mm coverslips, 400 l in 35 mm dishes, 800 l in 60 mm 
dishes) and placed in the incubator to adhere for 1 hour. Further D-MEM was then 
added to give approximately 500 l per 13 mm coverslip or 2 ml per 35 mm dish. 
The following day, the medium was changed and compounds added as appropriate. 
Primary  microglia  obtained  in  this  manner  were  always  used  within  3  days  of 
removal from the mixed glial culture. 
 
Staining  using  the  microglial  marker  Bandeiraea  simplicifolia  isolectin  B4 
demonstrated that microglia obtained from three different preparations were 96.3 ± 
1.2 % pure, with the majority of the contaminating cells being of the oligodendrocyte 
lineage (Ioanna Sevastou, personal communication). 
 
2.2.1.2. Microglial cell lines 
 
Because  of  the  difficulties  of  obtaining  large  numbers  of  primary  microglia  and 
culturing them in a “ramified” state, and as a means to minimise the use of animals 
in  experiments,  immortalised  cell  lines  are  often  used  to  represent  cultured 
microglia.  The  mouse  microglial  cell  lines  BV-2  and  N9  are  two  of  the  most 
commonly used as models of primary microglia in culture. Of the two, the BV-2 cell 
line appears to be more frequently used in published studies, particularly in recent 
years (128 references found for BV-2 microglial cells in NCBI PubMed in 2008 and 
2009 to date, compared with 21 references for N9 cells).  
 
The BV-2 cell line was originally derived from mouse microglial cultures obtained 
from newborn animals of the C57BL/6 strain, transformed with the v-raf and v-myc 
oncogenes of the J2 retrovirus (Blasi et al. 1990). BV-2 cells have been shown to 
resemble  primary  microglia  morphologically,  electrophysiologically  and 
functionally.  BV-2  cells  phagocytose  inactivated  yeast  cells  and  latex  beads  and 
maintain the constitutive and inducible secretory properties of primary microglia. In 
addition, this phenotype is maintained over time in in vitro culture (Blasi et al. 1990; 
Bocchini  et  al.  1992).  A  more  recent  study  strengthened  these  original  findings, 
demonstrating that the genes upregulated by LPS in BV-2 microglia mirror those 
upregulated in primary microglia, although the upregulation in BV-2 cells was often 
less pronounced (Lund et al. 2006). 104 
 
 
The N9 cell line was derived originally from microglial cultures from embryonic day 
13  outbred  CD1  mice,  transformed  with  the  v-myc  oncogene  from  the  3RV 
retrovirus  (Corradin  et  al.  1993).  N9  microglia  have  been  shown  to  respond  to 
classical  microglial  activating  stimuli  such  as  LPS,  IFN  and  TNFα  with  NFκB 
expression, and release of NO, TNFα and chemokines, in a similar way to primary 
microglia (Corradin et al. 1993; Meda et al. 1995; Bonaiuto et al. 1997). Although it 
has been claimed that N9 cells may not be phagocytically active (Zhang et al. 2003), 
phagocytosis of E. Coli bioparticles (Stefano et al. 2009), latex beads (Bruce-Keller 
et al. 2001), dextran beads and myelin (Pinteaux-Jones 2007) by N9 microglia has 
been demonstrated in recent years. 
 
Both BV-2 (Moss and Bates 2001) and N9 (Roychowdhury et al. 2003) cell lines 
have been previously utilised in studies investigating microglial glutathione levels, 
although in neither case were results compared with those for primary microglia. 
 
2.2.1.2.1. Culture of the BV-2 mouse microglial cell line 
 
The BV-2 mouse microglial cell line was a kind gift from Dr. Claudie Hooper (MRC 
Centre  for  Neurodegenerative  Research,  Institute  of  Psychiatry,  Kings  College 
London,  UK)  and  originally  obtained  from  Dr.  FS  Tzeng  (Department  of  Life 
Sciences, National Cheng Kung University, Taiwan). BV-2 microglial  cells were 
cultured  in  pyruvate-free  D-MEM  with  4500  mg.L
-1  glucose,  supplemented  with 
10% FBS, 2 mM glutamine, 100 units.ml
-1 penicillin, 100 g.ml
-1 streptomycin and 
125 ng.ml
-1 amphotericin B fungicide, at 37°C in a humidified atmosphere of 6.0% 
CO2 in air. Medium was changed at least weekly and when confluent, cells were 
removed from the flask using 2 ml 400-600 U.ml
-1 accutase in  Dulbecco‟s  PBS 
containing  0.5  mM  EDTA  and  3  mg.L
-1  phenol  red.  Cells  were  pelleted  by 
centrifugation in an Eppendorf 5804R benchtop centrifuge at 4500 rpm (3645 g) for 
5 min. Cells were counted using a haemocytometer and plated as required at 0.5-2 x 
10
4 cells on 13 mm glass coverslips and at 5-10 x 10
4 cells per well in 35 mm culture 
dishes, and typically used after 2-3 DIV. 
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2.2.1.2.2. Culture of the N9 mouse microglial cell line 
 
The N9
 microglial cell line was a kind gift from Dr. Paola Ricciardi
 Castagnoli (CNR 
Cellular and Molecular Pharmacology Centre,
 Milan, Italy). N9 mouse microglial 
cells  were  cultured  in  pyruvate-  and  NaHCO3-free  Dulbecco‟s  modified  Eagle 
medium (D-MEM) with 4500 mg.L
-1 glucose, supplemented with 5% newborn calf 
serum  (NCS),  4.4  mM  NaHCO3,  57.2  µM  -mercaptoethanol,  50  units.ml
-1 
penicillin,  50  g.ml
-1  streptomycin,  100  g.ml
-1  kanamycin  and  50  g.ml
-1 
gentamicin. Medium was changed at least weekly and when confluent cells were 
scraped  from  the  flask  and  pelleted  by  centrifugation  in  an  Eppendorf  5804R 
benchtop centrifuge at 4500 rpm (3645 g) for 5 min. Cells were counted using a 
haemocytometer and plated as required at 1-2 x 10
4 cells on 13 mm glass coverslips 
and at 8-10 x 10
4 cells per well in 35 mm culture dishes, and typically used after 2-3 
DIV. 
 
 
2.2.2  Determination  of  intracellular  reduced  glutathione  levels  with  reverse-
phase HPLC 
 
2.2.2.1 Principle 
 
Reduced glutathione (GSH) was separated from other constituents of samples by 
means of reverse-phase high performance liquid chromatography (HPLC). In this 
method  the  mobile  phase,  here  15  mM  orthophosphoric  acid  (OPA),  is  forced 
through a chromatography column (the stationary phase) under high pressure. The 
column contains C18 chains (octadecasilyl) bonded to microscopic silicone beads. 
Hydrophobic interactions with the C18 chains retard the progress of molecules as 
they are forced through the column. Time taken for a given molecule to be eluted 
from the column (its retention time) depends upon its hydrophobicity and is identical 
under the same conditions. 
 
An electrochemical method of detection was used to quantify GSH levels of samples 
(Riederer et al. 1989). Eluent from the column passes into the electrical cell (model 
5010),  part  of  the  Coulochem  II  electrochemical  detector  (ESA  Analytical, 106 
 
Aylesbury,  UK).  The  porous  graphite  analytical  cell  contains  two  electrodes  in 
series, set to constant voltages optimised for the molecule being studied. At each 
electrode,  molecules  within  the  eluent  are  oxidised,  and  the  electrons  released 
produce a current. The voltage at the upstream electrode (E1) is below that which the 
molecule  of  interest  will  oxidise  to  eliminate  the  more  readily  oxidised  species 
within the sample. The downstream electrode (E2) is set to a voltage at which the 
molecule of interest readily oxidises, and is connected to the integrator, which draws 
a chromatograph representing the current produced at E2 in real time. Molecules are 
identified by their retention time; the peak height at this time corresponds to the 
current they induce at E2, which is directly proportional to the concentration of the 
molecule of interest. Figure 2.2 shows some typical chromatograms. 
 
A suitable voltage at E2 for a molecule of interest is determined by means of a 
voltammogram; a standard concentration of the molecule of interest is run through 
the column at a range of different voltages, and peak height is plotted against voltage 
(fig. 2.3). The optimal voltage is that which gives a maximal or almost maximal peak 
height whilst keeping background current low and producing a clean, narrow peak 
on the chromatograph.  
 
2.2.2.2 Preparation of cells 
 
Cells were cultured in 35 mm dishes, and following treatment of cells as desired, 
medium was removed, and cells were gently rinsed with phosphate-buffered saline 
(PBS; 154 mM NaCl, 1.84 mM KH2PO4, 9.81 mM K2HPO4.3H2O, pH adjusted to 
7.2-7.3 with further addition of KH2PO4/K2HPO4.3H2O as necessary). Cells were 
detached  by  incubation  for  5  minutes  with  200  l  400-600  U.ml
-1  accutase  in 
Dulbecco‟s PBS containing 0.5 mM EDTA and 3 mg.L
-1 phenol red, transferred to 
1.5 ml tubes and pelleted by centrifugation in a Jouan A14 microcentrifuge at 7000 
rpm  (2465  g)  for  10  minutes.  Pellets  were  resuspended  in  Earle‟s  balanced  salt 
solution (EBSS), typically 20 l, 5 l of which was then removed for determination 
of protein content (see 2.2.11). The remainder was snap frozen on dry ice and stored 
at -80C.  
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Figure 2.2. Examples of chromatograms produced following injection of 5 µM reduced 
glutathione  (A)  and  a  sample  from  activated  BV-2  cells  (B),  with  E1=100mV  and 
E2=600mV. The retention time of reduced glutathione is just over 13 minutes. The peak at 
around 5 minutes in (B) may be due to components present in the Earle’s balanced salt 
solution (EBSS) in which the BV-2 sample is resuspended. Note also the slightly less stable 
baseline in (B) which may be due to small amounts of other compounds in the sample. 
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Figure 2.3. Voltammogram constructed using 10 µM reduced glutathione (GSH) standard 
(red). GSH chromatograms with a sample from each of control N9 cells (blue) and BV-2 
cells (green) are also shown to demonstrate that the shape of the chromatogram for GSH 
with this setup remains the same. The voltage at E1 was maintained at 100 mV throughout. 
Here the optimum voltage at E2 is 650 mV as this gives a near-maximal response, and at 
higher  voltages  the  background  current  was  too  high  to  be  used  routinely  and  the 
chromatography became noisy.  
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 2.2.2.3 Measurement of reduced glutathione 
 
The  GSH  concentrations  of  samples  were  measured  electrochemically  following 
separation by reverse-phase HPLC, using a method based on that of Riederer et al. 
(1989) (Gegg et al. 2005). The mobile phase was 15mM OPA, made up in water 
purified  to  an  electrical  resistance  of  18.2  Mohms.cm
-1  (PureLab  Maxima,  Elga, 
Derbyshire, UK). Samples were thawed and GSH was extracted by the addition of a 
suitable volume of 15 mM OPA (185 l-985 µl) followed by thorough vortexing. 
Protein was pelleted by centrifugation in an Eppendorf 5415R centrifuge at 10 000 g 
for 5 minutes. The supernatant was injected into the HPLC, either by means of a 
Hamilton syringe (Sigma Aldrich, Dorset, UK) and Rheodyne manual injector (20 µl 
injection loop) or a Jasco autosampler (model AS-2055 Plus; Jasco, Essex, UK), 
which injected 50 µl. In either case the samples passed through a 3 mm x 10 mm 
guard column, and into a 4.6 mm x 250 mm analytical column packed with 5 M 
octadecasilyl-silica  (HPLC  Technology  Co  Ltd,  purchased  from  Chromacol  Ltd, 
Hertfordshire, UK). Both columns were housed in a block heater (model 7970; Jones 
Chromatography, Mid Glamorgan, UK) and maintained at 30C. The mobile phase 
was pumped through the system at 0.5 ml.min
-1 by a Jasco PU-1580 pump (Jasco, 
Essex, UK). With this setup the pressure in the column was in the range 50 - 70 
kg.cm
-2. With a new column, the retention time for GSH was around 13.7 minutes, 
electrode potentials were set at E1=100 mV and E2=450 mV, and the total run time 
used  was  18  minutes.  A  Chromjet  integrator  (model  SP4400;  ThermoFinnigan, 
Thermo Fisher Scientific, Hemel Hempstead, UK), connected to  the downstream 
electrode, recorded the generated current and produced chromatograms in real-time. 
Standards of two or three concentrations of GSH in 15 mM OPA were run within 
each  experiment  (fig.  2.4)  to  allow  GSH  concentrations  of  the  samples  to  be 
calculated by comparison. These were corrected for sample dilution, normalised for 
protein content, and expressed as nmol.mg
-1 protein. 
 
Data  produced  by  this  method  were  relatively  consistent  in  terms  of  percentage 
change from control with test conditions. However the actual values in nmol.mg
-1 
protein did show some degree of variation. This echoes the variability in reported 
values as mentioned in section 1.5.3. In any case, the importance of absolute values 110 
 
of glutathione content of cells in culture is questionable, as it has been shown to be 
affected by culture conditions (Dringen et al. 1999b). Data are presented wherever 
possible in nmol.mg
-1 protein, but values are not necessarily comparable between 
experiments. Therefore all necessary controls and comparison values were run in 
every experiment, and are not shared between figures. For example, where LPS was 
added in combination with other compounds, an LPS-only control was run in the 
same experiment rather than referring to earlier results for LPS-treated cells. 
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Figure 2.4. Example of a typical reduced glutathione (GSH) reverse-phase HPLC standard 
curve constructed with 2 µM, 5 µM and 10 µM GSH in 15 mM OPA. In this case, r
2=0.9991. 
 
 
To  check  GSH  recovery,  some  cells  were  scraped  as  normal  and  having  been 
resuspended in EBSS, the suspension was split in two. To half was added a known 
concentration of GSH and to the other half an equivalent volume of EBSS. The two 
samples were then run through the assay. The efficiency of the GSH method is given 
by: 
 
Recovery  =   concentration difference according to chromatogram   x 100 
                                   actual concentration difference 
 
GSH recovery using this method was calculated to be 77.5 ± 3.4 % (n=6). 111 
 
2.2.2.4 Measurement of oxidised and total glutathione 
 
As well as the reduced form, GSH, oxidised glutathione (GSSG) may also be present 
in cells. To calculate total glutathione levels (i.e. GSH + GSSG), from which GSSG 
levels  can  be  calculated,  cells  were  prepared  for  HPLC  as  above,  but  following 
resuspension in EBSS samples were split in half. One half of each sample was used 
to measure GSH, as above. The other half was treated with glutathione reductase 
(GR; EC 1.6.4.2), in the presence of reduced nicotinamide adenosine dinucleotide 
phosphate  (NADPH),  in  order  to  convert  GSSG  to  GSH  (Stewart  et  al.  2002). 
Samples were incubated at 37C for 10 minutes, in a Techne Dri-Block model DB-
2D block heater, with an equal volume of 100 mM KH2PO4, 3.4 mM EDTA buffer, 
pH 7.6, containing 500 M NADPH and 2 units GR. Samples were snap-frozen on 
dry  ice  and  GSH  levels  determined  by  HPLC  exactly  as  above.  The  difference 
between total glutathione concentration and GSH concentration was used to calculate 
the concentration of GSSG. 
 
The efficiency of the GR protocol in converting GSSG to GSH was calculated by 
preparing standards containing known concentrations of GSSG and following the 
above protocol. Alongside, GSH standards were prepared, frozen and run, following 
the protocol for samples for GSH measurement. These were used to calculate GSH 
method efficiency for the experiment (see above). GR protocol efficiency can then 
be calculated as follows: 
 
Efficiency  =              Percentage of GSSG detected by HPLC                         x 100% 
                            Efficiency of GSH protocol within same experiment 
 
The efficiency of the GR method as used here was calculated to be 85.4 ± 4.8 % 
(n=4). 
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2.2.3  Determination  of  intracellular  glutathione  levels  by  imaging  with 
monochlorobimane 
 
Imaging of monochlorobimane (MCB) fluorescence was carried out to determine the 
cellular  levels  of  GSH  and  as  a  comparative  technique  to  HPLC  determination 
(Chatterjee et al. 1999; Keelan et al. 2001). MCB is a non-fluorescent bimane, freely 
permeable across plasma membranes. It is conjugated to GSH by the endogenous 
enzyme  glutathione  S-transferase  (GST;  EC  2.5.1.18)  to  produce  a  fluorescent 
adduct, with an excitation wavelength of 380 nm and an emission wavelength of 485 
nm. This provides a way to visualise GSH within live cells and to quantify the GSH 
concentration by measuring fluorescence intensity. 
 
Cells were plated on coverslips in 24 well plates and allowed to reach no more than 
50% confluency. An optimised concentration of MCB (50 µM for BV-2 microglial 
cells, 100 µM for primary microglia) was added directly to the media in the wells 
and  the  cells  were  returned  to  the  incubator  (37C,  6.0%  CO2)  for  30  minutes. 
Coverslips were carefully removed and rinsed gently in warmed basic medium (153 
mM NaCl, 3.5 mM KCl, 0.4 mM KH2PO4, 20 mM N-Tris(hydroxymethyl)methyl-2-
aminoethanesulphonic  acid  (TES),  5  mM  NaHCO3,  1.2  mM  Na2SO4,  1.2  mM 
MgCl2, 2.6 mM CaCl2, 5 mM glucose). An Olympus (Tokyo, Japan) IX70 inverted 
fluorescence microscope, with an Olympus UApo 40 x Oil Iris objective, was used 
in  combination  with  Perkin  Elmer  Imaging  Suite  v4.0  software  to  quantify  the 
fluorescence for analysis. The excitation wavelength used was 360 nm and emission 
> 490 nm was  recorded.  Identically treated coverslips were viewed with a Zeiss 
Axioskop 2 fluorescence microscope (Oberkochen, Germany), using a 40 x Neofluar 
objective, with an excitation wavelength of 365 nm and emission > 490 nm recorded. 
Images  (as  presented in figure 3.5B) were  captured  with a  Zeiss AxioCam  HRc 
camera and Zeiss Axiovision 3.1 software. 
 
To check the specificity of MCB for GSH over other thiols, ethacrynic acid (EA), an 
inhibitor  of  GST,  was  used  to  block  GS-MCB  formation  (Ploemen  et  al.  1990; 
Keelan et al. 2001). EA (500 M) was added to BV-2 cells 10 minutes prior to MCB 
addition. Due to the higher MCB concentration used for primary microglial cells, a 113 
 
higher  EA  concentration  (1  mM)  was  necessary  to  inhibit  MCB  binding  and 
eliminate fluorescence. 
 
 
2.2.4 Determination of glutathione levels  in  cell  medium using the GSH-Glo 
glutathione assay kit 
 
The GSH-Glo glutathione assay kit (Promega) uses a two-step reaction system to 
quantify  reduced  glutathione  using  a  luminescent  signal  (fig.  2.5).  Luciferin  is 
produced  from  luciferin-NT,  a  luciferin  derivative,  by  glutathione  S-transferase 
(GST; EC 2.5.1.18), but only in the presence of reduced glutathione (GSH). In the 
second reaction, stabilised luciferase from Photinus pyralis (EC 1.13.12.7) causes 
release of light by luciferin. 
 
 
 
Step 1: 
                                  GST 
      luciferin-NT + GSH                           luciferin + GS-R 
 
Step 2: 
          luciferase 
      luciferin + ATP + O2                           oxyluciferin + PPi + AMP + CO2 + light 
 
 
Figure 2.5.  The GSH-Glo glutathione assay uses a two-step process 
 
 
The  experiment  was  performed  according  to  the  manufacturer‟s  instructions. 
Microglial cells were plated and cultured until sufficiently confluent and medium 
was changed to serum-free, phenol red-free medium (which was otherwise identical 
to that used for routine culture), before being treated experimentally as required. At 
the end of the incubation period, medium was removed and centrifuged at 10 000 
rpm (5031 g) for 2 minutes in a Jouan A14 microcentrifuge to pellet any cell debris. 114 
 
50 µl of sample was combined with 50 µl of GSH-Glo reagent (supplied with kit), 
which contains luciferin-NT and glutathione S-transferase in 50 mM tricine buffer 
pH 7.9, in a well of an opaque white Packard 96-well polystyrene OptiPlate. This 
was  mixed  briefly  on  a  plate  shaker  and  incubated  at  room  temperature  for  30 
minutes. One hundred microlitres of luciferin detection reagent (reconstituted with 
luciferin  detection  buffer  according  to  the  manufacturer‟s  instructions)  was  then 
added to each well, before the plate was briefly shaken once more and incubated at 
room  temperature  for  a  further  15  minutes.  Luminescence  was  recorded  using  a 
Tecan  GENios  plate  reader.  Glutathione  concentrations  of  samples  in  each 
experiment were calculated using a standard curve which was run alongside samples 
(fig. 2.6). 
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Figure  2.6.  Typical  GSH  standard  curve  produced  using  the  GSH-Glo  assay  kit 
(r
2=0.9956). 
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2.2.5. A comparison of the three methods used to measure glutathione 
 
HPLC is often used to measure GSH concentrations in biological samples. It is well-
known as  being  a sensitive and reliable method of quantification, quoted in  one 
paper as being able to detect 0.5 µM GSH (Kamencic et al. 2000), and found in 
experiments conducted for this thesis, and elsewhere (Stewart et al. 2002; Frade et 
al.  2008)  to  reliably  detect  concentrations  of  1  µM  and  below.  This  level  of 
sensitivity allows robust detection of GSH in microglial cell extracts. However, the 
method is rather time-consuming, especially where an autosampler is unavailable. 
When  measuring  the  GSH  content  of  cultured  cells,  relatively  large  amounts  of 
protein  are  required  for  each  measurement,  such  as  is  easily  obtainable  when 
immortalised cell lines are used, but  can pose  a problem in  the case of primary 
microglia. 
 
It is difficult to assess the sensitivity of the monochlorobimane imaging method of 
GSH measurement  in  whole cells, as  fluorescence is  only expressed  as arbitrary 
fluorescence  units  or  relative  to  relevant  controls.  However,  in  previous  studies 
microglial  GSH  has  been  robustly  detected  using  MCB  (Chatterjee  et  al.  1999, 
2000). In tissue homogenates, a MCB fluorescence method has been shown to detect 
0.5 µM GSH, suggesting a sensitivity comparable to that of HPLC (Kamencic et al. 
2000). Imaging using MCB has the advantage of allowing simultaneous assessment 
and comparison of GSH levels in different cell types in co-culture (Chatterjee et al. 
1999). It is however important to note that intracellular GS-MCB fluorescence may 
be affected by export via multidrug resistance-associated proteins (Mrps) (Waak and 
Dringen 2006). 
 
According  to  the  manufacturer,  the  GSH-Glo  assay  kit  is  able  to  detect  GSH 
concentrations as low as 3 nM, and only small volumes of samples are required. 
Additionally, the assay is quick and simple to conduct. However, the running costs 
of such a kit-form assay are much higher compared with those of the other methods 
utilised here. Therefore the GSH-Glo assay kit is only used in this thesis to measure 
GSH  levels  in  microglial  conditioned  medium,  where  it  was  not  possible  to  use 
HPLC or MCB imaging. 
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2.2.6. Determination of glutamate levels in cell medium 
 
2.2.6.1 Principle 
 
Glutamate  is  the  most  abundant  excitatory  neurotransmitter  in  the  mammalian 
nervous  system.  Its  location  must  however  be  tightly  regulated  as  continuous 
exposure of neurones to high levels of extracellular glutamate leads to excitotoxicity 
(Frandsen  et  al.  1989).  Astrocytes  play  the  major  role  in  uptake  of  released 
glutamate via excitatory amino acid transporters (EAATs), (Okamoto and Quastel 
1972; Storck et al. 1992; Pines et al. 1992). However, microglia have also been 
shown to have an impact on extracellular glutamate levels, (e.g. Noda et al. 1999; 
Nakajima et al. 2001b). 
 
In  vivo  the  enzyme  L-glutamate  dehydrogenase  (EC  1.4.1.3)  mediates  the 
interconversion  of  L-glutamate  and  -ketoglutarate  (Fisher  1985)  (fig.  2.7).  The 
conversion of L-glutamate to -ketoglutarate, by removal of the amino group, is part 
of the pathway converting nitrogen-containing proteins into suitable substrates for 
the tricarboxylic acid cycle in respiration. The reverse reaction allows incorporation 
of nitrogen into organic molecules to allow protein formation, and is the only source 
of de novo amino acid synthesis in mammals. Regulation of this reversible reaction 
can  occur  allosterically  through  relative  abundance  of  adenine  and  guanine 
nucleotides; higher levels of ADP and GDP suggest energy depletion and therefore 
drive the catabolism of glutamate, while higher levels of ATP and GTP favour the 
inclusion of nitrogen for protein formation (Frieden 1959b; Cross and Fisher 1970). 
 
                                    NAD
+                NADH + H
+ 
 
 
-ketoglutarate + NH4
+  L-glutamate  +  H2O 
 
                                      NADP
+            NADPH + H
+ 
 
Figure  2.7.  L-glutamate  dehydrogenase catalyses  the  conversion  of  L-glutamate into  -
ketoglutarate. 117 
 
The preferred cofactor in the catabolism of glutamate is NAD
+, however NADP
+ can 
also be utilised (Frieden 1959a). When excited with light of wavelength 340 nm, 
NADH and NADPH fluoresce, whilst NAD
+ and NADP
+ do not. This phenomenon 
can be used to quantify the concentration of glutamate in a sample. Following a short 
incubation  at  37C  in  the  presence  of  an  excess  of  NAD
+  (or  NADP
+)  and  L-
glutamate  dehydrogenase  (GDH),  fluorescence  is  directly  proportional  to  the 
concentration of glutamate (Nicholls and Sihra 1986). 
 
2.2.6.2 Optimisation of the existing method  
 
Before using this assay it is important that it be validated in this laboratory for use 
with our samples of microglial conditioned medium (CM). 
 
Standards of glutamate were prepared in basic medium (BM; 120 mM NaCl, 3.5 mM 
KCl,  0.4  mM  KH2PO4,  20  mM  N-Tris(hydroxymethyl)methyl-2-
aminoethanesulphonic acid (TES), 5 mM NaHCO3, 1.2 mM Na2SO4, 5 mM glucose) 
and in serum-free culture medium (SFM). One hundred microlitres of each of these 
or of CM was incubated with 1 mM NAD
+ or NADP
+ and 10 – 50 U GDH at 37ºC 
for 2 - 12 minutes, made up to a total reaction volume of 1 ml with BM. A Techne 
Dri-Block  model  DB-2D  block  heater  was  used  to  maintain  the  incubation 
temperature. NADH or NADPH levels were determined using a Perkin-Elmer LS-2 
B fluorimeter with excitation at 340 nm; emission greater than 430 nm or 460 nm 
was recorded.  
 
Although the original assay was run using NAD
+ as the cofactor (Nicholls and Sihra 
1986), a number of recent publications report the use of NADP
+ (Sim et al. 2006; 
Yang and Wang 2008; Kilbride et al. 2008), therefore these cofactors were first 
compared  in  the  assay.  Both  were  used  at  a  concentration  of  1  mM  as  this  is 
commonly reported in the literature. Emission greater than 460 nm was recorded. 
Ten, 25 or 50 U GDH was used in 1 ml total volume. Fifty units per ml appears to be 
most commonly used for the fluorimetric detection of glutamate (Syed et al. 2007; 
Yang  and  Wang  2008),  however  10  U.ml
-1  GDH  has  been  used  successfully  in 
previous versions of this assay in this laboratory (Pinteaux-Jones et al. 2008). 
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It appears that either NADP
+ or NAD
+ may be used as a cofactor to give a standard 
curve with good linearity, and that in either case 1 mM is sufficient within the range 
of  glutamate  concentrations  used  (fig.  2.8).  The  regression  coefficient  (r
2)  was 
consistently higher at each GDH concentration with NAD
+ rather than NADP
+. In 
addition, the signal in the presence of NAD
+ was also slightly higher. Therefore the 
assay was validated and used with NAD
+ (1 mM) as the cofactor. Interestingly, r
2 
was  also  consistently  higher  with  lower  GDH  concentrations.  Although  the 
fluorescence is higher with more GDH, the basal fluorescence is also increased. The 
reason for this is unclear; any glutamate present in the enzyme preparation would 
likely be metabolised by GDH prior to utilisation in the experiment. However, the 
inclusion of a control lacking glutamate, but including GDH, and the use of such a 
control  as  “zero”  would  eliminate  the  problem  of  any  increase  in  the  basal 
fluorescence.  
 
Some samples of CM from control BV-2 microglia were also tested with the same 
three GDH  concentrations  (table 2.1).  It  is  possible that some component of the 
medium could inhibit the enzyme or that GDH levels could become a limiting factor 
and mask higher glutamate concentrations. Treatment of BV-2 cells with LPS for 24 
hours appeared to increase their glutamate release so that extracellular concentrations 
are  44-50%  higher  than  control.  Although  there  are  differences  between  the 
glutamate concentrations calculated with different GDH concentrations, there does 
not appear to be a trend in either absolute concentration or in % increase with LPS 
treatment with increasing amounts of GDH, suggesting that these differences are not 
due to  different GDH levels.  Indeed, such differences  due to  sampling  error  are 
likely considering that this data derives from a single experiment. This data shows 
that 10 U GDH is sufficient for such samples, as using more of the enzyme had no 
effect on the outcome. 
 
Although 460 nm is reported to be the peak of the emission of NADH (Lakowicz et 
al. 1992), the original paper on which this method is based (Nicholls and Sihra 1986) 
records emission above 430 nm. Therefore standard curves were run in parallel with 
emission above 460 nm and 430 nm recorded (fig. 2.9). The resulting curves have 
similar r
2 values, but the signal is substantially higher at 460 nm. Therefore 460nm 
will continue to be used in this assay. 119 
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Figure 2.8. L-glutamate standard curves prepared using different amounts of GDH in the 
presence of 1 mM NADP
+ (A) or 1 mM NAD
+ (B). Standard concentrations of L-glutamate 
(0 – 400 µM) were prepared in basic medium and 100 µl was incubated for 8 minutes at 
37C with 1 mM NADP
+ and 10, 25 or 50 U GDH (final volume 1 ml). Samples were excited 
with light of wavelength 340 nm and emission greater than 460 nm was recorded. Data 
represent the results of two independent experiments, each consisting of two samples per 
condition. 
 
 
 
[GDH] (U)  [L-glu]  in  control 
CM (M) 
[L-glu] in LPS  
CM (M) 
% increase in  
[L-glu] with LPS 
10  188.9  278.9  47.6 
25  213.3  308.0  44.4 
50  176.8  264.5  49.6 
 
Table 2.1. L-glutamate levels in samples of CM from control BV-2 cells and those treated 
with LPS (1 µg.ml
-1) for 24 hours, determined in each case by standard curves constructed 
using the same amount of GDH (see fig. 2.8). Samples (100 µl) were incubated for 8 minutes 
at 37ºC with 1 mM NAD
+ and 10 – 50 U GDH (total volume 1 ml). Data represent the 
results of a single experiment, consisting of two samples per condition. 
A  B 120 
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Figure 2.9. L-glutamate standard curves prepared using emission wavelengths of 430 nm 
and  460  nm  after  excitation  at  340  nm.  Standard  concentrations  of  L-glutamate  were 
prepared in basic medium and 100 µl was incubated for 8 minutes at 37C with 1 mM NAD
+ 
and 10 U GDH (final volume 1 ml). Data represent the results of a single experiment, 
consisting of two samples per condition. 
 
 
It is also important to check that the 8 minute incubation used historically in this 
laboratory is sufficiently long to allow the reaction to run to completion and the 
fluorescence to plateau. Figure 2.10 shows a time course experiment run using a 
blank (BM with GDH and NAD
+), 200 µM glutamate, control BV-2 CM and CM 
from LPS-treated BV-2 cells (1 µg.ml
-1 for 24 hours). This demonstrates that in all 
cases, 8 minutes is indeed a sufficient incubation time for the experiment. 
 
The issue about the medium in which glutamate standards should be made also needs 
to be addressed, as it is not clear whether BM or culture medium has been previously 
used in this laboratory, and there is a chance that the components of culture medium, 
which would be present in test samples, could have a slight effect upon fluorescence. 
Therefore  parallel  standard  curves  were  prepared  in  BM  and  serum-free  BV-2 
culture  medium  (SFM)  (fig.  2.11),  using  all  the  standard  conditions  determined 
above. The standard curves are of approximately the same linearity and the slopes 
are very slightly different. SFM alone has a slightly higher fluorescence than BM121 
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Figure 2.10. Time course of GDH-catalysed reaction for samples of CM from control BV-2 
cells and those treated with LPS (1 µg.ml
-1) for 24 hours. Samples or standards (100 µl) 
were incubated with 1 mM NAD
+ and 10 U GDH for 2 - 12 minutes at 37C (total assay 
volume, 1 ml). Samples were excited with light of wavelength 340 nm and emission greater 
than 460 nm was recorded. Data represent the results of a single experiment, consisting of 
two samples per condition. 
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Figure 2.11. L-glutamate standard curves prepared in SFM and BM. Samples (100 µl) were 
incubated with 1 mM NAD
+ and 10 U GDH for 8 minutes at 37C (total assay volume, 1 
ml). Samples were excited with light of wavelength 340 nm and emission with a wavelength 
greater  than  460  nm  was  recorded.  Data  represent  the  results  of  a  single  experiment, 
consisting of two samples per condition. 122 
 
alone,  possibly  due  to  the  phenol  red  present.  BM  containing  higher  (300  M) 
concentrations of glutamate gave a slightly higher reading than SFM containing the 
same  glutamate  concentration.  However,  the  standard  curves  do  lie  along  very 
similar lines, especially between 100 M and 200 M glutamate, the range in which 
most samples of conditioned medium tend to lie. Therefore it is probably equally 
valid to use a standard curve prepared in basic medium and one prepared in serum-
free BV-2 culture medium. 
 
It is important to note that serum-free culture medium has been used here. If samples 
of serum-containing CM are used, a sample of identical fresh culture medium needs 
should  be  taken  in  order  to  measure  basal  levels  of  glutamate.  Serum  contains 
glutamate and the amount probably varies between preparations of medium. 
 
2.2.6.3 Optimised protocol 
 
The  presence  of  glutamate  in  culture  medium  was  assessed  by  fluorometric 
quantification of NADH. Samples of conditioned medium from cultured cells were 
centrifuged at 10 000 rpm (5031 g) for 2 minutes in a Jouan A14 microcentrifuge to 
pellet any cell debris, and transferred to fresh tubes. Wherever possible, samples 
were assayed fresh, immediately upon removal from cells, but if necessary they were 
stored at -20C. One hundred microlitres of each sample was incubated with 1 mM 
NAD
+ and 10 U GDH for 8 minutes at 37°C, made up to a total volume of 1 ml with 
BM. NADH levels were determined using a Perkin-Elmer LS-2 B fluorimeter with 
excitation  at  340  nm;  emission  greater  than  460  nm  was  recorded.  A  glutamate 
standard curve, constructed in basic medium, was run with each experiment. Blanks, 
consisting of basic medium with NAD
+ and GDH, allowed all other measurements to 
be corrected for any glutamate contamination of the reagents or basal fluorescence. 
In addition, a control sample of fresh medium identical to that in which cells were 
cultured was  assayed for comparison  with  test  samples.  Triplicate readings  were 
taken from each sample to increase accuracy and in most cases conditions were run 
in duplicate in each experiment. 
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2.2.7 Determination of nitrate/nitrite levels in cell medium as an indicator of 
iNOS activity 
 
Nitric oxide (NO) is a highly reactive gas with diverse functions in mammalian cells. 
Originally  described  as  endothelium-derived  relaxing  factor  (Furchgott  and 
Zawadzki 1980), it is a vasodilator in the cardiovascular system (Ignarro et al. 1987; 
Palmer et al. 1987), and, being small and readily diffusible, also acts as a signalling 
molecule, both intra- and intercellularly (e.g. Wood et al. 1990). As it is a highly 
reactive  free  radical,  it  is  also  employed  defensively,  being  produced  by 
macrophages  and  microglia  in  response  to  the  presence  of  certain  pathogenic 
components, such as LPS (Stuehr and Marletta 1985, 1987; Stuehr et al. 1989). NO 
is produced by the enzyme nitric oxide synthase (NOS; EC 1.14.13.39) through the 
oxidation  of  L-arginine  to  L-citrulline  (Moncada  et  al.  1989).  There  are  three 
different isoforms of this enzyme, the predominant one in microglia being inducible 
NOS (iNOS) (Forstermann et al. 1991; Hevel et al. 1991). NO is highly unstable, 
and undergoes a series of reactions with molecules present in biological fluids, with 
the stable end-products nitrate (NO3
-) and nitrite (NO2
-) (Marletta et al. 1988): 
 
2 NO + O2    2 NO2 
2 NO2    N2O4        N2O4 + H2O    NO2
- + NO3
- 
NO2 + N2O4 + H2O    NO + 2 NO3
- 
NO + NO2    N2O3        N2O3 + H2O    2 NO2
- 
 
 
The  relative  amounts  of  nitrate  and  nitrite  produced  depend  upon  the  particular 
reactions  taking  place.  Measuring  the  total  nitrate  and  nitrite  levels  therefore 
represents the best indication of NO concentration, and may be viewed as an indirect 
indication of NOS activity. 
 
Here nitrate was reduced to nitrite with acidified vanadium (III) chloride and nitrite 
was detected using the Griess reaction using an adaptation of the method of Miranda 
et al. (2001). 
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Samples of conditioned medium from cultured cells were centrifuged at 10 000 rpm 
(5031 g) for 2 minutes in a Jouan A14 microcentrifuge to pellet any cell debris, 
transferred to fresh tubes and stored at –20C until needed. The reaction was run in 
96 well plate format and standard curves of 0-100 µM sodium nitrate and sodium 
nitrite were run on each plate (fig. 2.12). Nitrate concentrations of samples were 
corrected for the efficiency of conversion of nitrate to nitrite, as calculated from the 
standard curves. All samples and standards were run in triplicate. Ten microlitres of 
80  mg.ml
-1  vanadium  (III)  chloride  in  10  M  HCl  was  added  to  200  µl  of 
standard/sample in each well. One hundred microlitres of Greiss reagent (0.1% (w/v) 
N-(-1-naphyl)-ethylenediamine and 1% (w/v) sulphanilamide in 5% H3PO4) which 
reacts with nitrite to give a pink colour, was added to each well and plates were 
incubated  at  room  temperature  for  30-45  minutes  in  the  dark.  Absorbance  was 
measured at 540 nm using an Anthos HT11 microplate reader. 
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Figure  2.12.  Typical  sodium  nitrate  and  nitrite  standard  curve  (r
2=0.998  for  nitrate; 
r
2=0.9995 for nitrite). Here there is an average conversion efficiency of nitrate to nitrite of 
39.8%. 
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2.2.8 Measurement of intracellular ATP and ADP levels 
 
2.2.8.1 Measurement of ATP levels 
 
ATP is the universal energy store, providing energy for all active cellular processes 
through the cleavage of its two high energy phosphoanhydride bonds. There is a high 
turnover of ATP in the cell, and it is continually regenerated from ADP and AMP. 
ATP depletion is characteristic of cells under stress. 
 
The luciferase from Photinus pyralis (EC 1.13.12.7) catalyses the following reaction: 
 
ATP + D-luciferin + O2    oxyluciferin + PPi + AMP + CO2 + light 
 
Light output of the reaction can be measured quantitatively using a luminometer. At 
low ATP concentrations, the light output is directly proportional to the concentration 
of ATP in the sample. 
 
Cells were plated on 35 mm dishes and cultured until sufficiently confluent. The 
culture medium was changed for serum-free medium (unless otherwise stated) at 
least several hours prior to addition of test compounds. Following treatment with 
these compounds as required, the medium was removed and the cells rinsed gently 
with phosphate-buffered saline (PBS; 154 mM NaCl, 1.84 mM KH2PO4, 9.81 mM 
K2HPO4.3H2O,  pH  adjusted  to  7.2-7.3  with  further  addition  of 
KH2PO4/K2HPO4.3H2O as necessary). The cells were then scraped in 50 µl of PBS, 
transferred to a 1.5 ml tube, snap frozen on dry ice and stored at -20ºC until needed. 
 
An ATP assay kit (Roche Diagnostics) was used to determine ATP concentrations, 
run broadly in line with the manufacturer‟s instructions. One hundred and seventy 
microlitres of cell lysis reagent (supplied with the kit) was added to cell samples 
immediately upon defrosting and samples were incubated at room temperature for 5 
minutes. Fifty microlitres of this treated sample was combined with 100 µl dilution 
buffer (supplied with the kit). To this mixture was added 50 µl luciferase reagent 
(made up in dilution buffer according to the manufacturer‟s instructions) and the 
luminescence was measured immediately using a Labtech Jade luminometer. Three 126 
 
readings were taken at 5 second intervals and the average of these was taken as the 
luminescence  measurement.  Each  sample  was  run  in  triplicate  and  each  test 
condition was repeated three times in each experiment. Concentrations of ATP were 
determined using a standard curve (fig. 2.13), normalised for protein content (see 
2.2.11) and expressed as nmol.mg
-1 protein.  
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Figure 2.13. Typical ATP standard curve. When the log10 of the bioluminescence reading is 
plotted  against  the  log10  of  the  ATP  concentration,  a  sigmoidal  curve  is  produced 
(r
2=0.9956). This can then be used to calculate the ATP concentrations of samples. 
 
 
2.2.8.2 Measurement of ADP levels and ATP:ADP ratios 
 
Measurement of the ADP levels within a sample and calculation of the ATP:ADP 
ratio can give more detailed information about the state of the cell. With a small 
alteration to the basic protocol, ATP and ADP levels can be measured successively 
in the same sample (Pocock and Nicholls 1998; Kingham and Pocock 2000). In the 
presence of pyruvate kinase (EC 2.7.1.40), ATP can regenerated from ADP with the 
conversion of phosphoenolpyruvate (PEP) to pyruvate: 
 
phosphoenolpyruvate + ADP    pyruvate + ATP 
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Cell samples were diluted with cell lysis reagent and incubated as before, and 50 µl 
of this was combined with 100 µl dilution buffer containing 8 U pyruvate kinase. 
The ATP level was measured as before. PEP (in a small volume; final concentration 
20 µM) was then added to the mixture to begin the ATP regeneration reaction and 
the sample was incubated for 1 minute at room temperature. Three readings were 
taken at  5 second intervals  as  before, and the  average of these was  taken as  an 
estimate of the total ATP + ADP luminescence measurement. In the presence of 
ADP alone, a small, dose-dependent luminescent signal was seen before addition of 
PEP, however this was < 2% luminescence observed after ATP regeneration from 
ADP by pyruvate kinase and PEP, and < 2% luminescence observed with ATP of the 
same concentration, and was therefore considered negligible. 
 
 
2.2.9 Measurement of lactate dehydrogenase release 
 
Lactate dehydrogenase (LDH; EC  1.1.1.27) is  a soluble cytosolic enzyme which 
mediates  the  interconversion  of  lactate  and  pyruvate,  being  especially  important 
under hypoxic conditions. The loss of membrane integrity which occurs during both 
apoptosis and necrosis leads to the release of cytosolic components, including LDH, 
which is stable for at least 3 days in serum-free culture medium (Koh and Choi 
1987). The LDH content of cell medium following treatment is therefore commonly 
used  as  an  indicator  of  cell  viability  and  has  been  used  successfully  as  such  in 
microglia and other monocytic cells (Decker and Lohmann-Matthes 1988; Kingham 
et al. 1999). 
 
LDH levels were determined using a method based on that of (Dringen et al. 1998). 
Cells were plated in 16 mm culture dishes and medium was changed to serum-free 
medium  before  cells  were  treated  as  required.  The  medium  was  removed  and 
centrifuged at 10 000 rpm (5031 g) for 1 minute in a Jouan A14 microcentrifuge to 
pellet any cell debris. Ten microlitres of the resulting supernatant was combined with 
90 µl of 80 mM Tris-HCl buffer pH 7.2 containing 200 mM NaCl in a well of a 96 
well  test  plate.  To  this  was  added  100  µl  of  80  mM  Tris-HCl  buffer  pH  7.2 
containing  200  mM  NaCl,  3.2  mM  sodium  pyruvate  and  0.4  mM  NADH.  The 
conversion of NADH to NAD
+ (coupled to the conversion of pyruvate to lactate) 128 
 
was followed by measuring the absorbance at 340 nm of the samples every minute 
for six minutes, using a Tecan GENios plate reader. A decrease in the absorbance 
represents a loss of NADH, and the more LDH in the sample, the more rapid the 
decrease.  The  rate  of  decline  of  absorbance  was  then  normalised,  with  0% 
representing the decline when the test sample was serum-free medium alone, and 
100% representing the decline in the presence of a sample from cells treated for 30 
minutes with 1% Triton X-100. Each sample was assayed in triplicate and each test 
condition repeated at least twice in each experiment. An example of the raw data 
generated in this experiment is presented in figure 2.14. 
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Figure 2.14. Typical result of the LDH assay, demonstrating the declines in absorbance at 
340 nm observed with serum-free medium, conditioned medium from control BV-2 cells and 
conditioned medium from BV-2 cells treated with 1% Triton X-100 for 30 minutes. The 
proportion of LDH release by the control cells, and therefore plasma membrane disruption, 
was calculated to be 17.6% in this case. 
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2.2.10 Fluorescence Microscopy 
 
2.2.10.1 The fluorescence microscope 
 
A Zeiss Axioskop 2 fluorescence microscope (Oberkochen, Germany) was used to 
obtain images of iNOS immunocytochemistry, and of nuclear stains to assess cell 
death. In all cases, cells were viewed with a 40 x Neofluar objective. Images were 
captured using a Zeiss AxioCam HRc camera and Zeiss Axiovision 3.1 software. 
 
2.2.10.2 Immunocytochemistry to identify iNOS expression 
 
BV-2  microglial  cells  and  primary  microglia  were  cultured  on  13  mm  glass 
coverslips  and  treated  as  required,  and  then  fixed  with  4%  paraformaldehyde  in 
phosphate-buffered  saline  (PBS;  154  mM  NaCl,  1.84  mM  KH2PO4,  9.81  mM 
K2HPO4.3H2O,  pH  adjusted  to  7.2-7.3  with  further  addition  of 
KH2PO4/K2HPO4.3H2O  as  necessary)  and  stored  at  4ºC  until  required  for 
immunofluorescence. Cells were permeabilised in 100% ice cold methanol for 20 
minutes at 20ºC and then washed three times with PBS. Cells were blocked with 4% 
normal goat serum (NGS) for 30 minutes at room temperature. Following removal of 
NGS, 200 µl rabbit anti-mouse iNOS antibody at 1:250 dilution in PBS was added to 
each coverslip  and incubated in a wet box at 4ºC overnight. The following day, 
coverslips were washed three times with PBS and incubated with 200 µl goat anti-
rabbit tetramethyl rhodamine iso-thiocyanate (TRITC) conjugated antibody at 1:500 
dilution in PBS for 2 hours in the dark at room temperature. Coverslips were washed 
a further three times with PBS (in the dark) and incubated with 200 µl DNA-staining 
dye 4',6-Diamidino-2-Phenylindole (DAPI) at 1:1000 dilution in PBS for 1 minute in 
the dark at room temperature. Coverslips were washed once more with PBS, rinsed 
with dH2O and mounted on a glass slide with Vectashield mountant. The edges of 
each coverslip were sealed to prevent the cells drying out and slides were stored in 
the dark at -20ºC. 
 
Cells were first viewed under an excitation wavelength of 365 nm, with emission 
over  490  nm  recorded  to  visualise  DAPI  staining.  Images  were  captured  with 
automatic  exposure  time.  TRITC  immunofluorescence  in  the  same  field  was 130 
 
captured by excitation with light of wavelength 485 nm with emission over 530 nm 
recorded. In this case, all images were captured with an exposure time of 20 seconds. 
Brightness, contrast and colour balance were adjusted identically in all images to 
allow  fair  comparison  between  treatments.  Negative  controls  were  performed  in 
which  the  primary  antibody  was  replaced  with  PBS,  to  check  for  non-specific 
binding of the secondary antibody. 
 
2.2.10.3 Measurement of cell death using Hoechst-33342 and propidium iodide 
 
2´-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5´-bi-1H-benzimidazole 
(Hoechst-33342) and propidium iodide (PI) both bind DNA, but Hoechst-33342 is 
lipophilic  and  readily  crosses  plasma  membranes,  while  PI  is  impermeant  to 
functional plasma membranes, and can only bind the nuclear DNA when membrane 
integrity  is  compromised.  Additionally,  when  excited  with  ultraviolet  light 
(wavelength  350nm),  bound  Hoechst-33342  fluoresces  blue,  with  maximum 
emission at 461 nm (Latt and Stetten 1976), whilst bound PI fluoresces red (617 nm 
maximum emission) when excited with light of wavelength 494 nm. Therefore, the 
addition of Hoechst-33342 and PI together to live (i.e. not fixed) cells allows live 
and dead cells to be distinguished. All nuclei stain blue with Hoechst-33342, whilst 
only the nuclei of dead cells stain red with PI. The % cell death can therefore be 
calculated (Bonfoco et al. 1995; Kingham and Pocock 2001). 
 
Cells were plated on 13 mm coverslips in cell culture plates, media changed and 
cells treated as required. Cells were incubated in the dark at 37ºC with 1.25 µg.ml
-1 
PI for 30 minutes and 4 µg.ml
-1 Hoechst-33342 for 15 minutes, added directly to the 
medium. Coverslips were removed from plates and rinsed gently in warmed basic 
medium  (153  mM  NaCl,  3.5  mM  KCl,  0.4  mM  KH2PO4,  20  mM  N-
Tris(hydroxymethyl)methyl-2-aminoethanesulphonic  acid  (TES),  5  mM  NaHCO3, 
1.2 mM Na2SO4, 1.2 mM MgCl2, 2.6 mM CaCl2, 5 mM glucose). Each coverslip 
was placed face-down on a glass slide and viewed immediately.  Cells were first 
viewed  under  an  excitation  wavelength  of  365  nm,  with  emission  over  490  nm 
recorded  to  visualise  Hoechst-33342  staining.  PI  staining  the  same  field  was 
captured by excitation with light of wavelength 485 nm with emission over 530 nm 
recorded.  131 
 
2.2.11  Measurement of gene  expression by  evaluation  of mRNA levels  using 
reverse transcription and polymerase chain reaction 
 
2.2.11.1 Principle 
 
The reverse transcriptase polymerase chain reaction (RT-PCR) is a method allowing 
investigation of gene expression through quantitative analysis of mRNA expression. 
The method consists of four distinct steps. First, the RNA from the cells or tissue of 
interest must be isolated. Next, a complementary DNA (cDNA) copy is produced of 
all of the RNA extracted from the cells using an RNA-dependent DNA polymerase 
enzyme  (reverse  transcriptase;  EC  2.7.7.49).  The  PCR  itself  involves  the 
amplification of the DNA complimentary to  the mRNA of interest  only. This  is 
possible  since  the  DNA  polymerase  enzyme  responsible  for  this  amplification 
requires an oligonucleotide primer complimentary to a small section of cDNA in 
order to initiate synthesis. Therefore if primers are designed of a sequence which 
exists only within the mRNA/cDNA of interest, the PCR becomes specific for this 
gene. Two primers are required for each gene of interest, both of which have unique 
sequences and which span (ideally) a 200-600 base pair portion of the mRNA of 
interest.  
 
PCR is controlled by temperature changes; first, a 94C dissociation phase separates 
double-stranded DNA to allow primers to anneal in the second phase. The optimum 
temperature  for  the  annealing  phase  (optimum  annealing  temperature,  OAT)  is 
worked out for each individual primer and averaged for each primer pair. It depends 
on  the  relative  cytosine/guanine  and  adenine/thymine  nucleotide  content  of  the 
primers and is given by: 
 
OAT = Tm - 4C 
 
Where Tm is the melting temperature, given by: 
 
Tm = 4(G+C) + 2(T+A) C 
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Where  G  is  the  number  of  guanine  nucleotides,  C  is  the  number  of  cytosine 
nucleotides, T is the number of thymine nucleotides and A is the number of adenine 
nucleotides in the primer. 
 
However the annealing temperature should not exceed 65C, so as to be sufficiently 
different from the temperature used in the third phase, elongation. In this phase a 
complementary strand of DNA is synthesised for each existing strand by means of 
the  Thermophilus  aquaticus  (Taq)  DNA  polymerase  (EC  2.7.7.7).  Thermophilus 
aquaticus is a bacterium, first discovered in thermal springs, which can withstand 
high temperatures, such as that used for the dissociation phase here. The elongation 
phase is conducted at 72C, the optimum temperature for Taq DNA polymerase.   
 
Each  time  the  dissociation-annealing-elongation  cycle  is  repeated  each  existing 
strand is copied and therefore the number of copies of the cDNA of interest doubles, 
in an exponential manner. As reagents are consumed the reaction slows and then at 
some point stops altogether. The result is that over time the number of copies of the 
cDNA of interest takes on an S-shaped growth curve (fig. 2.15).  
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Figure  2.15.  The  number  of  copies  of  cDNA  of  interest  increases  exponentially  before 
slowing and levelling off due to some limiting factor.  133 
 
It is important with each gene of interest to optimise the number of cycles used so 
that this falls within the maximum growth phase and differences in expression can be 
clearly seen. A more recent development is quantitative real-time PCR, in which a 
fluorescent  dye  is  used  to  visualise  DNA.  After  each  cycle  the  DNA  can  be 
quantified by measuring fluorescence so that the S-shaped curve can be followed and 
compared between samples. 
 
The final step in RT-PCR allows visualisation of the amount of DNA produced in 
the PCR, and comparison between samples. PCR products are run on an agarose gel 
stained with ethidium bromide, which intercalates into DNA and fluoresces under 
UV light. The densities of the bands on the ethidium bromide gel correspond directly 
to the amount of mRNA in the original sample.  
 
As a control to test for equal amounts of total mRNA within the original sample, RT-
PCR is also performed for a gene whose expression is thought to remain constant. 
The density of the bands for the gene of interest on the gel can then be corrected for 
the density of the bands for the control genes. Here two control genes were used, 
glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH;  EC  1.2.1.12),  an  enzyme 
involved in glycolysis, and the cytoskeletal protein -actin. 
 
2.2.11.2 Extraction of mRNA from cells 
 
RNase-free  consumables  were  used  throughout  and  surfaces  and  gloves  were 
regularly sprayed with RNase inhibitor. Cells were scraped using TRIzol reagent 
according to manufacturer‟s instructions. Following removal of all medium, cells 
were rinsed with PBS and then scraped into 1 ml TRIzol using a plastic scraper. The 
TRIzol was transferred into autoclaved RNase-free safelock tubes and incubated at 
room temperature for at least 5 minutes. Two hundred microlitres of chloroform 
were added and tubes were shaken vigorously for 15 seconds and then incubated at 
room temperature for a further 2-3 minutes. The tubes were spun at 11 200 rpm (11 
600 g) in an Eppendorf 5415R benchtop centrifuge for 15 minutes at 4C and the 
clear  upper  aqueous  phase  was  transferred  into  new  tubes,  taking  care  not  to 
contaminate  this  with  material  from  the  lower  phases.  RNA  was  precipitated  by 
mixing with 0.5 ml isopropyl alcohol and incubating at room temperature for 10 134 
 
minutes.  RNA  was  then  pelleted  by  spinning  at  11  200  rpm  (11  600  g)  for  10 
minutes  at  4ºC.  The  resulting  supernatant  was  removed  and  RNA  pellets  were 
washed  with  1 ml 75% ethanol, vortexed and  spun  at  8200 rpm  (6200  g) for 5 
minutes at 4C. The supernatant was removed and the RNA pellet was allowed to 
completely  dry  before  being  dissolved  in  an  appropriate  volume  (20-100  l, 
depending on the size  of the pellet) of dH2O  treated  with  the nuclease inhibitor 
diethyl pyrocarbonate (DEPC). Tubes were incubated at 60C for 10 minutes to aid 
dissolving. Pellets were then frozen (-80C) and defrosted to read the absorbance at 
260  nm  (A260)  and  at  280  nm  (A280)  on  a  Pharmacia  Biotech  Ultraspec  2000 
spectrophotometer. The ratio A260 / A280 indicates the purity of the RNA, where pure 
RNA gives a ratio of 2.  
 
The Beer-Lambert law states that  
 
A260 = RNA extinction coefficient (25 µl.µg
-1.cm
-1 x RNA concentration (µg.µl
-1)  
x path length (1 cm) 
 
So, RNA concentration (µg.ml
-1) = A260 x 40 x dilution factor 
 
In this case, [RNA] (µg.µl
-1)  =  A260 x   40   x 400  =  A260 x 16 
                                         1000      3                    3 
 
 
2.2.11.3 Reverse transcription 
 
Reverse  transcription  was  carried  out  using  Moloney  murine  leukaemia  virus 
(MMLV)  reverse  transcriptase  (RT).  Up  to  3  g  (13.5  l)  RNA  was  reverse 
transcribed. This was made up to 13.5 µl with DEPC-treated dH2O, and to this was 
added  0.25  g  (1  l  of  0.25  g.l
-1)  oligo(dT)12-18  primer  and  40  units  (1  µl) 
RNaseOUT recombinant ribonuclease inhibitor. This mixture was incubated at 70C 
for 10 minutes before being quenched on ice. Fourteen and a half microlitres of RT 
mastermix  were  then  added  to  each  tube,  containing  per  tube,  6  l  5X  buffer 
(supplied with the MMLV RT enzyme), 3 l 0.1 M dithiothreitol (DTT), a further 40 
units (1 l) RNaseOUT, 1.5 l 10 mM deoxynucleotide triphosphates (dNTPs) and 3 135 
 
l (600 units) MMLV RT. Final concentrations in the reaction mixture were 10 mM 
DTT, 2.67 units.l
-1 RNaseOUT, 0.5 mM dNTPs, 8.33 ng.l
-1 oligo(dT)12-18 primer, 
20 units.l
-1 MMLV RT; final volume, 30 l. Tubes were vortexed and centrifuged 
briefly and incubated at 37C for 1 hour 20 minutes. The reaction was terminated by 
heating to 70C for 10 minutes and tubes were then transferred to ice. DEPC-treated 
dH2O was added to  give a concentration equivalent to 20 ng reverse transcribed 
RNA.l
-1 (for example, if 3 g RNA was reverse transcribed, 120 l DEPC-treated 
dH2O  was  added  to  give  a  total  volume  of  150  l).  Finally  the  MMLV  reverse 
transcriptase was destroyed with a 5 minute incubation at 100C, then the samples 
were  transferred  to  ice  and  stored  at  –20C.  A  negative  control  without  reverse 
transcriptase  was  run  alongside  every  reverse  transcribed  sample.  To  check  for 
contamination with cellular DNA, these negative control samples were subsequently 
run through a PCR for a control housekeeping gene. 
 
2.2.11.4 Polymerase chain reaction 
 
A PCR was run on the product of 0.125 ng reverse transcribed RNA (6.25 µl). To 
each tube was added 18.75 l PCR mastermix containing, per tube, 2.5 l 10X Taq 
DNA  polymerase  buffer  (supplied  with  the  enzyme),  0-1.5  l  50  mM  MgCl2 
(concentration optimised for each primer by experiment; see table 2.2), 1 l of each 
of the relevant forward and reverse primers at 2.5 M, 0.125 l 10 mM dNTPs, 
0.625 units Taq DNA polymerase (0.125 l of 5 units.l
-1) and 12.5-14 l DEPC-
treated  dH2O  to  make  up  the  volume.  Final  concentrations  of  reagents  were  as 
follows: 0-3 mM MgCl2 as optimised, 0.1 M each of forward and reverse primers, 
50  M  dNTPs,  0.025  units.l
-1  Taq  DNA  polymerase;  final  volume,  25  l.  The 
reaction consists of an initial dissociation at 94C for 5 minutes, followed by an 
optimised number of cycles (see table 2.2) of a 30 second dissociation at 94C, a 30 
second annealing phase at the OAT (calculated for each primer, see table 2.2 and 
section 2.2.10.1 above) and a 30 second elongation phase at 72C. The reaction ends 
with a further 7 minute elongation phase, and then the samples are cooled to 4C. 
PCRs were run on control genes (here GAPDH and -actin) which are believed to be 136 
 
  Species  Forward 
sequence  
(5’–3’) 
Reverse 
sequence  
(5’–3’) 
Amplicon 
size (bp) 
Optimum 
annealing 
temperature 
(OAT; C) 
Optimum 
[MgCl2] 
(mM) 
Number 
of PCR 
cycles 
Source  Reference 
β-actin  rat, 
mouse 
ATC GTG GGC 
CGC CCT AGG 
CAC 
TGG CCT TAG 
GGT TCA GAG 
GGG C 
330 
(genomic) / 
243 (cDNA) 
65  2  22 
Dr Rattray, 
Kings College 
London* 
Tortarolo 
et al. 
(2004) 
GAPDH  rat, 
mouse 
TGG TGC CAA 
AAG GGT CAT 
CAT CTC C  
GCC AGC CCC 
AGC ATC AAA 
GGT G  
559  60  2  22 
Sigma 
Genosys 
 
Taylor et 
al. (2003) 
r EAAT1  rat, 
mouse 
TCC TCA TTC ATG 
CCG TCA TCG TCC 
TCT TGG TTT CGC 
TGT CTG GCA CG  653  65  1.5  35 
Dr Rattray, 
Kings College 
London* 
Tortarolo 
et al. 
(2004) 
r EAAT2  rat, 
mouse 
AGC CGT GGC 
AGC CAT CTT CAT 
AGC 
ATG TCT TCG TGC 
ATT CGG TGT 
TGG G 
326  65  1.5  35 
Dr Rattray, 
Kings College 
London 
Tortarolo 
et al. 
(2004) 
m xCT  mouse  TAC CAC CAT CAG 
TGC GGA 
GG 
GTA TCG AAG 
ATA AAT CAG TCC 
TGC 
~350-400  55  1.5  35 
Dr Rattray, 
Kings College 
London 
 
r xCT  rat, 
mouse 
CCT GGC ATT TGG 
ACG CTA CAT 
TCA GAA TTG CTG 
TGA GCT TGC A  182  64  2.5  35 
Sigma 
Genosys 
 
Tomi et al. 
(2002) 
 
Table  2.2.  Polymerase  Chain  Reaction  (PCR)  primers  and  their  properties.  bp,  base  pairs;  EAAT,  excitatory  amino  acid  transporter;  GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; m, mouse; r, rat; xCT, the specific subunit of the xc
- transporter. *duplicates purchased from Sigma 
Genosys.
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expressed at the same level irrespective of the conditions, alongside the genes of 
interest.  
 
2.2.11.5 Agarose gel electrophoresis 
 
Following PCR 5 l of 6 x gel loading dye was added to each 25 l sample and 15 µl 
of sample + dye was loaded into each lane of a 1% w/v agarose gel in Tris/borate/ 
EDTA buffer, containing 0.5 μg.ml
-1 ethidium bromide. 10 µl (1 µg) 100 bp DNA 
ladder was loaded alongside.  The gel was run for approximately 2 hours at 100-120 
V. Gels were de-stained in dH2O for 15 minutes and then viewed under UV light 
using  a  Gel-Pro  Imager  system.  Images  were  captured  using  a  CoolSNAP-Pro 
camera and band densities were determined using Gel-Pro Analyzer v 3.1.  
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2.2.12 Determination of protein levels using the Bradford assay 
 
Protein concentration was determined using the Bradford assay (Bradford 1976), 96 
well plate format. An appropriate volume (< 10 µl) of sample or standard was added 
to each well, followed by 200 µl Coomassie reagent. Plates were incubated at room 
temperature for 5-10 minutes and absorbance at 595 nm was measured using a Tecan 
GENios plate reader. A standard curve with 0-6 mg.ml
-1 BSA was run on each plate 
(fig. 2.16). All samples and standards were run in triplicate. 
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Figure 2.16. Typical standard curve for Bradford protein assay, constructed with 0-6 mg.ml
-
1  bovine  serum  albumin  (BSA).  A  standard  curve  in  triplicate  was  run  on  each  plate. 
r
2=0.9934. 
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2.2.13 Data analyses 
 
Data presented represent at least n=3, unless otherwise indicated. Microsoft Excel 
and GraphPad Prism 4 were used to analyse and present data and statistical analyses 
were run in  GraphPad  Prism.  Unless  otherwise stated, graphs  are presented, and 
results quoted, as mean  standard error of the mean (s.e.m.). Student‟s t tests were 
used in cases where only two groups were compared. A one-way analysis of variance 
(ANOVA) was used to establish statistical significance between three or more data 
sets. Dunnett‟s post-hoc test was employed when comparing all groups with one 
control  group,  whilst  the  moderately  conservative  Tukey‟s  „Honest  Significant 
Difference‟ post-hoc test was used where multiple comparisons were required. These 
post-hoc  tests  were  selected  due  to  the  fact  that  they  correct  for  multiple 
comparisons, so that the likelihood of a type I error (false positive result) does not 
increase for larger data sets. A two-way ANOVA was used to establish significance 
in  cases  where  two  independent  treatment  variables  were  investigated,  with 
Bonferroni‟s  post-hoc  tests  as  appropriate.  A  p  value  smaller  than  0.05  was 
considered  statistically  significant;  *p<0.05,  **p<0.01,  ***p<0.001,  n.s.,  not 
significant (p>0.05). 
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Chapter 3 
Results I: 
Microglial glutathione levels  
and glutathione release  
following microglial activation 
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3.1. Introduction and summary of results 
 
Activated microglia release nitric oxide (NO) and superoxide as a cytotoxic attack 
mechanism against invading pathogens (Colton and Gilbert 1987; Chao et al. 1992; 
Klegeris and McGeer 1994; Ding et al. 1997; Sankarapandi et al. 1998; Possel et al. 
2000). However reactive oxygen and nitrogen species (ROS and RNS) derived from 
NO and superoxide may also cause local cellular damage by reacting with proteins, 
lipids and nucleic acids (Valko et al. 2007) and by inhibiting mitochondrial energy 
metabolism, preventing the production of adenosine triphosphate (ATP) (Bolaños et 
al. 1995). Microglial antioxidants are therefore likely to be important in protecting 
microglia  from  such  oxidative  damage.  Indeed,  microglia  have  been  shown  to 
contain  levels  of  glutathione  significantly  higher  than  in  astrocytes  or  neurones 
(Chatterjee et al. 1999; Hirrlinger et al. 2000), and measured in primary cultures 
containing 90% microglia in the range 25 - 40 nmol.mg
-1 protein (Hirrlinger et al. 
2000; Persson et al. 2006), and in the BV-2 and N11 microglial cell lines as 55 - 60 
nmol.mg
-1 protein (Moss and Bates 2001). 
 
It is less clear how the glutathione levels in microglia are modified by microglial 
activation. Reduced glutathione (GSH) levels in the BV-2 and N11 microglial cell 
lines have been shown to decline in the presence of lipopolysaccharide (LPS) and 
interferon- (IFN) (Moss and Bates 2001), and in the case of N11 cells, the decrease 
was blocked by inhibition of inducible nitric oxide synthase (iNOS) (Moss and Bates 
2001). Biochemical determination of GSH levels in N9 cells also demonstrated a 
decrease  following  LPS  and  IFN  treatment  (Roychowdhury  et  al.  2003). 
Additionally, in mixed glial cultures containing 10 – 20% microglia, fluorescence of 
monochlorobimane (MCB), a marker of GSH, was found to decline by around 40% 
in microglia following treatment with LPS and IFN (Chatterjee et al. 2000), whilst 
the GSH content of the co-cultured astrocytes remained stable. Preincubation with 
the iNOS inhibitor N-iminoethyl-lysine blocked this decline. It therefore appears that 
the production of NO following microglial activation causes a decline in cellular 
GSH  levels.  Conversely,  in  primary  cultures  of  rat  microglia,  intracellular  GSH 
levels have been found to increase in the presence of LPS or tumour necrosis factor-142 
 
α (TNFα) (Dopp et al. 2002; Persson et al. 2006), determined by MCB fluorescence, 
an enzymatic method, and high performance liquid chromatography (HPLC). 
 
It is hypothesised that the measurement of GSH in primary microglia and the BV-2 
and N9 cell lines here will reveal significant effects of microglial activation upon 
intracellular  GSH.  However,  based  upon  previous  studies  it  is  unclear  whether 
microglial activation will lead to an increase or a decrease in GSH levels. A NO-
dependent decrease in intracellular GSH as found previously (Chatterjee et al. 2000; 
Moss and Bates 2001) may be due to increased utilisation of GSH as an antioxidant 
(Chatterjee  et  al.  2000),  or  to  inhibition  of  mitochondrial  ATP  production  and 
therefore reduced availability of ATP for GSH synthesis (Moss and Bates 2001). An 
increase in GSH levels following microglial activation may indicate the presence of 
a compensatory pathway, upregulating GSH levels in anticipation of an oxidative 
insult. Previous studies have suggested that upregulation of the xc
- transporter, which 
imports cystine for GSH synthesis, may underlie such an increase (Persson et al. 
2006). Another possible target is glutamate-cysteine ligase (GCL), which catalyses a 
potentially rate-limiting step in GSH synthesis (Meister and Anderson 1983); indeed, 
enhanced GCL expression has been demonstrated in astrocytes upon exposure to NO 
(Gegg et al. 2003). 
 
It is also unclear whether microglia release GSH. Microglia have been shown to 
express functional multidrug resistance-associated protein 1 (Mrp1) (Ballerini et al. 
2002; Dallas et al. 2003), and GSH was shown to be necessary for vincristine export 
from the Mrp1-expressing MLS-9 microglial cell line (Dallas et al. 2003). However, 
a study in which robust GSH release by astrocytes was demonstrated, microglial 
GSH release could not be detected (Hirrlinger et al. 2002c). 
 
Here, the GSH levels of two commonly-used mouse microglial cell lines, BV-2 and 
N9, were determined, and the effects of a number of compounds associated with 
microglial activation upon GSH levels were studied. BV-2 microglia had a control 
GSH concentration of around 50 nmol.mg
-1 protein, which was transiently increased 
by microglial activation by LPS or fraction V albumin in a concentration-dependent 
manner,  being  significantly  different  from  control  levels  after  16  –  24  hours‟ 
incubation. The effect of LPS was not altered by pre-incubation of BV-2 cells with 143 
 
iNOS inhibitors. N9 microglia had a higher basal GSH concentration of around 80 
nmol.mg
-1  protein.  Activation  of  this  cell  line  with  the  same  compounds  led  to 
concentration-dependent decreases in GSH levels, which were maintained over time. 
Due to practical considerations, it was not possible to assess the impact of iNOS 
inhibition upon the GSH content of N9 cells here, although iNOS inhibition has been 
shown elsewhere to prevent declines in the GSH levels in cells of the N11 cell line 
(Moss and Bates 2001), another cloned line produced alongside N9 cells (Righi et al. 
1989), which  appears to behave similarly  (Ricciardi-Castagnoli and Paglia 1992; 
Corradin et  al. 1993).  Neither the Alzheimer‟s disease- (AD-) associated protein 
chromogranin  A  (CGA)  nor  residues  25-35  of  the  β  amyloid  peptide  (Aβ25-35) 
significantly altered the GSH content of either cell line. Analysis of intracellular 
GSH of primary rat microglia revealed a GSH concentration of around 30 nmol.mg
-1 
protein,  which  was  elevated  by  microglial  activation  with  LPS  alone  or  in 
combination with IFN, and fraction V albumin, although to a lesser extent than in 
BV-2 cells. BV-2 cells therefore represent a more suitable model for microglia in 
such investigations. 
 
Conditioned  medium  from  BV-2  and  primary  microglial  cultures  was  found  to 
consistently contain GSH, demonstrating a low level of GSH release by microglia. 
This appears to be the first demonstration of GSH release by primary microglia. The 
role of microglia-derived GSH is as yet undetermined. 
 
 
3.2. Microglia express iNOS and release NO upon activation 
 
Expression of iNOS was detected directly by means of immunocytochemistry, and 
also by measurement of the release of nitrate and nitrite, the stable metabolites of 
NO. In the absence of activators, just 8.5 ± 5.5 % of primary microglia in culture 
were positively stained for iNOS (fig. 3.1). Treatment of microglia with LPS, IFN, 
LPS  and  IFN  in  combination  or  fraction  V  albumin  significantly  increased  the 
number of cells expressing iNOS. LPS (1 µg.ml
-1; fig. 3.1B) or fraction V albumin 
(2 mg.ml
-1; fig. 3.1E) caused 65.5 ± 12.5 % and 57.8 ± 12.0 % of cells, respectively, 
to express iNOS. Enlarged amoeboid cells were visible, particularly in the presence144 
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Figure 3.1. (previous page) iNOS expression by primary microglia under control (A) and 
activated (B-E) conditions. Cells were incubated with (B) LPS (1 µg.ml
-1), (C) LPS + IFN 
(100 U.ml
-1), (D) IFN or (E) fraction V albumin (2 mg.ml
-1) for 24 hours before fixation. 
iNOS (red) was visualised using immunocytochemistry, and nuclei were visualised using 
4',6-diamidino-2-phenylindole (DAPI; blue). Cells were counted by eye; any cell with 
visible cytoplasmic red staining was deemed to be positive for iNOS. Representative images 
are shown. F, Data represent the mean ± s.e.m. of two (C-E) or three (A, B) independent 
experiments,  each  consisting  of  two  coverslips  per  condition,  with  at  least  three  fields 
viewed per coverslip. This represents a total of approximately 1200 (C-E) or 1800 (A, B) 
cells per condition. Data were analysed with a one-way ANOVA (p=0.0002), with Dunnett’s 
post-test (*p<0.05, **p<0.01, compared with control). Magnification, 40X. Scale bar, 20 
μm.                
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of LPS. Treatment with LPS in combination with IFN (100 U.ml
-1) led to a similar 
high proportion of iNOS-positive cells (64.7 ± 11.7 %), but as demonstrated in figure 
3.1B and C, the staining was less striking and the presence of IFN seemed to reduce 
the appearance of large amoeboid cells. Following treatment with IFN alone, 43.4 ± 
7.6  %  microglial  cells  expressed  iNOS  (fig.  3.1D),  and  very  few  microglia 
demonstrated the enlarged amoeboid phenotype. 
 
BV-2 cells also had a low level of basal iNOS expression (fig. 3.2A), with 13.1 ± 4.8 
% control cells positively stained. In contrast to the situation in primary microglia, 
immunohistochemical iNOS detection in BV-2 cells demonstrated that LPS + IFN 
gave  the  most  prominent  iNOS  expression,  with  79.8  ±  12.8  %  cells  strongly 
expressing iNOS throughout their cytoplasm (fig. 3.2C). As illustrated by the images 
presented  here,  there  were  consistently  far  fewer  cells  adhered  to  the  coverslip 
following treatment with LPS + IFN (fig. 3.2C), and to a lesser extent, IFN alone 
(fig. 3.2D). Just 27.6 ± 4.4 % of cells expressed iNOS following LPS treatment (fig. 
3.2B), which was not significantly different from control, but 68.9 ± 10.3 % of cells 
treated  with  IFN  alone  expressed  iNOS  (fig.  3.2D).  Treatment  with  fraction  V 
albumin  caused  68.6  ±  10.5  %  of  BV-2  cells  to  express  iNOS,  with  the  cells 
appearing smaller and more rounded (fig. 3.2E). 
 
These  results  in  BV-2  cells  reflect  published  data  demonstrating  that  LPS  alone 
causes little or no nitrate and nitrite production by BV-2 cells, whilst LPS + IFN 
significantly increase nitrate/nitrite (Moss and Bates 2001; Horvath et al. 2008). In 
addition,  IFN  alone  has  been  shown  to  cause  a  similar  level  of  nitrate/nitrite 
production to LPS + IFN (Shen et al. 2005); the two treatments were found here to 
lead to iNOS expression in a similar proportion of BV-2 cells (fig. 3.2F). 
 
In the case of N9 microglia, iNOS expression was inferred from measurement of 
nitrate and nitrite levels in conditioned medium (fig. 3.3). LPS + IFN was the only 
treatment to significantly increase nitrate/nitrite release by N9 cells, giving levels 30-
fold higher than control. This is in accordance with published data, demonstrating 
increased  iNOS  protein  expression  and  activity  and  increased  nitrite  production, 
following LPS + IFN treatment of N9 cells (Mayo and Stein 2007). Although no147 
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Figure  3.2. (previous  page)  iNOS  expression  by  BV-2  microglia  under  control  (A)  and 
activated (B-E) conditions. Cells were incubated with (B) LPS (1 µg.ml
-1), (C) LPS + IFN 
(100 U.ml
-1), (D) IFN or (E) fraction V albumin (2 mg.ml
-1) for 24 hours before fixation. 
iNOS (red) was visualised using immunocytochemistry, and nuclei were visualised using 
4',6-diamidino-2-phenylindole (DAPI; blue). Cells were counted by eye; any cell with 
visible cytoplasmic red staining was deemed to be positive for iNOS. Representative images 
are shown. F, Data represent the mean ± s.e.m. of three independent experiments, each 
consisting  of  two  coverslips  per  condition,  with  three  fields  viewed  per  coverslip.  This 
represents a total of 1100 cells per condition on average. Data were analysed with a one-
way  ANOVA  (p<0.0001),  with  Dunnett’s  post-test  (**p<0.01  compared  with  control). 
Magnification, 40X. Scale bar, 20 μm.   
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Figure 3.3. The effect of a number of compounds associated with microglial activation upon 
nitrate and nitrate levels in N9 microglial conditioned medium. N9 cells were cultured in the 
presence of LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 nM), Aβ25-35 (25 µM), fraction V 
albumin (2 mg.ml
-1), or a combination, for 24 hours before nitrate and nitrite levels in 
conditioned medium were determined by the Griess assay. Data represent the mean ± s.e.m. 
of at least three independent experiments, each consisting of two replicates per condition. 
Data were analysed with a one-way ANOVA (p<0.0001) with Dunnett’s post-test (**p<0.01 
compared with control). 
 
                 
 
 
 
 150 
 
other  conditions  were  statistically  significant,  nitrate/nitrite  levels  following  LPS 
treatment  were  more  than  7-fold  higher  than  control,  and  following  fraction  V 
albumin treatment were almost 4-fold higher. By contrast, IFN alone, Aβ25-35 (25 
µM) or CGA (500 nM) failed to even double control nitrate/nitrite levels. 
 
 
3.3. ATP levels in BV-2 microglia upon activation  
 
Figure 3.4Ai demonstrates that ATP levels in plated BV-2 microglial cells showed a 
general decline over time, regardless of whether or not the culture medium contained 
serum. Fraction V albumin  significantly increased ATP  levels  following 8 or 24 
hours‟  incubation.  Although  there  was  also  a  trend  towards  an  increase  in  the 
presence of LPS, this failed to reach statistical significance. In contrast, 24 hours‟ 
exposure to IFN alone or in combination with LPS produced ATP levels slightly, 
but not significantly lower than the serum-free medium (SFM) control. The effect of 
the treatments relative to SFM control is demonstrated in figure 3.4Aii. 
 
Preliminary data suggested that the ratio of adenosine diphosphate (ADP) to ATP in 
plated BV-2 cells was high (fig. 3.4C), and that total ATP + ADP levels (fig. 3.4B) 
and the ADP/ATP ratio (fig. 3.4C) declined over time in all cells cultured in SFM, 
but not those cultured in medium containing 10% foetal bovine serum (FBS) (serum-
containing medium, SCM).  
 
 
3.4. Measuring intracellular reduced glutathione using two methods: 
reverse-phase  high  performance  liquid  chromatography  and 
imaging using monochlorobimane 
 
Reverse-phase high performance liquid chromatography (HPLC) and quantification 
of monochlorobimane (MCB) fluorescence for measurement of intracellular GSH 
were used to measure intracellular GSH levels of BV-2 microglial cells (fig. 3.5). 
BV-2  cells  were  incubated  with  LPS  (1  µg.ml
-1),  LPS  +  IFN  (100  U.ml
-1)  or 
fraction V rat albumin (2 mg.ml
-1) for 24 hours before GSH analysis. Using HPLC 151 
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Figure  3.4. The effect of microglial activators upon ATP levels, total ATP + ADP levels and 
the ADP/ATP ratio over time. BV-2 cells were cultured in SCM, SFM, or in SFM in the 
presence  of  LPS  (1  µg.ml
-1),  IFN  (100  U.ml
-1),  fraction  V  albumin  (2  mg.ml
-1)  or  a 
combination for 8, 24 or 48 hours. Cells were scraped and ATP and ADP levels determined 
with a luminescence-based ATP assay kit. Data represent the results of one experiment (B, 
C) or three independent experiments (A), each consisting of three samples per condition. Ai, 
ATP levels, expressed as nmol.mg
-1 protein, were analysed with a two-way ANOVA, which 
showed a highly significant effect (p<0.001) of time and a highly significant effect (p<0.001) 
of treatment upon ATP levels, with no significant interaction between time and treatment. 
Bonferroni’s post-tests were conducted to compare all conditions with the SFM control (   ) 
at each time point (*p<0.05). Aii, The same data expressed as a percentage of SFM control 
at each time point highlights the comparative effects of the treatments. 
A 
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Figure 3.5. (previous page) The effect of microglial activation upon GSH levels in BV-2 
microglial cells, as measured with reverse-phase HPLC (A) and quantitative analysis of 
monochlorobimane imaging (B). A, BV-2 cells were cultured in medium containing 10% 
FBS in the presence of LPS (1 µg.ml
-1), LPS + IFN (100 U.ml
-1) or fraction V albumin (2 
mg.ml
-1) for 24 hours. Data represent the mean ± s.e.m. of nine independent experiments, 
each consisting of two samples per condition. Dunnett’s multiple comparison post-test was 
used  to  determine  the  significance  of  the  effects  of  individual  treatments  (*p<0.05, 
**p<0.01, compared with control). B, BV-2 cells were cultured in SFM in the presence of 
LPS (1 µg.ml
-1) (iii), LPS + IFN (100 U.ml
-1) (iv) or fraction V albumin (2 mg.ml
-1) (v) for 
24 hours. Cells were incubated with 50 µM MCB for 30 minutes before imaging. Image i 
represents control cells. For image ii and where indicated in vi, 500 µM ethacrynic acid 
(EA)  was  added  10  minutes  prior  to  MCB.  i-v,  Representative  images  are  shown. 
Magnification,  40X.  Scale  bar,  20  μm.  vi,  Data  are  expressed  as  %  average  control 
fluorescence  in  each  experiment.  Each  data  set  was  analysed  with  a  one-way  ANOVA 
(p<0.0001  in  each  case).  Data  represent  the  mean  ±  s.e.m.  of  3  –  6  independent 
experiments, each consisting of one or two coverslips per condition, with typically six fields 
analysed  per  coverslip.  Tukey’s  multiple  comparison  post-test  was  used  to  establish 
significance  of  the  effects  of  individual  treatments  (*p<0.05,  **p<0.01,  ***p<0.001, 
compared with control or as indicated).  154 
 
the concentration of GSH in control cells was calculated to be 48.9 ± 3.4 nmol.mg
-1 
protein.  Both  methods  demonstrated  a  significant  increase  in  intracellular  GSH 
following all three treatments. LPS caused a 62.8 ± 17.2 % increase according to the 
HPLC  method  and  a  69.4  ±  21.0  %  increase  according  to  MCB  fluorescence 
quantification.  Following  treatment  with  LPS  +  IFN,  intracellular  GSH  levels 
increased  by  46.7  ±  9.0  %  and  71.9  ±  22.2  %  according  to  HPLC  and  MCB 
fluorescence, respectively. Fraction V albumin had a similar effect to LPS, causing a 
58.3 ± 15.9 % increase in intracellular GSH according to HPLC and a 67.9 ± 24.9 % 
increase  according  to  quantification  of  MCB  fluorescence.  The  glutathione  S-
transferase  (GST)  inhibitor  ethacrynic  acid  (EA;  500  µM)  significantly  blocked 
MCB fluorescence under each condition, suggesting that the majority of the MCB 
fluorescence  is  due  to  conjugation  of  the  bimane  to  GSH  rather  than  any  other 
cellular thiols. There was no significant difference between any of the conditions 
when EA was added prior to MCB, suggesting that these compounds do not affect 
the  binding  of  MCB  to  other  thiols,  and  that  the  differences  are  indeed  due  to 
changes  in  GSH  levels.  Both  these  methods  measure  only  the  reduced  form  of 
glutathione, and theoretically an increase or decrease in GSH could simply indicate 
an  equal  and  opposite  change  in  the  level  of  oxidised  glutathione  (GSSG).  By 
incubating samples with glutathione reductase (GR), GSSG is converted to GSH so 
that subsequent HPLC analysis measures the total glutathione levels in a cell. Table 
3.1 shows that following a number of different treatments, there was no difference 
between intracellular GSH and total glutathione in BV-2 cells, suggesting that all 
intracellular glutathione is present in the reduced form. 
 
 
3.5.  Different  effects  of  microglial  activation  upon  reduced 
glutathione levels in BV-2 and N9 microglial cells 
 
By means of reverse-phase HPLC, the GSH levels of another mouse microglial cell 
line, N9, were determined, to compare with BV-2 GSH levels. BV-2 and N9 cells 
were incubated with LPS (1 µg.ml
-1), LPS + IFN (100 U.ml
-1), IFN, fraction V rat 
albumin (2 mg.ml
-1), CGA (500 nM) or Aβ25-35 (25 µM) for 24 hours before GSH 
analysis (fig. 3.6). The intracellular GSH concentration of control N9 cells was 70%155 
 
 
 
 
 
 
  [GSH]  
(nmol.mg
-1 protein) 
 
[GSH + GSSG] 
(nmol.mg
-1 protein) 
control  35.9 ± 1.93  35.9 ± 1.99 
LPS  56.1 ± 5.52  55.1 ± 4.59 
LPS + IFN  83.3 ± 13.95  82.6 ± 13.26 
IFN  40.5 ± 5.83  40.0 ± 5.81 
fr V albumin  61.7 ± 9.60  59.6 ± 7.93 
Aβ25-35  66.6 ± 11.36  65.2 ± 10.91 
CGA  33.7 ± 2.58  33.3 ± 2.63 
AIDA  23.2 ± 0.81  22.5 ± 0.93 
 
 
 
 
 
Table 3.1. A comparison of GSH and total glutathione (GSH + GSSG) in BV-2 microglial 
cells under a number of conditions. BV-2 cells were cultured in the presence of LPS (1 
µg.ml
-1), IFN (100 U.ml
-1), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), CGA (500 nM), 
myelin (10 mg.ml
-1), AIDA (250 µM) or a combination. GSSG was converted to GSH using 
GR, and GSH was detected with reverse-phase HPLC. Data represent the mean ± s.e.m. of 
three independent experiments, each consisting of two samples per condition. Student’s t 
tests were used to compare [GSH] with [GSH + GSSG] under each condition and there was 
no significant difference under any condition tested. 156 
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Figure 3.6. The effect of microglial activation with various compounds upon GSH levels in 
N9 (A) or BV-2 (B) microglial cells. N9 or BV-2 cells were cultured for 24 hours in the 
presence of LPS (1 µg.ml
-1), IFN (100 U.ml
-1), fraction V albumin (2 mg.ml
-1), CGA (500 
nM), Aβ25-35 (25 µM) or a combination for 24 hours, and intracellular GSH levels were 
determined by reverse-phase HPLC. A, Data represent the mean ± s.e.m. of three (CGA, 
Aβ25-35), six (fraction V albumin) or seven (control, LPS, LPS + IFN, IFN) independent 
experiments, each consisting of at least two samples per condition. B, Data represent the 
mean ± s.e.m. of three (CGA, Aβ25-35) or nine (control, LPS, LPS + IFN, IFN, fraction V 
albumin) independent experiments, each consisting of two samples per condition. Each data 
set was analysed using a one-way ANOVA, which concluded that treatments had a highly 
significant effect upon GSH level in both cell lines (p=0.0003 for N9, A; p<0.0001 for BV-2, 
B). Dunnett’s multiple comparison post-test was used to determine the significance of the 
effects of individual treatments (*p<0.05, **p<0.01, compared with control).  
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higher than that of control BV-2 cells, at 83.4 ± 6.9 nmol.mg
-1 protein. In addition, 
while  microglial  activation  with  LPS,  LPS  +  IFN  and  fraction  V  albumin 
significantly increased GSH levels in BV-2 cells, by 62.8 ± 17.2 %, 46.7 ± 9.0 % and 
58.3 ± 15.9 % respectively (fig. 3.6B), N9 GSH levels were decreased under the 
same conditions, by 31.3 ± 5.8 %, 46.6 ± 6.5 % and 26.2 ± 5.8 % respectively (fig. 
3.6A). The condition having the most similar effect upon GSH levels in BV-2 and 
N9 cell lines was treatment with IFN alone, which caused a statistically significant 
30.9 ± 6.4 % decrease in N9 cells and a (non-significant) 23.8 ± 6.1 % decrease in 
BV-2  cells.  Treatment  with  Aβ25-35  or  CGA  had  no  significant  effect  upon 
intracellular GSH in either cell line. 
 
 
3.6. The differences between BV-2 and N9 microglial cells were not 
due to differential sensitivity to the activators 
 
The different effects of the compounds associated with microglial activation upon 
GSH levels in BV-2 and N9 microglial cells may be due to different sensitivities to 
the  activators,  and  these  different  responses  may  represent  different  parts  of  a 
common  biphasic  concentration-dependent  response.  Therefore  intracellular  GSH 
levels of BV-2 and N9 cells were determined with a range of concentrations of LPS 
(1 ng.ml
-1 – 10 µg.ml
-1) and fraction V albumin (0.1 – 2 mg.ml
-1). 
 
Figure 3.7 demonstrates that LPS caused a concentration-dependent decrease in GSH 
levels in N9 microglial cells (fig. 3.7A) and a concentration-dependent increase in 
BV-2 microglial GSH levels (fig. 3.7B). The effect upon BV-2 cells was gradual and 
became  significant  at  1  µg.ml
-1  LPS,  while  in  N9  cells  0.1  µg.ml
-1  LPS  had  a 
significant effect. The effect in N9 cells was also more abrupt; there appears to be a 
threshold between 10 ng.ml
-1 and 0.1 µg.ml
-1 LPS, at which the intracellular GSH 
concentration  drops  from  around  130  nmol.mg
-1  protein  to  around  80  nmol.mg
-1 
protein. 
 
Fraction V albumin caused a trend towards a concentration-dependent decrease in 
GSH levels in N9 cells (fig. 3.8A) and a trend towards a concentration-dependent158 
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Figure 3.7. The effect of LPS upon GSH levels in N9 (A) or BV-2 (B) microglial cells. Cells 
were cultured for 24 hours in the presence of LPS (1 ng.ml
-1 – 10 µg.ml
-1), and intracellular 
GSH levels were determined by reverse-phase HPLC. Data represent the mean ± s.e.m. of 
three independent experiments, each consisting of two samples per condition. Each data set 
was analysed with a one-way ANOVA, which showed a highly significant effect of LPS 
concentration upon GSH levels in each case (p<0.0001). Dunnett’s multiple comparison 
post-test was used to determine the significance of the effect of each concentration (*p<0.05, 
**p<0.01, compared with control). 
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Figure  3.8.  The  effect  of  fraction  V  albumin  upon  GSH  levels  in  N9  (A)  or  BV-2  (B) 
microglial cells. Cells were cultured for 24 hours in the presence of fraction V albumin (0.1 
– 2 mg.ml
-1), and intracellular GSH levels were determined by reverse-phase HPLC. Data 
represent  the  mean  ±  s.e.m.  of  three  independent  experiments,  each  consisting  of  two 
samples per condition. Each data set was analysed with a one-way ANOVA, which showed 
the effect of fraction V albumin concentrations upon GSH levels to be non-significant in 
either case (p=0.2404 for N9, A; p=0.0625 for BV-2, B). 160 
 
increase in GSH levels in BV-2 cells (fig. 3.8B), although in this case the effect was 
not found to be statistically significant in either cell line.  
 
In  an  attempt  to  enhance  the  effect  of  fraction  V  albumin,  and  because  serum 
contains a certain amount of albumin, the medium on plated BV-2 microglia was 
changed to SFM several hours before the addition of fraction V albumin. SFM is 
used when preparing samples for a number of other experiments but is not routinely 
used when preparing BV-2 cells for HPLC because the cells begin to detach in the 
absence of serum, reducing the number available for GSH determination. Comparing 
the effect of fraction V albumin upon GSH levels in BV-2 cells cultured in SCM 
with those cultured in SFM does indeed reveal a significant difference (p<0.0001, 
fig. 3.9). Importantly, the GSH content in control cells in the different media did not 
significantly differ (49.2 ± 5.1 nmol.mg
-1 protein with SCM, 54.3 ± 3.9 nmol.mg
-1 
protein with SFM), although adding as little as 0.25 mg.ml
-1 fraction V albumin to 
BV-2 cells in SFM led to a significant increase in intracellular GSH levels. The 
effect of fraction V albumin on GSH levels in BV-2 cells in SFM became highly 
significant compared with control (p < 0.001) at 1 mg.ml
-1. Interestingly, with 0.1 – 
1 mg.ml
-1 fraction V albumin, BV-2 cells in SFM consistently contained 33 % more 
GSH than those cultured in SCM. With 2 mg.ml
-1 fraction V albumin, the difference 
declined to 19 %. 
 
 
3.7. The differences between BV-2 and N9 microglial cells were not 
due to differences in the temporal responses to the activators 
 
The apparent opposite effects of microglial activation upon GSH levels in BV-2 and 
N9 microglial cell lines could be due to temporal aspects of the response. A time 
course analysis of GSH levels in N9 cells (fig. 3.10) showed that control GSH levels 
remained fairly constant over at least 48 hours, and suggested that GSH levels in 
cells treated with LPS, LPS + IFN, CGA or Aβ25-35 remained fairly consistently 
below  control  levels  from  4  hours  onwards.  However,  due  to  technical 
considerations, LPS + IFN and Aβ25-35 could not be repeated a sufficient number of 
times to allow statistical analyses. The effect of LPS was found to be statistically161 
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Figure 3.9. The effect of fraction V albumin upon BV-2 microglial GSH levels in SCM or 
SFM. BV-2 cells were plated in SCM, which was changed either to fresh SCM or to SFM 
before cells were exposed to fraction V albumin (0 – 2 mg.ml
-1) for 24 hours. GSH levels 
were determined by reverse-phase HPLC. Data represent the mean ± s.e.m. of two (SFM) or 
three (10 % FBS) independent experiments, each consisting of two samples per condition. 
Data were analysed by means of a two-way ANOVA, which concluded that the effect of 
fraction V albumin concentration and the effect of the type of medium in which the cells 
were  cultured  were  both  highly  significant  (p<0.0001),  with  no  significant  interaction 
between  the  two  (p=0.7767).  Bonferroni’s  post-tests  were  carried  out  to  determine  the 
significance  of  the  effect  of  each  concentration  of  fraction  V  albumin,  in  each  type  of 
medium (*p<0.05, **p<0.01, ***p<0.001, compared with relevant control). 162 
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Figure 3.10. Time course of changes in GSH levels in N9 microglial cells. N9 cells were 
cultured for 2, 4, 8, 16, 24 or 48 hours in the presence of LPS (1 µg.ml
-1), LPS + IFN (100 
U.ml
-1), CGA (500 nM) or Aβ25-35 (25 µM), and reduced glutathione (GSH) levels were 
determined  using  reverse-phase  HPLC.  Data  represent  the  mean  ±  s.e.m.  (where 
appropriate)  of  one  (LPS  +  IFN,  Aβ25-35),  two  (CGA),  three  (LPS)  or  four  (control) 
independent experiments, each consisting of two samples per condition. A one-way ANOVA 
was carried out on control, LPS and CGA data at each time point. Stastistical significance 
(i.e. p<0.05) was only established at 48 hours (p=0.0439); Dunnett’s post test was used to 
compare the LPS and CGA treatment with control at this time point (*p<0.05 compared 
with control). 163 
 
significant only following 48 hours‟ incubation. The lack of statistical significance at 
earlier  time  points  may  be  due  to  the  relatively  high  levels  of  inter-experiment 
variability. 
 
The time course of the experiment in BV-2 microglial cells is clearly different (fig. 
3.11A). Intracellular GSH levels in plated BV-2 cells declined steadily over time, 
with a GSH concentration in control cells at 72 hours only 35 % of that at 2 hours. 
Treatment  of  BV-2  cells  with  LPS  caused  intracellular  GSH  levels  to  rise  to  a 
maximum at 16 - 24 hours  and then to decline sharply and return to control levels by 
around 48 hours. Fraction V had a similar effect, although this was less pronounced 
and therefore did not reach statistical significance. LPS + IFN appeared to slightly 
stabilise the time-dependent decline in GSH levels between 16 and 48 hours. This 
treatment  caused  cells  to  detach  from  the  plate  over  time,  and  a  72  hour 
measurement was not possible. There was no significant effect of IFN alone at any 
time point. 
 
The  effects  of  the  iNOS  inhibitors  2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine 
hydrochloride  (AMT-HCl;  150  nM)  (Nakane  et  al.  1995)  and  N-[[3-
(aminomethyl)phenyl]methyl]-ethanimidamide  dihydrochloride  (1400W;  10  µM) 
(Garvey et al. 1997) upon the time course of the effect of LPS upon BV-2 microglial 
GSH levels were also investigated (fig. 3.11B). When tested alone, neither AMT-
HCl nor 1400W gave intracellular GSH levels significantly different from control at 
2, 24 or 72 hours. When BV-2 cells were exposed to AMT-HCl or 1400W for 1 hour 
prior to LPS addition, intracellular GSH levels were not significantly different at any 
time point to those found when LPS alone was used. In addition, the intracellular 
GSH  concentration  in  BV-2  cells  following  exposure  to  AMT-HCl  was  not 
significantly different to that following exposure to 1400W, in either the absence or 
presence of LPS. As demonstrated by figure 3.11C, these concentrations of AMT-
HCl and 1400W inhibited 35.1 ± 2.2 % and 78.8 ± 1.2 %, respectively, of the LPS-
induced nitrate and nitrite production by primary microglial cells. 
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Figure 3.11. (previous page) A, B, Time course of changes in GSH levels in BV-2 microglial 
cells. BV-2 cells were cultured for 2, 8, 16, 24, 48 or 72 hours in the presence of LPS (1 
µg.ml
-1), IFN (100 U.ml
-1), fraction V albumin (2 mg.ml
-1), AMT-HCl (150 nM), 1400W (10 
µM), or a combination, and GSH levels were determined using reverse-phase HPLC. Where 
used in combination, cells were pre-incubated with AMT-HCl or 1400W for 1 hour before 
addition of LPS. Data represent the mean ± s.e.m of five (control, LPS, fraction V albumin) 
or three (all other data sets) independent experiments, each consisting of two samples per 
condition. Data were analysed as one set with a one-way ANOVA at each time point, which 
showed significant differences between treatments at 16 hours (p<0.01) and at 24 hours 
(p<0.0001). At these time points, Tukey’s multiple comparison post-tests were performed 
(*p<0.05,  **p<0.01  compared  with  control).  C,  The  effect  of  iNOS  inhibitors  upon 
microglial NO production as measured by nitrate and nitrite release. Primary microglial 
cells were preincubated with AMT-HCl (150 nM) or 1400W (10 µM) for 1 hour before 
addition  of    LPS  (1  µg.ml
-1).  Conditioned  medium  was  removed  after  24  hours  for 
nitrate/nitrite measurement. Data represent mean ± s.e.m. of four samples per condition, 
from one experiment. 
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3.8. Activation of primary microglia led to changes in GSH levels 
similar to those seen in BV-2 cells 
 
The effect of microglial activation upon intracellular GSH levels is clearly different 
in  BV-2  and  N9  microglial  cells,  and  this  does  not  appear  to  be  explained  by 
different sensitivities to the compounds or by temporal differences. Therefore, GSH 
levels in primary rat microglia were determined by means of reverse-phase HPLC 
(fig.  3.12)  and  quantitative  analysis  of  MCB  fluorescence  (fig.  3.13).  Control 
primary rat microglia were found to contain GSH at a concentration of 28.1 ± 2.0 
nmol.mg
-1 protein (fig. 3.12) as determined by reverse-phase HPLC. Following 24 
hours‟ incubation with 1 µg.ml
-1 LPS, this was increased by 29.7 ± 20.1 % to 36.4 ± 
5.6 nmol.mg
-1 protein. The GSH concentration following 24 hours‟ incubation with 
2 mg.ml
-1 fraction V albumin was 32.6 ± 4.0 nmol.mg
-1 protein, representing a 16.0 
±  14.4  %  increase  above  control.  However,  due  to  the  relatively  high  level  of 
variation  under  each  condition,  neither  of  the  changes  observed  was  statistically 
significant. 
 
Quantitative analysis of MCB fluorescence in primary microglia suggested that LPS, 
LPS  +  IFN  (100  U.ml
-1)  and  fraction  V  albumin  all  significantly  increased 
microglial GSH content (fig. 3.13). Incubation of microglia with LPS for 24 hours 
resulted in a GSH level 31.9 ± 9.2 % above control level, incubation with LPS + 
IFN gave a 49.5 ± 11.9 % increase above control, and incubation with fraction V 
albumin gave a 40.5 ± 5.7 % increase above control. Incubation with IFN alone, 
however, did not significantly alter MCB fluorescence. EA (1 mM) significantly 
blocked MCB fluorescence under each condition, suggesting that the majority of the 
MCB fluorescence is due to conjugation of the bimane to GSH rather than any other 
cellular thiols. There was no significant difference between any of the conditions 
when EA was added prior to MCB, suggesting that these treatments do not affect the 
binding of MCB to other thiols, and that the differences are indeed due to changes in 
GSH levels. 
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Figure 3.12. The effect of microglial activation upon GSH levels in primary rat microglia, 
as measured by reverse-phase HPLC. Primary rat microglia were cultured for 24 hours in 
the presence of LPS (1 µg.ml
-1) or fraction V albumin (2 mg.ml
-1). Data represent the mean 
±  s.e.m.  of  four  independent  experiments,  each  consisting  of  one  or  two  samples  per 
condition.  Data  were  analysed  with  a  one-way  ANOVA,  which  failed  to  demonstrate  a 
significant effect of treatment upon GSH levels (p=0.31). 168 
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Figure 3.13. The effect of microglial activation upon microglial GSH levels, as measured 
with quantitative analysis of MCB imaging. Primary rat microglial cells were cultured in 
SFM in the presence of LPS (1 µg.ml
-1), IFN (100 U.ml
-1), fraction V albumin (2 mg.ml
-1), 
or a combination for 24 hours. Cells were incubated with 100 µM MCB for 30 minutes 
before imaging. Where indicated, 1 mM ethacrynic acid was added 10 minutes prior to 
MCB. Data represent the mean ± s.e.m. of four independent experiments, each consisting of 
1 – 4 (typically 3) coverslips per condition, with typically six fields analysed per coverslip. 
Data  are  expressed  as  %  average  control  fluorescence  in  each  experiment,  and  was 
analysed with a one-way ANOVA which showed there to be highly significant differences 
between conditions (p<0.0001). Tukey’s multiple comparison post-test was used to establish 
significance  between  individual  data  sets  (*p<0.05,  ***p<0.001,  when  compared  with 
control or between test conditions as indicated). 169 
 
3.9. GSH release by BV-2 microglial cells 
 
It  has  not  been  firmly  established  whether  microglia  release  GSH.  Because 
components of the culture medium (Dulbecco‟s modified Eagle medium, D-MEM) 
interfere  with  the  electrochemical  detection  used  with  HPLC,  BV-2  microglial 
conditioned medium was analysed for GSH content by means of a luminescent GSH 
detection  assay.  In  five  independent  experiments  BV-2  conditioned  medium 
contained micromolar levels of GSH. Following 8 hours‟ incubation, very little GSH 
was detected in microglial conditioned medium, and there was no difference in the 
release by control and activated cells (fig. 3.14A). Following 16 hours‟ incubation, 
control  conditioned  medium  contained  4.9  ﾱ  1.6  μM  GSH,  and  LPS  (1  μg.ml
-1) 
conditioned medium contained 25.1 ﾱ 13.2 μM GSH, representing a significant 417 
± 272 % increase above control (fig. 3.14A). In contrast, conditioned medium from 
BV-2 cells treated with LPS + IFN (100 U.ml
-1) contained just 7.1 ﾱ 2.5 μM GSH 
(fig. 3.14A). Following 24 hours‟ incubation, control conditioned medium contained 
6.9 ± 1.9 µM GSH, LPS conditioned medium contained 20.0 ± 6.0 µM GSH, and 
LPS + IFN conditioned medium contained 8.6 ﾱ 2.2 μM GSH (fig. 3.14A). Data 
therefore  suggest  that  very  little  GSH  release  occurs  for  the  first  8  hours  of 
incubation, that LPS-induced GSH release occurs mostly between 8 and 16 hours‟ 
incubation,  and  that  LPS  +  IFN  treatment  leads  to  a  GSH  release  profile  very 
similar to that of untreated cells throughout (fig. 3.14A). 
 
The import of cystine via the xc
- transporter may be a rate-limiting factor in GSH 
synthesis. Therefore the effects of supplementary cystine (to a total of 1 mM) and the 
xc
-  inhibitor  aminopimelic  acid  (APA)  (2.5  mM)  upon  BV-2  GSH  release  were 
investigated. As shown in figure 3.14B, supplementary cystine enhanced BV-2 GSH 
release by  around 50% in  control  and  LPS-treated cells.  Such an effect  was  not 
evident  in  the  case  of  LPS  +  IFN-treated  cells.  In  contrast,  APA  consistently 
decreased GSH release, by 59.2 ± 5.8 %, 79.3 ± 5.2 % and 61.8 ± 16.0 %, for 
control, LPS-treated and LPS + IFN-treated cells, respectively. When the data set 
was  analysed  as  a  whole,  a  two-way  analysis  of  variance  (ANOVA)  failed  to 
demonstrate a significant  effect  of cystine/APA in  the medium  (p=0.0918) or of 
LPS/IFN treatment (p=0.0749). However, analysis of the control and APA data  170 
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Figure 3.14. (previous page) GSH is present in BV-2 microglial conditioned medium. A, BV-
2 cells were cultured in the presence of LPS (1 µg.ml
-1) or IFN (100 U.ml
-1) for 8, 16 or 24 
hours.  B,  BV-2  cells  were  cultured  for  1  hour  in  serum-free  DMEM  containing 
supplementary L-cystine (to a total of 1 mM) or aminopimelic acid (APA; 2.5 mM) before 
the addition of LPS and IFN for 24 hours. C, BV-2 cells were cultured in the presence of L-
glutamate  (10  µM  –  1  mM)  for  24  hours.  Conditioned  medium  was  analysed  for  GSH 
content using the GSH-Glo assay kit. A, Data represent the mean ± s.e.m. of four (8h, 16h) 
or five (24h) independent experiments. Data were analysed with a two-way ANOVA, which 
demonstrated a significant effect of incubation time (p=0.0167) and treatment (p=0.0172) 
upon GSH release. Bonferroni’s post-test was used to test for significant differences between 
treatments at each time point; *p<0.05 compared with control. B, Data represent the results 
of three (cystine, APA) or five (DMEM) independent experiments. Data were analysed with 
a two-way ANOVA, which failed to demonstrate a significant effect of cystine/APA presence 
(p=0.0918) or LPS/IFN treatment (p=0.0749) upon GSH release. C, Data represent the 
results of three (10 μM, 100 μM, 1000 μM glutamate) or five (0 μM glutamate) independent 
experiments. Data were analysed with a one-way ANOVA (p=0.6979, n.s.). 172 
 
sets, without the cystine data, with a two-way ANOVA found the effect of APA to 
be significant (p=0.0112), but not that of LPS/IFN treatment (p=0.1304). Analysis 
of the control and cystine data sets, without the APA data, failed to demonstrate 
significant effects of cystine (p=0.4632) or of LPS/IFN treatment (p=0.0596). The 
lack of significance of the effect of cystine is likely to be due to the high levels of 
inter-experiment variability. 
 
The effect of exogenous glutamate (10 µM – 1 mM) upon GSH release was also 
investigated. Treatment with 1 mM glutamate led to 52.1 ± 7.5 % lower GSH levels 
in  conditioned  medium  compared  with  control  conditioned  medium  (fig.  3.14C). 
However,  a  one-way  ANOVA  failed  to  demonstrate  this  to  be  significant 
(p=0.6979), again probably due to the variability of the data. 
 
Levels of lactate dehydrogenase (LDH) in conditioned medium were determined, as 
a measure of cell stress and lysis, to ascertain whether the GSH release detected may 
be due to toxicity of the compounds, causing cell lysis, rather than specific release of 
GSH. Control cells released 12.6 ± 1.14 % of the total LDH. Figure 3.15 shows that 
the only treatments to elicit significant LDH release above this were LPS (1 µg.ml
-1) 
in combination with IFN (100 U.ml
-1), which caused 23.3 ± 2.05 % LDH release at 
16  and  39.8  ±  3.98  %  release  at  24  hours,  and  IFN  alone,  which  only  caused 
significant  release  (23.4  ±  3.79  %)  after  24  hours‟  incubation  (fig.  3.15A).  In 
contrast, after 24 hours‟ incubation, LPS alone, fraction V albumin (2 mg.ml
-1) , 
cystine (to a total of 1 mM) or APA (2.5 mM) did not cause significant LDH release 
above control levels (fig. 3.15B). 
 
 
3.10. GSH release by primary microglial cells 
 
Primary  microglial  conditioned  medium  was  also  analysed  for  GSH  content,  to 
establish  whether  primary  microglia  may  also  release  GSH.  Low  micromolar 
concentrations of GSH were detected in primary microglial conditioned medium in 
four independent experiments. The effect of microglial activation with LPS and IFN 
as well as the effect of cystine and the xc
- inhibitor APA upon GSH release were173 
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Figure 3.15. LDH release by BV-2 microglial cells as an indicator of cell viability. BV-2 
microglia were cultured in the presence of LPS (1 µg.ml
-1), IFN (100 U.ml
-1), fraction V 
albumin (2 mg.ml
-1), SIB-1757 (50 µM), supplementary L-cystine (to a total of 1 mM), APA 
(2.5 mM) or a combination for 8, 16 or 24 hours and conditioned medium was assayed for 
lactate  dehydrogenase  (LDH)  content.  0%  represents  the  LDH  content  of  serum-free 
medium  and  100%  the  LDH  content  of  conditioned  medium  following  30  minutes’ 
incubation with 1% Triton X-100. Data represent the mean ± s.e.m. of three independent 
experiments, each consisting of two or three samples per condition. Data were analysed with 
a  one-way  ANOVA  with  Dunnett’s  multiple  comparison  post-test,  *p<0.05,  **p<0.01 
compared with control. 
A 
B 174 
 
investigated (fig. 3.16). Because BV-2 microglia did not demonstrate appreciable 
GSH release following 8 hours‟ incubation, primary microglial conditioned medium 
was  only  analysed  following  16  and  24  hours‟  incubation.  Individual  one-way 
ANOVAs at each time point failed to demonstrate a significant effect of LPS/IFN 
treatment upon GSH release in the absence or presence of cystine or APA (p > 0.65 
in each case). Indeed, there did not even appear to be a consistent trend towards an 
effect of either LPS or LPS + IFN treatment.  
 
 
3.11. Discussion 
 
3.11.1. GSH content of BV-2 and N9 cells is affected differently by identical 
activating stimuli; BV-2 cells are more like primary microglia 
 
Using  reverse-phase  HPLC,  GSH  levels  of  BV-2  and  N9  microglial  cells  under 
control  and  activated  conditions  were  determined  in  parallel.  Under  control 
conditions,  BV-2  and  N9  cells  contained  48.9  ±  3.4  and  83.4  ±  6.9  nmol.mg
-1 
protein, respectively.  A number of studies  upon microglia  appear to  report GSH 
concentrations  normalised  to  a  control  (Dopp  et  al.  2002;  Roychowdhury  et  al. 
2003), but the GSH concentrations determined here are similar to other reported 
values for microglial cell lines (Moss and Bates 2001).  
 
Strikingly,  where  LPS,  LPS  +  IFN  and  fraction  V  albumin  caused  significant 
increases in BV-2 GSH levels, identical treatments caused significant decreases in 
N9 GSH levels (fig. 3.6). In N9 cells (fig. 3.6A), LPS or IFN alone had similar 
effects, and the two compounds appeared to have an additive effect. In BV-2 cells 
(fig. 3.6B), while LPS significantly increased GSH levels, treatment with IFN had 
no significant effect. When measured by HPLC, the GSH content of BV-2 cells 
following treatment with LPS and IFN in combination represented an intermediate 
between  the  GSH  content  observed  following  incubation  with  each  of  the 
compounds  alone.  Different  effects  of  these  microglial  activators  upon  the  GSH 
levels  in  these  microglial  cell  lines  could  indicate  differences  in  the  signalling 
pathways following activation. This could have important implications, since LPS is  175 
 
 
 
L
P
S

L
P
S
 
+
 
I
F
N
L
P
S

L
P
S
 
+
 
I
F
N
L
P
S

L
P
S
 
+
 
I
F
N
-1
0
1
2
3
4
5
6
16h
24h
+ cystine + APA DMEM
[
G
S
H
]
 
i
n
 
m
e
d
i
u
m
 
(

M
)
           
         
 
Figure  3.16.  GSH  is  present  in  primary  microglial  conditioned  medium.  Primary  rat 
microglia were pre-incubated for 1 hour in serum-free DMEM containing supplementary L-
cystine (to a total of 1 mM) or aminopimelic acid (APA; 2.5 mM), before the addition of LPS 
(1 µg.ml
-1) and IFN (100 U.ml
-1) for 16 or 24 hours. Conditioned medium was analysed for 
GSH  content  using  the  GSH-Glo  assay  kit.  Data  represent  the  mean  ±  s.e.m.  of  three 
(cystine)  or  four  (DMEM,  APA)  independent  experiments.  Data  were  analysed  with 
individual one-way ANOVAs, which failed to demonstrate an effect of LPS/IFN treatment in 
serum-free DMEM or in the presence of cystine or APA at either time point (p > 0.65 in all 
cases, n.s.).  176 
 
commonly used in both cell lines as a model of microglial activation, often in the 
investigation of activation-associated intracellular signalling pathways. 
 
The effects of microglial activation with LPS, IFN and fraction V albumin upon 
GSH levels in primary microglia were also investigated, using both reverse-phase 
HPLC  and  quantitative  analysis  of  MCB  imaging  (fig.  3.12  and  3.13).  The 
intracellular GSH level of primary microglia was found to be 28.1 ± 2.0 nmol.mg
-1 
protein, in agreement with previous reports (Hirrlinger et al. 2000; Persson et al. 
2006). Activation of microglia with LPS (1 µg.ml
-1) for 24 hours caused around a 30 
% increase in GSH levels. This result only reached statistical significance for the 
MCB imaging data, likely due to the fact that large numbers of coverslips can be 
imaged and analysed using this method, reducing the indicators of variation, whilst 
large  numbers  of  cells  are  required  for  HPLC  analysis  and  therefore  fewer 
measurements could be taken. Exposure of primary microglia to fraction V albumin 
(2 mg.ml
-1) led to a 40.5 % increase in GSH levels, as measured by MCB imaging 
but only a non-significant 16.0 % increase when determined by HPLC. This may be 
due to the fact that cells prepared for HPLC were cultured in medium containing 10 
%  FBS  to  prevent  detachment  and  maintain  maximum  protein  content,  so  as  to 
ensure the best possible signal on HPLC. In contrast, the medium on cells used for 
MCB imaging was changed to SFM prior to the addition of activators. FBS in the 
medium is likely to contain a certain amount of albumin, however as demonstrated 
here (fig. 3.9), although this  may mask to  some extent the effects  of exogenous 
albumin, it does not appear to affect the basal GSH levels. The data presented here 
suggest that, in terms of the effects of microglial activation upon GSH levels, BV-2 
cells are more akin to primary microglia than are N9 cells. The high numbers of cells 
required  for  HPLC  analysis,  and  the  low  signal  to  noise  ratio  observed  when 
measuring primary microglial GSH levels by HPLC justify the use of the BV-2 cell 
line as a microglial model in this situation. The data produced must however be 
interpreted with caution. 
 
3.11.2. The two methods of GSH quantification: advantages and disadvantages 
 
Here  reverse-phase HPLC  and quantification of MCB fluorescence were used to 
measure the intracellular GSH levels of BV-2 microglial cells. Similar results were 177 
 
produced with the two methods, with LPS, LPS + IFN and fraction V albumin 
significantly increasing intracellular GSH levels in both cases (fig. 3.5). HPLC is 
renowned as a highly sensitive and accurate measure (Riederer et al. 1989; Frade et 
al.  2008),  and  has  the  advantage  of  yielding  absolute  GSH  levels,  while  MCB 
imaging  gives  data  in  arbitrary  fluorescence  units  which  can  be  normalised  as 
appropriate. Relatively large amounts  of protein are however required for HPLC 
determination, whereas an imaging method such as that using MCB allows analysis 
of  many  more  conditions  utilising  fewer  cells.  The  latter  method  is  therefore 
particularly useful in the case of primary microglial cells whose quantity is limited. 
 
Potential drawbacks of the MCB imaging method are centred on the fact that it relies 
upon endogenous GST to conjugate the bimane to GSH. Should any treatment of the 
cells alter GST expression or activity, this could result in a change in MCB-GSH 
conjugation efficiency and therefore affect the fluorescence levels at the end of the 
incubation  period,  an  outcome  which  would  be  interpreted  as  a  change  in  GSH 
concentration. Indeed, a 1.7-fold upregulation of GST protein has been demonstrated 
in BV-2 microglia following 24 hours‟ exposure to 100 ng.ml
-1 LPS, as has a 1.2-
fold upregulation of GST gene expression in primary microglial cultures following 4 
hours‟ exposure (Lund et al. 2006). LPS has also been shown to upregulate mRNA 
and protein expression for the GSTπ isoform in macrophages  (Xue et  al. 2005). 
Cadmium  treatment  of  primary  microglia,  which  increased  ROS  levels  and  was 
neurotoxic  in  mixed  neurone/glia  cultures,  led  to  up  to  2.7-fold  increased  GSTπ 
mRNA expression levels (Yang et al. 2007). Conversely, viral infection of N9 cells 
was shown to significantly downregulate GSTπ gene expression (McKimmie et al. 
2006). GST expression and activity has been shown to decrease in AD (Lovell et al. 
1998b), although cell-specific expression was not identified. Immunohistochemical 
observations  have  however  demonstrated  an  upregulation  of  GSTμ  isoform  in 
microglia in AD (Tchaikovskaya et al. 2005).  
 
Nevertheless, regardless of the rate, the GST-catalysed reaction should achieve a 
steady  state  given  sufficient  incubation  time,  provided  MCB  does  not  become 
limiting. For this reason it is important to follow the time course of the reaction and 
select  an  appropriate  MCB  incubation  time.  However  some  cell  types,  notably 
astrocytes,  rapidly  export  the  GS-MCB  conjugate  via  Mrp1  (Waak  and  Dringen 178 
 
2006),  a  phenomenon  characterised  by  a  rapid  decrease  in  fluorescence  after  a 
relatively  short  period  of  incubation  (Chatterjee  et  al.  1999).  In  these  instances, 
fluorescence intensity may never attain the “steady state” enabling determination of 
GSH concentration; the fluorescence profile over time would more likely reflect the 
relative rates of the activities of GST and Mrp1.  
 
There  are  a  number  of  different  GST  isoforms,  with  different  cell  types  having 
different  expression  profiles.  Microglia  have  been  shown  to  express  GSTμ 
(Tchaikovskaya et al. 2005) and GSTπ (McKimmie et al. 2006; Yang et al. 2007). 
Affinity for MCB varies between GST isoforms (Cook et al. 1991; Ublacker et al. 
1991), therefore it is not necessarily valid to compare different cell types under the 
same conditions (Chatterjee et al. 1999, 2000; Keelan et al. 2001), unless their GST 
isoform profiles have been verified as being similar. It should also be noted that the 
MCB-GSH adduct has inhibitory effects upon GST-catalysed reactions, with an IC50 
in the tens of micromolar range (Cook et al. 1991), indicating a possibility of end-
product inhibition of the reaction. 
 
EA  is  used  to  inhibit  the  conjugation  of  MCB  to  GSH.  EA  also  forms  a  (non-
fluorescent)  conjugate  with  MCB,  with  both  EA  and  the  MCB-EA  conjugate 
inhibiting  GST  activity  (Ploemen  et  al.  1990;  Awasthi  et  al.  1993).  The  data 
presented here (fig 3.5B) demonstrate that when pre-treated with 500 µM EA, BV-2 
cells under different conditions have a fluorescence level 21 – 51% of that of MCB-
treated control cells. A higher concentration of EA may have been more efficacious, 
but due to its inhibition of GST and depletion of mitochondrial GSH, EA itself has 
deleterious effects upon microglia in culture (Roychowdhury et al. 2003). Indeed, 
higher concentrations or longer incubations tested in this study caused the microglia 
to die and detach from the coverslip, rendering imaging impossible. 
 
In addition  to  the GST-catalysed specific  conjugation of MCB, the bimane non-
enzymatically and non-specifically conjugates to thiols including GSH and cysteine, 
producing around 20% of the fluorescence observed for GSH in the presence of GST 
(Fernandez-Checa  and  Kaplowitz  1990).  Such  non-enzymatic  conjugation  could 
therefore account for a large proportion of the fluorescence detected following EA 
treatment.  Another factor affecting the  efficacy  of EA could  be the  existence of 179 
 
different GST isoforms, which may have different affinities for EA as well as for 
MCB  (Ploemen  et  al.  1990).  As  described  previously,  selective  upregulation  of 
specific  GST  isoforms  may  occur  in  microglia  under  certain  conditions 
(Tchaikovskaya et al. 2005; McKimmie et al. 2006; Yang et al. 2007). It is therefore 
not  unreasonable  to  suggest  that  treatments  applied  to  microglia  here  may  have 
selectively upregulated an isoform of GST with a lower affinity for EA. 
 
3.11.3. Integration of results with published data 
 
The difference observed here between primary microglia and BV-2 cells on the one 
hand, and N9 microglial cells on the other, may go some way towards explaining the 
dichotomy in the literature. The two previous studies detecting an increase in GSH 
levels following microglial activation (Dopp et al. 2002; Persson et al. 2006) both 
utilised microglia-rich primary cultures. LPS has also been shown to increase the 
GSH levels of macrophages in culture (Sato et al. 1995, 2001). However, Chatterjee 
et al. (2000) demonstrated a decrease in microglial GSH within a mixed glial culture 
following LPS + IFN treatment, with little or no effect upon co-cultured astrocytes. 
This result clearly contradicts findings for primary microglia, as presented here and 
elsewhere, but one cannot exclude the possibility that this may be due to interactions 
between the astrocytes and microglia in the culture. Direct GSH interactions between 
astrocytes  and  neurones  have  been  well-characterised;  astrocytes  release  GSH 
(Yudkoff et al. 1990; Sagara et al. 1996; Dringen et al. 1999b) via Mrp1 (Hirrlinger 
et al. 2002c; Minich et al. 2006), which is broken down by astrocyte- and neurone-
associated ectoenzymes (Dringen et al. 1997, 2001) to provide the limiting substrate 
for  neuronal  GSH  synthesis,  L-cysteine.  Intercellular  GSH  interactions  involving 
microglia have not yet been demonstrated, although microglia have been shown to 
express Mrp1 (Ballerini et al. 2002; Hirrlinger et al. 2002a; Dallas et al. 2003) and it 
has been demonstrated here and elsewhere (Dallas et al. 2003) that microglia may 
have an ability to release GSH.  
 
Astrocytes and microglia functionally express the xc
- transporter (Allen et al. 2001; 
Pow 2001; McBean 2002), and maintenance of intracellular GSH levels is dependent 
upon xc
--mediated cystine uptake  (Cho and Bannai  1990;  Barger et  al.  2007).  If 
astrocytic xc
- activity exceeds that of microglia, cystine levels in the medium may be 180 
 
depleted by astrocytes, resulting in a reduced availability for microglial uptake and 
GSH synthesis. Alternatively astrocytes may modify microglial behaviour in a more 
indirect  way,  through  bidirectional  intercellular  communication.  For  example, 
activated  microglia  release  cytokines  such  as  TNFα  and  interleukin  1β  (IL-1β) 
(Hanisch  2002),  which  can  alter  the  expression  profile  of  genes  involved  in 
immunity  and  signalling  in  astrocytes  (Falsig  et  al.  2006).  Subsequent  release 
products of astrocytes could potentially modulate aspects of microglial behaviour, 
perhaps  affecting  GSH  synthesis  or  inducing  GSH  release  via  microglial  Mrp1 
transporters. 
 
The results presented here are in agreement with previous studies of N9 cells and 
N11 cells, documenting a 50-85% decrease in GSH levels following activation with 
LPS + IFN (Moss and Bates 2001; Roychowdhury et al. 2003). N11 cells represent 
one of the other clones produced alongside N9 cells (Righi et al. 1989), and the two 
have been shown to be very similar (Ricciardi-Castagnoli and Paglia 1992; Corradin 
et al. 1993).  However, using an identical reverse-phase HPLC method to that used 
here (Riederer et al. 1989), Moss and Bates (2001) also reported that the GSH levels 
in BV-2 cells decreased by approximately 40% following LPS + IFN exposure. 
There is a slight difference between the preparation of samples for HPLC analysis 
between this study and that of Moss and Bates (2001), which could plausibly effect 
the efficiency of GSH quantification, for example, but which would not be expected 
to lead to directly opposing results. The availability of cystine in the culture medium 
may have implications for GSH synthesis, but both here and in the previous study 
(Moss and Bates 2001), BV-2 cells were cultured in D-MEM, which contains 200 
µM cystine as standard (Dulbecco and Freeman 1959), supplemented with 10 % 
FBS.  
 
3.11.4. GSH content as a balance between cystine import and protection against 
oxidative damage 
 
LPS added to microglia or macrophages has been shown to enhance L-glutamate 
release (Piani and Fontana 1994; Sato et al. 1995; Domercq et al. 2007) by increased 
expression of the xc
- transporter system (Sato et al. 2001; Barger et al. 2007). Since 
the xc
- transporter imports cystine in exchange for glutamate, enhanced glutamate 181 
 
release would be accompanied by increased cystine import. There is however some 
evidence  to  suggest  that  the  LPS-stimulated  upregulation  of  xc
-  and  consequent 
glutamate  release  becomes  desensitised  at  particularly  high  LPS  concentrations 
(Piani and Fontana 1994; Sato et al. 1995, 2001) and over extended periods of time 
(Sato et al. 1995). High concentrations of glutamate competitively inhibit cystine 
uptake  (Bannai  1986;  Watanabe  and  Bannai  1987;  Sato  et  al.  1999; Patel  et  al. 
2004), so sustained glutamate release in the presence of LPS may eventually inhibit 
cystine uptake, perhaps explaining the apparent desensitisation of glutamate release. 
In  addition,  in  macrophages  at  least,  IFN  appears  to  attenuate  the  LPS-induced 
enhancement of glutamate release (Sato et al. 1995), thus further limiting cystine 
uptake  via  xc
-.  Decreased  cystine  import  may  cause  depletion  of  intracellular 
cysteine, therefore compromising de novo GSH synthesis. LPS and IFN both cause 
iNOS expression and NO release in BV-2 cells, but the effect of the combination of 
LPS and IFN has a much greater effect than either compound alone (fig. 3.2; Blasi 
et al. 1995; Chang et al. 2008), creating a higher demand for antioxidants such as 
GSH. GSH may be used simply as an electron donor, in which case it is regenerated 
by GR, or it may be irreversibly conjugated to electrophilic centres, such as in the 
detoxification of peroxidised lipids. The intracellular GSH content at any one point 
is likely to reflect the balance between the rate of GSH synthesis, which may be 
determined  by  that  of  cystine  uptake  via  xc
-,  and  the  demand  upon  GSH  as  an 
antioxidant following NO- (and superoxide-) mediated oxidative damage. This  is 
summarised in fig. 3.17. 
 
Moss and Bates (2001) used a high LPS concentration of 10 µg.ml
-1, in combination 
with IFN to bring about the decrease in GSH levels. Here 10 µg.ml
-1 LPS alone led 
to an increase in GSH levels. LPS (1 µg.ml
-1) + IFN also resulted in an increase in 
GSH levels relative to control, but a slight decrease relative to 1 μg.ml
-1 LPS alone, 
perhaps due to the associated enhancement of iNOS expression and NO production 
and consequent increased demand on GSH. It is not implausible that the presence of 
IFN with 10 µg.ml
-1 LPS could have much greater effects. The tenfold higher LPS 
concentration  in  combination  with  IFN  could  have  a  substantially  higher  effect 
upon iNOS expression and NO production, or upon the production of other reactive 
species, so that the rate of GSH consumption exceeds the rate of synthesis. Since 10182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17.  A summary of the effects of LPS and IFN upon xc
- expression and activity and 
GSH levels in microglia. LPS and IFN both induce iNOS expression and consequent NO 
production, with the combined effect of the two being greater than that of either compound 
alone. GSH is consumed by the cell in protecting against oxidative stress, to which NO may 
contribute. LPS also may enhance cystine export via the xc
- transporter system, which may 
represent the rate-limiting step in GSH synthesis. IFN may attenuate the LPS-induced xc
- 
upregulation. This hypothesis may explain the differences between the results obtained in 
this study and those obtained in a published study (Moss and Bates 2001). Cys, L-cystine; 
glu,  L-glutamate;  GSH,  reduced  glutathione;  IFN,  interferon-;  IFNR,  IFN  receptor; 
iNOS,  inducible  nitric  oxide  synthase;  LPS,  lipopolysaccharide;  NO,  nitric  oxide;  O2
-, 
superoxide; ONOO
-, peroxynitrite; TLR4, toll-like receptor 4; xc
-, xc
- L-glutamate/L-cystine 
antiporter system. 
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µg.ml
-1 LPS + IFN was not tested here, and Moss and Bates (2001) did not publish 
results obtained with lower LPS concentrations, it is not possible to say for certain 
whether these data are truly contradictory or evidence for a biphasic effect of LPS in 
the presence of IFN upon GSH levels in BV-2 microglia. 
 
Temporal analysis of the effect of activation upon GSH levels in BV-2 microglia 
demonstrated  an  overall  decline  in  BV-2  GSH  levels  over  time,  which  was  less 
pronounced in the presence of IFN (fig. 3.11A). Since the cells were plated and 
exposures carried out in medium containing 10 % FBS, which allows the cells to 
proliferate, this decrease over time may be related to the increasing density of BV-2 
cells in the culture plate. Indeed, iNOS expression in both control and activated BV-
2 cells is slightly elevated when the plated cells are more confluent (Dr. Claudie 
Hooper and Ioanna Sevastou, personal communication). Consequent increases in NO 
production may place extra demands upon GSH without upregulating its synthesis. 
However, two different iNOS inhibitors, which were shown to attenuate the release 
of nitrate and nitrite by microglia (fig. 3.11C), had no effect upon GSH levels in 
either control or LPS-treated BV-2 cells (fig. 3.11B), and did not prevent the decline 
in  GSH  levels  over  time.  This  suggests  that  in  BV-2  cells  under  the  conditions 
investigated here, GSH levels were not significantly affected by NO. However, the 
slight upregulation of iNOS expression may be indicative of a low level of activation 
in densely populated BV-2 cultures (Dr. Claudie Hooper, personal communication), 
therefore  there  may  also  be  increased  release  of  glutamate  by  the  cells.  Since 
glutamate is a competitive inhibitor of cystine uptake via xc
- (Bannai 1986; Patel et 
al. 2004), glutamate accumulation over time may slow the rate of GSH synthesis by 
decreasing cystine availability. This could be exaggerated if cystine levels in the 
medium significantly deplete over time due to cellular uptake and utilisation.  
 
The time course of the effect of LPS upon GSH levels bears a certain resemblance to 
the time course of the effect of LPS upon the uptake of cystine by macrophages 
(Sato et al. 1995). In this study, cystine uptake was very low in control macrophages 
and increased dramatically with incubation with 1 ng.ml
-1 LPS, up to 12 hours. After 
24 hours‟ incubation with LPS, cystine uptake had begun to decline and by 48 hours, 
it was about one-third of that at 12 hours. An adaptation of figure 1 from Sato et al. 184 
 
(1995) is presented alongside the time course of the effect of LPS on GSH content in 
figure 3.18. The implications of this similarity are limited by the fact that although 
microglia and macrophages are of the same lineage and share many characteristics, 
they are fundamentally different cell types. In addition, different LPS concentrations 
were used in the two studies. This observation is nonetheless interesting, and may 
suggest that in the presence of LPS, the GSH concentration in BV-2 cells is highly 
dependent upon cystine import via xc
-. 
 
Conversely, in the case of N9 cells, GSH levels appeared to remain fairly stable over 
time in control and activated cells (fig. 3.10). Microglial activation does not appear 
to transiently upregulate GSH synthesis as may be the case for BV-2 cells. It is likely 
that treatment of N9 microglia with LPS and/or IFN induces the production of NO 
(and possibly other ROS and RNS), which places an increased demand upon GSH as 
an antioxidant, and thus causes a sustained decrease in GSH levels. This hypothesis 
is supported by published data in the N11 cell line, similar to the N9 line, which 
demonstrates that GSH depletion can be prevented by iNOS inhibition (Moss and 
Bates 2001). 
 
3.11.5. Fundamental differences between BV-2 and N9 cell lines  
 
The  data  presented  here  clearly  demonstrate  a  very  significant  difference  in  the 
regulation  of  GSH  levels  in  N9  and  BV-2  microglial  cells.  Although  the  data 
concerning  GSH  levels  presented  by  Moss  and  Bates  (2001)  deviates  from  that 
found here, some differences were found between BV-2 and N11 cells, the latter of 
which  are  very  similar  to  N9  cells  as  used  here  (Righi  et  al.  1989;  Ricciardi-
Castagnoli and Paglia 1992; Corradin et al. 1993). For example, decreases in the 
GSH levels of N11 cells were prevented by inhibition of iNOS, whilst decreases in 
the  GSH  levels  of  BV-2  cells  were  not  (Moss  and  Bates,  2001).  The  extent  of 
mitochondrial  complex  inhibition  by  microglial  activation  also  differed  slightly 
between the two cell lines (Moss and Bates, 2001).  
 
There  are  a  number  of  fundamental  differences  in  the  production  and 
immortalisation of the N9 and BV-2 cell lines, which are summarised in table 3.2. 
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Figure 3.18. The time course of the rate of cystine uptake by LPS-treated macrophages 
shows similarity to the time course of the GSH content of LPS-treated microglia. A, The 
effect of 1 ng.ml
-1 LPS
 upon the rate of cystine uptake by peritoneal macrophages, adapted 
from Sato et al.  (1995). B, The effect of 1 μg.ml
-1 LPS upon the GSH content of BV-2 
microglial cells, from figure 3.11. 
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  N9  BV-2 
Mouse strain  CD1  C57BL/6 
Age of mouse  ED 12-13  Newborn 
Brain areas  Ventral mesencephalon & 
cerebral cortex 
 
Cerebral cortex 
 
Primary culture method  Serum free astrocyte 
conditioned medium on 
polyornithine-coated dishes 
 
Shaking and selective 
plastic adherence of mixed 
brain cultures 
Oncogenes  v-myc  
(3RV retrovirus) 
v-raf/v-myc  
(J2 retrovirus) 
 
 
Table 3.2.  Differences in the generation of N9 and BV-2 mouse microglial cell lines. 
 
 
 
The  CD1  mouse  strain  is  an  outbred  line,  not  genetically  defined,  whereas  the 
C57BL/6 strain is inbred, with well-defined characteristics. C57BL/6 mice exhibit a 
Th1-dominant  immune  response,  characterised  by  T  cell  IFN  release,  which 
stimulates macrophages to release NO (Mills et al. 2000). Microglia harvested from 
this strain therefore may exhibit enhanced iNOS/NO responses to activation. Indeed, 
in one study incubation of N9 cells with 1 µg.ml
-1 LPS for 18 hours induced < 10 
µM nitrite release, while incubation of BV-2 cells with the same LPS concentration 
for 24 hours induced > 25 µM nitrite release (Chang et al. 2008). Clearly, these 
results are not directly comparable due to the slightly longer incubation period with 
BV-2s. However, few studies have been published which directly compare the two 
cell lines. 
 
In addition, there are likely to be differences between microglia at embryonic day 
12-13 and those of a newborn mouse. Microglia are derived from monocytes and 
begin entering the brain at around embryonic day 5. Initially microglia assume an 
amoeboid phenotype and have an active role in phagocytosing debris from apoptotic 187 
 
neurones  and  degenerating  processes  during  central  nervous  system  (CNS) 
development.  Amoeboid  microglia  differentiate  into  ramified  microglia  and  by 
around post-natal day 15 few amoeboid cells remain (Ferrer et al. 1992; Ling and 
Wong 1993). Therefore, embryonic microglia may have a more pro-inflammatory 
phenotype as a result of their amoeboid morphology at this developmental stage. The 
higher basal GSH levels in N9 microglia relative to BV-2 microglia could reflect 
their embryonic origin; additionally it is possible that amoeboid microglia in the 
developing brain simply react differently to activation compared with more ramified 
post-natal  microglia.  Indeed,  a  comparison  of  primary  microglia  obtained  from 
neonatal mouse and rat brain with primary microglia obtained from adult mouse and 
rat brain demonstrated significant age-related differences in NO and cytokine release 
(Schell et al. 2007). Primary microglia used in this study were prepared from post-
natal day 2-5 rats, therefore the similarity of BV-2 cells rather than N9 cells to these 
primary microglia could simply be a reflection of the developmental stage. 
 
A difference between the culture conditions of BV-2 and N9 cells concerns the fact 
that  N9  culture  medium  contains  the  antioxidant  β-mercaptoethanol  (βME;  57.2 
µM). βME reduces disulphide bonds and therefore may be likely to convert cystine 
into  cysteine  in  the  culture  medium,  thus  preventing  cystine  uptake  for  GSH 
synthesis.  However,  βME  has  been  reported  to  increase  cystine  uptake  and 
intracellular  GSH  levels  in  peripheral  monocytes  (Messina  and  Lawrence  1992), 
spleen cells (Burger et al. 1982), insulin-secreting cells (Janjic and Wollheim 1992), 
and embryonic cells (Takahashi et al. 2002), through the formation of a cystine – 
βME disulphide which is taken up in these cell types by the Na
+-independent system 
of neutral L-amino acid transport (Ishii et al. 1981; Ohmori and Yamamoto 1983). 
Since there are no reports of microglial expression of this uptake system (Bode 2001; 
Wagner et al. 2001), it is unclear what effect βME may have upon N9 microglia in 
culture,  and  whether  formation  of  the  cystine  –  βME  disulphide  would  enhance 
cystine uptake or prevent it. βME (50 µM) was also used for N9 cell culture by 
Roychowdhury et al. (2003), whose investigations demonstrated decreases in GSH 
content upon LPS + IFN treatment. However, there is no record of βME use in 
another study documenting activation-induced decreases in GSH levels in BV-2 and 
N11  microglial  cell  lines  (Moss  and  Bates  2001),  suggesting  that  βME  was  not 
responsible for the observed declines in GSH levels. 188 
 
 
3.11.6. Other potential differences between GSH metabolism in BV-2 and N9 
cell lines 
 
The differences between N9 and BV-2 cells could lead to differences in one or more 
of a number of elements related to GSH metabolism. For example, N9 cells may 
have a reduced capacity for GSH regeneration following oxidation. In BV-2 cells 
GSSG levels  were negligible under a number of different  conditions  (table 3.1). 
GSSG  levels  in  N9  cells  were  however  not  determined,  but  a  failure  of  GR  to 
convert  GSSG  back  to  GSH  at  an  adequate  rate  during  oxidative  stress  could 
increase GSSG levels and explain the decreased GSH levels following microglial 
activation.  
 
GSH may be irreversibly consumed through conjugation to other molecules in the 
detoxification of xenobiotics (Smith et al. 1977; Younes et al. 1980) as well as in 
some normal metabolic processes (Elce and Harris 1971; Soderstrom et al. 1985). 
For example, leukotriene C4, an inflammatory mediator which may be released by 
microglia (Matsuo et al. 1995), is formed by conjugation of GSH to leukotriene A4 
(Soderstrom et al. 1985). A decrease in GSH levels, as seen here in N9 cells, could 
therefore represent enhanced leukotriene C4 production and release.  
 
3.11.7. End-product inhibition of glutamate-cysteine ligase 
 
Glutamate-cysteine  ligase  (GCL,  also  known  as  -glutamylcysteine  synthase) 
catalyses the formation of -glutamylcysteine (GC) from glutamate and cysteine, 
the rate limiting step in GSH biosynthesis (Meister and Anderson 1983). GSH, the 
end product of the pathway, can competitively inhibit GCL by interacting with the 
glutamate binding site, with an apparent Ki of 2.3 mM (Richman and Meister 1975). 
The molar concentration of GSH in astrocytes was calculated as approximately 3.2 
mM (Chatterjee et al. 1999), and microglia are reported to have higher intracellular 
GSH levels than astrocytes (Chatterjee et al. 1999; Hirrlinger et al. 2000; Noack et 
al. 2000). This suggests that the GSH concentration within microglia is in the range 
for feedback inhibition upon GCL. The GSH level in control N9 microglial cells was 
found here to be 70% higher than that in control BV-2 cells (fig. 3.6). Perhaps the 189 
 
greater abundance of GSH in N9 cells provides a tonic inhibition of GSH synthesis, 
therefore reducing the rate at which the cells are able to replace GSH in the presence 
of  ROS  and  RNS  which  may  place  demands  upon  GSH  as  an  antioxidant.  The 
possibility also exists of indirect regulation of GCL by microglial activation. Indeed, 
in astrocytes, NO donors caused an upregulation of GCL expression and activity and 
an increase in intracellular GSH levels (Gegg et al. 2003). 
 
3.11.8. ATP and GSH levels in BV-2 microglia 
 
It was found here that ATP levels in BV-2 cells decline over time in culture. This is 
at odds with the stable ATP levels observed in N9 cells over 24 hours (Kingham and 
Pocock 2000), and occurred whether cells were cultured in SFM or SCM, suggesting 
that it did not represent a deleterious effect of serum removal. Most published studies 
have measured ATP levels at one time point (e.g. Moss and Bates 2001; Chenais et 
al. 2002), or if a number of time points were used, data were normalised to control 
levels at the same time point (e.g. Yang et al. 2002), therefore it cannot necessarily 
be assumed that ATP levels remained constant over time in such studies. Preliminary 
experiments here suggested a high ADP/ATP ratio in BV-2 cells, and a decline in 
total ATP + ADP levels over time following removal of serum, perhaps suggesting 
either an accumulation of AMP or a release of ATP.  
 
Intracellular accumulation of AMP and an increased AMP:ATP ratio is a sign of 
energy  depletion  and  may  upregulate  a  number  of  aspects  of  cellular  energy 
metabolism through the activation of 5‟-AMP-dependent protein kinase (Bolaños et 
al. 2008). Microglial ATP release has been demonstrated in activated N9 microglial 
cells (Ferrari et al. 1997) and macrophages (Sperlagh et al. 1998). Extracellular ATP 
has been shown in vitro to affect microglial morphology (Honda et al. 2001), to 
cause elevation of intracellular Ca
2+ (McLarnon et al. 1999), and release of cytokines 
(Inoue 2002), and to have a chemotactic effect (Honda et al. 2001; Davalos et al. 
2005), suggesting that microglial ATP release may cause chemotaxis and activation 
of further microglia, amplifying any microglial response. 
 
Fraction  V  albumin  was  the  only  compound  to  significantly  affect  the  ATP 
concentration in BV-2 microglia, more than doubling it after 24 hours‟ incubation. 190 
 
This may relate to the ability of albumin to cause proliferation of microglia (Hooper 
et al. 2005). Published data have demonstrated decreases in ATP levels in BV-2 and 
N11 microglial cells after 16 – 20 hours‟ incubation with LPS + IFN (Moss and 
Bates 2001; Chenais et  al. 2002), and a delayed decrease following exposure of 
primary microglia or N9 cells to CGA for at least 22 hours (Kingham and Pocock 
2000). Here, LPS + IFN and IFN alone led to slightly lower ATP levels at 24 
hours, although this was not found to be statistically significant. Conversely, LPS 
alone caused a trend towards an increase in ATP levels, although the effect was less 
pronounced than that of fraction V albumin. 
 
NO and its derivative peroxynitrite inhibit mitochondrial ATP synthesis (Bolaños et 
al. 1995; Brookes et al. 1999; Chenais et al. 2002), and are widely reported to be 
anti-proliferative in a number of cell types both in vitro and in vivo (Garg and Hassid 
1989; Kawahara et al. 2001; Gibbs 2003). However more recent studies have shown 
the relationship between NO and ROS production, and ATP levels and proliferation 
to  be  more  complicated.  The  gram-positive  bacterial  cell  wall  component 
lipoteichoic acid  (LTA), which increased iNOS immunoreactivity  (Kinsner et  al. 
2005), had proliferative effects upon microglia at low doses, but decreased viability 
at  higher  concentrations  (Jiang-Shieh  et  al.  2005).  Similarly,  the  cytokine 
interleukin-5 (IL-5) increased nitrite production by microglia whilst also stimulating 
proliferation (Liva and de Vellis 2001). There is also some evidence for involvement 
of superoxide-derived ROS in control of cell proliferation, and therefore perhaps 
ATP levels (Jekabsone et al. 2006; Mander et al. 2006).  
 
Protective functions of NO and peroxynitrite have been demonstrated in some cell 
types. NO may upregulate the glycolytic pathway, leading to compensatory ATP 
production and maintenance of the mitochondrial membrane potential (Almeida et 
al. 2001), whilst peroxynitrite may increase the activity of the pentose phosphate 
pathway, leading to enhanced NADPH levels to regenerate the reduced form of the 
antioxidant glutathione (García-Nogales et al. 2003). Such a regulation of energy 
metabolism may be implicated here, especially in the case of fraction V albumin 
treatment  of  BV-2  cells,  where  iNOS  expression  occurred  alongside  elevated 
intracellular  ATP  and  GSH  levels,  and  proliferation  was  evident  (Hooper  et  al. 
2005). 191 
 
 
Studies have shown that LPS and IFN stimulate iNOS expression and NO release 
through  the  activation  of  distinct  signalling  pathways  in  BV-2  cells  (Shen  et  al. 
2005), and that while IFN potentiates the LPS-induced release of some cyto- and 
chemokines, it attenuates the LPS-induced release of others (Hausler et al. 2002). It 
is therefore quite plausible that LPS and IFN could have different effects upon ATP 
levels, despite the fact that they increase iNOS expression to a similar extent. 
 
ATP  is  required  for  the  GCL-catalysed  synthesis  of  GC  from  cysteine  and 
glutamate, and for the GSH synthase-catalysed formation of GSH from GC and 
glycine (Snoke and Bloch 1952; Snoke et al. 1953). Should energy depletion occur 
following  microglial  activation,  de  novo  GSH  synthesis  would  likely  be 
compromised. Indeed, the effects of different treatments of BV-2 cells upon ATP 
levels appears to mirror to some extent their effects upon intracellular GSH levels. 
The time course of changes in ATP and GSH levels under different conditions is 
presented in figure 3.19. In control cells and in the presence of LPS and fraction V 
albumin, changes in ATP and GSH levels are clearly correlated, with the decline in 
ATP level preceding the decline in GSH level in each case. The ATP levels of BV-2 
microglial  cells  may  therefore  be  an  important  determinant  of  intracellular  GSH 
levels. However, in the case of IFN alone or in combination with LPS, a striking 
decline  in  ATP  levels  was  seen,  whilst  GSH  levels  remained  rather  stable.  This 
implicates the involvement of other factors in determining GSH levels under these 
conditions. For comparison, all the graphs in figure 3.19 are drawn on identical axes. 
 
ATP levels of N9 microglia were not tested in this study, although a previous report 
from this laboratory indicated that ATP levels of plated N9 cells remain relatively 
stable over time (Kingham and Pocock 2000), not unlike intracellular GSH levels of 
N9 cells as determined in this study (fig. 3.10).  
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Figure 3.19. Comparison of the time course of changes in ATP (   ) and GSH (   ) levels in 
BV-2 cells. Data taken from figures 3.4 and 3.11 and plotted according to treatment (A, 
control; B, LPS; C, LPS + IFN; D, IFN; E, fraction V albumin) demonstrate a correlation 
between the changes in ATP and GSH levels over time and following different treatments. 
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3.11.9. Implications for neuroinflammatory disease 
 
Albumin is the most abundant plasma protein, but due to its size, is only present at 
high levels in the CNS under conditions of blood-brain barrier (BBB) dysfunction, as 
may be found in neuroinflammatory conditions (Hooper et al. 2005). As shown here 
and elsewhere (Hooper et al. 2009), fraction V albumin induces iNOS expression 
and NO release by microglia. Albumin has also been found to induce microglial 
superoxide production (Si et al. 1997). Such ROS and RNS may be harmful to the 
microglia themselves as well as to neighbouring cells; alternatively they may have a 
role in the control of mitochondrial respiration, as seen in other cell types including 
astrocytes (Almeida et al. 2001). The enhanced ATP and GSH content of fraction V 
albumin-treated  microglia  demonstrated  here  may  be  indicative  of  an  enhanced 
metabolism, in accordance with the proliferative effect of albumin (Hooper et al. 
2005).  As  demonstrated  in  figure  3.19,  the  ATP  content  of  fraction  V  albumin-
treated cells is higher relative to their GSH content than under any other condition. 
 
Treatment of microglia with the AD-related proteins Aβ or CGA causes microglial 
neurotoxicity (Kingham et al. 1999; Taylor et al. 2002). Here neither protein was 
found to enhance the release of nitrate and nitrite by N9 microglia. However, other 
studies  have  demonstrated  enhanced  iNOS  expression  and  NO  production  by 
microglia treated with CGA (Taupenot et al. 1996; Kingham et al. 1999; Kingham 
and Pocock 2000; Hooper and Pocock 2007). In all cases primary microglia were 
used, and the difference between nitrate/nitrite levels in control and CGA-treated 
cells was shown to be less pronounced in the case of N9s (Kingham and Pocock 
2000). CGA also causes microglial apoptosis (Kingham et al. 1999; Kingham and 
Pocock 2000; Hooper and Pocock 2007), but this is not likely to be due to GSH 
depletion as CGA did not significantly alter the GSH content of either BV-2 or N9 
microglial cells. 
 
Aβ peptides have been shown to be neurotoxic directly, as well as through their 
effects upon microglia (Taylor et al. 2002, 2003). Here Aβ25-35 did not significantly 
alter nitrate and nitrite release by N9 microglia, in accordance with other studies 
(Goodwin et al. 1995; Meda et al. 1995) which demonstrate that priming by the 
cytokine IFN is required to stimulate iNOS expression and NO release. Aβ1-40 has 194 
 
been previously shown to increase microglial glutamate release via the xc
- transporter 
(Qin et al. 2006), suggesting that microglia may be taking up cystine at a higher rate, 
allowing a higher rate of GSH synthesis. As Aβ peptides including Aβ25-35 upregulate 
microglial  superoxide  production  (McDonald  et  al.  1997;  Combs  et  al.  1999), 
enhanced rates of cystine uptake and GSH synthesis may be necessary to balance the 
demand upon GSH and maintain GSH levels close to control level, as found in both 
BV-2 and N9 microglial cell lines in the present study. 
 
3.11.10. Microglial GSH release 
 
Here  low  micromolar  levels  of  GSH  were  consistently  detected  in  conditioned 
medium  from  BV-2  and  primary  rat  microglial  cells  following  16  –  24  hours‟ 
incubation, indicating that microglia are capable of releasing small amounts of GSH. 
Macrophages have been shown to release thiols (Watanabe and Bannai 1987), and 
more recently, GSH specifically (Sato et al. 2001). Vincristine export by cells of the 
rat MLS-9 microglial cell line has been demonstrated to depend upon intracellular 
GSH, suggesting cotransport via Mrp1 (Dallas et al. 2003). However, this appears to 
be the first demonstration of GSH release by primary microglial cells.  
 
In BV-2 cells, but not in primary microglia, LPS increased GSH release. LPS in 
combination  with  IFN  did  not  enhance  GSH  release  in  either  primary  or  BV-2 
microglia. This may be related to the relative iNOS expression levels induced by 
LPS and LPS + IFN treatment in the two cell types. As shown here (figs. 3.1 and 
3.2)  and  elsewhere  (Shen  et  al.  2005;  Horvath  et  al.  2008),  LPS  alone  leads  to 
relatively low levels of iNOS expression and NO release by BV-2s, but high levels 
of iNOS expression and NO release by primary microglia. LPS + IFN treatment 
leads to a much higher level of iNOS expression in BV-2s. LPS treatment of BV-2 
cells may therefore be the anomaly here, in that it may cause upregulation of GSH 
synthesis without high levels of NO production and the associated demand upon 
GSH as an antioxidant. This would also fit with the large increase in intracellular 
GSH in BV-2 cells following LPS treatment. In contrast, LPS + IFN treatment of 
BV-2  cells  and  LPS  treatment  of  primary  microglia  are  likely  to  increase  GSH 195 
 
utilisation as well as its synthesis; less striking increases in intracellular GSH are 
seen under these conditions. 
 
The xc
- inhibitor APA seemed to decrease microglial release of GSH and reduced the 
LPS-mediated  enhancement  of  GSH  release  in  BV-2  cells,  although  statistical 
significance was not attained in these preliminary experiments. A difference may 
suggest that GSH release is somewhat dependent upon cystine import via xc
-, and 
may implicate the intracellular GSH pool as the source of the released GSH.  
 
In the case of BV-2 cells at least, the GSH release detected was not due simply to 
lysis of the cells, as LPS markedly elevated the GSH content of conditioned medium, 
but did not elevate the LDH content, a widely-used measure of cell lysis. In contrast, 
the highest LDH content of conditioned medium occurred following LPS + IFN 
treatment,  a  condition  which  did  not  significantly  alter  GSH  content.  However, 
significant LDH release following treatment with LPS + IFN or IFN alone has 
important  implications  for  previous  or  subsequent  data  relating  to  other  release 
products of BV-2 microglia under such activated conditions. This finding suggests 
that  regulated  release  may  be  overestimated,  unless  measurements  of  release  are 
corrected for lysis by simultaneous LDH release measurement. 
 
In a previous study investigating GSH release by different CNS cell types in primary 
cultures,  microglial  GSH  release  was  not  detected  (Hirrlinger  et  al.  2002c). 
However, GSH release was only monitored for 6 hours, whilst in the present study 
the GSH content of the medium was measured over 24 hours. In accordance with the 
published study (Hirrlinger et al. 2002c), during the first 8 hours very little GSH 
appeared to be released by BV-2 cells. GSH release in the aforementioned study was 
measured by culturing cells in a salt solution consisting of 44 mM NaHCO3, 110 
mM NaCl, 1.8 mM CaCl2, 5.4 mM KCl, 0.8 mM MgSO4, 0.92 mM NaH2PO4 and 5 
mM  D-glucose  (Hirrlinger  et  al.  2002c).  This  solution  is  routinely  used  for  the 
measurement of GSH release by astrocytes (Dringen et al. 1997, 1999b; Stewart et 
al. 2002; Gegg et al. 2005; Minich et al. 2006; Frade et al. 2008), however when 
BV-2 cells were cultured in such a solution here, they displayed retracted processes 
and ruffled membranes and a larger proportion of microglia became detached than 
those cultured in D-MEM. In addition, GSH release was barely detectable when the 196 
 
salt  solution  was  used,  and  modulation  of  release  by  LPS  was  not  apparent,  in 
contrast  to  cells  cultured  in  phenol  red-free  D-MEM.  A  second  simple  medium, 
designated basic medium (BM), consisting of 5 mM NaHCO3, 153 mM NaCl, 2.6 
mM CaCl2, 3.5 mM KCl, 1.2 mM MgCl2, 1.2 mM Na2SO4, 0.4 mM KH2PO4, 20 
mM  N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid  (TES) and 5 mM 
D-glucose, which is used widely in this laboratory, was less detrimental towards 
microglial cells. However, a standard curve made up in BM was not linear and again, 
LPS  could  not  be  shown  to  modulate  GSH  release.  It  therefore  appears  that 
modulation of microglial GSH release by LPS requires a component of D-MEM not 
present in these simple media, perhaps specific amino acids. As the xc
- inhibitor APA 
appeared to decrease BV-2 GSH release to a low level and prevent its modulation by 
LPS, a lack of cystine in the medium could have a similar effect. Although the use of 
phenol red-free D-MEM does considerably reduce the signal to noise ratio of the 
assay, the  coefficient of determination for the standard  curve was  consistently ≥ 
0.99, and of those tested here, this appeared to be the only condition under which 
GSH release and its modulation could be reliably detected.  
 
The likely role of microglial-derived GSH is unclear. GSH released by astrocytes 
supplies cysteine for neuronal GSH synthesis, but in order for released GSH to be 
utilised by neurones it first needs converting to cysteinylglycine by the ectoenzyme 
-glutamyl transpeptidase (GT). The detection of GSH in conditioned medium here 
in  the  absence  of  the  GT  inhibitor  acivicin  (Dringen  et  al.  1997)  suggests  that 
microglial GT activity is low or absent, in accordance with other reports (Murata et 
al. 1997; Ruedig and Dringen 2004). Neuronal GT activity is also low (Shine and 
Haber 1981; Philbert et al. 1995; Ruedig and Dringen 2004), therefore a direct GSH 
transfer from microglia to neurones seems unlikely. However, astrocytes have high 
GT  activity  (Ruedig  and  Dringen  2004),  and  could  perhaps  process  microglial-
derived, as well as astrocyte-derived GSH for neuronal use. Under conditions of 
persistent stress, astrocyte GSH is likely to become depleted; perhaps microglia act 
as a secondary source of GSH to ensure continued neuroprotection. Astrocytes have 
also been shown to take up GSH (Kannan et al. 2000); therefore microglia may 
supply GSH to astrocytes so that their neuroprotective function is not compromised. 
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Microglia have been shown to express functional Mrps (Ballerini et al. 2002; Dallas 
et  al.  2003),  proteins  associated  with  the  efflux  of  xenobiotics.  In  particular, 
microglia have been shown to express Mrp1 (Ballerini et al. 2002; Hirrlinger et al. 
2002a; Dallas et al. 2003), which can transport GSSG (Leier et al. 1996), glutathione 
conjugates (Loe et al. 1996) and drugs in cotransport with GSH (Zaman et al. 1995; 
Loe et al. 1998), as well as some drugs alone or conjugated or cotransported with 
other molecules (Konig et al. 1999; Leslie et al. 2001). The presence of GSH in 
microglial conditioned medium suggests that of these options, cotransport may most 
likely be occurring; GSH release by microglia may therefore simply be a by-product 
of Mrp-mediated export of other molecules. 
 
GSH has been detected extracellularly in the brain and in the CSF at micromolar 
concentrations (Anderson et al. 1989; Yang et al. 1994; Lada and Kennedy 1997; Do 
et al. 2000; Wang and Cynader 2000; Calabrese et al. 2002, 2003; Kawakami et al. 
2006),  indicating  that  not  all  GSH  released  is  broken  down  by  ectoenzymes. 
Microglia  may  be  responsible  for  maintaining  an  extracellular  GSH  level  for 
antioxidant or other functions. 
 
There is significant evidence supporting a role of GSH as a neuromodulator. GSH 
may  be  capable  of  binding  to  the  glutamate-binding  sites  of  the  N-methyl-D-
aspartate (NMDA) (Yoneda et al. 1990; Leslie et al. 1992; Ogita et al. 1995; Varga 
et  al.  1997;  Jenei  et  al.  1998)  and  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (Varga et al. 1989, 1997; Jenei et al. 
1998), and may have consequences for glutamate, NMDA and AMPA-stimulated 
pathways  (Janaky  et  al.  1993,  2007,  2008).  Extracellular  GSH  may  also  form 
disulphide bonds with the µ-opioid, neurokinin-1 and kainate receptors and affect 
their ligand-binding properties (Liu and Quirion 1992). GSH also potentiates activity 
of the Ca
2+-sensing receptor through interaction with the amino acid binding site, 
which is distinct from the Ca
2+ binding site (Wang et al. 2006). In addition, GSH 
may  enhance  glutamate  uptake  (Varga  et  al.  1994).  A  number  of  studies  have 
identified two GSH binding sites on CNS tissues (Ogita and Yoneda 1987, 1988; 
Guo et al. 1992; Janaky et al. 2000), where binding at one site cannot be inhibited by 
glutamate receptor ligands, and is postulated to be a GSH-specific site, thus perhaps 198 
 
identifying GSH as a novel neurotransmitter (Guo et al. 1992; Guo and Shaw 1992; 
Lanius et al. 1994; Janaky et al. 2000). 
 
3.11.11. Conclusion 
 
Microglial  activation  upregulates  the  production  of  ROS  and  RNS  by  microglia, 
suggesting that antioxidants such as GSH are likely to be important in protecting 
microglia from oxidative damage. The effect of microglial activation by LPS and 
fraction  V  albumin  upon  intracellular  GSH  is  different  in  BV-2  and  N9  mouse 
microglial  cell  lines.  The  effect  upon  BV-2  cells  is  a  transient  increase  in  GSH 
levels,  whilst  in  N9  cells,  GSH  levels  below  control  are  established  following 
activation and maintained over time. GSH levels are a result of a balance between 
the rate of GSH synthesis and the demands upon GSH as an antioxidant as well as 
reactions which irreversibly consume GSH. It is proposed that in the case of BV-2 
cells, microglial activation leads to a transient upregulation in GSH synthesis, which 
may be related to increased xc
- activity or ATP levels. In N9 cells however, GSH 
utilisation  appears  to  have  the  greatest  impact  upon  GSH  levels,  leading  to  a 
sustained decrease in cellular GSH content. Whatever the difference between the cell 
lines, BV-2 cells appear to be more similar to primary microglia. BV-2 cells will 
therefore be used in further experiments concerning GSH levels and xc
- where it is 
not possible to use primary microglia, particularly in GSH quantification by HPLC 
where  relatively  large  amounts  of  protein  are  required.  The  AD-related  proteins 
CGA and Aβ25-35 did not significantly alter the GSH levels of BV-2 or N9 microglial 
cells.  This  suggests  that  GSH  demand  and  utilisation  are  balanced  by  GSH 
regeneration and de novo synthesis effectively under these conditions. 
 
Contrary to one previous report (Hirrlinger et al. 2002c), but in accordance with 
another (Dallas et al. 2003), microglia appear to release low levels of GSH, and such 
release appears to depend somewhat upon the activity of the xc
- transporter system. 
This appears to be the first demonstration of GSH release by primary microglia. The 
function of microglia-derived GSH is yet to be established; it may enable transfer of 
the antioxidant between cell types, maintain an extracellular GSH pool, or represent 
a signalling role of GSH. 199 
 
 
 
Chapter 4 
Results II: 
Microglial glutathione and  
glutamate transporters 
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4.1. Introduction and summary of results 
 
Elevated  extracellular  glutamate  levels,  leading  to  excitotoxicity  and  oxidative 
glutamate toxicity, have been implicated in the pathogenesis of many neurological 
diseases.  A  decrease  in  glutamate  uptake  and  decreased  astrocyte  expression  of 
excitatory  amino  acid  transporters  (EAATs)  1  and  2  have  been  reported  in 
Alzheimer‟s disease (AD) (Cross et al. 1987; Cowburn et al. 1988; Scott et al. 1995; 
Masliah et al. 1996; Li et al. 1997; Liang et al. 2002). A decline in the expression of 
EAAT1 and 2 have also been described in multiple sclerosis (MS) and its animal 
model  experimental  autoimmune  encephalomyelitis  (EAE)  (Werner  et  al.  2001; 
Ohgoh et al. 2002; Pitt et al. 2003). 
 
Microglia have been shown to express EAATs and the xc
- transporter system, which, 
under  normal  circumstances,  mediate  the  import  and  export  of  glutamate, 
respectively (Kondo et al. 1995; Lopez-Redondo et al. 2000; Nakajima et al. 2001b; 
McBean 2002; Jacobsson et al. 2006; O'Shea et al. 2006; Barger et al. 2007). In the 
previous chapter, compounds associated with microglial activation were found to 
affect the reduced glutathione (GSH) content of BV-2, N9 and primary microglial 
cells. One of the potentially limiting factors in GSH synthesis is cystine import via 
the glutamate/cystine antiporter system xc
-, thus upregulated GSH synthesis may be 
coupled with enhanced glutamate release. Concurrent glutamate uptake by microglial 
EAATs  may  limit  or  reverse  enhanced  levels  of  glutamate.  Although  millimolar 
levels of glutamate are present intracellularly, EAATs and xc
- may be located in 
close  vicinity  to  one  another  so  that  EAAT-mediated  glutamate  uptake  may  be 
directly coupled to xc
- activity (Igo and Ash 1998; Rimaniol et al. 2001; Persson et 
al.  2006).  Changes  in  the  expression  of  microglial  glutamate  transporters  upon 
activation or under conditions of disease may therefore affect extracellular glutamate 
levels.  The  effects  of  lipopolysaccharide  (LPS),  the  standard  in  vitro  microglial 
activator,  albumin,  to  which  microglia  may  be  exposed  upon  blood-brain  barrier 
(BBB) damage, and chromogranin A (CGA) and β amyloid peptide (residues 25-35; 
Aβ25-35),  proteins  upregulated  in  Alzheimer‟s  disease  (AD),  upon  microglial 
glutamate release and glutamate transporter expression were therefore investigated. 
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Microglia  were  found  to  express  mRNA  for  EAAT1,  EAAT2  and  the  specific 
subunit of xc
-, xCT. However, the microglial cells lines BV-2 and N9 expressed the 
EAATs at much lower levels than primary microglia; their EAAT mRNA expression 
was close to the limit of detection under the conditions used. LPS and fraction V 
albumin  enhanced  glutamate  release  and  upregulated  EAAT2  and  xCT  mRNA 
expression. However CGA and Aβ25-35 were not found to have any effects upon the 
extracellular glutamate levels or upon microglial transporter expression. 
 
Inhibition of xc
- by aminoadipic acid (AAA) and aminopimelic acid (APA) caused a 
decline in microglial GSH content, highlighting the importance of cystine uptake via 
this transporter for GSH synthesis. The xc
- transporter appeared to have a dominant 
effect in BV-2 cells, endowing these cells with an ability to buffer the extracellular 
glutamate concentration to 170 - 200 µM, approximately equal to the extracellular 
cystine  concentration.  However,  high  levels  of  extracellular  glutamate  may 
compromise GSH synthesis through decreased cystine uptake via xc
-. In contrast, low 
(1 – 10 µM) levels of exogenous glutamate increased intracellular GSH levels. These 
observations  may  indicate  an  involvement  of  microglia  in  glutamate  release  in 
neuroinflammatory and neurodegenerative disease, and may also have implications 
for microglial GSH levels, and consequently microglial survival under conditions of 
elevated extracellular glutamate. 
 
 
4.2.  Microglial  glutamate  release  increases  following  microglial 
activation 
 
Primary  microglia  were  exposed  to  LPS,  interferon-  (IFN),  LPS  and  IFN  in 
combination or fraction V albumin for 24 hours in serum-free medium (SFM) (fig. 
4.1). Fresh SFM was found to contain 15.8 ﾱ 6.3 μM, and conditioned medium from 
control cells contained 14.0 ﾱ 0.9 μM, implying that untreated primary microglia did 
not  modify  the  glutamate  content  of  the  medium  (fig.  4.1).  However,  24  hours‟ 
treatment  with  LPS  (1  μg.ml
-1)  significantly  elevated  the  glutamate  content  of 
conditioned  medium  by  222.7  ﾱ  47.4  %  to  45.2  ﾱ  6.6  μM,  and  treatment  with 
fraction V albumin (2 mg.ml
-1) significantly elevated the glutamate content by 257.0  202 
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Figure  4.1.  The  effect  of  microglial  activation  upon  L-glutamate  levels  in  microglial 
conditioned medium. Primary rat microglia were plated at 1 x 10
5 cells per 13mm coverslip, 
culture medium was changed to SFM and cells were cultured in the presence of LPS (1 
µg.ml
-1), IFN (100 U.ml
-1), fraction V albumin (2 mg.ml
-1) or a combination for 24 hours, 
before L-glutamate levels in the supernatant were determined. A sample of fresh SFM was 
also  tested  for  comparison.  Data  represent  the  mean  ±  s.e.m.  of  three  independent 
experiments, each consisting of three replicates per condition. Data were analysed using a 
one-way ANOVA (p<0.0001), with Dunnett’s multiple comparison post-test to compare all 
treatments with control. (**p<0.01, n.s. p>0.05, n=3). 203 
 
± 70.5 % to 50.1 ﾱ 9.9 μM (fig. 4.1). A combination of LPS and IFN more than 
doubled the glutamate content of conditioned medium to 35.6 ﾱ 6.5 μM, but this was 
not found to be significantly different from control (fig. 4.1). IFN alone had no 
effect; conditioned medium contained 13.9 ﾱ 0.7 μM following 24 hours‟ treatment 
(fig. 4.1). These results suggest that LPS and fraction V albumin increase glutamate 
release by primary microglia. 
 
Similar experiments were carried out using BV-2 (figs. 4.2 and 4.3) and N9 cells 
(fig. 4.4). Conditioned medium from control BV-2 cells contained 121.7 ﾱ 3.7 μM 
glutamate  when  cultured  in  serum-containing  medium  (SCM)  comprising  10  % 
foetal  bovine  serum  (FBS)  (fig.  4.2A),  and  174.9  ﾱ  18.2  μM  glutamate  when 
cultured in SFM. Whether the experiment was conducted using SCM (fig. 4.2A) or 
SFM (fig. 4.2B), conditioned medium from BV-2 cells exposed to LPS alone or in 
combination  with  IFN  had  significantly  higher  glutamate  concentrations  than 
control, suggesting enhanced glutamate release under these conditions. Conditioned 
medium from LPS-treated cells had 53.3 ± 16.7 % higher glutamate compared to 
control when the experiment was conducted with SCM (fig. 4.2A), and 59.5 ± 17.6 
% higher glutamate in SFM (fig. 4.2B). LPS in combination with IFN caused a 46.1 
± 17.2 % increase in glutamate in SCM (fig. 4.2A), and a 74.1 ± 22.3 % increase in 
SFM (fig. 4.2B). Fraction V albumin caused a significant 39.9 ± 15.1 % increase in 
the glutamate content of SCM (fig. 4.2A). In SFM, fraction V albumin treatment 
increased glutamate levels by 83.5 ± 22.3 % (fig. 4.2B), but due to the variation in 
the data and the fact that these data derive from three independent experiments while 
the other points on figure 4.2B derive from seven or fourteen experiments, this result 
did not prove to be statistically significant. When BV-2 cells were exposed to IFN 
alone or the AD-associated protein CGA in  SCM,  there were no changes  in  the 
glutamate content of the conditioned medium (fig. 4.2A). Aβ25-35 treatment caused a 
21.1 ± 3.7 % increase in glutamate in BV-2 conditioned medium, but this was not 
found here to be significantly different from control levels (fig. 4.2A). 
 
The time course of glutamate release by BV-2 microglia exposed to LPS or fraction 
V  albumin  was  investigated.  Culture  medium  was  changed  to  SFM  before  the 
addition of compounds because of the variable glutamate concentration of serum,204 
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Figure  4.2.  The  effect  of  microglial  activation  upon  L-glutamate  levels  in  BV-2  cell 
conditioned medium. BV-2 microglial cells were cultured in medium containing 10% FBS 
(A) or SFM (B) and exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 nM), fraction 
V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination for 24 hours, before L-glutamate 
levels in the supernatant were determined. A, Data represent the mean ± s.e.m. of two (IFN, 
CGA, Aβ25-35), three (LPS, LPS + IFN, fraction V albumin) or five (control) independent 
experiments, each consisting of two replicates per condition. Data were analysed with a 
one-way  ANOVA  (p=0.0029),  followed  by  Dunnett’s  multiple  comparison  post-test 
(*p<0.05, **p<0.01, compared with control). B, Data represent the mean ± s.e.m. of three 
(fraction  V  albumin),  seven  (LPS  +  IFN)  or  fourteen  (control,  LPS)  independent 
experiments.  Data  were  analysed  with  a  one-way  ANOVA  (p=0.0075),  followed  by 
Dunnett’s multiple comparison post-test (*p<0.05 compared with control). 
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Figure 4.3. Time course of the effects of LPS and fraction V albumin upon L-glutamate 
levels in BV-2 microglial cell conditioned medium. BV-2 cells in serum-free medium were 
exposed to LPS (1 µg.ml
-1) or fraction V albumin (2 mg.ml
-1) for 2 – 72 hours, before L-
glutamate levels in the supernatant were determined. Data are presented as % control value 
at each time point and represents the mean ± s.e.m. of three independent experiments, except 
for  control  and  LPS  at  24  hours,  where  data  represent  the  mean  ±  s.e.m.  of  thirteen 
independent  experiments.  Raw  data  at  each  time  point  were  analysed  using  a  one-way 
ANOVA (p=0.983 at 2h; p=0.976 at 4h; p=0.9773 at 6h; p=0.9736 at 8h; p=0.2125 at 16h; 
p=0.0078 at 24h; p=0.0396 at 48h; p=0.5134 at 72h); where p<0.05 (24h, 48h) Dunnett’s 
multiple comparison post-test was carried out (*p<0.05 compared with control). 206 
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Figure 4.4. The effects of microglial activation upon L-glutamate levels in N9 microglial 
cell conditioned medium. N9 cells were cultured in medium containing 5% newborn calf 
serum and exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 nM), Aβ25-35 (25 µM), 
fraction V albumin (2 mg.ml
-1) or a combination for 24 hours, before L-glutamate levels in 
the supernatant were determined. Data represent the mean ± s.e.m. of three (LPS, IFN, 
Aβ25-35, fraction V albumin), five (CGA), six (LPS + IFN) or eight (control) independent 
experiments, each consisting of 2 – 4 replicates per condition. Data were analysed with a 
one-way ANOVA (p=0.0043) with Dunnett’s multiple comparison post-test to compare all 
treatments with control (**p<0.01). 207 
 
and because the changes following treatment were consistently more pronounced in 
SFM (fig. 4.2). In addition, as serum promotes cell proliferation, over longer periods 
of time enhanced or reduced glutamate release could reflect the effects of densely 
populated  cells  rather  than  the  treatments  themselves.  Figure  4.3  shows  the 
glutamate concentration of the culture medium following 2 – 72 hours‟ exposure to 
LPS or fraction V albumin. The glutamate content of control conditioned medium in 
this experiment was 164.5 ﾱ 11.1 μM (n=35). The two treatments had similar effects 
over time. No changes in the glutamate concentration of the conditioned medium 
were found until after 8 hours‟ exposure. After 16 hours‟ incubation, LPS caused the 
glutamate content of conditioned medium to increase by 64.1 ± 11.1 %, and fraction 
V albumin caused it to increase by 64.0 ± 16.2 %, however neither was found to be 
statistically significant compared with control. Glutamate release was significant in 
both cases following 24 and 48 hours‟ exposure; at 48 hours the glutamate levels in 
the conditioned medium of LPS-treated cells were 87.6 ± 28.2 % above control, and 
those in the conditioned medium of fraction V albumin-treated cells were 84.4 ± 
14.6 % above control. Extracellular glutamate levels appeared to reach a plateau at 
this point, and may have even declined slightly between 48 and 72 hours.  
 
The glutamate content of control N9 microglial conditioned medium was 1204 ± 
106.4 nmol.mg
-1 protein. In the case of N9 cells, of the compounds tested, only a 
combination  of  LPS  and  IFN  significantly  increased  the  glutamate  level  of  the 
conditioned medium by 85.8 ± 30.7 (fig. 4.4). LPS and IFN alone increased levels 
by 44.2 ±  27.4 %  and  69.5 ±  29.8 % respectively, but  neither was  found to  be 
significantly different from control (fig. 4.4). In contrast to the results seen with 
primary microglia and BV-2 cells (figs. 4.1, 4.2 and 4.3), treatment of N9 cells with 
fraction  V  albumin  did  not  cause  any  change  in  the  glutamate  levels  of  N9 
conditioned medium (fig. 4.4). CGA treatment was also without effect, and exposure 
of  N9  cells  to  Aβ25-35  caused  a  non-significant  32.1  ±  24.2  %  decrease  in  the 
glutamate content of conditioned medium (fig. 4.4). 
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4.3. Microglial expression of mRNA for EAAT1 
 
Primary rat microglia were found to consistently express mRNA for the glutamate 
transporter EAAT1 (GLAST). Figure 4.5 demonstrates a representative agarose gel 
of PCR products, with the relevant gel for β-actin mRNA for comparison. As seen in 
figure  4.5,  LPS  (1  µg.ml
-1)  and  fraction  V  albumin  (2  mg.ml
-1)  appear  to 
downregulate the expression of EAAT1 mRNA. The AD-related proteins CGA and 
Aβ25-35 did not however appear to  alter the levels of EAAT1 mRNA in primary 
microglia (fig. 4.5B). 
 
A  robust  band  on  the  agarose  gel  following  PCR  run  on  a  sample  of  mRNA 
extracted from whole mouse brain demonstrated that the primer recognises mouse as 
well as rat EAAT1 (fig. 4.6A), making it suitable for use with the BV-2 and N9 cell 
lines. As demonstrated by figures 4.6 and 4.7, BV-2 and N9 microglia expressed 
EAAT1 mRNA at very low levels. In some cases, faint but definite bands were 
detected on the agarose gel (e.g. figs. 4.6A and 4.7), whilst in other cases bands were 
hardly detected (e.g. fig. 4.6B). Such low expression, at the limit of detection, is 
likely to compromise the accuracy of the data. In the case of BV-2 cells, no bands 
were detectable for 5 of 9 control samples. However, when BV-2 cells were treated 
with  fraction  V  albumin,  four  samples,  from  four  independent  experiments, 
contained detectable amounts of EAAT1 mRNA. In two of these four experiments, 
no EAAT1 mRNA was detected in control cells. This could represent an interesting 
finding, although as mentioned above, data must be interpreted with caution when 
mRNA levels are close to the limit of detection. In the case of N9 cells, no bands 
were detected on the agarose gel for 3 of 5 samples from control cells, and for 4 of 5 
samples from LPS + IFN-treated cells. 209 
 
 
      
 
 
 
 
 
 
Figure 4.5. The effect of microglial activation upon EAAT1 mRNA expression by primary 
rat microglia. Plated primary microglia were exposed to LPS (1 µg.ml
-1), CGA (500 nM), 
fraction V albumin (2 mg.ml
-1) or Aβ25-35 (25 µM) for 24 hours before extraction of RNA. 
Following reverse-transcription, PCR was performed for EAAT1and β-actin according to 
optimised conditions (35 and 22 cycles respectively; see Materials and Methods for further 
details). PCR products were run on 1% agarose gel with ethidium bromide, and bands 
visualised under UV light. mRNA extracted from whole rat brain was run as a positive 
control. Bands for EAAT1 were consistently detectable. Gels shown are representative of 
three (Aβ25-35), four (LPS,  fr V albumin, CGA), or seven (control) independent experiments. 
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Figure  4.6.  The  effect  of microglial  activation  upon  EAAT1  mRNA  expression  by  BV-2 
microglia. Plated BV-2 cells were exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 
nM), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination, for 24 hours before 
extraction of RNA. Following reverse-transcription, PCR was performed for EAAT1 and β-
actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole rat brain was 
run as a positive control. Four (LPS + IFN, CGA, Aβ25-35, fr V albumin), five (LPS) or 
seven  (control)  independent  experiments  were  carried  out.  Results  from  two  such 
experiments are presented, illustrating inter-experiment variability. 
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Figure  4.7.  The  effect  of  microglial  activation  upon  EAAT1  mRNA  expression  by  N9 
microglia. Plated N9 cells were exposed to LPS (1 µg.ml
-1) and  IFN (100 U.ml
-1) for 24 
hours before extraction of RNA. Following reverse-transcription, PCR was performed for 
EAAT1 and β-actin according to optimised conditions (35 and 22 cycles respectively; see 
Materials and Methods for further details). PCR products were run on 1% agarose gel with 
ethidium bromide, and bands visualised under UV light. mRNA extracted from whole rat 
brain  was  run  as  a  positive  control.  Gels  shown are  representative  of  two independent 
experiments, one consisting of two, and one of three replicates per condition.  
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4.4. Microglial expression of mRNA for EAAT2 
 
Primary  rat  microglia  also  expressed  EAAT2  mRNA  (fig.  4.8).  EAAT2  mRNA 
expression  was  undetectable  in  four  of  seven  samples  from  control  cells.  In  the 
presence of LPS or fraction V albumin, primary microglia were consistently found to 
express mRNA for EAAT2. In contrast, neither CGA nor Aβ25-35 appeared to alter 
the level of EAAT2 mRNA expression in primary microglial cells (fig. 4.8).  
 
In a similar situation to that for EAAT1, BV-2 and N9 cells were only found to 
express mRNA for EAAT2 at a very low level (fig. 4.9 and 4.10). The positive 
controls again confirm that the primers recognise mouse EAAT2 mRNA (fig. 4.10), 
and show that the PCR conditions used were adequate to give a good signal where 
EAAT2  was  expressed  (figs.  4.9  and  4.10).  A  band  on  the  agarose  gel  was  not 
detectable in 7 of 9 samples of control BV-2 cells (fig. 4.9) and in 4 of 7 samples of 
control N9 cells (fig. 4.10). In the case of BV-2 cells,  LPS treatment  may have 
slightly increased the levels of EAAT2 mRNA, as an increase was consistently seen 
(fig. 4.9), and only 2 of 7 samples of LPS-treated BV-2 cells did not produce a 
detectable band upon agarose gel electrophoresis. LPS + IFN, fraction V albumin 
and Aβ25-35 did not appear to affect EAAT2 mRNA levels of BV-2 microglia (fig. 
4.9). Following treatment with CGA, EAAT2 bands were consistently not detected 
in five independent experiments (fig. 4.9). However, as the mRNA levels were close 
to the limit of detection of the experiment, all such observations must be interpreted 
with caution. In addition, treatment of N9 microglial cells with LPS + IFN did not 
appear to  alter the  expression of mRNA for EAAT2, and the limited  results  for 
fraction V albumin, CGA and Aβ25-35 did not indicate any striking effects of these 
compounds (fig. 4.10). 
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Figure 4.8. The effect of microglial activation upon EAAT2 mRNA expression by primary 
rat microglia. Plated primary microglia were exposed to LPS (1 µg.ml
-1), CGA (500 nM), 
fraction V albumin (2 mg.ml
-1) or Aβ25-35 (25 µM) for 24 hours before extraction of RNA. 
Following reverse-transcription, PCR was performed for EAAT2 and β-actin according to 
optimised conditions (35 and 22 cycles respectively; see Materials and Methods for further 
details). PCR products were run on 1% agarose gel with ethidium bromide, and bands 
visualised under UV light. mRNA extracted from whole rat brain was run as a positive 
control. Gels shown are representative of three (Aβ25-35), four (LPS,  fr V albumin, CGA), or 
seven (control) independent experiments.  
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Figure  4.9.  The  effect  of microglial  activation  upon  EAAT2  mRNA  expression  by  BV-2 
microglia. Plated BV-2 cells were exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 
nM), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination, for 24 hours before 
extraction of RNA. Following reverse-transcription, PCR was performed for EAAT2 and β-
actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole rat brain was 
run as a positive control. Gels shown are representative of five (LPS + IFN, CGA, Aβ25-35, 
fr V albumin), six (LPS) or eight (control) independent experiments.  
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Figure  4.10.  The  effect  of  microglial  activation  upon  EAAT2  mRNA  expression  by  N9 
microglia. Plated N9 cells were exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 
nM), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination, for 24 hours before 
extraction of RNA. Following reverse-transcription, PCR was performed for EAAT2 and β-
actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole rat and mouse 
brains were run as positive controls. Gels shown are from a single experiment, consisting of 
two replicates per condition (fraction V albumin, CGA, Aβ25-35) or representative of three 
independent experiments, one consisting of one, and two consisting of two replicates per 
condition (control, LPS + IFN).  
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 4.5. Microglial expression of mRNA for the xc
- transporter system 
 
The  glutamate/cystine  antiporter  xc
-  is  expressed  at  the  plasma  membrane  as  a 
heterodimer consisting of the 4F2hc glycoprotein, which is associated with a number 
of transport systems, and the specific protein xCT (Sato et al. 1999; Bassi et al. 
2001). Here the expression of xc
- was assessed by measuring mRNA levels for the 
specific  xCT  subunit.  xCT  mRNA  expression  was  consistently  detected  in  all 
samples of primary microglia and BV-2 and N9 microglial cells. 
 
The expression of xCT mRNA in primary rat microglia was rather variable, although 
LPS and fraction V albumin consistently upregulated xCT mRNA expression (fig. 
4.11).  The  AD-related  proteins  CGA  and  Aβ25-35  did  not  appear  to  affect  the 
expression  of  mRNA  for  the  xCT  subunit  of  xc
-  (fig.  4.11).  A  primer  designed 
against mouse xCT detected robust expression of xCT mRNA by BV-2 and N9 cells, 
as well as mouse brain positive controls (figs. 4.12 and 4.13). Treatment with LPS, 
LPS + IFN or fraction V albumin also appeared to upregulate xCT mRNA levels in 
BV-2 cells (fig. 4.12). As was the case for primary microglia, neither CGA nor Aβ25-
35 seemed to have an effect upon BV-2 cell expression of xCT mRNA (fig. 4.12). In 
the case of N9 microglial cells however, there was little evidence for any effect of 
LPS + IFN, fraction V albumin, CGA or Aβ25-35 upon the expression of xCT mRNA 
(fig. 4.13).  
 
 
4.6. xc
- inhibition decreases GSH levels in BV-2 microglial cells 
 
Cystine  import  via  xc
-  is  thought  to  be  a  limiting  factor  for  GSH  synthesis  in 
microglia, and glutamate taken up via EAATs may drive cystine uptake via xc
-. The 
effects of compounds modulating xc
- and EAAT2 activity upon GSH levels in BV-2 
and N9 microglial cells were therefore investigated, by means of reverse-phase high 
performance liquid chromatography (HPLC) with electrochemical detection of GSH. 
D-MEM, in which the cells were cultured, contains 200 μM cystine (Dulbecco and 
Freeman  1959).  Increasing  the  cystine  content  to  300  µM  or  600  µM  had  no 
significant  effect  upon  intracellular  GSH  levels  of  BV-2  cells  (fig.  4.14A).  The217 
 
 
 
     
 
 
 
 
         
 
         
Figure 4.11. The effect of microglial activation upon xCT mRNA expression by primary rat 
microglia.  Plated  primary  microglia  were  exposed  to  LPS  (1  µg.ml
-1),  CGA  (500  nM), 
fraction V albumin (2 mg.ml
-1) or Aβ25-35 (25 µM) for 24 hours before extraction of RNA. 
Following  reverse-transcription,  PCR  was  performed  for  xCT  and  β-actin  according  to 
optimised conditions (35 and 22 cycles respectively; see Materials and Methods for further 
details). PCR products were run on 1% agarose gel with ethidium bromide, and bands 
visualised under UV light. mRNA extracted from whole rat brain was run as a positive 
control. Bands for xCT were consistently detectable. Gels shown are representative of two 
(Aβ25-35), three (fr V albumin, CGA), four (LPS) or seven (control) independent experiments.  
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Figure  4.12.  The  effect  of  microglial  activation  upon  xCT  mRNA  expression  by  BV-2 
microglia. Plated BV-2 cells were exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 
nM), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination, for 24 hours before 
extraction of RNA. Following reverse-transcription, PCR was performed for xCT and β-
actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole mouse brain 
was run as a positive control. Bands for xCT were consistently detectable. Gels shown are 
representative of five (LPS + IFN, CGA, fraction V albumin, Aβ25-35), six (LPS) or eight 
(control) independent experiments.  
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Figure  4.13.  The  effect  of  microglial  activation  upon  xCT  mRNA  expression  by  N9 
microglia. Plated N9 cells were exposed to LPS (1 µg.ml
-1), IFN (100 U.ml
-1), CGA (500 
nM), fraction V albumin (2 mg.ml
-1), Aβ25-35 (25 µM), or a combination, for 24 hours before 
extraction of RNA. Following reverse-transcription, PCR was performed for xCT and β-
actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole rat and mouse 
brain were run as positive controls. Bands for xCT were consistently detectable. Gels shown 
are from a single experiment, consisting of two replicates per condition (fraction V albumin, 
CGA, Aβ25-35), or representative of three independent experiments, two consisting of two, 
and one of three replicates per condition (control, LPS + IFN).  
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Figure 4.14. The effect of compounds acting at the xc
- and EAAT2 transporters upon BV-2 
(A) and N9 (B) microglial GSH levels. BV-2 or N9 cells were cultured for 24 hours in the 
presence of supplementary L-cystine (to give a total of 300 or 600 µM), L-cysteine (100 or 
500 µM), N-acetyl-cysteine (NAC; 0.1 or 1 µM) or dihydrokainate (DHK; 100 or 250 µM), 
and GSH levels were determined by reverse-phase HPLC. Data represent the mean ± s.e.m. 
of three independent experiments, each consisting of two replicates per condition. Data were 
analysed with a one-way ANOVA (A, p=0.71, n.s.; B, p=0.6327, n.s.). 
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reduced analogue of cystine, cysteine (100 or 500 µM), to which cystine is converted 
intracellularly  following  import,  also  had  no  effect  when  added  to  the  culture 
medium (fig. 4.14A). Similarly, the xc
- substrate agonist and antioxidant N-acetyl- 
cysteine (NAC; 0.1 or 1 µM), which can be deacetylated to cysteine intracellularly 
and thus act as a GSH precursor (Magnusson et al. 1989; Sjodin et al. 1989), was 
without  effect  (fig.  4.14A).  Blockade  of  the  EAAT2  glutamate  transporter  with 
dihydrokainate (DHK; 100 or 250 µM) (Johnston et al. 1979; Pocock et al. 1988; 
Robinson et al. 1991; Arriza et al. 1994) also had no effect upon BV-2 microglial 
GSH levels (fig. 4.14A). Identical concentrations of supplementary cystine, cysteine, 
NAC and DHK were also without significant effect upon the GSH content of N9 
microglial cells (fig. 4.14B). 
 
Because BV-2 cells appear to respond more similarly to primary microglia in terms 
of the effect of microglial activation upon the GSH content (chapter 3) and xCT gene 
expression  (figs.  4.11  and  4.12),  further  investigation  of  the  impact  of  the  xc
- 
transporter upon GSH levels, under control and activated (1 µg.ml
-1 LPS) conditions, 
was limited to BV-2 cells (fig. 4.15). In this experiment, control cells were found to 
contain 29.7 ± 1.7 nmol.mg
-1 protein GSH, and LPS treatment increased levels by 
66.3 ± 10.5 % to 49.3 ± 3.1 nmol.mg
-1 protein (fig. 4.15). A higher concentration of 
cystine (to give a total of 1 mM) had no significant effect upon GSH levels in either 
non-activated or activated cells, although a trend towards an increase was seen in 
non-activated cells, where cystine increased the GSH level to 40.3 ± 3.4 nmol.mg
-1 
protein (an increase of 35.8 ± 11.6 %), and attenuated the difference between GSH 
levels in non-activated and activated cells (fig. 4.15). Aminopimelic acid (APA; 2.5 
mM)  (Qin  et  al.  2006),  an  inhibitor  of  the  xc
-  transporter  system  (Bannai  1986; 
Watanabe and Bannai 1987), significantly decreased the GSH level in non-activated 
BV-2 cells by 53.7 ± 2.0 % to 13.7 ± 0.6 nmol.mg
-1 protein (fig. 4.15). Whilst APA 
did not significantly alter GSH levels in activated cells (n.s. when compared to LPS 
alone), APA prevented LPS from significantly increasing GSH levels compared with 
control  (hatched bar), whilst  in all other cases  LPS treatment  led to  GSH levels 
significantly higher than control levels. In the presence of supplementary cystine and 
APA, GSH levels in activated and non-activated cells were almost identical to those 
in non-cystine/APA-treated activated and non-activated cells. There were significant 
differences between non-activated cells (but not activated cells) in the presence of222 
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Figure 4.15. Further investigation into the effect of compounds acting at the xc
- transporter 
upon GSH levels in BV-2 microglial cells. BV-2 cells were cultured for 24 hours in the 
presence  of  supplementary  L-cystine  (to  give  a  total  of  1  mM),  APA  (2.5  mM)  or  a 
combination, before the addition of LPS (1 µg.ml
-1). After a further 24 hours, GSH levels 
were determined by reverse-phase HPLC. Data represent the mean ± s.e.m. of at least three 
independent  experiments,  each  consisting  of  two  replicates  per  condition.  Data  were 
analysed with a one-way ANOVA (p<0.0001), with Tukey’s multiple comparison post-test 
(*p<0.05, **p<0.01, ***p<0.001, n.s. p>0.05, compared with control (hatched bar) or as 
indicated). 223 
 
cystine and APA compared with either of the treatments alone, thus the addition of 
cystine slightly reversed the APA-induced decrease in GSH levels, and the addition 
of  APA  blocks  xc
-  to  some  extent,  even  in  the  presence  of  a  high  cystine 
concentration. 
 
4.7. Effects of xc
- antagonism upon microglial glutamate release 
 
In initial experiments, it appeared that the xc
- antagonist APA (250 µM – 2.5 mM) 
dose-dependently  decreased  the  elevated  extracellular  glutamate  observed  in  the 
presence  of  LPS  (1  µg.ml
-1)  and  LPS  +  IFN  (100  U.ml
-1)  (fig.  4.16A).  This 
compound was initially prepared in 80% acetic acid, according to the information 
supplied with the product. Although the acid was neutralised in the medium before it 
was added to cells, it appeared to have deleterious effects upon cells, so alternative 
solvents in which APA is soluble were investigated. It was found that APA was 
soluble in equimolar NaOH, for example 250 mM APA was soluble in 250 mM 
NaOH. As shown in figure 4.16B, APA (2.5 mM) dissolved in equimolar NaOH did 
not  affect  the  glutamate  levels  in  BV-2  conditioned  medium,  under  control  or 
activated (LPS, LPS + IFN) conditions. 
 
Aminoadipic acid (AAA) is also a xc
- transporter inhibitor (Bannai 1986; Watanabe 
and Bannai 1987; Piani and Fontana 1994). In contrast to APA, AAA (2.5 mM) 
(Kingham et al. 1999; Qin et al. 2006; Domercq et al. 2007) significantly decreased 
LPS and LPS + IFN-mediated increases in extracellular glutamate, although the 
resulting glutamate concentrations were still above that of non-activated cells (fig. 
4.17). Supplementary cystine (to give a total of 1 mM) did not have any significant 
effects upon glutamate levels in conditioned medium (fig. 4.17). Interestingly, there 
was a significant difference between extracellular glutamate levels following LPS 
treatment  of  cells  cultured  in  the  presence  of  cystine  and  those  cultured  in  the 
presence of cystine and APA, but not between LPS-treated cells with cystine and 
those with cystine and AAA (fig. 4.17). 
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Figure  4.16.  The  effect  of  pre-incubation  with  APA,  in  two  different  solvents,  upon  L-
glutamate levels in conditioned medium from control BV-2 microglial cells and those treated 
with LPS or LPS + IFN. Plated BV-2 microglia were cultured in SFM containing APA (250 
μM - 2.5 mM) for 24 hours before the addition of LPS (1 µg.ml
-1) alone or in combination 
with IFN (100 U.ml
-1). After a further 24 hours, L-glutamate levels in conditioned medium 
were determined. A, APA made up in 80% acetic acid, neutralised in the medium. Data 
represent the mean ± s.e.m. of three (at each APA concentration) or seven (in the absence of 
APA) independent experiments. Data were analysed with a two-way ANOVA, which showed 
a significant effect of LPS/IFN (p=0.0267) and a significant effect of APA (p=0.0041), but 
no significant interaction between the variables (p=0.67). B, APA made up in equimolar 
NaOH.  Data  represent  the  mean  ±  s.e.m.  of  three  independent  experiments.  Data  were 
analysed  with  a  two-way  ANOVA,  which  showed  a  significant  effect  of  LPS/IFN 
(p=0.0254),  but  no  significant  effect  of  APA  (p=0.6),  and  no  significant  interaction 
(p=0.69).  For  both  data  sets,  Bonferroni’s  post-tests  were  carried  out  to  compare  all 
concentrations of APA with non-APA treated cells in the absence and presence of LPS and 
LPS + IFN (*p<0.05 compared with the same treatment in the absence of APA). 
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Figure 4.17. The effect of pre-incubation with AAA, APA and L-cystine upon L-glutamate 
levels in conditioned medium from control BV-2 microglial cells and those treated with 
microglial activators. Plated BV-2 microglia were cultured in SFM containing AAA (2.5 
mM), APA (2.5 mM), supplementary L-cystine (to a total of 1 mM), or a combination, for 24 
hours before the addition of LPS (1 µg.ml
-1) or LPS + IFN (100 U.ml
-1). After a further 24 
hours L-glutamate levels in conditioned medium were determined. Data represent the mean 
± s.e.m. of at least three independent experiments for each condition. Data are presented as 
% control to highlight trends as there was a high level of variability when values were 
expressed in µM. Control [L-glutamate] in this experiment was 160.3 ± 20.4 µM. Data were 
analysed with a two-way ANOVA, which showed a significant effect of AAA/APA/L-cystine 
(p=0.0005)  and  a  significant  effect  of  LPS/IFN  (p<0.0001)  upon  final  extracellular  L-
glutamate levels. There was a less significant interaction between the variables (p=0.0427). 
Bonferroni’s post test was carried out to compare the effects of AAA/APA/L-cystine in the 
absence  and  presence  of  LPS  and  LPS  +  IFN    (**p<0.01,  compared  with  the  same 
condition in the absence of AAA/APA/L-cystine, or as indicated). 226 
 
4.8.  BV-2  cells  partially  buffer  exogenous  glutamate  in  culture 
medium 
 
By formulation, serum-free D-MEM in which BV-2 cells were plated contains no 
glutamate (Dulbecco and Freeman 1959). Addition of up to 100 µM glutamate to the 
culture  medium  had  very  little  effect  upon  the  glutamate  levels  in  conditioned 
medium (fig. 4.18). Conditioned BV-2 cell medium following 24 hours‟ culture in 
the presence of 0 – 100 µM glutamate contained between 170 µM and 200 µM 
glutamate (fig. 4.18), indicating that the presence of BV-2 microglia elevated the 
extracellular glutamate levels. However, in the presence of 1 mM glutamate, BV-2 
cells reduced the extracellular glutamate concentration from 598 ± 38 µM to 364 ± 
55  µM  over  the  24  hour  incubation  (fig.  4.18).  The  difference  between  1  mM 
glutamate as added and 598 µM as detected in SFM likely reflects the degradation of 
glutamate; the cell-free SFM sample was prepared at the same time as the glutamate-
supplemented culture medium and kept under identical conditions for the duration of 
the incubation. Under conditions of elevated glutamate, LPS (1 µg.ml
-1) appeared to 
have a less pronounced effect upon glutamate levels, with a significant 71.7 ± 13.3 
%  increase  (representing  a  difference  of  122.7  ±  22.7  µM)  in  the  absence  of 
exogenous  glutamate,  and  only  a  (non-significant)  15.8  ±  7.3  %  increase  (a 
difference of 57.7 ± 26.7 µM) in the presence of 1 mM exogenous glutamate (fig. 
4.18). 
 
As shown in figure 4.19, there was little effect of either the xc
- transporter antagonist 
APA  (2.5  mM)  or  the  EAAT2  antagonist  DHK  (250  µM)  upon  the  glutamate-
buffering effect of BV-2 microglia. In the presence of 1 mM glutamate both APA 
and DHK slightly (but significantly) attenuated the microglia-mediated reduction in 
glutamate  levels,  but  only  in  the  presence  of  LPS.  The  difference  between  LPS 
treatment in the presence of APA or DHK and LPS treatment alone was only around 
a quarter of that between LPS treatment and the cell-free SFM control.  
 
Cultured  microglia  in  vitro  have  been  shown  to  express  α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) (Noda et al. 2000; Mayer et al. 2001; 
Hagino et al. 2004; Christensen et al. 2006; Liu et al. 2006), kainate (Noda et al.227 
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Figure 4.18. BV-2 microglial cells buffer extracellular L-glutamate levels. BV-2 microglial 
cells were plated, medium was changed to SFM and cells were cultured in the presence of L-
glutamate (100 nM – 1 mM) for 2 hours before the addition of LPS (1 µg.ml
-1). After 24 
hours  conditioned  medium  was  removed  and  L-glutamate  levels  determined.  Cell-free 
controls were also prepared in SFM and maintained under the same conditions (SFM). Data 
represent the mean ± s.e.m. of three independent experiments. Data were analysed with a 
two-way ANOVA, which demonstrated a highly significant effect of BV-2 cell presence and 
LPS, and of exogenous L-glutamate upon final extracellular L-glutamate levels, and also 
that there  was  a  significant  interaction  between the  variables  (p<0.0001  in  each  case). 
Bonferroni’s post-test was used to compare cell-free controls with control cells, and control 
cells  with  LPS-treated  cells,  at  each  L-glutamate  concentration  (*p<0.05,  **p<0.01, 
***p<0.001, n.s. p>0.05, as indicated). 228 
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Figure 4.19. Neither APA or DHK appear to be able to inhibit the ability of BV-2 cells to 
counter high concentrations of exogenous L-glutamate added to the culture medium. BV-2 
microglial cells were cultured with SFM containing APA (2.5 mM) or DHK (250 µM) where 
indicated. L-glutamate (100 nM – 1mM) was added after 24 hours, and LPS (1 µg.ml
-1) after 
a further 2 hours. After 24 hours’ incubation, conditioned medium was removed and L-
glutamate levels determined. Data represent the mean ± s.e.m. of three (SFM, APA, APA + 
LPS, DHK, DHK + LPS) or four (control, LPS) independent experiments, each consisting of 
two replicates per condition. Data were analysed with a two-way ANOVA, which showed 
there  to  be  a  significant  effect  of  exogenous  L-glutamate  concentration,  and  of 
APA/DHK/LPS  treatment  upon  final  extracellular  L-glutamate  levels,  and  a  significant 
interaction between the variables (p<0.0001 in all cases). Bonferroni’s post-tests were used 
to  compare  treatments  within  each  L-glutamate  concentration  (*p<0.05  compared  with 
control at each L-glutamate concentration; #p<0.05 compared with LPS alone at each L-
glutamate concentration). 229 
 
2000) and N-methyl-D-aspartate (NMDA) (Liu et al. 2006) receptor subunits and to 
respond  physiologically  to  AMPA/kainate  receptor  agonists  (Noda  et  al.  2000; 
Mayer et al. 2001; Eun et al. 2004; Hagino et al. 2004; Christensen et al. 2006; Liu 
et al. 2006). Microglia have also been shown to express AMPA and NMDA receptor 
subunits in vivo under certain conditions (Ong et al. 1996; Gottlieb and Matute 1997; 
Kaur et al. 2005; Yamada et al. 2006; Newcombe et al. 2008). It was considered that 
Ca
2+ entry through such iGluRs may alter microglial glutamate uptake by altering the 
expression or activity of glutamate transporters. For example, the transcription factor 
cAMP-response element binding protein as well as a number of members of the 
basic helix-loop-helix transcription factor family may be activated by calmodulin in 
the presence of Ca
2+ (Hermann et al. 1998; West et al. 2001). Therefore, the NMDA 
receptor  antagonist  (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-
imine  (MK-801;  10  µM)  (Wong  et  al.  1986)  and  the  AMPA/kainate  receptor 
antagonist  6-cyano-7-nitroquinoxaline-2,3-dione  (CNQX;  20  µM)  (Honore  et  al. 
1988) were added to microglia prior to the addition of exogenous glutamate to assess 
whether  iGluRs  are  involved  in  the  microglial  buffering  of  glutamate  levels  in 
culture  medium.  As  demonstrated  in  figure  4.20,  neither  MK-801  nor  CNQX 
affected the ability of microglia to buffer exogenous glutamate. 
 
 
4.9. Primary microglia partially buffer moderate levels of exogenous 
glutamate in culture medium 
 
Primary  rat  microglia  were  cultured  in  the  presence  of  exogenous  glutamate,  to 
assess  the  ability  of  primary  microglia  to  buffer  glutamate  added  to  the  culture 
medium. Figure 4.21 shows that primary microglia did not cause an elevation in the 
glutamate  concentration  of  conditioned  medium  in  the  absence  of  exogenous 
glutamate in the way that BV-2 microglia did (fig. 4.18). Thus, when no glutamate 
was  added,  the  glutamate  concentration  found  in  cell-free  controls  (“SFM”)  and 
conditioned medium was almost identical. However, when 100 µM glutamate was 
added to the cells for 24 hours, the cells halved the apparent glutamate concentration, 
reducing  it  from  110.2  ±  12.4  µM  to  55.3  ±  9.7  µM.  When  1  mM  exogenous230 
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Figure 4.20. Ionotropic glutamate receptor antagonists have no effect upon L-glutamate 
levels  in  BV-2  cell  conditioned  medium.  BV-2  microglia  were  cultured  in  SFM  in  the 
presence of CNQX (20 µM) or MK-801 (10 µM) for 24 hours, before L-glutamate levels of 
the conditioned medium were determined. Where indicated, 1 mM exogenous L-glutamate 
was added to cultures 2 hours after addition of antagonists. Data represent the mean ± 
s.e.m. of three independent experiments, each consisting of two replicates per condition. 
Data were analysed with a two-way ANOVA, which showed that exogenous L-glutamate had 
a significant effect upon final extracellular L-glutamate concentrations (p<0.0001) but that 
there was no significant effect of the glutamate receptor antagonists (p=0.288), nor was 
there any significant interaction between the two variables (p=0.4545). 231 
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Figure 4.21. Primary microglial cells buffer extracellular L-glutamate levels to some extent. 
L-glutamate  levels  in  culture  medium  containing  supplementary  L-glutamate  before  and 
after 24 hours’ incubation with microglia. Primary rat microglia were plated at 1 x 10
5 cells 
per  13  mm  coverslip,  culture  medium  was  changed  to  SFM  and  cells  were  exposed  to 
exogenous L-glutamate (10 µM – 1 mM) for 24 hours, before L-glutamate levels in the 
conditioned medium were determined (CM). Cell-free controls were also prepared in SFM 
and maintained under the same conditions (SFM). Data represent the mean ± s.e.m. of three 
independent  experiments,  each  consisting  of  three  replicates  per  condition.  Data  were 
analysed with Student’s t tests to compare conditions in pairs, as indicated (*p<0.05, n.s. 
p>0.05). 232 
 
glutamate was added to the cultures, microglia slightly attenuated it, but this was not 
significant. 
 
 
4.10. Exogenous glutamate in culture medium may affect GSH levels 
 
BV-2 microglial cells were incubated with 1 nM – 1 mM glutamate for 24 hours 
before GSH levels were determined by quantitative analysis of monochlorobimane 
(MCB)  imaging.  This  demonstrated  a  highly  significant  effect  of  exogenous 
glutamate  upon  the  GSH  content  of  BV-2  microglia,  as  assessed  by  one-way 
ANOVA (p<0.0001) (fig. 4.22). Micromolar concentrations of glutamate were found 
to significantly increase GSH levels, with a 35.2 ± 9.9 % increase in BV-2 GSH 
levels  following  treatment  with  1  µM  glutamate  and  a  58.2  ±  18.5  %  increase 
following treatment with 10 µM glutamate (fig. 4.22). In addition, in the presence of 
1 mM glutamate, a (non-significant) 25.7 ± 4.6 % decrease in GSH levels compared 
with control was detected (fig. 4.22). 
 
 
4.11. Discussion 
 
4.11.1. Microglia express glutamate transporters 
 
Glutamate  transport  across  the  cell  surface  of  microglia  is  bidirectional.  Under 
normal circumstances, microglia take up glutamate by means of the EAATs (Lopez-
Redondo et al. 2000; Nakajima et al. 2001b) and release glutamate in exchange for 
cystine via the xc
- transporter system (Piani and Fontana 1994; Qin et al. 2006). 
Glutamate  levels  of  microglial  conditioned  medium  were  determined,  as  an 
indication  of  the  relative  activity  of  these  transporters.  In  the  case  of  primary 
microglia there was no difference between the glutamate concentration of SFM and 
that  of  control  conditioned  medium,  suggesting  either  that  the  activity  of  these 
transporters was very low, or that the levels of glutamate release and uptake were 
approximately  equal.  However  in  both  the  N9  and  BV-2  cell  line,  control 
conditioned  medium  contained  higher  concentrations  of  glutamate  than  fresh233 
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Figure 4.22. The effect of L-glutamate upon BV-2 microglial GSH levels. BV-2 cells were 
cultured in the presence of L-glutamate (1 nM – 1 mM) for 24 hours. GSH levels were 
determined by quantitative analysis of MCB imaging. Data represent the mean ± s.e.m. of 
five (10 nM), six (100 nM, 1 mM) or seven (0, 1 nM, 1 μM, 10 μM, 100 μM) experiments, 
each consisting of between one and six replicates per condition. Data were analysed with a 
one-way AVOVA (p<0.0001), with Dunnett’s post-test (*p<0.05, **p<0.01, compared with 
control). The data were obtained by Ruth Faram under my supervision.  234 
 
medium, suggesting a net glutamate release by N9 and BV-2 cells. Indeed, in the 
case of BV-2 cells, the glutamate concentration of control conditioned medium was 
similar whether the cells were cultured in SFM or SCM, despite the fact that fresh 
SFM contains lower levels of glutamate. This suggests that BV-2 cells maintain an 
extracellular glutamate concentration in the region of 100 – 200 µM. This may be 
due to net release up to a certain point, which is then balanced by high affinity 
uptake  by  EAATs  and/or  glutamate  competition  with  cystine  for  uptake  via  xc
- 
(Bannai 1986; Sato et al. 1995, 1999; Rimaniol et al. 2001; Patel et al. 2004). 
 
EAATs 1 and 2 were originally believed to be exclusively astrocytic transporters 
responsible for the maintenance of extracellular glutamate below neurotoxic levels 
(Danbolt et al. 1992; Rothstein et al. 1994, 1996; Lehre et al. 1995). Later studies 
demonstrated  expression  of  these  EAATs  by  microglia  (Swanson  et  al.  1997; 
Nakajima et al. 2001b) as well as macrophages (Rimaniol et al. 2000). In accordance 
with this, expression of both EAAT1 and EAAT2 mRNA was demonstrated here in 
primary rat microglia, and low levels of EAAT1 and EAAT2 mRNA expression 
were detected in BV-2 and N9 microglial cell lines. The expression of both EAATs 
by  the  microglial  cell  lines  was  very  low,  close  to  the  limit  of  detection,  and 
therefore  any  observations  from  these  experiments  should  be  interpreted  with 
caution. As well as the standard in vitro microglial activators LPS and IFN, the 
effects of albumin, CGA and Aβ25-35 upon the expression of EAAT1 and EAAT2 by 
microglia  were  investigated.  This  appears  to  be  the  first  report  investigating  the 
effects  of  these  neuroinflammation-related  proteins  upon  microglial  EAAT 
expression. The data obtained in the PCR experiments would be strengthened by 
studies  of EAAT protein expression and  determination  of transporter  function in 
primary  microglia,  as  post-transcriptional  events,  as  well  as  modifications  of  the 
protein in situ, may affect its true glutamate uptake ability. However, due to the large 
amounts  of protein that would likely be required, especially considering the low 
level  of  EAAT  expression  by  microglia,  it  was  not  possible  to  carry  out  such 
investigations here.  
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4.11.2. The effects of fraction V albumin upon glutamate transport is similar to 
that of LPS 
 
It is  demonstrated here  that  LPS  causes increased  glutamate levels  in  microglial 
conditioned  medium,  suggestive  of  glutamate  release  by  microglia.  This  is  in 
agreement  with  published  data  (Piani  and  Fontana  1994;  Nakamura  et  al.  2003; 
Domercq et al. 2007; Barger et al. 2007). In N9 cells, co-stimulation with IFN was 
necessary to give a significant increase in glutamate levels, and in BV-2 cells LPS 
alone or in combination with IFN gave similar significant increases in glutamate 
levels.  
 
In  addition,  the  data  presented  here  show  enhanced  microglial  glutamate  release 
following  treatment  with  fraction  V  albumin  in  primary  microglia  and  BV-2 
microglial  cells,  but  not in  N9  cells.  Albumin induces  superoxide production by 
primary microglia (Si et al. 1997; Nakamura et al. 2000) and was shown in the 
previous chapter and elsewhere (Hooper et al. 2009) to elevate iNOS expression in 
primary  and  BV-2  microglial  cells.  There  is  evidence  for  the  involvement  of 
superoxide (Barger et al. 2007; Jin et al. 2007) and NO (Li et al. 1999; Nakamura et 
al. 2003) in the pathways leading to enhanced glutamate release. Indeed, oxygen free 
radicals  have  been  shown  to  downregulate  EAAT-mediated  glutamate  uptake 
without affecting transporter expression (Volterra et al. 1994), probably by inducing 
disulphide bond formation between functional EAATs (Trotti et al. 1997b; Blanc et 
al. 1998). Albumin-induced glutamate release may therefore be mediated through a 
pathway involving NO or superoxide, or both of these reactive species. 
 
It  should  also  be  noted  that  albumin  has  been  shown  to  induce  microglial 
proliferation (Hooper et al. 2005), and since the glutamate release data for primary 
and BV-2 microglia were not corrected for protein levels, proliferation may have 
amplified  an  increased  release  rate  of  glutamate.  LPS  however,  has  an 
antiproliferative effect upon microglia (Gebicke-Haerter et al. 1989; Bianco et al. 
2006),  so  the  increased  glutamate  release  recorded  may  have  actually  been  an 
underestimate.  In  addition,  LPS  +  IFN  and  IFN  alone  cause  significant  LDH 
release after 24 hours in BV-2 cells at least (fig. 3.16), suggesting that glutamate 236 
 
release may be due simply to cell lysis. However in BV-2 cells, glutamate release 
following incubation with LPS + IFN was no higher than that following incubation 
with LPS alone, and IFN did not have any effect (fig. 4.2). Similar results were 
obtained for primary microglia (fig. 4.1). 
 
The  time  course  of  LPS-induced  glutamate  release  in  BV-2  cells  shows  clear 
similarities with that presented by Nakamura et al. (2003) for primary microglia. In 
this  published study, inhibitors of NOS and of the xc
- transporter were found to 
prevent  the  enhancement  of  glutamate  release.  Both  LPS  and  albumin-induced 
glutamate release appeared to have reached a plateau by 48 hours, suggesting that the 
rapid  phase of  glutamate release is  somewhat  transient.  In macrophages  at  least, 
evidence exists for a more transient upregulation of xc
- expression and cystine uptake 
upon LPS treatment (Sato et al. 1995, 2001; see fig. 3.18A). Indeed, between 12 and 
48 hours‟ exposure to LPS, the rate of cystine uptake was shown to decline sharply, 
so  that  by  48  hours,  the  cystine  uptake  rate  was  only  around  one  third  of  the 
maximum  observed  rate  (Sato  et  al.  1995).  Since  the  xc
-  transporter  exchanges 
cystine  and  glutamate  in  a  1:1  ratio  (Bannai  1986),  this  implies  a  simultaneous 
decrease in glutamate release rate.  
 
To  complement  these  glutamate  release  data,  the  expression  of  the  glutamate 
transporters EAAT1, EAAT2 and the xc
- system were investigated in microglia, by 
means of PCR. In the case of the xc
- system, mRNA levels of its specific subunit, 
xCT, were measured. The effects of LPS, particularly upon microglial expression of 
EAAT2  and  xCT,  are  fairly  well  characterised.  Here,  the  effects  of  fraction  V 
albumin  (as  well  as  the  AD-related  proteins  CGA  and  Aβ25-35)  upon  transporter 
mRNA expression were investigated alongside LPS.  
 
The expression of mRNA for EAAT1 by primary microglia appeared to decrease in 
the  presence  of  LPS.  This  is  at  odds  with  a  previous  study,  which  failed  to 
demonstrate  any  effect  of  LPS  upon  the  expression  of  EAAT1  protein  by  rat 
microglia  (O'Shea  et  al.  2006).  Other  published  studies  demonstrate  increased 
microglial  EAAT1 expression  in  vivo following traumatic brain  injury  in  the rat  
(van Landeghem et al. 2001) and in patients suffering with Prion disease (Chretien et 
al. 2004) and HIV (Vallat-Decouvelaere et al. 2003). However, all these published 237 
 
studies measure protein rather than mRNA expression, therefore post-translational 
modifications  could  account  for  this  discrepancy.  Alternatively,  the  differences 
between  this  study  and  the  in  vivo  studies  mentioned  above  could  relate  to  the 
differences between microglia in vitro and in vivo. A recent in vivo study found that 
following ischaemia, microglial EAAT1 expression appeared to be restricted to the 
earlier  stages  of  activation  and  was  not  present  on  more  highly  activated, 
phagocytosing microglia (Beschorner et al. 2007). It has been suggested that the 
process  of  isolating  and  culturing  microglia  leads  to  a  low  level  of  microglial 
activation (Rosenstiel et al. 2001). Microglia in culture may therefore represent those 
in an early stage of activation, and the addition of LPS may increase the level of 
activation to the stage at which EAAT1 gene expression becomes downregulated. 
Microglial EAAT1 mRNA expression appeared to similarly decrease in the presence 
of fraction V albumin.  
 
In the presence of LPS, primary microglia were found to upregulate their expression 
of  mRNA  for  EAAT2,  in  accordance  with  published  data  (Persson  et  al.  2005; 
Jacobsson et al. 2006; O'Shea et al. 2006). Increased microglial EAAT2 expression 
has also been demonstrated following viral infection in vitro (Persson et al. 2007) 
and in vivo (Chretien et al. 2002), and following brain and neuronal injury (Lopez-
Redondo et al. 2000; van Landeghem et al. 2001). Fraction V albumin also caused a 
consistent increase in EAAT2 mRNA expression.  
 
It is interesting that the data presented here suggest a decrease in EAAT1 mRNA 
expression, but  an increase in  EAAT2 expression following  LPS treatment. This 
suggests that microglia may consistently express one EAAT subtype, but that under 
stressful conditions EAAT1 expression may be replaced by that of EAAT2. Under 
conditions  of  oxidative  stress  and  hypoxia,  the  glutamate  uptake  capacity  of 
astrocytes may decrease (Volterra et al. 1994; Miralles et al. 2001; Dallas et al. 
2007)  and  microglial  EAAT-mediated  glutamate  uptake  may  partially  replace 
astrocyte glutamate uptake. A review which collated data for kinetic parameters of 
uptake showed that the average reported Km of rat EAAT2 for glutamate was 8-fold 
lower than that of EAAT1 (Gegelashvili and Schousboe 1998). Thus, replacement of 
EAAT1 with EAAT2 under stressful situations may be associated with an increased 
affinity  for  glutamate.  Alternatively,  it  may  be  that  the  microglial  capacity  for 238 
 
functional EAAT2 expression is greater than that of EAAT1, so that a switch from 
EAAT1 to EAAT2 would enhance the glutamate uptake capacity. A low level of 
microglial EAAT1 protein expression has been reported previously (O'Shea et al. 
2006);  such  low  expression  of  EAAT1  may  explain  the  lack  of  detection  of 
microglial EAAT1 protein in other studies (Nakajima et al. 2001b; Persson et al. 
2005; Jacobsson et al. 2006). 
 
A constitutive expression of xCT mRNA by primary microglia and cells of the BV-2 
and N9 cells lines was observed here. In primary microglia and BV-2 cells, LPS 
consistently increased xCT mRNA expression. LPS has previously been shown to 
increase the expression of xCT mRNA (Barger et al. 2007) and protein (Domercq et 
al.  2007),  with  a  concomitant  increase  in  glutamate  release  (Barger  et  al.  2007; 
Domercq et al. 2007). In addition, fraction V albumin consistently increased primary 
and BV-2 microglial xCT mRNA expression. This observation fits with recent data 
demonstrating  that  the  increased  extracellular  glutamate  following  treatment  of 
microglia with fraction V or pure albumin was prevented by the xc
- inhibitor AAA 
(Hooper et al. 2009).  
 
Coincident upregulation of microglial EAAT2 and xCT mRNA expression, which 
has  been  confirmed  at  the  protein  level  following  LPS  treatment  (Persson  et  al. 
2005; Jacobsson et al. 2006; O'Shea et al. 2006; Domercq et al. 2007), may indicate 
complementary  functions  of  these  proteins.  For  example,  an  enhancement  of 
glutamate  uptake  via  EAAT2  might  counteract  the  enhanced  glutamate  release 
occurring  as  a  consequence  of  increased  xc
-  activity.  Alternatively,  glutamate 
imported via EAAT2 may provide glutamate in the direct vicinity of xc
- transporters 
and  thereby  contribute  to  the  maintenance  of  sufficient  cystine  uptake  for  GSH 
synthesis (Igo and Ash 1998; Rimaniol et al. 2001; Persson et al. 2006). 
 
4.11.3. Implications for Alzheimer’s disease 
 
The proteins CGA and Aβ25-35 are upregulated in AD, and microglia may come into 
contact with them during disease pathogenesis. Both have been shown to activate 
microglia in  vitro (Taupenot et al. 1996; McDonald et al. 1997; Kingham et al. 
1999; Combs et al. 2001; Le et al. 2001). In the present study, neither protein was 239 
 
found  to  significantly  alter  the  extracellular  glutamate  levels  of  BV-2  or  N9 
microglial  cells, despite the fact  that slightly lower  concentrations  of  CGA have 
previously been shown to have effects including the elevation of glutamate release in 
primary  microglial  cells  (Kingham  et  al.  1999;  Hooper  and  Pocock  2007),  and 
similar concentrations of Aβ25-35 have other effects upon microglia in vitro (Klegeris 
and McGeer 1997; Noda et al. 1999; Taylor et al. 2002). Only the full-length Aβ 
peptide Aβ1-40 appears to have been found to enhance microglial glutamate release in 
cultured  microglia  (Klegeris  and  McGeer  1997;  Qin  et  al.  2006),  which  was 
suggested  to  be  via  increased  xc
-  activity.  Conversely,  electrophysiological  data 
suggest that Aβ25-35 may increase the activity of microglial glutamate transporters of 
the EAAT type (Noda et al. 1999). 
 
PCR for the EAATs demonstrated little effect of CGA or Aβ25-35 upon microglial 
EAAT1  or  EAAT2  mRNA  expression.  In  addition,  neither  CGA  nor  Aβ25-35 
appeared to alter the expression of xCT mRNA, despite the fact that an increase in 
extracellular glutamate following microglial treatment with Aβ1-40 was prevented by 
the xc
- inhibitors AAA and APA (Qin et al. 2006). The regulation of cell surface xc
- 
expression  and  activity  may  however  occur  at  stages  downstream  of  gene 
transcription; an LPS-induced enhancement of glutamate release has been shown to 
occur in the presence mRNA or protein synthesis inhibitors suggesting that increased 
activity of existing transporters or increased trafficking to the plasma membrane may 
be involved (Barger et al. 2007). 
 
BBB damage is associated with AD as well as MS and other neurological conditions 
(Alafuzoff et al. 1983; Skoog et al. 1998; Fiala et al. 2002). Therefore microglia may 
be exposed to albumin during disease pathogenesis, which may affect  microglial 
expression of glutamate transporters and enhance glutamate release, even if proteins 
specifically associated with AD, such as CGA and Aβ25-35 do not. In addition, AD is 
associated with increased levels of oxidative stress  (Nunomura  et al. 2006). The 
redox status of the cell has been shown to affect EAAT activity independently of 
transporter expression, with oxygen free radicals downregulating, and antioxidants 
upregulating  EAAT-mediated  glutamate  uptake,  through  inducing  and  reducing 
disulphide  bonds  between  functional  EAATs  (Volterra  et  al.  1994;  Trotti  et  al. 240 
 
1997b; Blanc et al. 1998; Begni et al. 2004). Such post-translational modifications 
may therefore affect microglial glutamate uptake in AD. 
 
4.11.4. xc
- inhibition affects microglial GSH content but has less of an effect 
upon glutamate release 
 
There was no effect of DHK upon GSH levels in BV-2 or N9 microglial cells. This 
may reflect a low level of EAAT2 expression, as suggested by low mRNA levels, or 
it may suggest that EAAT2 activity simply has little effect upon GSH levels under 
non-activated conditions. Exogenous cystine, cysteine or NAC also did not affect the 
cellular GSH content of either cell line, and was also shown in chapter 3 not to affect 
microglial GSH release. This suggests that the levels of cystine already present in the 
medium  (200  µM)  are  not  limiting  for  GSH  synthesis.  Inhibition  of  the  xc
- 
transporter in  BV-2  cells  did  however decrease  GSH levels,  confirming that xc
--
mediated cystine uptake is crucial for microglial GSH synthesis. Paradoxically, xc
- 
transporter inhibition had little effect upon extracellular glutamate levels. However, 
AAA is a competitive transportable inhibitor (Tsai et al. 1996; Pow 2001), therefore 
the uptake of AAA is likely to be coupled to the export of glutamate or other xc
- 
substrate. The small decline in extracellular glutamate in the presence of AAA under 
some conditions may reflect the replacement of a proportion of the glutamate export 
with re-export of the imported AAA. The mechanism of xc
- inhibition by APA is 
likely to be identical to that of AAA given that the compounds are both glutamate 
analogues, the only difference between the two being that APA contains a 7-carbon 
chain  where  AAA  has  a  6-carbon  chain,  and  considering  their  similar  inhibition 
characteristics (Bannai 1986; Watanabe and Bannai 1987; Piani and Fontana 1994). 
Therefore  this  explanation  for  a  lack  of  significant  alteration  of  extracellular 
glutamate despite xc
- inhibition can be extended to APA. 
 
Rather  high  concentrations  (2.5  mM)  of  AAA  and  APA  were  used  here,  in 
accordance with published work (Kingham et al. 1999; Qin et al. 2006; Domercq et 
al.  2007).  However,  as  AAA  and  APA  are  glutamate  analogues,  such  high 
concentrations  may  have  non-specific  effects.  AAA  may  also  be  a  competitive 
substrate for Na
+-dependent glutamate transport by the EAATs (Tsai et al. 1996), 
and an inhibitor of glutamine synthetase (McBean 1994), thus potentially affecting 241 
 
other  aspects  of  glutamate  uptake  and  metabolism  in  microglia  besides  the  xc
- 
transporter.  APA,  on  the  other  hand,  is  also  a  low-affinity  NMDA  antagonist 
(Scanziani et al. 1997). It should therefore be considered that different non-specific 
effects of the compounds could explain the slightly different effects of AAA and 
APA upon microglial glutamate release. 
 
4.11.5. Microglial buffering of extracellular glutamate 
 
BV-2 cells, and to some extent, primary microglia, demonstrated a “buffer” function 
for glutamate levels in the culture medium. When high levels of glutamate were 
added to the medium, this was decreased in the presence of microglia over 24 hours. 
Although glutamate did appear to degrade in the medium, this is not likely to explain 
this  result  as  the  cell-free  controls  were  prepared  at  the  same  time  and  kept  in 
identical  conditions.  The  difference  between  cell-free  control  and  conditioned 
medium therefore appears to be due to an action of the cells. In the case of BV-2s, 
the extracellular glutamate concentration was raised to 170 – 200 µM even in the 
absence of exogenous glutamate, and following addition of up to 100 µM glutamate. 
Interestingly, this is very similar to the cystine concentration in D-MEM (200 µM), 
lending weight to the idea that this buffering action is purely due to the action of xc
-, 
and competition between glutamate and cystine for the transporter. This would also 
explain  the  decrease  in  extracellular  glutamate  following  addition  of  1  mM 
glutamate. In this light, it would be interesting to investigate this buffering effect in 
the presence of different concentrations of extracellular cystine.  
 
Surprisingly however, APA was not able to prevent the buffering effect seen at any 
glutamate concentration. The EAAT inhibitor DHK similarly had no effect. Since 
APA and DHK were not tested in combination, it is a possibility that EAATs could 
mediate  this  effect  in  the  absence  of  adequate  xc
-  function.  Alternatively,  the 
glutamate buffering capacity of BV-2 microglia may be due to a glutamate receptor-
mediated upregulation of the xc
- transporter, such that it may be partially inhibited by 
APA, but still sufficiently available to glutamate to mediate the changes observed 
within  24  hours.  Interestingly,  1  mM  glutamate  has  been  shown  to  increase 
microglial TNFα production through stimulation of AMPA/kainate receptors (Noda 
et  al.  2000),  and  TNFα  has  been  shown  to  upregulate  EAAT2  expression  and 242 
 
glutamate uptake (Persson et al. 2005). However in the case of BV-2 cells here, the 
AMPA/kainate  receptor  antagonist  did  not  alter  the  extracellular  glutamate 
concentration either in the absence of exogenous glutamate or following addition of 
1 mM glutamate, although this was not tested in combination with xc
- inhibition. 
Prolonged exposure to such a high concentration of glutamate may however cause 
desensitisation  of  glutamate  receptors  (Dingledine  et  al.  1999);  the  use  of  more 
physiological micromolar concentrations of glutamate or specific glutamate receptor 
agonists would be beneficial to clarify the situation and  allow elucidation of the 
mechanisms involved.  
 
In contrast to BV-2 cells, primary microglia did not increase extracellular glutamate 
in  the  absence  of  exogenous  glutamate.  Primary  microglia  were  also  unable  to 
counter the highest (1 mM) glutamate concentration. These effects are most likely to 
be due to differences in transporter expression. The less pronounced “buffer” effect 
in primary microglia may reflect a lower impact of xc
- upon glutamate levels relative 
to  the  EAATs.  As  described  above,  stimulation  of  microglial  AMPA/kainate 
receptors by 1 mM glutamate leads to TNFα production (Noda et al. 2000), which 
may mediate EAAT2 upregulation (Persson et al. 2005), and therefore increase the 
glutamate  uptake  capacity  of  microglia.  An  AMPA/kainate  receptor-dependent 
upregulation of EAATs by 1 mM glutamate has also been demonstrated in the rat 
optic nerve (Vallejo-Illarramendi et al. 2006). However 1 mM glutamate has also 
been shown to inhibit microglial glutamate uptake by EAATs, to a similar level as 
DHK  (Persson  et  al.  2005).  It  is  therefore  proposed  that  in  the  case  of  primary 
microglia, high levels of exogenous glutamate may inhibit EAAT-mediated uptake, 
while the xc
- transporter is not expressed at a level sufficient to significantly alter the 
extreme  glutamate  concentrations  that  BV-2  cells  modulated.  These  hypotheses 
relating to the glutamate-buffering ability of microglia are illustrated in figure 4.23. 
 
4.11.6. The buffering of exogenous glutamate affects microglial GSH content 
 
If the ability of microglia to attenuate high levels of glutamate in the culture medium 
is due to xc
- mediated transport, glutamate would be imported in place of cystine, 
thus potentially compromising GSH synthesis. Therefore the effect of exogenous 243 
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Figure 4.23. (previous page) Hypotheses to explain the glutamate-buffering capability of 
microglia. A, Under normal conditions, EAATs mediate glutamate uptake whilst xc
- releases 
glutamate  in  exchange  for  cystine.  This  allows  the  development  and  maintenance  of  a 
constant extracellular glutamate concentration. In BV-2 microglia, the effect of xc
- appears 
to dominate such that the extracellular glutamate concentration attained is approximately 
equivalent to the extracellular cystine concentration. In primary microglia, the activity of xc
- 
and  the  EAATs  appears  to  be  approximately  equal.  B,  Under  situations  of  elevated 
glutamate, glutamate may compete with cystine for uptake via xc
- (Bannai 1986; Watanabe 
and Bannai 1987; Sato et al. 1999; Tomi et al. 2002; Patel et al. 2004). The increased 
glutamate concentration may also increase the rate of EAAT-mediated glutamate uptake. In 
addition,  extracellular  glutamate  acting  upon  glutamate  receptors  of  the  AMPA/kainate 
subtypes may increase the expression of EAATs (Vallejo-Illarramendi et al. 2006), possibly 
through the stimulation of TNFα production (Noda et al. 2000), which has been shown to 
lead to enhanced EAAT expression and glutamate uptake (Persson et al. 2005). Glutamate 
acting upon other glutamate receptors may cause upregulation of xc
-. However, high levels 
of  glutamate  may  inhibit  EAATs  and  thus  limit  microglial  glutamate-buffering  capacity 
(Persson et al. 2005). cys, cystine; EAAT, excitatory amino acid transporter; glu, glutamate; 
GluR, glutamate receptor; iGluR, ionotropic glutamate receptor; TNFα, tumour necrosis 
factor α; xc
-; xc
- glutamate/cystine antiporter system. 245 
 
glutamate upon intracellular GSH levels was investigated. It was found that 1 – 10 
µM  glutamate  caused  a  significant  increase  in  GSH  levels,  as  determined  by 
quantitative analysis of MCB fluorescence. Glutamate has previously been shown to 
cause  increases  in  GSH  levels  in  macrophages,  an  effect  which  was  blocked  by 
EAAT  inhibitors  (Rimaniol  et  al.  2000,  2001).  However,  high  concentrations  of 
glutamate have also been shown to reduce the rate of microglial glutamate uptake by 
EAAT2 (Persson et al. 2005). The uptake of cystine, the limiting amino acid in GSH 
synthesis,  has  repeatedly  been  shown  to  be  competitively  inhibited  by  high 
concentrations of glutamate (Bannai 1986; Watanabe and Bannai 1987; Sato et al. 
1999; Tomi et al. 2002; Patel et al. 2004). In the presence of sufficient cystine, it is 
likely that optimum GSH synthesis is possible at a glutamate concentration which 
allows sufficient  glutamate uptake via EAATs to  provide glutamate in the direct 
vicinity of xc
- transporters and thereby allow a high rate of cystine uptake for GSH 
synthesis (Igo and Ash 1998; Rimaniol et al. 2001; Persson et al. 2006), without 
being high enough to inhibit either transporter (fig. 4.24). Indeed, in retinal Müller 
glial  cells,  it  was  demonstrated  that  the  presence  of  glutamate  and  cystine,  and 
functional  EAATs  and  xc
-  system  were  necessary  to  maintain  the  GSH  level 
(Reichelt et al. 1997). 
 
4.11.7. Conclusion 
 
It is demonstrated here that microglia express mRNA for glutamate transporters, and 
that this expression may be modified by microglial activation. LPS upregulates the 
expression of EAAT2 and xCT, the specific subunit of the xc
- transporter, but may 
downregulate the expression of EAAT1. Albumin may have similar effects. Both 
LPS and albumin were also shown to increase the glutamate levels of conditioned 
medium. However, CGA and Aβ25-35, two proteins upregulated in AD, could not be 
found to affect microglial glutamate transport. BV-2 cells only express low levels of 
EAAT mRNA and the effects of the glutamate/cystine antiporter system xc
- appear to 
dominate. This endows BV-2 cells with the ability to buffer extracellular glutamate 
concentrations,  through  competition  between  cystine  and  glutamate  for  transport. 
Primary  microglia  were  also  able  to  buffer  high  extracellular  glutamate 
concentrations to a limited extent, although it is unclear how important this would be 
in vivo, where astrocytes robustly express EAATs and have a much higher glutamate 246 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.24.  Summary  of  the  effects  of  glutamate  upon  amino  acid  uptake  for  GSH 
synthesis. Extracellular glutamate stimulates EAAT-mediated uptake, which drives cystine 
import via xc
-, and thus GSH synthesis. However, high levels of glutamate inhibit EAATs and 
compete with cystine for xc
--mediated transport. cys, L-cystine; EAAT, excitatory amino acid 
transporter;  GC,  -glutamylcysteine;  glu,  L-glutamate;  GSH,  glutathione;  xc
-,  xc
-  L-
glutamate/L-cystine antiporter system. 
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uptake capacity than microglia (Leonova et al. 2001; Persson et al. 2005), and are 
thought  to  be  primarily  responsible  for  maintaining  the  extracellular  glutamate 
concentration below neurotoxic levels (Rosenberg et al. 1992; Rothstein et al. 1996). 
Perhaps  microglial  glutamate  uptake  would  become  significant  only  under 
exceptional  circumstances.  The  consequences  of  such  glutamate  uptake  would 
depend upon the transporter(s) involved, but should the xc
- transporter be involved, 
this may compromise GSH synthesis through decreased cystine supply, and may be 
detrimental towards the microglia, especially in the event of CNS challenge.  
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Chapter 5 
Results III: 
The effects of metabotropic glutamate 
receptor modulation upon microglial 
glutathione content and glutamate release  
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5.1. Introduction and summary of results 
 
In the previous chapter, it was shown that L-glutamate has effects upon microglial 
GSH levels, and it was concluded that this is likely to be due to direct effects upon 
glutamate  transporters,  particularly  the  xc
-  glutamate/cystine  antiporter  system. 
However since microglia express ionotropic glutamate receptors (iGluRs) (Ong et al. 
1996; Gottlieb and Matute 1997; Noda et al. 2000; Mayer et al. 2001; Hagino et al. 
2004; Kaur et al. 2005; Christensen et al. 2006; Liu et al. 2006; Yamada et al. 2006; 
Newcombe et al. 2008) and metabotropic glutamate receptors (mGluRs) (Biber et al. 
1999;  Taylor  et  al.  2002,  2003;  Geurts  et  al.  2003,  2005;  Byrnes  et  al.  2009), 
alterations in extracellular glutamate concentration are also likely to affect microglia 
through  these  receptors.  Indeed,  mGluR2  activation  has  been  implicated  in 
microglial neurotoxicity (Taylor et al. 2002, 2005; Pinteaux-Jones et al. 2008), and 
activation of group III mGluRs (Taylor et al. 2003; Pinteaux-Jones et al. 2008) as 
well  as  mGluR5  (Byrnes  et  al.  2009)  has  been  shown  to  attenuate  microglial 
activation and to bring about a neuroprotective microglial phenotype. Thus, mGluRs 
of  all  three  groups  may  have  an  impact  upon  the  neurotoxic  or  neuroprotective 
potential of microglia. 
 
As shown in chapter 3 of this thesis and elsewhere (Chatterjee et al. 1999; Hirrlinger 
et al. 2000; Moss and Bates 2001; Persson et al. 2006), microglia contain high levels 
of the antioxidant glutathione (GSH). This is crucial for protecting microglia against 
oxidative stress, and thus ensuring their survival. However the benefit of microglial 
survival in vivo clearly depends upon the state of the microglia and whether they are 
expressing a neuroprotective or neurotoxic phenotype.  
 
In astrocytes, stimulation of group II or III mGluRs has been found to rescue an 
LPS-induced  decline  in  intracellular  GSH  (Zhou  et  al.  2006).  Group  II  mGluR 
agonists also rescued GSH depletion in dorsal root ganglion neurones and Schwann 
cells in co-culture following glucose-induced oxidative injury (Berent-Spillson and 
Russell 2007). This was accompanied by a reduction in the levels of reactive oxygen 
species (ROS) and superoxide and by neuroprotection (Berent-Spillson and Russell 
2007). In HT22 hippocampal neurones, group I mGluR agonists protected against 250 
 
oxidative glutamate toxicity, and partially rescued glutamate-induced GSH depletion 
(Sagara and Schubert 1998); indeed, increased mGluR1 expression was associated 
with  resistance  to  oxidative  glutamate  toxicity  (Sahin  et  al.  2006).  Enhanced 
expression of group I mGluRs by primary cultures of cortical neurones was found in 
the presence of elevated extracellular glutamate or cystine deprivation, conditions 
under  which  GSH  synthesis  may  be  compromised  (Sagara  and  Schubert  1998). 
Group I mGluR stimulation was also shown to be protective against kainate and 
oxygen-glucose  deprivation  toxicity  in  oligodendrocytes,  by  attenuation  of  ROS 
levels and restoration of the intracellular GSH level (Deng et al. 2004). 
 
The modulation of mGluRs may therefore have an effect upon cellular antioxidant 
defences, and thus cell fate, in a number of CNS cell types, although there do not 
appear to be any published accounts of the effects of mGluR modulation upon the 
GSH levels of microglia. It was postulated that, in addition to the known effects of 
microglial  mGluRs,  they  may  have  the  potential  to  affect  the  GSH  system  of 
microglia. This may include effects upon GSH synthesis, altering the rate of cystine 
uptake via xc
- (Berent-Spillson and Russell 2007), or the expression of glutamate-
cysteine ligase (GCL) (Sagara and Schubert 1998; Sahin et al. 2006), both of which 
are  potentially  rate-limiting  steps  in  the  GSH  synthesis  pathway.  Increased  or 
decreased GSH synthesis would likely affect intracellular GSH levels and therefore 
have implications for the fate of the cell. Alternatively, mGluR stimulation may have 
direct, GSH-independent effects upon mitochondrial ROS production, for example 
via the production of the antiapoptotic protein Bcl-2, as shown in HT22 cells (Sahin 
et al. 2006). Such an effect would reduce the demand upon GSH as an antioxidant, 
preserving cellular GSH for continual protection. 
 
In  addition  to  the  effects  upon  microglial  GSH  content,  the  effects  of  mGluR 
modulation upon glutamate release and nitric oxide (NO) production (measured by 
quantification  of  nitrate  and  nitrite,  stable  NO  metabolites)  were  examined,  and 
preliminary investigations were carried out into the effects of mGluR modulation 
upon  microglial  glutamate  transporter  messenger  ribonucleic  acid  (mRNA) 
expression.  The  effects  of  iGluR  antagonists  upon  microglial  GSH  content  and 
glutamate release were also investigated, to ascertain the impact of microglial iGluR 
expression upon glutamate/cystine balance and GSH levels. 251 
 
 
In cells of the BV-2 microglial cell line, the use of specific antagonists showed that 
mGluR1α stimulation increased intracellular GSH levels, while mGluR5 stimulation 
decreased GSH levels. The effects of the same antagonists upon glutamate release 
were less striking. In accordance with this, modulation of the xc
- transporter system 
had little effect upon group I mGluR-mediated alterations in GSH levels, and in 
preliminary experiments group I mGluR compounds did not appear to have effects 
upon xc
- mRNA expression. It is proposed that mGluR1 and mGluR5 may have 
opposing effects upon certain aspects of the behaviour of microglia, and perhaps 
different effects upon neurotoxicity or neuroprotection. 
 
In  N9  microglial  cells,  the  group  III  mGluR  agonist  L-(+)-2-amino-4-
phosphonobutyric acid (L-AP4) decreased GSH levels. This compound has also been 
shown to enhance microglial neuroprotection (Taylor et al. 2003; Pinteaux-Jones et 
al.  2008),  and  explanations  were  sought  to  explain  these  findings  concurrently. 
Group III mGluR stimulation may promote GSH consumption through its utilisation 
as  an  antioxidant,  thus  detoxifying  reactive  oxygen  species  more  efficiently  and 
protecting  neurones  from  oxidative  stress.  Alternatively,  activation  of  group  III 
mGluR  may  decrease  the  expression  or  activity  of  the  xc
-  transporter,  an  effect 
observed with the group III agonist (RS)-4-phosphonophenylglycine ((RS)-PPG) in 
preliminary  investigations  into  xCT  mRNA  expression  in  N9  cells.  This  would 
decrease the availability of cystine for GSH synthesis but reduce glutamate release 
and the likelihood of oxidative glutamate toxicity towards neurones. Finally, it was 
considered  that  group  III  mGluR  stimulation  may  promote  release  of  GSH,  its 
oxidised form GSSG, or cysteinylglycine (or a conjugate thereof) which may be 
taken up by neurones to supply cysteine for neuronal GSH synthesis. 
 
This  appears  to  be  the  first  demonstration  of  mGluR-mediated  effects  upon 
microglial GSH levels, showing that the effects of extracellular glutamate upon GSH 
levels may not be limited to direct effects upon glutamate transporters, and further 
highlighting the importance and therapeutic potential of microglial mGluRs.  
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5.2. The effects of ionotropic glutamate receptor antagonists upon 
GSH levels in BV-2 cells  
 
BV-2  microglial  cells  were  treated  with  the  α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic  acid  (AMPA)/kainate  receptor  antagonist  6-cyano-7-
nitroquinoxaline-2,3-dione  (CNQX)  (Honore  et  al.  1988)  and  the  N-methyl-D-
aspartate  (NMDA)  receptor  antagonist  (+)-5-methyl-10,11-dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine  (MK-801)  (Wong  et  al.  1986)  prior  to 
determination of intracellular GSH levels. Antagonists were tested alone, as well as 
in the presence of 10 μM and 1 mM glutamate. Figure 5.1A demonstrates that MK-
801 had no effect, either in the absence or presence of exogenous glutamate.  
 
Antagonism of non-NMDA receptors with CNQX also did not have a statistically 
significant  effect  at  any  glutamate  concentration,  although  CNQX  did  appear  to 
enhance  the  differences  between  the  GSH  content  in  the  presence  of  different 
concentrations of glutamate. Thus, 10 μM glutamate was found to enhance the GSH 
content of BV-2 microglial cells from 37.3 ± 2.1 nmol.mg
-1 protein to 46.2 ± 7.5 
nmol.mg
-1 protein, but in the presence of CNQX, 10 μM glutamate enhanced the 
GSH content from 25.4 ± 5.9 nmol.mg
-1 protein to 51.3 ± 12.1 nmol.mg
-1 protein, 
which was found to be statistically significant. Likewise, the difference between the 
GSH content of cells  exposed to  10 μM  glutamate and those exposed to  1 mM 
glutamate was not significant, whilst the difference between the effects of 10 μM 
glutamate  +  CNQX,  and  1  mM  glutamate  +  CNQX  was  statistically  significant. 
Neither CNQX nor MK-801 had any effect upon glutamate levels in BV-2 microglial 
conditioned medium (fig. 5.1B). 
 
 
5.3.  The  group  III  mGluR  agonist  L-AP4  causes  a  significant 
decrease in N9 GSH levels 
 
The  effects  of  specific  mGluR  agonists  upon  GSH  levels  in  N9  cells  were 
investigated. The group III mGluR agonist L-AP4 caused a 49.1 ± 2.9 % decrease in 
the GSH content of N9 microglial cells (fig. 5.2). In addition, slight decreases in N9  253 
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Figure 5.1. The effect of glutamate receptor antagonists upon (A) BV-2 microglial GSH 
levels and (B) L-glutamate levels in conditioned medium. BV-2 microglia were cultured in 
the presence of CNQX (20 µM) or MK-801 (10 µM) for 2 hours before the addition of L-
glutamate (10 µM or 1 mM where indicated). After 24 hours, L-glutamate levels in culture 
medium were determined and GSH levels were measured by reverse-phase HPLC. A, Data 
represent the mean ± s.e.m. of three (all CNQX, MK-801 conditions), five (10 μM glu), seven 
(1 mM glu) or fifteen (control) experiments, each consisting of two replicates per condition. 
Results in the absence of exogenous L-glutamate were analysed with a one-way ANOVA 
(p=0.08; n.s.), and the entire data set was analysed with a two-way ANOVA which showed 
that overall, exogenous L-glutamate had a significant effect upon GSH levels (p=0.0023), 
while the antagonists did not (p=0.6125), nor was there any significant interaction between 
the  two  variables  (p=0.3695).  Bonferroni’s  post-test  was  used  to  compare  identical 
treatments in the presence of different L-glutamate concentrations (*p<0.05 as indicated, in 
all  other  cases  p>0.05).  B,  Data  represent  the  mean  ±  s.e.m.  of  three  independent 
experiments, each consisting of two replicates per conditions. Data were analysed with a 
one-way ANOVA (p=0.6393; n.s.). 
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Figure 5.2. The effects of specific mGluR agonists upon GSH levels in N9 microglial cells. 
N9 cells were cultured in the presence of DHPG (100 µM), tADA (250 µM), DCG IV (500 
nM),  NAAG  (50  µM),  L-AP4  (100  µM)  or  (RS)-PPG  (100  µM)  for  24  hours  and 
intracellular GSH levels were determined by reverse-phase HPLC. Data represent the mean 
± s.e.m. of three (DHPG, tADA, NAAG, L-AP4, (RS)-PPG), six (DCG IV) or eight (control) 
independent experiments, each consisting of at least two replicates per condition. Data were 
analysed with a one-way ANOVA (p=0.0117), with Dunnett’s multiple-comparison post-test 
(*p<0.05 compared with control). 
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GSH  levels  were  demonstrated  following  24  hours‟  incubation  with  the  group  I 
mGluR agonists (RS)-3,5-dihydroxyphenylglycine (DHPG) (35.3 ± 8.6 % decrease) 
and trans-azetidine-2,4-dicarboxylic acid (tADA) (25.6 ± 6.6 % decrease), the group 
II agonist N-acetyl-L-aspartyl-L-glutamic acid (NAAG) (24.4 ± 6.8 % decrease) and 
the group III agonist (RS)-PPG (20.8 ± 16.9 % decrease), although these were not 
shown to be statistically significant.  
 
There was no significant effect of any mGluR agonists or antagonists upon the LPS 
+ IFN-induced decrease in GSH levels in N9 cells (fig. 5.3A). However, L-AP4 
slightly enhanced the decline in the GSH content of N9 cells caused by LPS + IFN 
(fig. 5.3A) and fraction V albumin (fig. 5.3B), and further experiments may find this 
to be a consistent, significant effect. 
 
 
5.4.  mGluR  agonists  have  no  effect  upon  GSH  levels  in  BV-2 
microglia 
 
In contrast to the modulation detected in N9 cells (fig. 5.2), specific mGluR agonists 
had no effect upon the GSH levels in BV-2 microglial cells (fig. 5.4.). 
 
 
5.5. mGluR1α antagonism decreases BV-2 GSH levels and mGluR5 
antagonism increases BV-2 GSH levels, while antagonism of group 
II and III mGluRs has no effect 
 
The effects of specific mGluR antagonists upon BV-2 GSH levels were investigated, 
in the absence and presence of exogenous glutamate. Whilst the group II mGluR 
antagonist  (RS)-1-amino-5-phosphonoindan-1-carboxylic  acid  (APICA)  and  the 
group  III  mGluR  antagonist  (S)-2-amino-2-methyl-4-phosphonobutanoic  acid 
(MAP4)  had  no  effect  upon  GSH  levels,  selective  group  I  mGluR  antagonism 
appeared to modulate BV-2 GSH levels (fig. 5.5). Treatment with 250 µM (RS)-1-
aminoindan-1,5-dicarboxylic  acid  (AIDA),  an  mGluR1α-selective  competitive 
antagonist led to a 32.5 ± 7.4 % decrease in BV-2 GSH levels, and the mGluR5-256 
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Figure 5.3. (legend overleaf) 
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Figure 5.3. (previous page) Preliminary investigations into the effect of mGluR modulation 
upon activation-induced changes in GSH levels in N9 microglial cells. N9 cells were pre-
incubated with DHPG (100 µM), tADA (250 µM), AIDA (250 µM), DCG IV (500 nM), 
NAAG (50 µM), MCCG (500 µM), L-AP4 (100 µM), (RS)-PPG (100 µM) or MAP4 (500 
µM) for 30 minutes before the addition of (A) LPS (1 µg.ml
-1) + IFN (100 U.ml
-1), (B) 
fraction V albumin (2 mg.ml
-1) or (C) CGA (500 nM). Cells were then cultured for 24 hours 
before intracellular reduced glutathione (GSH) levels were  determined by reverse-phase 
HPLC. A, Data represent the mean ± s.e.m. of two independent experiments, each consisting 
of two replicates per condition. Data were analysed with a one-way ANOVA (p=0.0012), 
with  Tukey’s  post-test.  All  treatments  were  found  to  significantly  decrease  GSH  levels 
compared with control (***p<0.001), but no mGluR compounds were found to significantly 
alter the LPS + IFN-induced decline in GSH content. B, C, Data represent the results of 
one experiment, consisting of two replicates per condition. 258 
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Figure 5.4. The effects of specific mGluR agonists upon BV-2 microglial GSH levels. BV-2 
cells were cultured in the presence of DHPG (100 µM), tADA (250 µM), CDPPB (500 nM), 
DCG IV (500 nM), NAAG (50 µM), L-AP4 (100 µM) or (RS)-PPG (100 µM) for 24 hours, 
and GSH levels were determined by reverse-phase HPLC. Data represent the mean ± s.e.m. 
of three independent experiments, each consisting of two replicates per condition. Data were 
analysed with a one-way ANOVA (p=0.9996, n.s.). 259 
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Figure  5.5.  The  effect  of  specific  mGluR  antagonists,  in  the  absence  and  presence  of 
elevated  L-glutamate  levels,  upon  BV-2  microglial  GSH  levels.  BV-2  microglia  were 
cultured in the presence of AIDA (250 µM), SIB-1757 (50 µM), APICA (200 µM) or MAP4 
(500 µM) for 2 hours before the addition of L-glutamate (10 µM or 1 mM). After 24 hours, 
GSH levels were determined by reverse-phase HPLC.  Data represent the mean ± s.e.m. of 
three (APICA; 10 μM glu + AIDA, SIB-1757, APICA, MAP4; 1 mM glu + AIDA, SIB-1757, 
APICA, MAP4), five (SIB-1757, 10 μM glu), six (MAP4), seven (1 mM glu), nine (AIDA) or 
fifteen (control) independent experiments, each consisting of two replicates per condition. 
Results in the absence of exogenous L-glutamate were analysed with a one-way ANOVA 
(p<0.0001)  with  Dunnett’s  post-test  to  compare  treatments  with  control  (*p<0.05, 
**p<0.01). The entire data set was analysed with a two-way ANOVA which showed that 
overall, exogenous L-glutamate had a significant effect upon GSH levels (p=0.0062), as did 
the mGluR antagonists (p<0.0001), but there was no significant interaction between the two 
variables (p=0.9704). Bonferroni’s post-test was used to compare identical conditions in the 
presence of different L-glutamate concentrations but no significant differences were found. 
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selective non-competitive antagonist 6-methyl-2-(phenylazo)-3-pyridinol (SIB-1757) 
(50  µM)  induced  a  72.8  ±  14.6  %  increase  in  GSH  levels.  Both  the  effect  of 
glutamate and the effect of mGluR antagonists was significant, as tested with a two-
way ANOVA. However, no differences were observed with each antagonist in the 
presence of different glutamate concentrations (0, 10 µM, 1 mM). 
 
The effects  of  group  I  mGluR modulation upon GSH levels  in  BV-2  cells  were 
further  investigated  (fig.  5.6).  AIDA  concentration-dependently  decreased  GSH 
levels, with 1 mM AIDA giving levels just 40.4 ± 3.6 % of control. There was no 
effect  of  adding  the  group  I  mGluR  agonists  DHPG  or  tADA  upon  the  AIDA-
induced decrease in  GSH levels.  The SIB-1757-mediated increase in  BV-2 GSH 
levels did not appear to be modulated by increasing the L-cystine concentration in 
the medium or by the addition of the xc
- transporter inhibitor aminopimelic acid 
(APA). In addition, neither 250 µM AIDA nor 50 µM SIB-1757 altered the LPS-
induced  increase  in  GSH  levels.  Surprisingly,  another  mGluR5-selective  non-
competitive  antagonist,  3-((2-methyl-1,3-thiazol-4-yl)ethynyl)-pyridine  (MTEP) 
(100 nM), was not found to have a significant effect upon GSH levels in BV-2 cells.  
 
 
5.6.  mGluR  agonists  and  antagonists  have  no  effect  upon  L-
glutamate levels in BV-2 or N9 conditioned medium 
 
Because evidence suggests a link between glutamate transport and GSH synthesis, 
mGluR  agonists  and  antagonists  were  also  tested  for  an  effect  on  extracellular 
glutamate levels. Preliminary data suggested that there was little effect of mGluR 
modulation upon the glutamate concentration of BV-2 cell conditioned medium (fig. 
5.7). Indeed, the effects of AIDA, DCG IV, NAAG, APICA, L-AP4, (RS)-PPG and 
MAP4 were not found to be statistically significant. Other compounds also appeared 
to  be without effect,  with  the exception of the mGluR5-specific non-competitive 
antagonist  SIB-1757,  which  may  have  caused  a  slight  increase  in  extracellular 
glutamate levels. 
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Figure 5.6. Further investigation of the effect of group I-specific mGluR antagonists upon 
BV-2 microglial GSH levels. BV-2 cells were cultured in the presence of AIDA (100 – 100 
µM), SIB-1757 (50 or 100 µM), LPS (1 µg.ml
-1), DHPG (100 or 500 µM), tADA (250 µM or 
1 mM), supplementary L-cystine (to give a total of 1 mM), APA (2.5 mM), MTEP (100 nM), 
or a combination for 24 hours before GSH levels were determined by reverse-phase HPLC. 
Where DHPG or tADA were used, these were added to cells 30 minutes prior to AIDA 
treatment. Where L-cystine and APA were used, these were added 24 hours prior to SIB-
1757 treatment. Data represent the mean ± s.e.m. of one (100 μM SIB-1757), five (LPS, 50 
μM  SIB-1757),  nine  (250  μM  AIDA),  twenty  (control)  or  three  (all  other  conditions) 
independent experiments, each consisting of two replicates per condition. All data except 
those  for  100  μ  M  SIB-1757  were  analysed  using  a  one-way  ANOVA  (p<0.0001),  with 
Tukey’s  multiple  comparison  post-test  (*p<0.05,  **p<0.01,  ***p<0.001,  n.s.,  p>0.05, 
compared with control or as indicated). 262 
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Figure  5.7.  The  effect  of  mGluR  modulation  upon  L-glutamate  levels  in  BV-2  cell 
conditioned medium. BV-2 microglial cells were cultured in medium containing 10% FBS in 
the presence of DHPG (100 µM), tADA (250 µM), CDPPB (500 nM), AIDA (250 µM), 
MTEP (100 nM), SIB-1757 (50 µM), DCG IV (500 nM), NAAG (50 µM), APICA (200 µM), 
L-AP4 (100 µM), (RS)-PPG (100 µM), MAP4 (500 µM), or a combination for 24 hours, 
before L-glutamate levels in the supernatant were determined. Data represent the results of 
one experiment, consisting of two replicates per condition (DHPG, tADA, CDPPB, MTEP, 
MTEP + DHPG, SIB-1757), or the mean ± s.e.m. of two (AIDA, NAAG, L-AP4, (RS)-PPG), 
three (DCG IV, APICA),  four (MAP4) or eight (control) independent experiments, each 
consisting of two replicates per condition. Data for control, AIDA, DCG IV, NAAG, APICA, 
L-AP4, (RS)-PPG and MAP4 were analysed with a one-way ANOVA (p=0.2414, n.s.). 
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Specific  mGluR  agonists  were  also  tested  for  effects  on  glutamate  levels  in  N9 
microglial conditioned medium (fig. 5.8). Whilst no compounds had a significant 
effect, slight increases were observed in the presence of the group II agonists DCG 
IV  and  NAAG  and  the  group  III  agonists  L-AP4  and  (RS)-PPG  (fig.  5.8).  In 
particular, L-AP4 increased the glutamate concentration by 63.2 ± 34.2 %, although 
this was not significant due to the variability of the data. In addition, there was no 
significant  effect  of  any  mGluR  agonists  or  antagonists  upon  the  LPS  +  IFN-
induced increase in glutamate levels in N9 conditioned medium (fig 5.9).  
 
 
5.7.  High  concentrations  of  the  mGluR5  antagonist  SIB-1757 
increase L-glutamate levels in BV-2 conditioned medium, but at this 
level SIB-1757 is toxic to BV-2 cells 
 
Because  SIB-1757  and  AIDA  had  effects  upon  GSH  levels  in  BV-2  cells,  and 
because SIB-1757 showed a slight tendency towards increasing glutamate levels in 
conditioned  medium  in  preliminary  experiments,  the  effects  of  these  compounds 
upon  extracellular  glutamate  levels  were  investigated  in  more  detail.  As 
demonstrated  in  figure  5.10A,  treatment  of  cells  with  the  mGluR5-specific 
antagonist SIB-1757 concentration-dependently increased the glutamate content of 
BV-2 conditioned medium. A concentration of 500 µM was necessary to cause a 
significant  increase,  approximately  doubling  the  control  glutamate  concentration. 
SIB-1757 is an orange coloured compound. To check that the apparent enhancement 
of glutamate was not due to SIB-1757 autofluorescence, identical fresh dilutions of 
the compound in SFM were assayed, and the fluorescence seen was not different 
from  SFM  alone.  Zero  point  five  percent  dimethyl  sulfoxide  (DMSO),  the  final 
DMSO content of cell medium following treatment with 500 µM SIB-1757, did not 
have an effect upon glutamate levels in BV-2 conditioned medium. SIB-1757 and 
LPS were found to have an additive effect; SIB-1757 (50 µM) in combination with 
LPS gave a glutamate concentration 81.3 ± 19.5 % above control, while 50 µM SIB-
1757 alone increased glutamate levels by 26.5 ± 5.0 % and LPS alone increased 
levels  by  44.8  ±  13.0  %.  This  suggests  that  antagonism  of  microglial  mGluR5 
enhanced the LPS-induced increase in extracellular glutamate. 264 
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Figure 5.8. The effects of specific mGluR agonists upon L-glutamate levels in N9 microglial 
cell conditioned medium. N9 cells were cultured in medium containing 5% newborn calf 
serum and exposed to DHPG (100 µM), tADA (250 µM) DCG IV (500 nM), NAAG (50 µM), 
L-AP4 (100 µM) or (RS)-PPG (100 µM) for 24 hours, before L-glutamate levels in the 
supernatant were determined. Data represent the mean ± s.e.m. of eight (control) or three 
(all other conditions) independent experiments, each typically consisting of two replicates 
per condition. Data were analysed with a one-way ANOVA (p=0.1411, n.s.). 265 
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Figure  5.9.  The  effect  of  mGluR  modulation  in  the  presence  of  LPS  +  IFN  upon  L-
glutamate levels in N9 microglial cell conditioned medium. N9 cells were pre-incubated with 
DHPG (100 µM), tADA (250 µM), AIDA (250 µM), DCG IV (500 nM), NAAG (50 µM), 
MCCG (500 µM), L-AP4 (100 µM), (RS)-PPG (100 µM) or MAP4 (500 µM) for 30 minutes 
before the addition of  LPS (1 µg.ml
-1) + IFN (100 U.ml
-1). Cells were then cultured for 24 
hours before L-glutamate levels in the supernatant were determined. Data represent  the 
mean  ±  s.e.m.  of  two  independent  experiments,  each  consisting  of  two  replicates  per 
condition. Data were analysed with a one-way ANOVA (p=0.0006), with Tukey’s post-test 
(*p<0.05, **p<0.01, ***p<0.001 compared with control). There was no significant effect of 
any mGluR compound upon the LPS + IFN-induced enhancement of glutamate release. 266 
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Figure 5.10. (legend overleaf) 267 
 
Figure 5.10. (previous page) The effects of AIDA and SIB-1757 upon L-glutamate levels in 
BV-2 cell conditioned medium. BV-2 microglial cells were cultured in SFM for 24 hours in 
the presence of LPS (1 µg.ml
-1), SIB-1757 (1 – 500 µM), DMSO (0.5%), AIDA (25 – 1000 
µM), DHPG (100 or 500 µM), or a combination, before L-glutamate levels of conditioned 
medium  were  determined.  Data  are  expressed  as  %  control  due  to  variation  between 
absolute values. Control [L-glutamate] in this experiment was 127.7 ± 17.7 µM. A, Data 
represent the mean ± s.e.m. of one (DMSO), two (all concentrations of SIB-1757 in SFM), 
three (1 μM, 5 μM,  10 μM, 100 μM, 500 μM SIB-1757) or four (control, LPS, 50 μM SIB-
1757, 50 μM SIB-1757 + LPS, SFM) independent experiments. All data except those for 
DMSO  were  analysed  with  a  one-way  ANOVA  (p<0.0001)  with  Tukey’s  multiple-
comparison post tests (*p<0.05, ***p<0.001, compared with control; n.s., not significant as 
indicated). B, Data represent the mean ± s.e.m. of two (25 μM AIDA), three (100 μM AIDA, 
1000 μM AIDA, 100 μM DHPG, 500 μM DHPG, 250 μM AIDA + 100 μM DHPG, 250 μM 
AIDA  +  500  μM  DHPG)  or four  (control,  LPS,  250  μM  AIDA,  250  μM  AIDA  +  LPS) 
independent  experiments.  Data  were  analysed  with  a  one-way  ANOVA  (p=0.0029)  with 
Tukey’s multiple-comparison post tests (*p<0.05 compared with control). 268 
 
In contrast, the mGluR1α antagonist AIDA had no effect upon glutamate levels in 
BV-2  microglial  conditioned  medium  (fig.  5.10B).  However  250  µM  AIDA  in 
combination with LPS gave a glutamate concentration 19.4 ± 13.1 % above control, 
which was not significant, whereas LPS alone caused a significant 44.8 ± 13.0 % 
increase  in  glutamate  release.  This  suggests  that  AIDA  may  attenuate  the  LPS- 
induced  glutamate  increase,  although  the  difference  between  results  with  LPS  + 
AIDA and LPS alone was not found to be statistically significant. 
 
BV-2  cell  death  was  assessed  by  means  of  staining  with  Hoechst-33342  and 
propidium iodide (PI) and by measurement of lactate dehydrogenase (LDH) release. 
Figure  5.11A  demonstrates  that  500  µM  SIB-1757,  which  induced  significant 
increases in glutamate in conditioned medium, is toxic to BV-2 cells, causing 43.4 ± 
10.7 % of cells to stain with PI, indicating compromised plasma membrane function 
and therefore cell death. By contrast, 50 µM SIB-1757 caused only 14.7 ± 4.3 % 
BV-2 cell death, compared to 5.3 ± 0.6 % of control cells which stained with PI. LPS 
(1 µg.ml
-1), AIDA (250 µM) and 0.5% DMSO were similarly non-toxic to BV-2 
microglial cells. Determination of LDH levels in conditioned medium showed that 
50 µM SIB-1757 did not significantly elevate LDH above control levels (fig. 5.11B), 
confirming that SIB-1757 is non-toxic at this concentration. 
 
Supplementary cystine (to a total of 1 mM) in the medium and the xc
- inhibitors 
aminoadipic acid (AAA) (2.5 mM) and APA (2.5 mM) were used to investigate 
whether the potentiation of LPS-induced glutamate release by SIB-1757 involves an 
effect  upon  the  xc
-  transporter.  As  shown  in  figure  5.12,  AAA  significantly 
attenuated the increases in extracellular glutamate with LPS (1 µg.ml
-1) and LPS + 
SIB-1757, and there was a significant difference between LPS-induced glutamate 
release in the presence of supplementary cystine and in the presence of cystine and 
APA, as  demonstrated previously (see chapter  4). However under all conditions, 
there was consistently a slightly higher level of glutamate in the presence of SIB-
1757 compared with control cells, and in the presence of SIB-1757 + LPS compared 
with LPS-treated cells. 
 
Inducible  nitric  oxide  synthase  (iNOS)  expression  and  consequent  NO  release  is 
often  associated  with  microglial  glutamate  release  and  cell  death.  However,269 
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Figure 5.11. BV-2 microglial cell death following exposure to LPS, SIB-1757 and AIDA. 
BV-2 cells were cultured for 24 hours in the presence of LPS (1 µg.ml
-1), SIB-1757 (5 – 500 
µM), AIDA (250 µM), or a combination, and cell death was assessed by Hoechst-33342 and 
propidium iodide staining (A) or LDH release (B). A, Data represent the mean ± s.e.m. of 
three independent experiments, each consisting of two replicates per condition. Data were 
analysed with a one-way ANOVA (p<0.0001) with Tukey’s multiple comparison post-test 
(***p<0.001 compared with control; all other conditions n.s.). B, Data represent the mean 
± s.e.m. of four independent experiments, each consisting of two or three replicates per 
condition. Data were analysed with a one-way ANOVA (p=0.0665, n.s.). 
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Figure 5.12. The effect of pre-incubation with AAA, APA and L-cystine upon L-glutamate 
levels in conditioned medium from control BV-2 microglial cells and those treated with SIB-
1757 and LPS. Plated BV-2 microglia were cultured in SFM containing AAA (2.5 mM), APA 
(2.5 mM), supplementary L-cystine (to a total of 1 mM), or a combination, for 24 hours 
before the addition of LPS (1 µg.ml
-1) and SIB-1757 (50 µM). After a further 24 hours L-
glutamate levels in conditioned medium were determined. Data represent the mean ± s.e.m. 
of  at  least  three  independent  experiments  for  each  condition.  Data  are  presented  as  % 
control  to  highlight  trends  as  there  was  a  high  level  of  variability  when  values  were 
expressed in µM Control [L-glutamate] in this experiment was 160.3 ± 20.4 µM. Data were 
analysed with a two-way ANOVA, which showed both the presence of AAA/APA/L-cystine 
and  the  exposure  to  LPS/SIB-1757  to  have  a  significant  effect  upon  L-glutamate  levels 
(p=0.0003 and p<0.0001 respectively). There was no significant interaction between the 
variables  (p=0.0845).  Bonferroni’s  post  test  was  carried  out  to  compare  the  effects  of 
AAA/APA/L-cystine  under  each  pre-tested  condition.  (*p<0.05,  compared  to  the  same 
condition in the absence of AAA/APA/L-cystine, or as indicated). 271 
 
immunocytochemistry  for  iNOS  in  BV-2  cells  in  three  independent  experiments 
showed that cells treated with 50 µM SIB-1757 did not express iNOS any more 
highly than control cells (fig. 5.13). 
 
 
5.8. mGluR-mediated modulation of transporter mRNA expression 
 
In the search for an explanation for the effects of mGluRs agonists and antagonists 
upon the GSH content and the glutamate release/uptake balance of microglia, the 
effects of a number of mGluR agonists and antagonists upon glutamate transporter 
mRNA were investigated. Due to the effects of the group I antagonists AIDA and 
SIB-1757 in BV-2 microglial cells, these investigations were focussed on the effects 
of group I mGluRs. 
 
As previously demonstrated in chapter 4 of this thesis, the expression of mRNA for 
EAAT1 and EAAT2 by microglia of the BV-2 and N9 cell lines was very low and 
close to the limit of detection, such that in some experiments mRNA could not be 
detected at all. The group I mGluR antagonists AIDA and SIB-1757 did not appear 
to have an effect upon the expression of mRNA for EAAT1 (fig. 5.14) or EAAT2 
(fig. 5.15) by BV-2 microglial cells. In the case of EAAT2, mRNA was not detected 
in  7  of  9  samples  of  control  cells,  and  EAAT2  mRNA  could  not  be  detected 
following treatment of BV-2 cells with any mGluR agonist or antagonist (fig. 5.15). 
Low levels of mRNA for EAAT2 were consistently detected in samples from N9 
cells, and in a single experiment, there was no evidence for any effect of specific 
agonists or antagonists of group I, II or III mGluRs upon EAAT2 mRNA levels (fig. 
5.16). In the case of primary microglial cells, preliminary data suggested there was 
no effect of group I mGluR-specific compounds upon the expression of EAAT2 
mRNA (fig. 5.17B), but some compounds may have had effects upon the expression 
of EAAT1. As shown in figure 5.17A, the mGluR5-specific allosteric antagonist 
MTEP  (100  nM)  appeared  to  downregulate  and  MTEP  in  combination  with  the 
mGluR5  positive  allosteric  modulator  3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide (CDPPB) (500 nM) appeared to upregulate the expression of EAAT1 
                 272 
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Figure 5.13. iNOS expression by BV-2 microglia following 24 hours incubation with (B) or 
without  (A)  SIB-1757  (50  µM).  Cells  were  fixed  and  iNOS  was  visualised  using 
immunocytochemistry. Representative images are shown. LPS + IFN, used as a positive 
control in each experiment, consistently led to high levels of iNOS expression (>75 % cells 
postively stained). Magnification, 40X. Scale bar, 20 μm. C, Data represent the mean ± 
s.e.m. of three independent experiments, each consisting of two coverslips per condition, 
with three fields viewed per coverslip. Data were analysed with a Student’s t test, which 
failed to demonstrate a significant difference in iNOS expression between control and SIB-
1757-treated cells (p=0.0852). 
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Figure 5.14. The effect of group I mGluR antagonists upon EAAT1 mRNA expression by BV-
2 microglia. Plated BV-2 cells were exposed to AIDA (250 μM) or SIB-1757 (50 μM) for 24 
hours before extraction of RNA. Following reverse-transcription, PCR was performed for 
EAAT1 and β-actin according to optimised conditions (35 and 22 cycles respectively; see 
Materials and Methods for further details). PCR products were run on 1% agarose gel with 
ethidium bromide, and bands visualised under UV light. mRNA extracted from whole rat 
brain was run as a positive control. Gels shown are representative of three (AIDA, SIB-
1757) or seven (control) independent experiments.  
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Figure  5.15.  The  effect  of  mGluR  modulation  upon  EAAT2  mRNA  expression  by  BV-2 
microglia. Plated BV-2 cells were exposed to DHPG (100 µM), tADA (250 µM), AIDA (250 
µM), CDPPB (500 nM), MTEP (100 nM), SIB-1757 (50 μM), DCG IV (500 nM), NAAG (50 
µM), MCCG (500 µM), L-AP4 (100 µM), (RS)-PPG (100 µM), or MAP4 (500 µM) for 24 
hours before extraction of RNA. Following reverse-transcription, PCR was performed for 
EAAT2 and β-actin according to optimised conditions (35 and 22 cycles respectively; see 
Materials and Methods for further details). PCR products were run on 1% agarose gel with 
ethidium bromide, and bands visualised under UV light. mRNA extracted from whole rat 
brain was run as a positive control. Gels shown are representative of three (AIDA, SIB-
1757) or seven (control) independent experiments. For all other conditions, one experiment 
was conducted; EAAT2 mRNA expression was not detected under any condition. 
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Figure 5.16. Preliminary investigation into the effect of mGluR modulation upon EAAT2 
mRNA expression by N9  microglial cells. Plated N9 microglia were exposed to DHPG (100 
µM), tADA (250 µM), AIDA (250 µM), CDPPB (500 nM), MTEP (100 nM), DCG IV (500 
nM), NAAG (50 µM), L-AP4 (100 µM), (RS)-PPG (100 µM), or MAP4 (500 µM) for 24 
hours before extraction of RNA. Following reverse-transcription, PCR was performed for 
xCT  and  β-actin  according  to  optimised  conditions  (35  and  22  cycles  respectively;  see 
Materials and Methods for further details). PCR products were run on 1% agarose gel with 
ethidium bromide, and bands visualised under UV light. mRNA extracted from whole rat 
brain was run as a positive control. Data represent the results of one experiment. 
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Figure 5.17. (legend overleaf) 
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Figure 5.17. (previous page) Preliminary investigation into the effect of group I mGluR 
modulation upon (A) EAAT1 and (B) EAAT2 mRNA expression by primary microglial cells. 
Plated  microglia  were  exposed  to  DHPG  (100  µM),  tADA  (250  µM),  AIDA  (250  µM), 
CDPPB (500 nM), MTEP (100 nM), or a combination, for 24 hours before extraction of 
RNA. Following reverse-transcription, PCR was performed for EAAT1 (A), EAAT2 (B) and 
β-actin (A,B), according to optimised conditions (35, 35 and 22 cycles respectively; see 
Materials and Methods for further details). PCR products were run on 1% agarose gel with 
ethidium bromide, and bands visualised under UV light. mRNA extracted from whole rat 
brain was run as a positive control. Data represent the results of one experiment. 278 
 
mRNA. As these data derive from a single experiment, further replicates would be 
required to substantiate these findings. 
 
Primary  microglial  cells,  and  microglia  of  the  BV-2  and  N9  cell  lines,  were 
consistently  found  to  express  mRNA  for  xCT,  the  specific  subunit  of  the  xc
- 
transporter (figs. 5.18, 5.19 and 5.20, and previously shown in chapter 4). The effects 
of specific group I mGluR agonists and antagonists upon xCT mRNA expression in 
primary microglia was investigated. The group I mGluR antagonist AIDA appeared 
to  slightly  increase  xCT  mRNA,  although  the  data  is  derived  from  just  one 
experiment (fig. 5.18). In an attempt to verify this finding, the effects of AIDA and 
SIB-1757, the mGluR5-specific antagonist which was previously shown to increase 
the GSH content and glutamate release by BV-2 cells, were tested upon BV-2 xCT 
mRNA  expression.  However,  data  from  three  independent  experiments  failed  to 
demonstrate an effect of either AIDA or SIB-1757 (fig. 5.19). In addition, in a single 
preliminary experiment, no striking effect of any of a number of specific group I, II 
and III mGluR agonists and antagonists was found (fig. 5.19). However, in the case 
of N9 cells, data from a single experiment suggested that the expression of mRNA 
for xCT may decrease following treatment with the group II mGluR agonist NAAG 
(50  µM),  the  group  III  agonist  (RS)-PPG  (100  µM)  or  the  group  III  antagonist 
MAP4 (500 µM) (fig. 5.20).  
 
 
5.9.  Consistent  elevation  of  nitrate  and  nitrite  release  from  N9 
microglial cells by the group I mGluR agonist DHPG 
 
To complement the data relating to GSH content and glutamate levels in conditioned 
medium, nitrate/nitrite release was measured following treatment of N9 microglial 
cells  with  specific  mGluR  agonists,  as  an  indication  of  iNOS  activity.  As 
demonstrated  in  figure  5.21,  none  of  the  agonists  tested  significantly  altered 
nitrate/nitrite levels in N9 conditioned medium, although the group I mGluR agonist 
DHPG caused a 72.1 ± 32.9 % increase. For comparison, under the same conditions, 
LPS + IFN treatment led to nitrate/nitrite levels 30-fold higher than control (fig. 
3.3).  Preliminary  measurements  of  nitrate/nitrite  release  in  the  presence  of279 
 
       
 
 
             
 
 
 
  
Figure 5.18. Preliminary investigation into the effect of group I mGluR modulation upon 
xCT mRNA expression by primary microglial cells. Plated microglia were exposed to DHPG 
(100 µM), tADA (250 µM), AIDA (250 µM), CDPPB (500 nM), MTEP (100 nM), or a 
combination, for 24 hours before extraction of RNA. Following reverse-transcription, PCR 
was performed for xCT and β-actin, according to optimised conditions (35 and 22 cycles 
respectively; see Materials and Methods for further details). PCR products were run on 1% 
agarose gel with ethidium bromide, and bands visualised under UV light. mRNA extracted 
from  whole  rat  brain  was  run  as  a  positive  control.  Data  represent  the  results  of  one 
experiment. 
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Figure  5.19.  Preliminary  investigations  into  the  effect  of  mGluR  modulation  upon  xCT 
mRNA expression by BV-2 microglial cells. Plated BV-2 microglia were exposed to DHPG 
(100 µM), tADA (250 µM), AIDA (250 µM), CDPPB (500 nM), MTEP (100 nM), SIB-1757 
(50 μM), DCG IV (500 nM), NAAG (50 µM), MCCG (500 µM), L-AP4 (100 µM), (RS)-PPG 
(100 µM), or MAP4 (500 µM) for 24 hours before extraction of RNA. Following reverse-
transcription, PCR was performed for xCT and β-actin according to optimised conditions 
(35  and  22  cycles  respectively;  see  Materials  and  Methods  for  further  details).  PCR 
products were run on 1% agarose gel with ethidium bromide, and bands visualised under 
UV light. mRNA extracted from whole rat brain was run as a positive control. In most cases, 
data  represent  the  results  of  one  experiment,  except  under  control  conditions  or  in  the 
presence of AIDA or SIB-1757,  where, data represent the results of three (AIDA, SIB-1757) 
or eight (control) independent experiments, and representative gels are shown. 
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Figure 5.20. Preliminary investigation into the effect of mGluR modulation upon xCT mRNA 
expression by N9  microglial cells. Plated N9 microglia were exposed to DHPG (100 µM), 
tADA (250 µM), AIDA (250 µM), CDPPB (500 nM), MTEP (100 nM), DCG IV (500 nM), 
NAAG (50 µM), L-AP4 (100 µM), (RS)-PPG (100 µM), or MAP4 (500 µM) for 24 hours 
before extraction of RNA. Following reverse-transcription, PCR was performed for xCT and 
β-actin according to optimised conditions (35 and 22 cycles respectively; see Materials and 
Methods  for further  details).  PCR  products  were  run  on  1%  agarose gel  with  ethidium 
bromide, and bands visualised under UV light. mRNA extracted from whole rat brain was 
run as a positive control. Data represent the results of one experiment. 
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Figure 5.21. The effect of specific mGluR agonists upon nitrate and nitrate levels in N9 
microglial conditioned medium. N9 cells were cultured in the presence of DHPG (100 µM), 
tADA (250 µM), DCG IV (500 nM), NAAG (50 µM), L-AP4 (100 µM) or (RS)-PPG (100 
µM) for 24 hours before nitrate and nitrite levels in conditioned medium were determined. 
Data represent the mean ± s.e.m. of at least three independent experiments, each consisting 
of two replicates per condition. Data were analysed with a one-way ANOVA (p=0.4349, 
n.s.). 
 283 
 
compounds  associated  with  microglial  activation  in  combination  with  mGluR 
agonists  and  antagonists  were  also  carried  out  (fig.  5.22).  DHPG  consistently 
elevated  the  nitrate/nitrite  levels  in  N9  microglial  conditioned  medium  in  the 
presence of LPS + IFN (fig. 5.22A), fraction V albumin (fig. 5.22B) and CGA (fig. 
5.22C).  Interestingly,  in  the  presence  of  LPS  +  IFN,  DHPG  had  the  effect  of 
elevating  nitrate/nitrite  levels  by  264.6  ±  36.9  nmol.mg
-1  protein,  while  in  non- 
activated cells the difference between the nitrate/nitrite levels of conditioned medium 
from control and DHPG-treated cells was just 6.8 ± 3.1 nmol.mg
-1 protein. 
 
 
5.10. Discussion 
 
In the previous chapter, glutamate was shown to affect microglial GSH levels and to 
modulate  glutamate  uptake/release  balance.  The  most  direct  way  in  which  these 
effects may be mediated is through modulation of glutamate transporters, however 
since  microglia  have  been  shown  to  express  iGluRs  and  mGluRs,  alterations  in 
glutamate levels would change the activation of these receptors and may have an 
impact  upon  GSH  levels.  The  effects  of  agonists  and  antagonists  of  glutamate 
receptors  upon  GSH  levels  were  therefore  investigated.  Studies  upon  glutamate 
release and nitrate/nitrite production and preliminary investigations of transporter 
expression were also carried out to complement the GSH data and give more of an 
insight into potential modulation mechanisms. 
 
5.10.1. The effects of ionotropic glutamate receptors 
 
Whilst  the  NMDA  antagonist  MK-801  was  without  effect,  the  AMPA/kainate 
antagonist CNQX (Honore et al. 1988) had a slight, but interesting effect upon GSH 
levels in the presence of different concentrations of glutamate. In the presence of 
CNQX, GSH levels in the presence of 10 μM glutamate were significantly higher 
than those in the absence of glutamate or in the presence of 1 mM glutamate; an 
effect not seen in the absence of CNQX. CNQX does not cross-react with mGluRs 
(Pin and Duvoisin 1995) or EAATs (Aprico et al. 2004; Wersinger et al. 2006), so 
this effect is attributable to its actions at iGluRs. In vitro, primary microglia and BV- 284 
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Figure 5.22. (legend overleaf) 
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Figure  5.22.  (previous  page)  Preliminary  investigations  upon  the  effect  of  mGluR 
modulation in the presence of microglial activators upon nitrate and nitrite levels in N9 
microglial cell conditioned medium. N9 cells were pre-incubated with DHPG (100 µM), 
tADA (250 µM), AIDA (250 µM), DCG IV (500 nM), NAAG (50 µM), MCCG (500 µM), L-
AP4 (100 µM), (RS)-PPG (100 µM) or MAP4 (500 µM) for 30 minutes before the addition 
of (A) LPS (1 µg.ml
-1) + IFN (100 U.ml
-1), (B) fraction V albumin (2 mg.ml
-1) or (C) CGA 
(500  nM).  Cells  were  then  cultured  for  24  hours  before  nitrate  and  nitrite  levels  in 
conditioned  medium  were  determined.  A,  Data  represent  the  mean  ±  s.e.m.  of  two 
independent  experiments,  each  consisting  of  two  replicates  per  condition.  Data  were 
analysed with a one-way ANOVA (p<0.0001), with Tukey’s post-test. All treatments were 
found to significantly elevate nitrate/nitrite levels compared with control (***p<0.001), but 
no  mGluR  compounds  were  found  to  significantly  alter  the  LPS  +  IFN-induced 
nitrate/nitrite elevation. B, C, Data represent the results of one experiment, consisting of two 
replicates per condition. 286 
 
  
2 cells have been shown to express functional AMPA/kainate receptors (Noda et al. 
2000; Mayer et al. 2001; Eun et al. 2004; Hagino et al. 2004; Christensen et al. 
2006;  Liu  et  al.  2006).  In  addition,  microglia  have  been  shown  to  possess 
AMPA/kainate receptor subunits in vivo during CNS development (Ong et al. 1996; 
Kaur  et  al.  2005),  following  transient  forebrain  ischaemia  (Gottlieb  and  Matute 
1997), and in multiple sclerosis (MS) tissue within active plaques (Newcombe et al. 
2008),  suggesting  that  AMPA/kainate  receptor-mediated  effects  upon  microglial 
GSH levels may be relevant under certain conditions in vivo. 
 
The data presented here suggest that functional AMPA/kainate receptors may have a 
stabilising  effect  upon  GSH  levels  in  the  presence  of  exogenous  glutamate,  as 
AMPA/kainate receptor inhibition with CNQX enhanced the differences between 
GSH  levels  at  different  glutamate  concentrations.  AMPA/kainate  receptors  may 
therefore have a role physiologically in maintaining microglial GSH levels in the 
event  of  altered  extracellular  glutamate  levels.  Indeed,  microglial  AMPA/kainate 
receptor  subunit  expression  has  been  shown  to  be  upregulated  in  vivo  under 
pathological conditions (Gottlieb and Matute 1997; Newcombe et al. 2008) when 
extracellular  glutamate  levels  may  be  elevated  (Buryakova  and  Sytinsky  1975; 
Benveniste et al. 1984; Hagberg et al. 1985; Faden et al. 1989; Perry and Hansen 
1990; Rothstein et al. 1990; Liu et al. 1991; O'Regan et al. 1997; Stover et al. 1997; 
Ritz et al. 2004; Homola et al. 2006). The intracellular signalling pathways through 
which AMPA/kainate receptor stimulation may stabilise GSH levels are currently 
unclear. However, microglial AMPA/kainate receptor stimulation may lead to the 
release of tumour necrosis factor α (TNFα) (Noda et al. 2000; Mayer et al. 2001; 
Hagino  et  al.  2004),  which  has  been  previously  shown  to  have  effects  upon 
microglial EAAT expression (Persson et al. 2005), xc
- activity (Piani and Fontana 
1994; Sato et al. 1995), and GSH levels (Dopp et al. 2002; Persson et al. 2006).  
 
5.10.2. The effect of group I metabotropic glutamate receptors 
 
Here,  effects  of  group  I  mGluR  modulation  were  observed  upon  GSH  content, 
glutamate release/uptake balance and potentially upon nitrate/nitrite production by 
microglial cells.  287 
 
 
The  mGluR5-specific  non-competitive  antagonist  SIB-1757  (Varney  et  al.  1999) 
increased  BV-2  GSH  levels,  and  although  it  also  dose-dependently  increased 
glutamate release, this was only significant at concentrations which were toxic to the 
cells. At a non-toxic concentration (50 µM), SIB-1757 had a highly significant effect 
upon  GSH  levels  but  no  significant  effect  upon  the  glutamate  content  of  BV-2 
conditioned medium. SIB-1757 had no effect upon the LPS-induced increase in GSH 
levels  but  appeared  to  potentiate  the  LPS-induced  increase  in  glutamate  release. 
Surprisingly,  a  second  mGluR5-specific  non-competitive  antagonist,  MTEP 
(Cosford  et  al.  2003b)  did  not  significantly  increase  BV-2  GSH  levels.  The 
concentration used (100 nM) was selected as it is an order of magnitude above in 
vitro Kd and IC50 values but well below that at which non-selective binding occurs 
(Cosford et al. 2003b). However, recent studies have utilised higher concentrations 
of  MTEP  (Lindstrom  et  al.  2008;  Salah  and  Perkins  2008)  and  since  only  one 
concentration was tested in this study, the results are not conclusive. 
 
Primary microglia express functional mGluR5  (Biber et al. 1999; Pinteaux-Jones 
2007; Byrnes et al. 2009), and the striking effect of the specific, non-competitive 
mGluR5 antagonist SIB-1757 upon BV-2 cells here suggests that these cells also 
express mGluR5. A recent study found that activation of microglial mGluR5 with 
(RS)-2-chloro-5-hydroxyphenylglycine  (CHPG)  inhibited  a  number  of  aspects  of 
LPS-induced microglial activation, including reactive oxygen species (ROS) and NO 
production, microglial proliferation, TNFα release, expression of the phagocytosis-
related protein galectin-3 and neurotoxicity (Byrnes et al. 2009). mGluR5-mediated 
protection  appeared  to  be  through  the  prototypical  group  I  mGluR  signalling 
pathway, involving phospholipase C (PLC), increases in intracellular Ca
2+ and PKC. 
The effects of SIB-1757 seen here do seem to complement this study, as inhibition of 
mGluR5 slightly potentiated LPS-induced glutamate release, suggesting that a tonic 
mGluR5  stimulation  was  limiting  glutamate  release.  The  increase  in  GSH  levels 
following SIB-1757 treatment may be a consequence of other effects, such as altered 
glutamate transport, or a direct effect of blocking the mGluR5 signal transduction 
pathway. In BV-2 cells, SIB-1757 and LPS both increased microglial GSH levels, 
but their effects did not appear to be additive. 
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The mGluR1α-specific antagonist AIDA (Pellicciari et al. 1995; Moroni et al. 1997) 
dose-dependently decreased GSH levels in BV-2 microglial cells, with GSH levels 
following treatment with 1 mM AIDA only 40% of control levels. In contrast, AIDA 
did not affect glutamate levels in BV-2 conditioned medium, but showed a trend 
towards attenuation of LPS-induced increases in both GSH content and glutamate 
release.  The  small  effects  of  AIDA  observed  here  are  consistent  with  low-level 
receptor expression (Geurts et al. 2003; Byrnes et al. 2009), although the marginal 
significance of 250 µM AIDA and greater effect of 1 mM upon GSH levels could 
reflect cross-reactivity of the compound with mGluR5 (Moroni et al. 1997), or with 
mGluR2, where it acts as a low-affinity agonist (Moroni et al. 1997). This does 
however seem unlikely since SIB-1757 caused an increase rather than a decrease in 
GSH levels, and selective group II mGluR agonists had no effect upon GSH levels 
(fig. 5.4). 
 
Modulation of group I mGluRs has been shown to have effects upon GSH levels in 
other CNS-associated cell types, lending support to the apparent effects of group I-
selective compounds upon microglial GSH levels. Glutamate toxicity in the HT22 
neuronal  cell  line  was  reduced  by  DHPG  and  potentiated  by  AIDA  (Luo  and 
DeFranco  2006)  and  group  I  mGluR  stimulation  rescued  glutamate-induced 
decreases in GSH (Sagara and Schubert 1998; Luo and DeFranco 2006). HT22 cells 
selected  for  resistance  to  glutamate  toxicity  had  5.3-fold  increased  mGluR1 
expression,  as  well  as  increased  vasoactive  intestinal  peptide  (VIP)  receptor  2 
(VPAC2)  expression.  Synergistic  actions  of  these  receptors  when  stimulated  by 
glutamate  and  VIP  respectively  increased  Bcl-2  expression,  which  increased 
intracellular  GSH  and  thereby  provided  protection  against  oxidative  glutamate 
toxicity  (Sahin  et  al.  2006).  DHPG  protected  against  KA,  oxygen/glucose 
deprivation  and  cystine  starvation-induced  GSH  depletion  in  oligodendrocyte 
precursor cells (OPCs) in OPC-enriched cultures prepared from mixed glial cultures 
(Deng et al. 2004). DHPG also elevated GSH levels in striatal slices (Maccarrone et 
al. 2008). 
 
It appears that the two group I mGluR subtypes have opposite effects upon GSH 
levels in BV-2 microglial cells. An effect of mGluR antagonists in the absence of 
specific agonists, and a lack of an effect of the group I mGluR agonists DHPG and 289 
 
tADA  and  the  mGluR5  positive  allosteric  modulator  CDPPB  suggest  that  the 
receptors are activated under control conditions. This may reflect the effect of the 
micromolar levels of glutamate present in the medium, of low levels of glutamate 
released by microglia, particularly BV-2 cells, under basal conditions (see chapter 4), 
or constitutive activation of these receptors (Prezeau et al. 1996; Pagano et al. 2000; 
Ango et al. 2001; Muhlemann et al. 2005). Thus, mGluR5 activation apparently 
decreases  intracellular  GSH levels,  whilst  activation of mGluR1α increases  GSH 
levels. 
 
There are a number of ways in which the effects of mGluR modulation upon GSH 
levels may be mediated. In terms of effects upon GSH synthesis, mGluRs could alter 
the expression or activity of EAATs, thus altering extracellular glutamate levels and 
affecting  the  activity  of  other  glutamate  receptors,  as  well  as  impacting  the 
intracellular  glutamate  pool  which  drives  cystine  uptake  via  xc
-.  Signalling  from 
mGluRs  could  also  directly  affect  xc
-  expression  or  activity,  thus  affecting 
intracellular availability of cystine, which may be a limiting factor in GSH synthesis. 
Although  here  the  antagonists  only  had  small,  non-significant  effects  upon 
extracellular  glutamate  levels,  suggesting  that  the  effects  upon  GSH  levels  are 
independent of glutamate transporter, the medium used in the glutamate assay was 
devoid of serum, cells were cultured in serum-containing medium (SCM) prior to 
GSH determination. Collation of control BV-2 medium samples tested throughout 
this study shows that SCM contains 98.8 ± 4.6 µM (n=10). Serum-free D-MEM does 
not contain any glutamate by formulation (Dulbecco and Freeman 1959). Therefore 
with serum-free medium there was likely to have been lower basal levels of mGluR 
activation, and less scope for the action of antagonists. This is supported by the fact 
that in the presence of LPS, which causes increased glutamate release and therefore 
would enhance mGluR activation, the antagonists had more pronounced effects.  
 
The expression of mRNA for EAAT1 and EAAT2 by the BV-2 and N9 microglial 
cell  lines  was  very  low,  close  to  the  limit  of  detection;  data  must  therefore  be 
interpreted with caution. However, neither AIDA nor SIB-1757 appeared to have a 
striking effect upon mRNA levels of either transporter in  BV-2 cells, and initial 
investigations did not provide any evidence of modulation of expression by other 
specific agonists and antagonists of mGluRs in either cell line.  290 
 
 
In  primary  microglial  cells,  preliminary  experiments  suggested  that  the  non-
competitive mGluR5 antagonist MTEP (Cosford et al. 2003b) may downregulate, 
and a combination of MTEP and a positive allosteric modulator of mGluR5, CDPPB 
(Lindsley et al. 2004; Kinney et al. 2005) may upregulate EAAT1 mRNA levels. 
This finding is at odds with studies in astrocytes, where stimulation of mGluR5 has 
been demonstrated to downregulate EAAT1 expression (Gegelashvili et al. 2000; 
Aronica et al. 2003). However, it is possible that different signalling pathways exist 
in different cell types. Clearly further experiments would be required to substantiate 
this finding, especially as CDPPB alone did not increase, and may have even slightly 
decreased the levels of mRNA for EAAT1. Allosteric interactions do however tend 
to be more complex than orthosteric interactions. Although the structure of CDPPB 
is notably different to that of MTEP and [
3H]-3-methoxy-5-(pyridin-2-ylethynyl)-
pyridine ([
3H]-methoxy-PEPy), which are rather similar (fig. 5.23), both MTEP and 
CDPPB  can  antagonise  [
3H]-methoxy-PEPy  binding,  although  with  markedly 
different affinities (Cosford et al. 2003b; Kinney et al. 2005). Recent data indicate 
that  the  binding  of  CDPPB  and  [
3H]-methoxy-PEPy  is  competitive  (Chen  et  al. 
2007),  suggesting  that  the  binding  sites  of  CDPPB  and  MTEP  may  overlap.  A 
positive  cooperative  interaction  of  glutamate  and  CDPPB  is  suggested  as  an 
explanation for the difference between the EC50 for potentiation of a response to 
glutamate by CDPPB and its much higher dissociation constant with respect to [
3H]-
methoxy-PEPy (Kinney et al. 2005; Chen et al. 2007). The unexpected effects of a 
combination  of  MTEP  and  CDPPB  compared  with  either  compound  alone  may 
reflect a complex interaction between the binding of these two ligands to mGluR5 in 
the presence of glutamate (serum-containing medium contains ~100 µM glutamate) 
in the modulation of EAAT1 expression. 
 
Alterations in the expression or activity of xc
- do not appear to be responsible for the 
changes in GSH content of BV-2 microglia. The increase in GSH levels seen in the 
presence of the mGluR5 antagonist SIB-1757 was not altered in the presence of 
elevated extracellular cystine levels or by the xc
- inhibitor APA, and its effects upon 
glutamate release were not modulated by supplementary cystine, AAA or APA. In 
addition,  there  did  not  appear  to  be  any  effects  of  group  I  mGluR  agonists  or 
antagonists upon xCT mRNA expression in N9 or BV-2 cell lines or in primary291 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23. The structures of the mGluR5 allosteric ligands 3-[(2-methyl-1,3-thiazol-4-
yl)ethynyl]-pyridine  (MTEP)  (Cosford  et  al.  2003b),  [
3H]-3-methoxy-5-(pyridin-2-
ylethynyl)-pyridine  ([
3H]-methoxy-PEPy)  (Cosford  et  al.  2003a),  and  3-cyano-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide  (CDPPB)  (Lindsley  et  al.  2004):  MTEP  and  [
3H]-
methoxy-PEPy share similar structures, while that of CDPPB is somewhat different. 
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microglial cells. Although AIDA has been reported to inhibit cystine uptake in rat 
striatal slices (Baker et al. 2002) and in dibutyryl-cyclic adenosine monophosphate- 
(dbcAMP-) treated astrocytes (Gochenauer and Robinson 2001), the concentration 
used (1 mM) in these studies may be sufficient to cause non-specific effects, such as 
mGluR2 agonism (Moroni et al. 1997). 
 
The effects of mGluR activity upon GSH levels could also be due to effects upon the 
intracellular GSH synthesising enzymes, glutamate-cysteine ligase (GCL) or GSH 
synthase. GCL is the rate-limiting enzyme in GSH synthesis (Meister and Anderson 
1983),  therefore  changes  in  its  expression  or  activity  are  likely  to  impact  upon 
cellular GSH levels. GCL upregulation has been demonstrated in a number of cell 
types, and was often associated with stressful stimuli, such as hydrogen peroxide 
(Ochi 1995), ROS (Ochi 1996), the lipid peroxidation product 4-hydroxy-2-nonenal 
(Liu et al. 1998b; Dickinson et al. 2002) and proinflammatory cytokines such as 
TNFα (Urata et al. 1996; Morales et al. 1997; Rahman et al. 1999; Takamura et al. 
2006).  Such  conditions  may  also  be  associated  with  microglial  activation.  GCL 
upregulation has been demonstrated in a glioma cell line (Gomi et al. 1997), but has 
not so far been shown in microglia. It is possible that signalling pathways occurring 
following  stimulation  of  mGluR1α  or  mGluR5  may  upregulate  or  downregulate, 
respectively, microglial GCL expression or activity. 
 
The effects of group I mGluR antagonists upon GSH levels in BV-2 microglia could 
be independent of GSH synthesis and simply be due to alteration of the rate of GSH 
consumption. SIB-1757 increased the GSH content of BV-2 cells, and it follows that 
the  underlying  stimulation  of  mGluR5  decreased  the  GSH  content.  However 
mGluR5 stimulation has also been shown to decrease the LPS-induced production of 
reactive oxygen and nitrogen species (Byrnes et al. 2009), and is therefore likely to 
diminish rather than enhance the demand upon GSH as an antioxidant. 
 
The data here also suggest that the group I mGluR agonist DHPG (Ito et al. 1992; 
Brabet et al. 1995) may enhance nitrate/nitrite production by N9 microglial cells. 
DHPG alone caused a slight, but non-significant increase in nitrate/nitrite levels, and 
preliminary data showed a consistent potentiation of the effects of the microglial 
activators LPS + IFN, fraction V albumin and CGA by DHPG. This does not appear 293 
 
to  be  in  agreement  with  a  recent  study  demonstrating  an  mGluR5-mediated 
inhibition of aspects of LPS-induced microglial activation, including NO production 
(Byrnes et al. 2009). This could be due to differences in receptor subtype expression. 
Byrnes et al. (2009) do not detect mGluR1α surface expression, whilst in N9 cells, 
mGluR1α and mGluR5 may be coexpressed (Pinteaux-Jones 2007), and may signal 
through  different  pathways,  as  appears  to  be  the  case  in  BV-2  cells.  Even  if 
mGluR1α is expressed at a lower level, this does not necessarily indicate that its 
effects are less potent than those of mGluR5, and there could be a dominant effect of 
mGluR1α in enhancing activation-induced NO production. 
 
It  therefore  appears  that,  to  some  extent  at  least,  the  two  subtypes  of  group  I 
mGluRs, mGluR1α and mGluR5, may have distinct effects in microglia. Different 
responses  following  mGluR1  and  mGluR5  activation  have  previously  been 
demonstrated in a number of systems. When heterologously expressed in CHO cells, 
mGluR1α and mGluR5 both couple to extracellular signal-related kinase (ERK), but 
the mGluR1α pathway is pertussis toxin-sensitive, suggesting coupling via a Gi/o G 
protein rather than the Gq/11 G protein typical of group I mGluRs  (Thandi et al. 
2002). In human embryonic kidney (HEK) cells, mGluR1α stimulation was found to 
lead to a single burst of Ca
2+ mobilisation, whilst mGluR5α caused intracellular Ca
2+ 
oscillations (Kawabata et al. 1996). In a later study, mGluR1 and mGluR5 expressed 
in  HEK  cells  were  demonstrated  to  cause  different  frequencies  of  inositol 
triphosphate (IP3) and Ca
2+ oscillations, leading to different frequencies of repetitive 
translocation of PKCβII between the plasma membrane and the cytosol (Dale et al. 
2001). The group I mGluR subtypes were found to utilise different sources of Ca
2+ 
for their signalling in hippocampal inhibitory neurones; mGluR1α stimulation caused 
Ca
2+ influx and release from intracellular stores, whilst mGluR5 stimulation only led 
to intracellular release of Ca
2+ (Topolnik et al. 2006). It is entirely possible that 
similar  differences  in  group  I  mGluR  signalling  could  lead  to  distinct effects  of 
mGluR1 and mGluR5 in microglia. 
 
Figure 5.24 summarises the apparent opposing actions of mGluR1α and mGluR5 in 
microglia,  based  upon  results  from  BV-2  and  N9  cells  presented  here,  in 
combination with the recently-published study in primary microglia (Byrnes et al. 
2009).  294 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24. Microglial group I mGluRs appear to have opposing actions upon aspects of 
microglial activation. mGluR1α activation appears to enhance the release of NO and ROS, 
whilst  mGluR5  activation  inhibits  NO  and  ROS  release,  TNFα  production,  glutamate 
release, microglial proliferation and neurotoxicity. In addition, mGluR1α increases, and 
mGluR5  decreases  microglial  GSH  content.  Glu,  L-glutamate;  GSH,  glutathione;  LPS, 
lipopolysaccharide;  MG,  microglia(l);  mGluR1α,  metabotropic  glutamate  receptor  1α; 
mGluR5,  metabotropic  glutamate  receptor  5;  NO,  nitric  oxide;  ROS,  reactive  oxygen 
species; TLR4, toll-like receptor 4; TNFα, tumour necrosis factor α; +, enhancement of 
LPS-induced characteristic; -, inhibition of LPS-induced characteristic; a, as demonstrated 
by (Byrnes et al. 2009); b, as suggested by BV-2 data; c, as suggested by preliminary N9 
data. 
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5.10.3. The effect of group II metabotropic glutamate receptors 
 
In this study, preliminary experiments suggested that the mGluR3 agonist NAAG 
appeared to decrease xCT mRNA expression in preliminary experiments in N9 cells. 
This  is  in  agreement  with  in  vivo  microdialysis  studies,  which  demonstrated  an 
autoregulatory mechanism whereby group II mGluR stimulation reduced glutamate 
release by decreasing xc
- transporter activity  (Baker et al. 2002; Xi et al. 2002). 
Interestingly, NAAG is an endogenous specific mGluR3 agonist of the mammalian 
CNS (Curatolo et al. 1965; Zaczek et al. 1983; Wroblewska et al. 1997). Such an 
effect of this peptide may therefore have in vivo relevance. Further experiments are 
however necessary in order to substantiate this finding.  
 
5.10.4. The effect of group III metabotropic glutamate receptors 
 
Microglia in culture express group III mGluRs (mGluR4, 6 and 8) (Taylor et al. 
2003) and microglial mGluR8 expression has been demonstrated in demyelinating 
and chronic MS lesions  (Geurts et  al.  2005).  In the present  study, the group  III 
mGluR agonist L-AP4 (Nakanishi 1992; Bushell et al. 1995) decreased GSH levels 
in N9 cells. L-AP4 may also have caused a slight increase in glutamate release, in 
agreement with an earlier report (Pinteaux-Jones et al. 2008), although due to inter-
experiment  variability  in  the  present  study  the  increase  was  not  found  to  be 
statistically  significant.  In  preliminary  experiments,  L-AP4  did  not  affect  the 
glutamate release induced by LPS + IFN. It is interesting that an effect of L-AP4 
was  observed  at  all,  given  that  N9  medium  contains  5  %  serum,  and  thus 
approximately 50 µM glutamate. This concentration of glutamate is within a similar 
range  to  that  reported  for  the  EC50/Kd  of  mGluR4  and  mGluR6  (Schoepp  et  al. 
1999),  and  may  therefore  be  expected  to  result  in  approximately  half-maximal 
activation of these receptors. L-AP4 is a more potent agonist at all group III mGluRs 
than glutamate (Schoepp et al. 1999), and at a concentration of 100 µM, as used 
here,  would  be  expected  to  fully  activate  the  receptors.  The  difference  between 
control and L-AP4-treated cells may therefore represent the difference between half 
and full activation of mGluR4 or mGluR6. High concentrations of G protein-coupled 
receptor  agonists  are  often  associated  with  receptor  desensitisation  and 
internalisation, however the desensitisation of mGluR4, at least, has been shown to 296 
 
be agonist-independent (Mathiesen and Ramirez 2006), suggesting that an effect of 
L-AP4 following a 24 hour exposure is entirely possible. 
 
Increased extracellular glutamate levels, as may have occurred in the presence of L-
AP4,  suggest  increased  operation  of  the  xc
-  transporter  or  decreased  activity  or 
reversal of EAATs. However, preliminary data here suggested that the group  III 
agonist (RS)-PPG may have decreased the levels of mRNA for xCT in N9 microglia, 
although L-AP4 did not appear to have the same effect, despite the fact that both 
compounds would be expected to act as agonists at microglial mGluRs 4, 6 and 8 at 
the concentrations tested (Conn and Pin 1997; Gasparini et al. 1999; Schoepp et al. 
1999). It may appear somewhat contradictory that the group III mGluR antagonist 
MAP4  also  appeared  to  decrease  xCT  mRNA  expression,  however  the 
agonist/antagonist profile of MAP4 is more complicated. Although its inhibition of 
L-AP4-mediated effects is well-characterised (Jane et al. 1994; Bushell et al. 1995; 
Knopfel et al. 1995; Salt and Eaton 1995; Vignes et al. 1995; Taylor et al. 2003), it 
has also been reported to act as a weak mGluR4a (Knopfel et al. 1995) and mGluR6 
(Laurie et al. 1997; Sekiyama et al. 1996) agonist. MAP4 may therefore be a group 
III mGluR partial agonist (Laurie et al. 1997), perhaps explaining its apparent ability 
to  emulate  the  effects  of  (RS)-PPG.  Glutamate  also  has  concentration-dependent 
effects upon xc
- and EAAT operation (see fig. 4.24); it may therefore have effects 
upon  these  transporters  at  several  different  levels.  Alterations  in  extracellular 
glutamate  levels  due  to  changes  in  transporter  function  provide  a  potential  for 
positive or negative feedback in this system.  
 
The decrease in xCT mRNA levels following group III mGluR stimulation suggested 
by preliminary PCR results would fit with the decrease in the GSH content of N9 
cells, as GSH synthesis is dependent upon cystine import via xc
-. The concurrent 
increase in extracellular glutamate may therefore be due to other effects of group III 
mGluR stimulation, perhaps upon the EAAT glutamate transporters. This may be an 
effect upon EAAT expression at the mRNA level; the effects of mGluR compounds 
other than those acting upon group I receptors upon EAAT mRNA expression were 
not  investigated in  primary microglia in  the present  study  and the expression of 
EAAT mRNA by BV-2s and N9s was very low, such that changes may not have 
been detected. Alternatively, post-transcriptional regulation of EAAT expression or 297 
 
activity  may  be  involved.  In  vivo,  a  group  III  mGluR  antagonist  prevented 
downregulation  of  EAAT2  protein  in  the  hippocampal  CA1  region  following 
transient ischaemia (Chen et al. 2005), implicating group III stimulation in EAAT2 
downregulation. In astrocytes in vitro, dbcAMP upregulated EAAT1 and EAAT2 
mRNA and protein expression, and increased glutamate uptake capacity (Eng et al. 
1997; Swanson et al. 1997; Schlag et al. 1998). Microglial group III mGluRs have 
been shown to  couple via Gi/o (Taylor  et  al. 2003), therefore the agonist L-AP4 
would  be  expected  to  decrease  the  availability  of  cAMP,  thus  perhaps  limiting 
EAAT2 expression. In addition, a decrease in EAAT activity may hinder xc
- activity 
by  limiting  its  access  to  intracellular  glutamate  to  drive  cystine  import,  thus 
potentially decreasing the rate of GSH synthesis, and providing another explanation 
for the decreased GSH content found following treatment with L-AP4. A hypothesis 
explaining the effects of group III mGluRs upon GSH levels, glutamate release and 
xCT expression is illustrated in figure 5.25. 
 
Neuroprotection  via  stimulation  of  group  III  mGluRs  on  both  astrocytes  and 
microglia  has  been  demonstrated  previously.  In  microglia,  L-AP4  prevented 
microglial neurotoxicity following stimulation with LPS, CGA or myelin (Taylor et 
al. 2003; Pinteaux-Jones et al. 2008), but in the case of myelin at least, L-AP4 did 
not have any effect upon myelin-induced iNOS expression, or glutamate or TNFα 
expression  (Pinteaux-Jones  et  al.  2008).  The  protective  effects  of  L-AP4  were 
dependent  upon  the  presence  of  microglia,  which  presumably  released 
neuroprotective  factors  into  the  medium.  Microglial  group  III  mGluRs,  when 
stimulated with L-AP4 or (RS)-PPG, are negatively coupled to AC (Taylor et al. 
2003), as are microglial group II mGluRs (Taylor et al. 2002), but these intracellular 
signalling  pathways  diverge  at  some  point  following  the  cAMP  decrease,  and 
stimulation  of  group  II  mGluRs  causes  neurotoxicity  (Taylor  et  al.  2002,  2005) 
whilst group III mGluRs are neuroprotective (Taylor et al. 2003; Pinteaux-Jones et 
al. 2008).  
 
Stimulation  of  microglial  group  III  mGluRs  therefore  appears  to  promote 
neuroprotection in the presence of a decrease in intracellular GSH levels. Perhaps the 
mechanism  of  neuroprotection  depletes  microglial  GSH.  For  example,  group  III 
mGluRs may upregulate the activity of antioxidant defences to allow the microglia to  298 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.25.  Hypothesis  to  explain  concurrent  GSH  depletion,  increased  extracellular 
glutamate and decreased xCT mRNA levels, as found in the case of N9 microglial cells 
following group III mGluR stimulation. Activation of group III mGluRs may downregulate 
EAAT expression or activity through inhibition of a cAMP-mediated enhancement of EAAT 
gene  transcription  or  otherwise  (Eng  et  al.  1997;Swanson  et  al.  1997;Schlag  et  al. 
1998;Chen et al. 2005). A decrease in EAAT expression would lead to less glutamate uptake 
and therefore increased extracellular glutamate levels. Data in this study suggested that 
group  III  mGluR  stimulation  may  downregulate  xCT  mRNA  levels,  which  would  likely 
decrease xc
- expression and activity and consequently compromise GSH synthesis. cAMP, 
cyclic adenosine monophosphate; cys, L-cystine; EAAT, excitatory amino acid transporter; 
glu,  L-glutamate;  gr  III  mGluR,  group  III  metabotropic  glutamate  receptor;  GSH, 
glutathione;  L-AP4,  L-(+)-2-amino-4-phosphonobutyric  acid;  (RS)-PPG,  (RS)-4-
phosphonophenylglycine;  xc
-  xc
-  glutamate/cystine  antiporter  system;  xCT,  the  specific 
subunit of xc
-. 
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detoxify potentially damaging reactive species, thus consuming GSH but protecting 
against neuronal damage. Since GSSG levels in the presence of L-AP4 were not 
tested, there is a possibility that this could account for the apparent depletion of 
GSH.  As  mentioned  above,  GCL,  the  rate-limiting  enzyme  in  GSH  synthesis 
(Meister  and  Anderson  1983),  has  been  noted  to  be  upregulated  in  hepatocytes, 
fibroblasts, endothelial and epithelial cells under a number of conditions which may 
also be associated with microglial activation (Ochi 1995, 1996; Urata et al. 1996; 
Morales et al. 1997; Liu et al. 1998b; Rahman et al. 1999; Dickinson et al. 2002; 
Takamura et al. 2006). It may be that in preventing proinflammatory effects, group 
III  mGluR  activation  removes  or  counteracts  such  potential  GCL-upregulatory 
stimuli. 
 
Activity of the xc
- transporter has been shown in vitro to be associated with oxidative 
glutamate toxicity towards neurones  (Piani and Fontana 1994; Barger and Basile 
2001; Qin et al. 2006; Barger et al. 2007) and oligodendrocytes (Domercq et al. 
2007; Matute 2007), therefore downregulation of the expression of this transporter, 
as suggested by preliminary PCR data, may promote neuronal and oligodendroglial 
survival. Microglial glutamate release may however have less of an impact in vivo, 
where astrocytes express EAATs at a high level, and are capable of dealing with 
high  concentrations  of  extracellular  glutamate  (Rothstein  et  al.  1996). Decreased 
microglial xc
- expression would likely limit cystine uptake and therefore decrease the 
rate of GSH synthesis, an effect demonstrated here in N9 cells treated with L-AP4. 
 
An  alternative  explanation  for  microglial  GSH  depletion  in  combination  with 
neuroprotection may be the supply of cysteine to neurones, thus enabling neuronal 
GSH synthesis. This function is normally performed by astrocytes, which release 
GSH  (Yudkoff  et  al.  1990;  Sagara  et  al.  1996;  Dringen  et  al.  1999b)  through 
multidrug resistance protein 1 (Mrp1) (Hirrlinger et al. 2002c; Minich et al. 2006). 
Microglia may also release GSH (Dallas et al. 2003; see chapter 3), and have been 
shown to express functional Mrp1, as well as other Mrp subtypes (Ballerini et al. 
2002; Hirrlinger  et  al.  2002a; Dallas  et  al.  2003). However, in order  to  provide 
cysteine for neuronal uptake and GSH synthesis, the released GSH must be broken 
down by GT (Dringen et al. 1997) which is expressed by astrocytes (Dringen et al. 
1997) but not at significant levels by microglia or neurones (Shine and Haber 1981; 300 
 
Philbert et al. 1995; Murata et al. 1997; Ruedig and Dringen 2004), suggesting that 
such  an  interaction  between  microglia  and  neurones  would  need  to  involve 
astrocytes or be GT-independent. GSSG is also a substrate for Mrp1 (Leier et al. 
1996; Heijn et al. 1997), and GSSG released by astrocytes was noted to be broken 
down in a GT-independent manner (Minich et al. 2006). Microglial GSSG release 
may  therefore  represent  a  GT-independent  cysteine  supply  route  for  neurones. 
Alternatively, there is the possibility that microglia release a different GSH precursor 
for  neurones,  such  as  cysteinylglycine  or  cysteine,  thus  eliminating  the  need  for 
extracellular  GT.  Since  the  release  of  either  of  these  molecules  would  deplete 
microglial  cyst(e)ine,  intracellular  GSH  levels  would  be  expected  to  fall  as  a 
consequence. Macrophages have been shown to release cysteine  (Gmunder et al. 
1990;  Yeh  et  al.  2000),  but  it  is  questionable  whether  microglia  would  release 
cysteine as part of a neuroprotective mechanism as it is also an agonist at NMDA 
receptors,  mediating  neuronal  excitotoxicity  at  high  concentrations  (Olney  et  al. 
1990; Lipton et al. 1993; Yeh et al. 2000). Cysteinylglycine is therefore a more 
likely candidate. Indeed, Mrp1-mediated transport of cysteinylglycine conjugates of 
isothiocyanates (Callaway et al. 2004) and the cysteinylglycine leukotriene LTD4 
(Schaub et al. 1991; Leier et al. 1994; Jedlitschky et al. 1996) have been reported. It 
is therefore plausible that cysteinylglycine or a cysteinylglycine conjugate may be 
exported by one of the Mrps expressed by microglia, to supply cysteine for neuronal 
GSH synthesis. 
 
5.10.5. Conclusion 
 
Further  to  published  data  demonstrating  microglial  neuroprotection  and 
neurotoxicity  following  differential  mGluR  stimulation,  data  are  presented  here 
showing modulation of microglial GSH levels by antagonists of group I mGluRs and 
the group III mGluR agonist L-AP4 in mouse microglial cell lines. This appears to 
be  the  first  demonstration  of  mGluR-mediated  modulation  of  microglial  GSH. 
Interestingly, stimulation of mGluR5 or of group III mGluRs, both of which have 
been shown to enhance microglial neuroprotection (Taylor et al. 2003; Pinteaux-
Jones  et  al.  2008;  Byrnes  et  al.  2009),  also  depleted  microglial  GSH  levels. 
Stimulation of mGluR5 appeared to decrease microglial glutamate release, whilst 301 
 
group III mGluR stimulation enhanced glutamate release, suggesting that different 
pathways  may  be  involved.  Microglial  GSH  is  crucial  in  the  defence  against 
oxidative stress, and depleted GSH may lead to compromised microglial function. 
Neuroprotection  following  microglial  mGluR  modulation  may  involve  increased 
GSH utilisation or a decrease in the rate of GSH synthesis; alternatively decreased 
GSH  levels  and  neuroprotection  may  be  unrelated  consequences  of  the  mGluR 
stimulation.  In  any  case,  GSH  depletion  over  time  may  compromise  the 
neuroprotective ability of microglia. Further study is required to confirm that the 
effects noted here also occur in primary microglia and to elucidate the signalling 
pathways involved. Because elevated extracellular glutamate levels and glutamate 
toxicity  are  implicated  to  some  extent  in  the  majority  of  neurodegenerative  and 
neuroinflammatory diseases, an understanding of microglial mGluRs and GSH is 
important to fully understand the role of microglia in these circumstances. A better 
understanding of microglia may also allow development of therapies to target the 
harmful effects of microglia without compromising their normal function. 
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General discussion 
 
The work presented here centred upon the investigation of the glutathione (GSH) 
levels  of  microglial  cells  in  vitro,  under  conditions  associated  with  microglial 
activation  and  neuroinflammatory  disease,  as  well  as  in  the  presence  of  specific 
agonists and antagonists of metabotropic glutamate receptors (mGluRs). In addition, 
any  concomitant  changes  in  glutamate  transporter  expression  and  extracellular 
glutamate levels were investigated, in order to help explain any changes in the GSH 
content of microglia.  
 
Microglia are the immune cells of the CNS, having a crucial role in detecting and 
removing  foreign  molecules  which  enter  the  brain.  This  involves  their  transient 
activation  to  a  more  immunocompetent  phenotype,  allowing  the  release  of 
antimicrobial  compounds  and  phagocytosis  of  debris.  Microglia  are  therefore 
fundamentally a functional part of the CNS, adapted to protect the more vulnerable 
cells, particularly neurones, from damage. Microglial dysfunction, in the form of 
chronic activation, may be implicated in neuroinflammatory conditions. However, 
the majority of observations of microglial behaviour are likely to have physiological, 
as well as pathological, significance. This often appears to be overlooked in studies 
focussing on the potential role of microglia in pathogenesis. 
 
Microglia,  like  all  metabolically  active  cells,  constantly  produce  reactive  oxygen 
species (ROS) during mitochondrial respiration. In addition, microglial activation 
leads to the production of nitric oxide (NO) and superoxide, which may give rise to a 
number  of  other  reactive  species,  including  peroxynitrite.  This  suggests  that 
antioxidants such as GSH are likely to be important in protecting microglia from 
oxidative  damage.  Indeed,  microglia  have  high  levels  of  GSH  and  the  enzymes 
involved  in  its  metabolism  (Chatterjee  et  al.  1999,  2000;  Hirrlinger  et  al.  2000, 
2002b;  Hollensworth  et  al.  2000;  Noack  et  al.  2000).  Previous  literature  has 
suggested that microglial GSH levels may be altered by microglial activation by 
LPS, IFN and TNFα, although reports exist both of increases and decreases in GSH 
levels (Chatterjee et al. 2000; Noack et al. 2000; Moss and Bates 2001; Dopp et al. 
2002; Roychowdhury et al. 2003; Persson et al. 2006). Here, it was found that GSH 304 
 
levels in the BV-2 mouse microglial cell line increased following treatment with the 
classical  microglial  activator  lipopolysaccharide  (LPS)  alone  and  in  combination 
with interferon- (IFN), whilst N9 microglial GSH levels decreased under identical 
conditions. The differences between the responses of the cell lines did not appear to 
be due to different sensitivities of the cell lines to the activators, nor to a temporal 
difference in the response. Parallel experiments performed in primary rat microglia 
suggested that in this situation, the BV-2 cell line more closely modelled primary 
microglia, with an increase in the GSH content following microglial activation.  
 
The major function of intracellular GSH is its antioxidant property. It is therefore 
clear that increased production of ROS and reactive nitrogen species (RNS) would 
place increased demand upon GSH, and in the absence of adequate synthesis may 
lead to  a declined GSH content. However, intracellular signalling pathways  may 
exist which allow the maintenance of intracellular GSH through enhanced synthesis. 
As  glutamate  and  glycine  are  present  at  high  levels  intracellularly,  cystine 
availability may limit  the rate of  GSH synthesis.  In  glial  cells,  cystine for GSH 
synthesis  is  supplied  via  the  xc
-  glutamate/cystine  antiporter;  studies  have 
demonstrated  LPS-induced  xc
-  upregulation  in  microglia  (Barger  et  al.  2007; 
Domercq  et  al.  2007),  perhaps  increasing  supply  of  this  potentially  limiting 
substrate. The rate-limiting enzyme in GSH synthesis is thought to be GCL (Meister 
and Anderson 1983), which has been shown in astrocytes to be upregulated in the 
presence of NO (Gegg et al. 2003). However, as both enzymes involved in GSH 
synthesis are ATP dependent, a compromised cellular energy status under conditions 
of oxidative stress may prevent adequate GSH synthesis to meet demand. In some 
cell types NO and peroxynitrite have been shown to upregulate glycolysis or the 
pentose-phosphate pathway, resulting in a rescue of ATP or NADPH production, 
respectively (Almeida et al. 2001, 2005). Whilst ATP might allow the continued 
synthesis  of  GSH,  NADPH  allows  reduction  of  oxidised  glutathione to  maintain 
GSH levels. The potential effects of microglial activation upon intracellular GSH 
levels are illustrated in figure 6.1. There may be differences in the underlying cell 
biology and signalling pathways of BV-2 and N9 cells, which somehow leads to the 
difference in the effects of activation upon the GSH levels in these cell lines. 
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Figure 6.1. Mechanisms by which microglial activators such as LPS, IFN or fraction V 
albumin may affect levels of intracellular GSH (circled). Solid arrows indicate reactions 
occurring; the enzymes responsible are in italics alongside. Dotted arrows indicate potential 
stimulatory/upregulatory effects, whilst dotted lines blocked at the end indicate potential 
inhibitory/downregulatory  effects.  GluCys,  -glutamylcysteine;  ADP,  adenosine 
diphosphate; ATP, adenosine triphosphate; cys, L-cystine; GCL, glutamate-cysteine ligase; 
GPx,  glutathione  peroxidase;  GR,  glutathione  reductase;  GSH,  glutathione;  GST, 
glutathione S-transferase; GSSG, oxidised glutathione; GS-X, S-conjugates of glutathione; 
IFN, interferon-; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; NADP
+, 
nicotinamide  adenine  dinucleotide  phosphate;  NADPH,  reduced  nicotinamide  adenine 
dinucleotide  phosphate;  NO,  nitric  oxide;  O2
-,  superoxide;  ONOO
-,  peroxynitrite;  PPP, 
pentose-phosphate pathway; R, cell surface receptor; xc
-, xc
- glutamate/cystine antiporter 
system.
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LPS or LPS + IFN treatment of BV-2 or primary microglia leads to ROS and RNS 
production, which is likely to cause oxidative stress and increase GSH consumption. 
There must therefore be a highly significant upregulation of GSH synthesis in BV-2 
and primary microglial cells, in order to cause a net increase in intracellular GSH. 
An  increase  in  extracellular  glutamate,  as  well  as  elevated  levels  of  messenger 
ribonucleic acid (mRNA) for both the excitatory amino acid transporter (EAAT2) 
and xCT, the specific subunit of the xc
- transporter, were found to be associated with 
LPS-induced  GSH  increases  in  BV-2  and  primary  microglial  cells.  Elevated  xc
- 
activity  enhances  the  cystine  uptake  capacity  of  microglia  and  therefore  may 
represent the mechanism by which LPS increases microglial GSH levels. However 
the  xc
-  transporter  releases  glutamate  in  exchange  for  cystine,  suggesting  that 
increased  microglial  cystine  uptake  and  GSH  synthesis  may  cause  toxicity  to 
neighbouring cells. A concurrent elevation of EAAT2 may indicate a mechanism to 
counteract the elevated glutamate release. Although millimolar levels of glutamate 
are present intracellularly, EAATs and xc
- may be located in close vicinity to one 
another so that EAAT-mediated glutamate uptake may be directly coupled to xc
- 
activity (Igo and Ash 1998; Rimaniol et al. 2001; Persson et al. 2006). The overall 
increase  in  extracellular  glutamate  under  conditions  of  microglial  activation 
suggested  that  xc
-  activity  is  likely  to  be  more  highly  upregulated  than  that  of 
EAAT2, unless EAAT2 transporters undergo reversal and contribute to glutamate 
release. In addition, the time course of GSH levels of BV-2 cells closely resembled 
that of their ATP levels, in both control and activated cells, perhaps reflecting the 
importance of de novo GSH synthesis in maintaining intracellular GSH. 
 
In contrast, it appears that N9 cells are either more susceptible to ROS than BV-2s, 
or are unable to upregulate GSH synthesis to the same degree. Therefore treatment of 
N9 cells with LPS or LPS + IFN led to a decrease in intracellular GSH as oxidative 
damage in the cell was dealt with. Indeed, a decrease in the intracellular GSH levels 
of N9 cells was also shown by Moss and Bates (2001), who also demonstrated that 
the decrease could be prevented by inhibition of iNOS, clearly implicating NO in the 
GSH decline.  
 
The experiments  presented here  failed to  find significant  effects  of two peptides 
upregulated in Alzheimer‟s disease (AD), chromogranin A (CGA) and β amyloid 307 
 
peptide (residues 25-35; Aβ25-35) upon the GSH content of microglia, the glutamate 
content  of  conditioned  medium  or  the  expression  of  mRNA  for  glutamate 
transporters.  This  is  surprising,  as  previous  studies  have  demonstrated  effects  of 
CGA and Aβ peptides at concentrations similar to those used here. The issue of LPS 
contamination  of compounds  used to  treat  microglia has  recently been raised by 
Weinstein et al. (2008), a finding which should prompt a re-evaluation of any studies 
involving the addition of compounds to microglia in vitro. Aβ or CGA contaminated 
with LPS would activate microglia, which may then be attributed to an action of the 
compound studied rather than potential contamination. A further consideration in 
this study is the use of the amyloidogenic portion of Aβ, Aβ25-35, rather than the full-
length  peptide.  Although  the  two  have  been  shown  to  have  similar  effects  in 
microglia (Yankner et al. 1990), it should be considered that differences in their 
actions may exist. In addition, the age of the Aβ25-35 and CGA used here and the 
number of freeze-thaw cycles the compounds may have been exposed to may go 
towards explaining their lack of an effect.  
 
However, albumin, to which microglia may be exposed following blood-brain barrier 
(BBB) damage in a number of neuroinflammatory and neurodegenerative conditions, 
including AD and multiple sclerosis (MS), was found to affect microglial GSH and 
glutamate  regulation.  Albumin  causes  microglial  NO  (Hooper  et  al.  2009)  and 
superoxide  (Si  et  al.  1997)  production,  which  might  be  expected  to  inhibit 
mitochondrial respiration and deplete GSH. However, GSH levels were found to 
increase  upon  treatment  with  “fraction  V”  (partially  purified)  albumin.  The 
intracellular  levels  of  ATP  were  also  found  to  increase  following  fraction  V 
treatment, and a correlation between ATP and GSH levels were observed. Thus, it 
appears that the NO produced upon fraction V treatment may be able to upregulate 
the glycolytic pathway in BV-2 microglia. The enhancement of ATP levels in BV-2 
cells and the GSH content of BV-2 and primary microglia in the presence of fraction 
V albumin may be related to the ability of albumin to cause microglial proliferation 
(Hooper et al. 2005). The upregultation of both ATP and GSH in BV-2 microglia 
was somewhat transient, suggesting that the cells might only be equipped to deal 
with transient oxidative insults, and that longer insults may be more detrimental. It is 
however possible that this is an artifact resulting from longer periods of time in 
culture, which may involve depletion of certain components of the cell medium or a 308 
 
build up of toxic release products. Albumin-induced increases in intracellular GSH 
and iNOS expression have been shown to be unaffected by the LPS neutralising 
agent  polymyxin  B,  suggesting  that  although  these  effects  are  similar  to  those 
observed in  the presence of  LPS,  they  are not  due to  LPS contamination of the 
fraction V albumin (Hooper et al. 2009).  
 
Fraction V albumin treatment also led to an increase in the glutamate content of 
microglial  conditioned  medium,  suggesting  an  altered  glutamate  uptake/release 
balance,  although  this  may  have  been  amplified  by  cell  proliferation  over  the 
incubation period. Some slight changes in the glutamate transporter expression of 
primary  microglia  at  the  mRNA  level  were  however  detected,  suggesting  a  real 
effect  upon  glutamate  release;  in  particular,  fraction  V  albumin  consistently 
increased xCT mRNA levels, potentially explaining both the enhanced GSH content, 
and the neurotoxicity of albumin-treated microglia in vitro (Hooper et al. 2009).  
 
Due  to  the  limited  availability  of  primary  microglia,  a  number  of  the  findings 
presented here only relate to the microglial cell lines BV-2 and N9, especially in the 
case of GSH determination by high performance liquid chromatography (HPLC), 
where large amounts of protein are required; indeed, on the few occasions where 
HPLC was used to assess the GSH content of primary microglia the effect of any 
treatment  was  small  compared  with  the  variability  of  the  data.  Therefore  an 
important follow-up to this project would be the extension of observations in the cell 
lines into primary microglia. Due to the difficulties of using the HPLC determination 
method,  it  may  be  necessary  to  use  alternative  means  of  measuring  primary 
microglial GSH content, such as the monochlorobimane imaging method used in this 
thesis, or a biochemical assay, such as the GSH-Glo assay used here to determine the 
GSH content of microglial conditioned medium. 
 
It is possible that the expression of mRNA for subtypes of glutamate transporters 
may not  accurately reflect  their functional  expression or activity. As well as  the 
possibility of post-transcriptional regulation, modulation of the activity of EAATs by 
the cellular redox potential has been demonstrated (Volterra et al. 1994; Trotti et al. 
1997a,  1997b,  1998;  Blanc  et  al.  1998;  Begni  et  al.  2004).  This  is  clearly  an 
important  consideration  in  this  study,  given  that  microglial  activation  increases 309 
 
oxidative  stress.  The  findings  regarding  the  expression  of  mRNA  for  glutamate 
transporters  would  therefore  be  greatly  strengthened  by  investigations  of  protein 
expression,  by  Western  blotting  to  evaluate  absolute  protein  levels  and 
immunofluorescence  to  determine  the  localisation  of  the  protein.  The  activity  of 
transporters could be investigated by uptake or release assays utilising radiolabelled 
substrate molecules. 
 
Primary microglia and those of the BV-2 cell line were also demonstrated to release 
low  levels  of  GSH  into  the  culture  medium.  This  appears  to  be  the  first 
demonstration of GSH release by primary microglial cells. Microglial GSH release is 
likely to occur through  multidrug resistance-associated proteins  (Mrps), probably 
Mrp1, as microglial expression of functional Mrp1 has been demonstrated (Ballerini 
et al. 2002; Hirrlinger et al. 2002a; Dallas et al. 2003), and export of the Mrp1 
substrate vincristine by microglia of the MLS-9 cell line was found to depend upon 
intracellular GSH (Dallas et al. 2003). Whether this microglial GSH release simply 
represents cotransport with exported molecules, or whether it fulfils a function in 
itself  is  yet  to  be  determined.  GSH  released  by  astrocytes  is  broken  down  by 
astrocyte and neurone-associated ectoenzymes to provide cysteine which is taken up 
by neurones for GSH synthesis (Dringen 2000). It is possible that microglial GSH 
release  may  have  a  similar  function,  although  microglia  lack  the  ectoenzyme  -
glutamyl  transpeptidase  (GT)  expressed  by  astrocytes  which  initiates  the 
extracellular processing of GSH (Murata et al. 1997; Ruedig and Dringen 2004). 
Uncleaved GSH released by microglia may act as an extracellular antioxidant; GSH 
is present extracellularly in vivo (Yang et al. 1994; Lada and Kennedy 1997) and 
may be important in detoxifying ROS and RNS released by CNS cells, especially 
microglia. Alternatively, GSH may act as a neuromodulator, either due to binding of 
the -glutamyl residue of GSH to glutamate binding sites (Varga et al. 1989, 1997; 
Yoneda et al. 1990; Leslie et al. 1992; Janaky et al. 1993, 2007, 2008; Ogita et al. 
1995; Jenei et al. 1998; Wang et al. 2006), or to the formation of disulphide bonds 
with the receptor (Liu and Quirion 1992). Evidence also exists suggesting that GSH 
may even represent a novel neurotransmitter (Guo et al. 1992; Guo and Shaw 1992; 
Lanius et al. 1994; Janaky et al. 2000).  
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Microglial  mGluRs  have  been  found  to  alter  microglial  behaviour,  making  them 
neuroprotective (Taylor et al. 2003; Pinteaux-Jones et al. 2008; Byrnes et al. 2009) 
or neurotoxic (Taylor et al. 2002, 2005; Pinteaux-Jones et al. 2008), depending upon 
the  particular  receptors  involved.  Concomitant  effects  upon  microglial  glutamate 
release  have  been  documented  (Pinteaux-Jones  et  al.  2008).  It  was  therefore 
proposed  that  mGluR  modulation  may  have  effects  upon  the  GSH  system  of 
microglia, perhaps by direct or indirect effects upon ATP levels, ROS levels, GCL 
activity or the activity of glutamate transporters. mGluR5 and has been shown to 
enhance the neuroprotective ability of microglia (Byrnes et al. 2009), and was found 
here to cause declines in microglial GSH levels. This may reflect an upregulated rate 
of GSH utilisation for detoxification of ROS and RNS, which may be responsible for 
the enhanced neuroprotection. The GSH decline was however accompanied by lower 
levels of glutamate release, but no detectable alterations in transporter expression at 
the  mRNA  level,  suggesting  decreased  activity  of  xc
-,  perhaps  due  to  post-
transcriptional  downregulation  or  decreased  protein  expression  at  the  plasma 
membrane. Such a downregulation of xc
- activity could explain the decreased GSH 
levels  through  compromised  synthesis,  but  how  this  might  be  related  to 
neuroprotection is unclear. 
 
It was interesting that mGluR1 was found here to have opposite effects to mGluR5; 
AIDA,  an  antagonist  at  mGluR1,  decreased  both  extracellular  glutamate  and 
intracellular GSH levels, suggesting that an underlying stimulation of mGluR1 was 
having a positive modulatory effect upon both. A recent paper evaluates the effect of 
group  I  mGluR  stimulation  upon  LPS-stimulated  microglia  (Farso  et  al.  2009), 
concluding that group I stimulation reduces microglial activation. However, upon 
closer inspection of the data, it appears that whilst DHPG, a group I agonist which 
may  have  a  slight  preference  for  mGluR5  (Schoepp  et  al.  1999),  does  reduce 
markers of microglial activation, AIDA, an mGluR1-preferring antagonist (Moroni 
et al. 1997), does not always  reverse the effects of DHPG. In particular, DHPG 
reduces microglial glutamate release, and AIDA potentiates the effect. Assuming 
that  the  response  to  DHPG  is  mGluR5-mediated  and  the  response  to  AIDA  is 
mGluR1-mediated, such a finding is in direct accordance with the data presented in 
this thesis, and lends weight to the hypothesis that mGluR1 and mGluR5 may have 
some opposing actions in microglia. Indeed, microglial group I mGluRs have been 311 
 
demonstrated to couple to two different G proteins, Gq/11, the prototypical group I 
coupling, leading to phosphatidylinositol hydrolysis and Ca
2+ mobilisation, and Gs, 
leading  to  adenylate  cyclase  activation  and  increased  cyclic  adenosine 
monophosphate levels (Biber et al. 1999; Byrnes et al. 2009). Alternatively, even if 
both  microglial  group  I  mGluRs  couple  via  Gq/11,  divergence  in  the  signalling 
pathway may be attained by eliciting different profiles of Ca
2+ release (Kawabata et 
al. 1996; Dale et al. 2001), or utilising different sources of Ca
2+ for this signalling 
(Topolnik et al. 2006). 
 
Group III mGluRs are also neuroprotective in vitro (Taylor et al. 2003), and in this 
study also caused a decline in the intracellular GSH levels of N9 cells. The pathway 
associated with  the  group  III mGluR-mediated decrease in  GSH content  may be 
different from that involved in the effects of mGluR5, as the decrease was associated 
with slightly elevated extracellular glutamate levels. This data could suggest a group 
III  mGluR-mediated  upregulation  of  microglial  antioxidant  function;  a 
downregulation  of  intracellular  GSH  levels  suggests  an  increased  rate  of  GSH 
utilisation, whilst increased extracellular glutamate may indicate an upregulation of 
xc
- to increase the supply of cystine for GSH synthesis. However, preliminary data 
suggested a downregulation of xCT expression at the mRNA level following group 
III  mGluR  stimulation,  a  finding  which,  if  substantiated  in  further  experiments, 
would prompt a re-evaluation of the pathway involved.  
 
An alternative explanation for neuroprotection in the presence of GSH depletion, as 
demonstrated  following  both  mGluR5  and  group  III  mGluR  stimulation,  is  the 
release of GSH to protect the more vulnerable CNS cell types. Astrocytes participate 
a pathway whereby they release GSH to supply cysteine to neurones, but microglia 
have not as yet been shown to do so. Microglial GSH release has been demonstrated 
here, but as microglia lack the ectoenzyme GT, the supply of cysteine to neurones 
would necessarily involve astroctyes or other GT-expressing cells. Alternatively, 
perhaps  microglial  GSH  release  maintains  or  enhances  extracellular  GSH  levels, 
allowing the detoxification of ROS and RNS released by microglia, before they are 
able to have detrimental effects upon the more vulnerable cells of the CNS. The 
GSH-Glo  assay,  used  successfully  here  to  detect  GSH  in  microglial  conditioned 
medium,  could  be employed to  test  this  hypothesis. By using co-cultures,  where 312 
 
purified neurones and purified microglia share the same culture medium, either by 
the use of inserts or with two coverslips placed side-by-side in a larger dish, it would 
be possible to test whether mGluR stimulation (or other treatments) affect neuronal 
GSH levels. Treating the co-culture and then processing the coverslips separately to 
determine the GSH levels in each cell type, would allow greater insight into the GSH 
interactions  between  microglia  and  neurones,  if  any  such  interactions  occur. 
Experiments such as this may also aid the elucidation of the function of microglial 
GSH release. A better understanding of the mechanisms involved in neuroprotection 
by microglial mGluR5 and those of group III would be advantageous, as microglial 
mGluRs  represent  a  possible  target  for  future  neuroprotective  strategies  in 
neuroinflammatory disease.  
 
Preliminary data suggested a possible decrease in xCT mRNA expression by N9 
cells following treatment with the specific mGluR3 agonist N-acetyl-L-aspartyl-L-
glutamic  acid  (NAAG).  NAAG  is  an  endogenous  peptide  (Curatolo  et  al.  1965; 
Zaczek et al. 1983; Wroblewska et al. 1997), thus, any effects upon microglia in 
vitro may  reflect  in  vivo activities of the peptide.  NAAG has  been shown to  be 
somewhat  neuroprotective  against  myelin-induced  microglial  neurotoxicity 
(Pinteaux-Jones  et  al.  2008),  paralleling  the  neuroprotective  effect  of  astrocyte 
mGluR3 stimulation (Corti et al. 2007). This contrasts with the neurotoxic effect of 
microglial mGluR2 stimulation (Taylor et al. 2002). Given further time and funding, 
further investigation of the neuroprotective and neurotoxic properties of microglia 
induced by mGluR modulation, particularly with relevance to glutamate transport 
and GSH homeostasis, would be a priority. 
 
Alterations  in  microglial  GSH  levels  may  have  implications  in  pathological 
situations. Enhanced microglial GSH levels under conditions of microglial activation 
would protect the microglia from the damaging reactive oxygen and nitrogen species 
produced during activation, but may allow the cell to persist in a situation where the 
detrimental bystander damage of such reactive species is more significant than the 
protective effect conferred. In addition, an enhancement of GSH levels is likely to 
involve  enhanced  cystine  import  via  xc
-,  with  an  accompanying  enhancement  of 
glutamate  release.  Conversely,  a  decline  in  microglial  GSH  levels  may  lead  to 313 
 
oxidative stress and microglial cell death, but whether this would be advantageous or 
deleterious for overall brain health would depend upon the particular situation. 
 
Should the GSH content of microglia be altered following activation, it is important 
to consider the effect this might have on other cell types, particularly neurones, in 
vivo. An in vitro model of intercellular interactions could be achieved by the use of 
co-culture or by transferring microglial conditioned medium onto neuronal cultures. 
The effect of microglial GSH depletion upon neuronal survival could be assessed by 
culturing microglia in the absence of cystine, which over time should deplete their 
GSH.  This  could  be  controlled  for  by  adding  cystine  to  the  cystine-depleted 
microglial conditioned medium before transferring it to separate neuronal cultures. It 
would also be of interest to assess the effect of such artificial GSH depletion in 
combination  with  microglial  activation  or  mGluR  modulation,  to  investigate  any 
contribution of microglial GSH content to the neuroprotective or neurotoxic potential 
of microglia. 
 
A number of in vitro studies from this lab and others report that microglia are toxic 
to  neurones  and  oligodendrocytes  by  co-culture  studies  or  transfer  of  microglial 
conditioned medium (Piani  and Fontana 1994;  Kingham  et  al.  1999;  Barger and 
Basile 2001; Kingham and Pocock 2001; Taylor et al. 2002; Domercq et al. 2007; 
Jin et al. 2007; Noda et al. 2007). This neurotoxicity is often at least partly attributed 
to microglial glutamate release following increased activity of the xc
- transporter. 
However, in vivo, astrocytes are responsible for the majority of glutamate uptake in 
the CNS (Rothstein et al. 1996), and are able to remove the high levels of glutamate 
released during synaptic activity and under normal circumstances prevent glutamate 
toxicity. The levels of glutamate released by microglial xc
- activity are likely to be 
much lower than those released synaptically, so the activity of astrocytic EAATs 
may  prevent  glutamate  released  by  microglia  from  ever  reaching  neuronal  or 
oligodendrocyte  receptors  or  transporters  to  cause  excitotoxicity  or  oxidative 
glutamate toxicity. Published rates of astrocyte and microglial EAAT activity and 
microglial xc
- activity vary enormously due to culture and experimental differences, 
so it is difficult to compare these and arrive at a valid conclusion. However, a recent 
in vitro co-culture study demonstrated that astrocytes can protect neurones from cell 314 
 
death  induced  by  100  µM  exogenous  glutamate  and  LPS-treated  microglial 
conditioned medium (Liang et al. 2008).  
 
Glutamate transporters expressed by astrocytes in vivo are however not uniformly 
expressed  across  the  plasma  membrane;  a  number  of  studies  have  shown  their 
expression to be enriched in the vicinity of synapses and in response to synaptic 
activity, and is has been suggested that factors released by neurones induce astrocyte 
EAAT expression (Theodosis et al. 2008). Whether or not astrocyte EAATs can take 
up  glutamate  released  by  microglia  may  therefore  depend  upon  the  interactions 
between  these  cell  types  and  the  relative  localisation  of  astrocyte  EAATs  and 
microglial xc
-. Cultured microglia and astrocytes certainly associate in vitro and may 
affect one another‟s behaviour (DeWitt et al. 1998). A splice variant of EAAT2 with 
identical kinetics to EAAT2 found parasynaptically has been found to be localised to 
astrocyte cell bodies and processes which are not associated with synapses (Sullivan 
et  al.  2004).  Such  a  transporter  is  likely  to  be  responsible  for  regulating  the 
glutamate concentration of the general extracellular milieu, perhaps dealing with low 
level continuous glutamate release as well as transient higher level release, due to 
spillover from synapses and perhaps from activated microglia with upregulated xc
- 
activity. Since microglial glutamate release is likely to be continuously occurring at a 
low  level,  being  upregulated  under  certain  conditions,  there  is  likely  to  be  an 
intrinsic  mechanism  to  remove  such  glutamate.  Whether  microglial  EAATs  are 
sufficiently  expressed  to  have  this  function  under  normal  conditions,  or  whether 
astrocytes are necessary, is unclear.  
 
Upregulation of microglial EAAT2 following microglial activation, and the ability of 
xc
- to import glutamate at high extracellular glutamate concentrations suggest that 
under conditions of elevated extracellular glutamate, microglia may play a part in 
countering elevated glutamate release and perhaps limit glutamate-mediated damage. 
This may be particularly important considering that the glutamate uptake capacity of 
astrocytes may decrease under conditions of oxidative stress and hypoxia (Volterra 
et al. 1994; Miralles et al. 2001; Dallas et al. 2007). 
 
In summary, this thesis has extended current knowledge regarding microglial GSH 
and the mechanisms by which its intracellular levels may be affected by activation 315 
 
and by mGluR stimulation. Microglial conditioned medium was found to contain 
GSH, suggesting microglial release; this being the first such observation in primary 
microglial cultures. This work has also uncovered a number of areas which merit 
further  investigation,  to  enable  a  better  understanding  of  the  significance  of 
alterations in microglial GSH, and whether these may play a part in the mechanisms 
behind microglial neuroprotection and toxicity.  316 
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